Protein Tyrosine Kinase/RTK

Protein-tyrosine kinases (PTKs) catalyze the transfer of the γ-phosphate of ATP to tyrosine residues of protein substrates, are critical components of signaling pathways that control cellular proliferation and differentiation. Two classes of PTKs are present in cells: the transmembrane receptor PTKs and the nonreceptor PTKs.

The RTK family includes the receptors for insulin and for many growth factors, such as EGF, FGF, PDGF, VEGF, and NGF. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. RTKs activate numerous signaling pathways within cells, leading to cell proliferation, differentiation, migration, or metabolic changes. In addition, nonreceptor tyrosine kinases (NRTKs), which include Src, JAKs, and Abl, among others, are integral components of the signaling cascades triggered by RTKs and by other cell surface receptors such as GPCRs and receptors of the immune system. NRTKs are critical components in the regulation of the immune system.

RTKs and NRTKs have been implicated in the progression of diseases such as cancer, diabetic retinopathy, atherosclerosis, and psoriasis. Protein kinases, including RTKs, are one of the most frequently mutated gene families implicated in cancer, which has prompted numerous studies on their role in cancer pathogenesis. There are four main mechanisms of RTK dysregulation in human cancers: genomic rearrangements, autocrine activation, overexpression and gain- or loss-of-function mutations. Currently, there are several clinically available small molecule inhibitors and monoclonal antibodies against specific RTKs.

References:

[1] Hubbard SR, et al. Annu Rev Biochem. 2000;69:373-98.
[2] Robinson DR, et al. Oncogene. 2000 Nov 20;19(49):5548-57.
[3] McDonell LM, et al. Hum Mol Genet. 2015 Oct 15;24(R1):R60-6.



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Target List in Protein Tyrosine Kinase/RTK

Ack1

Activated Cdc42 kinase 1; TNK2

Ack1 (Activated Cdc42 kinase 1) is an enzyme that in humans is encoded by the TNK2 gene. Ack1 binds to multiple receptor tyrosine kinases e.g. EGFR, MERTK, AXL, HER2 and insulin receptor (IR). Ack1 also interacts with Cdc42Hs in its GTP-bound form and inhibits both the intrinsic and GTPase-activating protein (GAP)-stimulated GTPase activity of Cdc42Hs. Ack1 is a survival kinase and shown to be associated with tumor cell survival, proliferation, hormone-resistance and radiation resistance. Ack1 has emerged as a new cancer target and multiple small molecule inhibitors have been reported.

Ack1 Inhibitors

AIM-100

Cat. No.: HY-15290

AIM-100 is a potent and selective **Ack1** inhibitor with an **IC_{50}** of 21.58 nM. AIM-100 also inhibits Tyr^{267} phosphorylation. AIM-100 does not inhibits other kinases including PI3-kinase and AKT subfamily members. AIM-100 has an anticancer effect.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNF-7

Cat. No.: HY-10943

GNF-7 is a multikinase inhibitor. GNF-7 is a **Bcr-Abl** inhibitor, with **IC_{50}**s of 133 nM and 61 nM for $Bcr\text{-}Abl^{WT}$ and $Bcr\text{-}Abl^{T315I}$, respectively.



Purity: 98.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KRCA-0008

Cat. No.: HY-12331

KRCA-0008 is a potent and selective ALK/Ack1 inhibitor with IC50 of 12 nM/4 nM for ALK and Ack1 respectively; displays drug-like properties without hERG liability.



Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ALK

Anaplastic lymphoma kinase; ALK tyrosine kinase receptor; CD246; Cluster of differentiation 246

Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, is predominantly expressed in the brain and implicated in neuronal development and cognition. ALK catalyzes the transference of a gamma-phosphate group from adenosine triphosphate (ATP) to a tyrosine residue on a substrate protein. Therefore, it catalyzes a tyrosine residue phosphorylation reaction on its substrate proteins. The phosphorylation and dephosphorylation of proteins are critical reactions catalyzed by different enzymes (kinases and phosphatases), which play critical roles in various cellular functions.

ALK gene activation is involved in the carcinogenesis process of several human cancers such as anaplastic large cell lymphoma, lung cancer, inflammatory myofibroblastic tumors and neuroblastoma, as a consequence of fusion with other oncogenes (NPM, EML4, TIM, etc) or gene amplification, mutation or protein overexpression. ALK is a transmembrane tyrosine kinase receptor that, upon ligand binding to its extracellular domain, undergoes dimerization and subsequent autophosphorylation of the intracellular kinase domain. When activated in cancer it represents a target for specific inhibitors, such as Crizotinib, Ceritinib, Alectinib etc. which use has demonstrated significant effectiveness in ALK-positive non-small cell lung cancer particularly.

ALK Inhibitors

2-Keto Crizotinib
(PF-06260182) Cat. No.: HY-13320

2-Keto Crizotinib (PF-06260182) is an active lactam metabolite of crizotinib.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

6-Demethoxytangeretin
Cat. No.: HY-N4126

6-Demethoxytangeretin is a citrus flavonoid isolated from Citrus depressa.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Alectinib
(CH5424802; RO5424802; AF802) Cat. No.: HY-13011

Alectinib (CH5424802) is a potent, selective, and orally available **ALK** inhibitor with an IC_{50} of 1.9 nM and a K_d value of 2.4 nM (in an ATP-competitive manner), and also inhibits **ALK F1174L** and **ALK R1275Q** with IC_{50}s of 1 nM and 3.5 nM, respectively.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Alectinib Hydrochloride (CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride)
Cat. No.: HY-13011A

Alectinib Hydrochloride (CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride) is a potent, selective, and orally available **ALK** inhibitor with an IC_{50} of 1.9 nM and a K_d value of 2.4 nM (in an ATP-competitive manner), and also inhibits **ALK F1174L** and **ALK R1275Q** with...



Purity: 99.89%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Alectinib-d6
(CH5424802-d6; RO5424802-d6; AF802-d6) Cat. No.: HY-13011S1

Alectinib-d6 is deuterium labeled Alectinib.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alectinib-d8
(CH5424802-d8; RO5424802-d8; AF802-d8) Cat. No.: HY-13011S

Alectinib-d8 (CH5424802-d8) is the deuterium labeled Alectinib.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK inhibitor 1
Cat. No.: HY-15357

ALK inhibitor 1 (compound 17) is a potent pyrimidin **ALK** inhibitor. ALK inhibitor 1 is a potent inhibitor of **testis-specific serine/threonine kinase 2** (**TSSK2**; IC_{50}=31 nM) and **focal adhesion kinase** (**FAK**; IC_{50}=2 nM).



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

ALK inhibitor 2
Cat. No.: HY-15358

ALK inhibitor 2 (compound 18) is a potent pyrimidin **ALK** inhibitor. ALK inhibitor 2 is a potent inhibitor of **testis-specific serine/threonine kinase 2** (**TSSK2**; IC_{50}=37 nM) and **focal adhesion kinase** (**FAK**; IC_{50}=5 nM).



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

ALK kinase inhibitor-1
Cat. No.: HY-19990

ALK kinase inhibitor-1 is an **anaplastic lymphoma kinase (ALK)** inhibitor extracted from patent US20130261106A1 compound I-202.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

ALK-IN-1
(Brigatinib analog) Cat. No.: HY-13464

ALK-IN-1 (Brigatinib analog) is a potent and selective active inhibitor of **anaplastic lymphoma kinase(ALK)**, Patent US20140066406 A1.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ALK-IN-12

Cat. No.: HY-108230

ALK-IN-12 is a potent and orally active **ALK** inhibitor with an **IC_{50}** of 0.18 nM. ALK-IN-12 also inhibits IGF1R and InsR (IC_{50}=20.3 and 90.6 nM). Antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK-IN-13

Cat. No.: HY-12973

ALK-IN-13 is an ALK inhibitor, extracted from patent US20130225528A1, example 19.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK-IN-5

Cat. No.: HY-128569

ALK-IN-5 is a potent, selective, and brain-penetrant inhibitor of **anaplastic lymphoma kinase (ALK)**, with an **IC_{50}** of 2.9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK-IN-6

Cat. No.: HY-128596

ALK-IN-6 (compound 11) is an orally bioavailable inhibitor of **anaplastic lymphoma kinase (ALK)**, with **IC_{50}** values of 71 nM, 18.72 nM and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK-IN-9

Cat. No.: HY-131244

ALK-IN-9 (compound 40) is a potent **ALK** inhibitor. ALK-IN-9 inhibits cell proliferation with IC_{50}s of <0.2 nM, <0.2 nM, 0.2 nM for Ba/F3-EML4-ALK, KM 12 (TPM3-TRKA), KG-I cell (OP2-FGFR1), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK/ROS1-IN-1

Cat. No.: HY-130794

ALK/ROS1-IN-1 (compound 2e) is a potent and selective anti crizotinib-resistant **ALK/ROS1** dual inhibitor, with **IC_{50}**s of 0.174 μM and 0.530 μM for ALK and ROS1 enzyme, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK5-IN-6

Cat. No.: HY-142950

ALK5-IN-6 is a potent inhibitor of **ALK5**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK5-IN-7

Cat. No.: HY-142949

ALK5-IN-7 is a potent inhibitor of **ALK5**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ASP3026

Cat. No.: HY-13326

ASP3026 is a potent, selective and orally active inhibitor of **anaplastic lymphoma kinase (ALK)**. ASP3026 induces apoptosis of tumor cells. ASP3026 can be used for the research of non-small cell lung cancer (NSCLC).



Purity: 99.90%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 50 mg, 100 mg

AZD-3463

(ALK/IGF1R inhibitor)

Cat. No.: HY-15609

AZD-3463 (ALK/IGF1R inhibitor) is an orally active **ALK/IGF1R** inhibitor, with a **K_i** of 0.75 nM for ALK. AZD3463 induces **apoptosis** and **autophagy** in neuroblastoma cells.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Belizatinib

(TSR-011) Cat. No.: HY-17603

Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC_{50} of 0.7nM for wild-type recombinant ALK kinase.



Purity: 99.66%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Brigatinib

(AP-26113) Cat. No.: HY-12857

Brigatinib (AP-26113) is a highly potent and selective **ALK** inhibitor, with an IC_{50} of 0.6 nM.



Purity: 99.98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Brigatinib-13C6

(AP-26113-13C6) Cat. No.: HY-12857S

Brigatinib-13C6 (AP-26113-13C6) is the 13C-labeled Brigatinib. Brigatinib (AP-26113) is a highly potent and selective **ALK** inhibitor, with an IC_{50} of 0.6 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Brigatinib-d3

(AP-26113-d3) Cat. No.: HY-12857S1

Brigatinib-d3 (AP-26113-d3) is the deuterium labeled Brigatinib. Brigatinib (AP-26113) is a highly potent and selective **ALK** inhibitor, with an IC_{50} of 0.6 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CEP-28122

Cat. No.: HY-18030

CEP-28122 is a highly potent and selective orally active ALK inhibitor with IC50 of 1.9 ± 0.5 nM in an enzyme-based TRF assay. IC50 value: 1.9 ± 0.5 nM Target: ALK in vitro: CEP-28122 is a potent inhibitor of recombinant ALK activity and cellular ALK tyrosine phosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CEP-28122 mesylate salt

Cat. No.: HY-18030A

CEP-28122 mesylate salt, a diaminopyrimidine derivative, is a potent, selective, and orally bioavailable **ALK** inhibitor, with an IC_{50} value of 1.9 nM for recombinant ALK kinase activity. CEP-28122 has antitumor activity in experimental models of ALK-positive human cancers.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CEP-37440

Cat. No.: HY-15841

CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).



Purity: 99.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ceritinib

(LDK378) Cat. No.: HY-15656

Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive **ALK** tyrosine kinase inhibitor with an IC_{50} of 200 pM. Ceritinib (LDK378) also inhibits **IGF-1R**, **InsR**, and **STK22D** with IC_{50} values of 8, 7, and 23 nM, respectively. Ceritinib (LDK378) shows great antitumor potency.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ceritinib D7

(LDK378 D7) Cat. No.: HY-15656S

Ceritinib D7 (LDK378 D7) is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ceritinib dihydrochloride

(LDK378 dihydrochloride) Cat. No.: HY-15656A

Ceritinib dihydrochloride (LDK378 dihydrochloride) is a selective, orally bioavailable and ATP-competitive **ALK** tyrosine kinase inhibitor with an IC_{50} of 200 pM.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CJ-2360

Cat. No.: HY-131909

CJ-2360 is a potent and orally active **ALK** inhibitor with **IC_{50}**s of 2.2, 4.0, 8.8, 6.3, and 8.9 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Con B-1

Cat. No.: HY-142287

ConB-1 is a potent and selective **ALK** inhibitor with low toxicity to normal cells.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Crizotinib

(PF-02341066)

Cat. No.: HY-50878

Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive **ALK** and **c-Met** inhibitor with **IC_{50}**s of 20 and 8 nM, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Crizotinib hydrochloride

(PF-02341066 hydrochloride)

Cat. No.: HY-50878A

Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual **ALK** and **c-Met** inhibitor with **IC_{50}**s of 20 and 8 nM, respectively.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Crizotinib-d5

(PF-02341066-d5)

Cat. No.: HY-50878S

Crizotinib-d5 (PF-02341066-d5) is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive **ALK** and **c-Met** inhibitor with **IC_{50}**s of 20 and 8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EML4-ALK kinase inhibitor 1

Cat. No.: HY-111752

EML4-ALK kinase inhibitor 1 is a potent orally active inhibitor of echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase **(EML4-ALK)**, with an **IC_{50}** of 1 nM.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ensartinib

(X-396)

Cat. No.: HY-103714

Ensartinib (X-396) is a potent and dual **ALK/MET** inhibitor with **IC_{50}**s of <0.4 nM and 0.74 nM, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ensartinib dihydrochloride

(X-396 dihydrochloride)

Cat. No.: HY-103714A

Ensartinib dihydrochloride (X-396 dihydrochloride) is a potent and dual **ALK/MET** inhibitor with **IC_{50}**s of <0.4 nM and 0.74 nM, respectively.



Purity: 99.46%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Entrectinib

(NMS-E628; RXDX-101)

Cat. No.: HY-12678

Entrectinib (NMS-E628) is a potent, orally available, and CNS-active **pan-Trk**, **ROS1**, and **ALK** inhibitor. Entrectinib inhibits TrkA, TrkB, TrkC, ROS1 and ALK with **IC_{50}** values of 1, 3, 5, 12 and 7 nM, respectively. Antitumor activity.



Purity: 99.32%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Envonalkib

Cat. No.: HY-145566

Envonalkib is a potent and orally active inhibitor of **ALK**, with **IC_{50}**s of 1.96 nM, 35.1 nM, and 61.3 nM for **WT** and **mutated L1196M** and **G1269S-ALK**. Envonalkib can be used for the research of non-small cell lung cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

F-1

Cat. No.: HY-112801

F-1 is a potent **ALK** and **ROS1** dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC_{50}s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALK^{WT}, $ROS1^{WT}$, ALK^{L1196M} and ALK^{G1202R}, respectively.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK1838705A

Cat. No.: HY-13020

GSK1838705A is a potent and reversible **IGF-IR** and the **insulin receptor** inhibitor with IC_{50}s of 2.0 and 1.6 nM, respectively. It also inhibits **ALK** with an IC_{50} of 0.5 nM.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HG-14-10-04

Cat. No.: HY-15801

HG-14-10-04 (example 10) is a potent and specific **ALK** inhibitor with an IC_{50} of 20 nM.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Iruplinalkib

(WX-0593)

Cat. No.: HY-145574

Iruplinalkib (WX-0593) is a potent, selective, and orally active inhibitor of **ALK** and **ROS1** tyrosine kinase. Iruplinalkib (WX-0593) shows favorable safety and promising antitumor activity in advanced NSCLC with ALK or ROS1 rearrangement.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Itacnosertib

(TP-0184)

Cat. No.: HY-109179

Itacnosertib (TP-0184) is both inhibitor to **JAK2**, **ACVR1 (ALK2)** and **ALK5** as described in WO2014151871.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

J-1063

Cat. No.: HY-145855

J-1063 is a potent, selective and orally active **ALK5** inhibitor with an IC_{50} of 0.039 μM. J-1063 shows anti-fibrotic effect by the inhibition of inflammatory infiltration, collagen deposition, and hepatocytes necrosis. J-1063 has the potential for the research of liver fibrosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JH-VIII-157-02

Cat. No.: HY-112140

JH-VIII-157-02 is a structural analogue of alectinib, acts as an **ALK** inhibitor, and shows an IC_{50} of 2 nM for echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) G1202R in cells.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KRCA-0008

Cat. No.: HY-12331

KRCA-0008 is a potent and selective ALK/Ack1 inhibitor with IC50 of 12 nM/4 nM for ALK and Ack1 respectively; displays drug-like properties without hERG liability.



Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lorlatinib

(PF-06463922)

Cat. No.: HY-12215

Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive **ROS1/ALK** inhibitor. Lorlatinib has K_is of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK^{L1196M}, respectively. Lorlatinib has anticancer activity.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lorlatinib-13C,d3

(PF-06463922-13C,d3)

Cat. No.: HY-12215S

Lorlatinib-13C,d3 (PF-06463922-13C,d3) is the 13C- and deuterium labeled Lorlatinib. Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive **ROS1/ALK** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MS4077

Cat. No.: HY-112156

MS4077 is an anaplastic lymphoma kinase (**ALK**) **PROTAC** (degrader) based on **Cereblon** ligand, with a K_d of 37 nM for binding affinity to ALK.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MS4078

Cat. No.: HY-112155

MS4078 is an anaplastic lymphoma kinase (**ALK**) **PROTAC** (degrader) based on **Cereblon** ligand, with a K_d of 19 nM for binding affinity to ALK.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-TAE 684

(TAE 684)

Cat. No.: HY-10192

NVP-TAE 684 (TAE 684) is a highly potent and selective **ALK** inhibitor, which blocks the growth of ALCL-derived and ALK-dependent cell lines with IC_{50} values between 2 and 10 nM.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Repotrectinib

(TPX-0005)

Cat. No.: HY-103022

Repotrectinib (TPX-0005) is a potent **ROS1** (IC_{50}=0.07 nM) and **TRK** (IC_{50}=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib potently inhibits WT **ALK** (IC_{50}=1.01 nM). Repotrectinib has anti-cancer activity.



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

RIPK2-IN-1

Cat. No.: HY-146694

RIPK2-IN-1 (compound 18f) is a potent **RIPK2** inhibitor with an IC_{50} of 51 nM. RIPK2-IN-1 inhibits **ALK2** with an IC_{50} of 5 nM. RIPK2-IN-1 has an IC_{50} of 390 nM on RIPK2/NOD2 in cell assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SIAIS117

Cat. No.: HY-146022

SIAIS117 is a potent **Brigatinib-PROTAC** degrader. SIAIS117 is a **ALK PROTAC** based on Brigatinib and VHL-1 conjunction. SIAIS117 can degrade **ALK G1202R** point mutation effectively. SIAIS117 blocks the growth of SR and H2228 cancer cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TL13-110

Cat. No.: HY-136195

TL13-110 is a negative control for TL13-112 (HY-123919) and a potent ALK inhibitor with an IC_{50} of 0.34 nM. TL13-110 does not degrade **ALK** in cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TL13-112

Cat. No.: HY-123919

TL13-112 is a potent and selective **ALK-PROTAC** degrader and inhibits **ALK** activity with an IC_{50} value of 0.14 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TL13-12

Cat. No.: HY-122582

TL13-12 is a potent and selective **ALK-PROTAC** degrader and inhibits **ALK** activity with an IC_{50} value of 0.69 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TL13-22

Cat. No.: HY-136194

TL13-22 is a negative control for TL13-12 (HY-122582) and a potent **ALK** inhibitor with an IC_{50} of 0.54 nM. TL13-22 does not degrade **ALK** in cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TP-008

Cat. No.: HY-125851

TP-008 is a potent, selective and orally active **(Activin-Like Kinase 5) ALK5** inhibitor with **pIC_{50}** and **pEC_{50}** values of 7.6 and 6.63, respectively. TGFβRI-IN-2 can produce observed cardiac toxicity in vivo at high dose.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TPX-0131

Cat. No.: HY-139279

TPX-0131 is a potent, selective, CNS-penetrant and orally active inhibitor of **wild-type ALK** (IC_{50} of 1.4 nM) and **ALK-resistant mutation**, e.g. **G1202R** (IC_{50} of 0.3 nM), **L1196M** (IC_{50} of 0.3 nM). TPX-0131 has strong antitumor activities.



Purity: ≥95.0%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg

TRK/ALK-IN-1

Cat. No.: HY-144732

TRK/ALK-IN-1 (compound 21) is a potent and dual inhibitor of **TRK** and **ALK**. TRK/ALK-IN-1 in the enzymatic assays is in good accordance with anti-proliferative activity with **IC_{50}** values of 2.2, 9.3 and 38 nM towards TRKA, ALK^{WT} and ALK^{L1196M}, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UNC5293

Cat. No.: HY-132200

UNC5293 is a **MERTK**-selective and potent inhibitor (K_i=190 pM). UNC5293 inhibits MERTK (IC_{50}=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WY-135

Cat. No.: HY-111416

WY-135 is an **ALK** (IC_{50}=1.4 nM) and **ROS1** (IC_{50}=1.1 nM) dual inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

X-376

Cat. No.: HY-16590

X-376 is a potent and highly specific **ALK** tyrosine kinase inhibitor (TKI) (IC_{50}=0.61 nM). X-376 is a less potent inhibitor of **MET** (IC_{50}=0.69 nM). X-376 displays potent anti-tumor activity.



Purity: 98.36%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

XST-14

Cat. No.: HY-137506

XST-14 is a potent, competitive and highly selective **ULK1** inhibitor with an **IC_{50}** of 26.6 nM. XST-14 induces **autophagy** inhibition by reducing the phosphorylation of the ULK1 downstream substrate.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zilurgisertib

Cat. No.: HY-145608

Zilurgisertib is a selective **ALK 2** inhibitor for treating diseases such as cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZX-29

Cat. No.: HY-135887

ZX-29 is a potent and selective **ALK** inhibitor with an **IC_{50}** of 2.1 nM, 1.3 nM and 3.9 nM for **ALK**, **ALK L1196M** and **ALK G1202R** mutations, respectively. ZX-29 is inactive against EGFR.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bcr-Abl

Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). More than 90% of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome. This abnormality is a consequence of fusion between the Abelson (Abl) tyrosine kinase gene at chromosome 9 and the break point cluster (Bcr) gene at chromosome 22, resulting in a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that has been implicated in the pathogenesis of CML. Compounds have been developed to selectively inhibit the tyrosine kinase.

Bcr-Abl Inhibitors & Activators

Adaphostin
(NSC 680410) Cat. No.: HY-103275

Adaphostin (NSC 680410), the adamantyl ester of AG957, is a potent **p210**$^{bcr/abl}$ inhibitor (**IC**$_{50}$=14 μM). Adaphostin induces apoptosis in T-lymphoblastic human leukemia cell lines (IC$_{50}$ ranging from 17 to 216 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AG957
(Tyrphostin AG957; NSC 654705) Cat. No.: HY-117718

AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-**BCR/ABL** tyrosine kinase activity. AG957 is a **bcr/abl** kinase inhibitor with an **IC**$_{50}$ of 2.9 μM for **p210**$^{bcr/abl}$ autokinase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Asciminib
(ABL001) Cat. No.: HY-104010

Asciminib (ABL001) is a potent and selective allosteric **BCR-ABL1** inhibitor, which inhibits Ba/F3 cells grown with an **IC**$_{50}$ of 0.25 nM.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AST 487
(NVP-AST 487) Cat. No.: HY-15002

AST 487 is a **RET** kinase inhibitor with **IC**$_{50}$ of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits **Flt-3** with **IC**$_{50}$ of 520 nM.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT9283
Cat. No.: HY-50514

AT9283 is a multi-targeted kinase inhibitor with potent activity against **Aurora A/B**, **JAK2/3**, **Abl (T315I)** and **Flt3** (**IC**$_{50}$s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo.



Purity: 99.70%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

AZD0424
Cat. No.: HY-112314

AZD0424 is an orally active, and dual selective **Src/Abl** kinase inhibitor with potential antineoplastic activity. AZD0424 induces **apoptosis** and cell cycle arrest in lymphoma cells.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Bafetinib
(INNO-406; NS-187) Cat. No.: HY-50868

Bafetinib is a potent and orally active **Lyn/Bcr-Abl** tyrosine kinase inhibitor. Bafetinib augments the activities of several proapoptotic Bcl-2 homology (BH)3-only proteins (Bim, Bad, Bmf and Bik) and induces apoptosis in Ph$^+$ leukemia cells via Bcl-2 family-regulated intrinsic apoptosis pathway.



Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BCR-ABL-IN-1
Cat. No.: HY-100314

BCR-ABL-IN-1 is an inhibitor of **BCR-ABL** tyrosine kinase, with a **pIC**$_{50}$ of 6.46, and may be used in the research of chronic myelogenous leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCR-ABL-IN-2
Cat. No.: HY-18819

BCR-ABL-IN-2 is an inhibitor of **BCR-ABL1** tyrosine kinase, with **IC**$_{50}$**s** of 57 nM, 773 nm for ABL1^{native} and ABL1^{T315I}, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCR-ABL-IN-3
Cat. No.: HY-136526

BCR-ABL-IN-3 is a potent and irreversible **Bcr-Abl** inhibitor with an **IC**$_{50}$ of ≤100 nM for Ba/F$_3$Bcr-Abl^{T315I}. BCR-ABL-IN-3 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCR-ABL-IN-4

Cat. No.: HY-142922

BCR-ABL-IN-4 is a **BCR-ABL** inhibitor with anticancer effects. BCR-ABL-IN-4 inhibits the cancer cell growth with IC_{50} values of 0.67 nM and 16 nM for K562 cells and BCR-ABL T315I transfected Ba/F3 cells, respectively (WO2021143927A1; compound 11).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bosutinib

(SKI-606)

Cat. No.: HY-10158

Bosutinib is a dual **Src/Abl** inhibitor with IC_{50}s of 1.2 nM and 1 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Bosutinib D8

(SKI-606 D8)

Cat. No.: HY-10158S

Bosutinib D8 (SKI-606 D8) is a deuterium labeled Bosutinib. Bosutinib is a dual **Src/Abl** inhibitor with IC_{50}s of 1.2 nM and 1 nM, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

c-ABL-IN-2

Cat. No.: HY-146527

c-ABL-IN-2 is a potent inhibitor of **c-Abl**. Activation of c-Abl has been implicated in various diseases, notably cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cenisertib

(AS-703569; R-763)

Cat. No.: HY-13072

Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of **Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3**.



Purity: 99.64%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CHMFL-ABL-039

Cat. No.: HY-126143

CHMFL-ABL-039 is a type II native **ABL** kinase and drug-resistant V299L mutant **BCR-ABL** inhibitor with the IC_{50}s of 7.9 nM and 27.9 nM, respectively. CHMFL-ABL-039 is used in the research of chronic myeloid leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CHMFL-ABL-053

Cat. No.: HY-101268

CHMFL-ABL-053 (Compound 18a) is a potent, selective, and orally available **BCR-ABL**, **SRC** and **p38** kinase inhibitor with IC_{50} values of 70, 90 and 62 nM against ABL1, SRC and p38, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CHMFL-ABL-121

Cat. No.: HY-119370

CHMFL-ABL-121 is a highly potent type II **ABL kinase** inhibitor with IC_{50}s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CHMFL-ABL/KIT-155

(CHMFL-ABL-KIT-155)

Cat. No.: HY-101034

CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active **type II ABL/c-KIT** dual kinase inhibitor (IC_{50}s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC_{50}=81 nM), CSF1R (IC_{50}=227 nM), DDR1 (IC_{50}=116 nM),...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CT-721

Cat. No.: HY-108704

CT-721 is a potent and time-dependent **Bcr-Abl kinase** inhibitor with an IC_{50} of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CZC-8004

(CZC-00008004) Cat. No.: HY-111138

CZC-8004 is a pan-kinase inhibitor and binds a range of tyrosine kinases, including **ABL** kinase.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Dasatinib

(BMS-354825) Cat. No.: HY-10181

Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual **Src/Bcr-Abl** inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Dasatinib hydrochloride

(BMS-354825 hydrochloride) Cat. No.: HY-10181A

Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual **Src/Bcr-Abl** inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively.



Purity: 98.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Dasatinib monohydrate

(BMS-354825 monohydrate) Cat. No.: HY-10181B

Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual **Src/Bcr-Abl** inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Dasatinib-d8

(BMS-354825-d8) Cat. No.: HY-10181S

Dasatinib D8 is a deuterium labeled Dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

DB07107

Cat. No.: HY-123390

DB07107 is a potent drug resistant **T315I mutant Bcr-Abl tyrosine kinase** inhibitor. DB07107 is also a potent **Akt1** inhibitor with an IC_{50} value of 360 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Debio 0617B

Cat. No.: HY-108417

Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML $CD34^+$ stem/progenitor cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Degrasyn

(WP1130) Cat. No.: HY-13264

Degrasyn (WP1130) is a cell-permeable **deubiquitinase (DUB)** inhibitor, directly inhibiting DUB activity of USP9x, USP5, USP14, and UCH37. Degrasyn has been shown to downregulate the antiapoptotic proteins **Bcr-Abl** and **JAK2**.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DPH

Cat. No.: HY-12070

DPH is a potent cell permeable **c-Abl** activator, which displays potent enzymatic and cellular activity in stimulating c-Abl activation. .



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Flumatinib

(HHGV678) Cat. No.: HY-13904

Flumatinib (HHGV678) is an orally available, selective inhibitor of **Bcr-Abl**. Flumatinib inhibits **c-Abl**, **PDGFRβ** and **c-Kit** with IC_{50}s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Flumatinib mesylate

(HHGV678 mesylate) Cat. No.: HY-13905

Flumatinib (HHGV678) mesylate is an orally active and selective inhibitor of **Bcr-Abl**. Flumatinib mesylate inhibits c-Abl, PDGFRβ and c-Kit with IC_{50} values of 1.2, 307.6 and 665.5 nM, respectively.



Purity: 99.97%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 500 mg

Flumatinib-d3

(HHGV678-d3) Cat. No.: HY-13904S

Flumatinib-d3 is deuterium labeled Flumatinib. Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GMB-475

Cat. No.: HY-125834

GMB-475 is a degrader of **BCR-ABL1** tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase **Von Hippel Lindau** (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GNF-2

Cat. No.: HY-11007

GNF-2 is a highly selective, allosteric, non-ATP competitive inhibitor of **Bcr-Abl**. GNF-2 inhibits Ba/F3.p210 proliferation with an IC_{50} of 138 nM .



Purity: 98.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNF-5

Cat. No.: HY-15738

GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0.22±0.1 uM (Wild type Abl).



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

GNF-7

Cat. No.: HY-10943

GNF-7 is a multikinase inhibitor. GNF-7 is a **Bcr-Abl** inhibitor, with IC_{50}s of 133 nM and 61 nM for $Bcr\text{-}Abl^{WT}$ and $Bcr\text{-}Abl^{T315I}$, respectively.



Purity: 98.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GZD856

Cat. No.: HY-101489

GZD856 formic is a potent and orally active **PDGFRα/β** inhibitor, with IC_{50}s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a $Bcr\text{-}Abl^{T315I}$ inhibitor, with IC_{50}s of 19.9 and 15.4nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GZD856 formic

Cat. No.: HY-101489A

GZD856 formic is a potent and orally active **PDGFRα/β** inhibitor, with IC_{50}s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a $Bcr\text{-}Abl^{T315I}$ inhibitor, with IC_{50}s of 19.9 and 15.4nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HG-7-85-01

Cat. No.: HY-15814

HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of **Bcr-Abl**, **PDGFRα**, **Kit**, and **Src kinases**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IHMT-TRK-284

Cat. No.: HY-146697

IHMT-TRK-284 (Compound 34) is a potent, orally active **type II TRK kinase** inhibitor with IC_{50} values of 10.5, 0.7, and 2.6 nM to **TRKA**, **B**, and **C** respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imatinib

(STI571; CGP-57148B)

Cat. No.: HY-15463

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits **BCR/ABL**, **v-Abl**, **PDGFR** and **c-kit** kinase activity.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

Imatinib D4

(STI571 D4; CGP-57148B D4)

Cat. No.: HY-15463S1

Imatinib D4 (STI571 D4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imatinib Mesylate

(STI571 Mesylate; CGP-57148B Mesylate)

Cat. No.: HY-50946

Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits **c-Kit**, **Bcr-Abl**, and **PDGFR** (IC_{50}=100 nM) tyrosine kinases.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

Imatinib-d8

(STI571-d8; CGP-57148B-d8)

Cat. No.: HY-15463S

Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

KW-2449

Cat. No.: HY-10339

KW-2449 is a multi-targeted kinase inhibitor of **FLT3**, **ABL**, **ABL**^{T315I} and **Aurora kinase** with IC_{50}s of 6.6, 14, 4 and 48 nM, respectively.



Purity: 99.85%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LXH254

Cat. No.: HY-112089

LXH254 is a potent, selective, orally active, type II **BRAF** and **CRAF** inhibitor, with IC_{50} values of 0.072 and 0.21 nM against CRAF and BRAF, respectively.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Lyn-IN-1

(Bafetinib analog)

Cat. No.: HY-12039

Lyn-IN-1 (Bafetinib analog) is a potent and selective dual Bcr-Abl/Lyn inhibitor, extracted from patent WO2014169128A1.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML786 dihydrochloride

Cat. No.: HY-14979A

ML786 dihydrochloride is a potent and orally bioavailable **Raf** inhibitor, with IC_{50}s of 2.1, 4.2, and 2.5 nM for ^{V600E}**ΔB-Raf**, **wt B-Raf**, and **C-Raf**, respectively. ML786 dihydrochloride also inhibits **Abl-1**, **DDR2**, **EPHA2**, **KDR**, and **RET** (IC_{50}=<0.5, 7.0, 11, 6.2, 0.8 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Multi-kinase inhibitor 1

Cat. No.: HY-103032

Multi-kinase inhibitor 1 is a potent **multi-kinase** inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of **PDGF-R**, **c-Kit** and **Bcr-abl**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nilotinib

(AMN107)

Cat. No.: HY-10159

Nilotinib is an orally available **Bcr-Abl** tyrosine kinase inhibitor with antineoplastic activity.



Purity: 99.96%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg

Nilotinib monohydrochloride monohydrate

(AMN107 monohydrochloride monohydrate)

Cat. No.: HY-10159A

Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly potent against **BCR-ABL**, and is active against many BCR-ABL mutants.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Nilotinib-d3

Cat. No.: HY-132549S

Nilotinib-d3 (AMN107-d3) is the deuterium labeled Nilotinib. Nilotinib is an orally available **Bcr-Abl** tyrosine kinase inhibitor with antineoplastic activity.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Nilotinib-d6

(AMN107-d6)

Cat. No.: HY-10159S

Nilotinib D6 (AMN107 D6) is a deuterium labeled Nilotinib. Nilotinib is an orally available **Bcr-Abl** tyrosine kinase inhibitor with antineoplastic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Nocodazole

(Oncodazole; R17934)

Cat. No.: HY-13520

Nocodazole (Oncodazole) is a rapidly-reversible inhibitor of **microtubule**. Nocodazole binds to β-tubulin and disrupts microtubule assembly/disassembly dynamics, which prevents mitosis and induces apoptosis in tumor cells.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Olverembatinib

(GZD824; HQP1351)

Cat. No.: HY-15666

Olverembatinib (GZD824) is a potent and orally active pan-**Bcr-Abl** inhibitor. Olverembatinib potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib strongly inhibits native Bcr-Abl and Bcr-Abl^{T315I} with **IC_{50}**s of 0.34 nM and 0.68 nM, respectively.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Olverembatinib dimesylate

(GZD824 dimesylate; HQP1351 dimesylate)

Cat. No.: HY-15666A

Olverembatinib (GZD824) dimesylate is a potent and orally active pan-**Bcr-Abl** inhibitor. Olverembatinib dimesylate potently inhibits a broad spectrum of Bcr-Abl mutants.



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

ON 146040

Cat. No.: HY-12338

ON 146040 is a potent **PI3Kα** and **PI3Kδ** (**IC_{50}**≈14 and 20 nM, respectively) inhibitor. ON 146040 also inhibits **Abl1** (**IC_{50}**<150 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD173955

Cat. No.: HY-10395

PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PKC.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

PD180970

Cat. No.: HY-103274

PD180970 is a highly potent and ATP-competitive **p210$^{Bcr-Abl}$ kinase** inhibitor, with an **IC_{50}** of 5 nM for inhibiting the autophosphorylation of **p210$^{Bcr-Abl}$**. PD180970 also inhibits **Src** and **KIT** kinase with **IC_{50}**s of 0.8 nM and 50 nM, respectively.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Pivanex

(AN-9; Pivalyloxymethyl butyrate)

Cat. No.: HY-120508

Pivanex (AN-9), a derivative of Butyric acid, is an orally active **HDAC** inhibitor. Pivanex down-regulates **bcr-abl** protein and enhances **apoptosis**. Pivanex has antimetastic and antiangiogenic properties.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Ponatinib

(AP24534) Cat. No.: HY-12047

Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ponatinib hydrochloride

(AP24534 hydrochloride) Cat. No.: HY-108766

Ponatinib (AP24534) hydrochloride is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: >98%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg, 100 mg

Ponatinib-d8

(AP24534-d8) Cat. No.: HY-12047S

Ponatinib D8 (AP24534 D8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 1 mg

PROTAC BCR-ABL1 ligand 1

Cat. No.: HY-130297

PROTAC BCR-ABL1 ligand 1, compound GMB-475, is the ligand of PROTAC that allosterically targets **BCR-ABL1** protein and recruits the E3 ligase Von Hippel-Lindau, resulting in ubiquitination and subsequent degradation of BCR-ABL1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Radotinib-d6

Cat. No.: HY-15728S

Radotinib-d6 is deuterium labeled Radotinib.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rebastinib

(DCC-2036) Cat. No.: HY-13024

Rebastinib (DCC-2036) is an orally active, non-ATP-competitive **Bcr-Abl** inhibitor for $Abl1^{WT}$ and $Abl1^{T315I}$ with IC_{50}s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.



Purity: 99.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

S116836

Cat. No.: HY-123450

S116836, a potent, orally active **BCR-ABL** tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SIAIS178

Cat. No.: HY-128756

SIAIS178 is a potent and selective **BCR-ABL** degrader based on PROTAC technology with an IC_{50} of 24 nM. SIAIS178 causes effective degradation of BCR-ABL protein by recruiting **Von Hippel-Lindau** (VHL) E3 ubiquitin ligase. SIAIS178 has anticancer activity.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

SNIPER(ABL)-013

Cat. No.: HY-111860

SNIPER(ABL)-013, conjugating GNF5 (ABL inhibitor) to Bestatin (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 20 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-015

Cat. No.: HY-111854

SNIPER(ABL)-015, conjugating GNF5 (ABL inhibitor) to MV-1 (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 5 μM .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-019

Cat. No.: HY-111873

SNIPER(ABL)-019, conjugating Dasatinib (ABL inhibitor) to MV-1 (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 0.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-020

Cat. No.: HY-111872

SNIPER(ABL)-020, conjugating Dasatinib (ABL inhibitor) to Bestatin (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein.

Purity: 99.44%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

SNIPER(ABL)-024

Cat. No.: HY-111861

SNIPER(ABL)-024, conjugating GNF5 (ABL inhibitor) to LCL161 derivative (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 5μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-033

Cat. No.: HY-111871

SNIPER(ABL)-033, conjugating HG-7-85-01 (ABL inhibitor) to LCL161 derivative (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 0.3 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-039

Cat. No.: HY-111874

SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 10 nM. IC_{50}s are 0.54 nM, 10 nM, 12 nM, and 50 nM for **ABL**, cIAP1, cIAP2, XIAP, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-044

Cat. No.: HY-111862

SNIPER(ABL)-044, conjugating HG-7-85-01 (ABL inhibitor) to Bestatin (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 10 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-047

Cat. No.: HY-111863

SNIPER(ABL)-047, conjugating HG-7-85-01 (ABL inhibitor) to MV-1 (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 2 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-049

Cat. No.: HY-111851

SNIPER(ABL)-049, conjugating Imatinib (ABL inhibitor) to Bestatin (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 100 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-050

Cat. No.: HY-111858

SNIPER(ABL)-050, conjugating Imatinib (ABL inhibitor) to MV-1 (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-058

Cat. No.: HY-111859

SNIPER(ABL)-058, conjugating Imatinib (ABL inhibitor) to LCL161 derivative (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 10 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vodobatinib

(K0706)

Cat. No.: HY-137460

Vodobatinib (K0706) is a potent, third generation and orally active **Bcr-Abl1 tyrosine kinase** inhibitor with an IC_{50} of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

XL228

Cat. No.: HY-15749

XL228 is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 5, 3.1, 1.6, 6.1, 2 nM for **Bcr-Abl**, **Aurora A**, **IGF-1R**, **Src** and **Lyn**, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMX Kinase

Bmx is a non-receptor tyrosine kinase belonging to the Tec kinase family. The protein contains a PH-like domain, which mediates membrane targeting by binding to phosphatidylinositol 3,4,5-triphosphate (PIP3), and a SH2 domain that binds to tyrosine-phosphorylated proteins and functions in signal transduction. The protein is implicated in several signal transduction pathways including the Stat pathway, and regulates differentiation and tumorigenicity of several types of cancer cells. Bmx is characterized by an N-terminal pleckstrin homology domain and has been shown to be a downstream effector of phosphatidylinositol 3-kinase. P21-activated kinase 1 (Pak1), another well characterized effector of phosphatidylinositol 3-kinase, has been implicated in the progression of breast cancer cells.

BMX Kinase Inhibitors

BMX-IN-1

(BMX kinase inhibitor) **Cat. No.:** HY-80002

BMX-IN-1 is a selective, irreversible inhibitor of **bone marrow tyrosine kinase on chromosome X (BMX)** that targets Cys^{496} in the BMX ATP binding domain with an IC_{50} of 8 nM, also targets the related Bruton's tyrosine kinase **(BTK)** with an IC_{50} value of 10.4 nM, but is more...



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

CHMFL-BMX-078

(CHMFL-BMX 078) **Cat. No.:** HY-101267

CHMFL-BMX-078 is a highly potent and selective type II irreversible **BMX** kinase inhibitor with an IC_{50} of 11 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

CHMFL-EGFR-202

Cat. No.: HY-101522

CHMFL-EGFR-202 is a potent, irreversible inhibitor of **epidermal growth factor receptor (EGFR) mutant kinase**, with IC_{50}s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Poseltinib

(HM71224; LY3337641) **Cat. No.:** HY-109010

Poseltinib, an orally active, selective and irreversible **Bruton's tyrosine kinase (BTK)** inhibitor (IC_{50} =1.95 nM), with 0.3, 2.3 and 2.4-fold selectivity for BTK over BMX, TEC and TXK, respectively.



Purity: 98.01%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Btk

Bruton tyrosine kinase

Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.

Btk plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. Btk is a kinase expressed exclusively in B cells and myeloid cells and has a well characterized, vital role in B cells highlighted by the human primary immune deficiency disease, X-linked agammaglobulinemia (XLA), which results from mutation in the Btk gene. Btk plays an essential role in the BCR signaling pathway. Antigen binding to the BCR results in B cell receptor oligomerization, Syk and Lyn kinase activation, followed by Btk kinase activation. Once activated, Btk forms a signaling complex with proteins such as BLNK, Lyn, and Syk and phosphorylates phospholipase C (PLC)γ2. This leads to downstream release of intracellular Ca^{2+} stores and propagation of the BCR signaling pathway through extracellular signal-regulated kinase and NF-κB signaling, ultimately resulting in transcriptional changes to foster B cell survival, proliferation, and/or differentiation.

Btk Inhibitors

(Rac)-IBT6A

Cat. No.: HY-13036

(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC_{50} of 0.5 nM.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(Rac)-IBT6A hydrochloride

Cat. No.: HY-13036C

(Rac)-IBT6A hydrochloride is a racemate of IBT6A hydrochloride. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC_{50} of 0.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-Sunvozertinib

((S)-DZD9008)

Cat. No.: HY-132842A

(S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against **EGFR** exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC_{50}=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively).



Purity: 99.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(±)-Zanubrutinib

((±)-BGB-3111)

Cat. No.: HY-101474

(±)-Zanubrutinib ((±)-BGB-3111) is a potent, selective and orally available **Bruton's tyrosine kinase (Btk)** inhibitor.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Acalabrutinib

(ACP-196)

Cat. No.: HY-17600

Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation **BTK** inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Acalabrutinib-d4

(ACP-196-d4)

Cat. No.: HY-17600S

Acalabrutinib D4 (ACP-196 D4) is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

ACP-5862

Cat. No.: HY-135334

ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an **IC_{50}** of 5.0 nM for **Bruton tyrosine kinase (BTK)**. ACP5862 is a weak timedependent inactivator of **CYP3A4** and **CYP2C8**.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

ACP-5862-d4

Cat. No.: HY-135334S

ACP-5862-d4 is deuterium labeled ACP-5862. ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Bruton tyrosine kinase (BTK).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

ARQ 531

(MK-1026)

Cat. No.: HY-112215

ARQ 531 (MK-1026) is a reversible non-covalent and orally active inhibitor of Bruton's Tyrosine Kinase (**BTK**), with **IC_{50}s** of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.



Purity: 99.24%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AS-1763

Cat. No.: HY-132877

AS-1763 is a potent, selective, noncovalent, and orally available inhibitor of **Bruton's tyrosine kinase** (IC_{50} = 0.85 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Atuzabrutinib

(SAR 444727; PRN473) Cat. No.: HY-132808

Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of **Btk (Bruton's tyrosine kinase)** inhibitor. Atuzabrutinib inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Avitinib

(Abivertinib; AC0010) Cat. No.: HY-19816

Avitinib (AC0010) is an irreversible, mutant-selective **EGFR** inhibitor that effectively inhibits EGFR T790M resistance mutations in non-small cell lung cancer (NSCLC). Abivertinib is also a novel **BTK** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCPyr

Cat. No.: HY-142621

BCPyr is a new candidate **BTK** degrader (DC_{50} = 800 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BIIB068

Cat. No.: HY-131342

BIIB068 is a potent, selective, reversible and orally active **BTK** inhibitor with an IC_{50} of 1 nM and a K_d of 0.3 nM. BIIB068 shows more >400-fold selective for **BTK** than other kinases. BIIB068 has the potential for autoimmune diseases research.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BIIB091

Cat. No.: HY-139984

BIIB091 is a highly selective, reversible **BTK** inhibitor for treating autoimmune diseases.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BLK-IN-1

Cat. No.: HY-144283

BLK-IN-1 (compound 1) is a selective and covalent inhibitor of **B-Lymphoid tyrosine kinase (BLK)** and **BTK**, with IC_{50}s of 18.8 nM and 20.5 nM, respectively. BLK-IN-1 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BLK-IN-2

Cat. No.: HY-144288

BLK-IN-2 (compound 25) is a potent and selective irreversible inhibitor of **B-Lymphoid tyrosine kinase (BLK)**, with an IC_{50} of 5.9 nM. BLK-IN-2 also inhibits **BTK** (IC_{50}=202.0 nM). BLK-IN-2 shows potent antiproliferative activities against several lymphoma cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-935177

Cat. No.: HY-101793

BMS-935177 is a potent and selective reversible inhibitor of Bruton's tyrosine kinase (**Btk**) with an IC_{50} of 3 nM.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-986142

Cat. No.: HY-101856

BMS-986142 is a potent and highly selective reversible inhibitor of **Bruton's tyrosine kinase** (**BTK**) with an IC_{50} of 0.5 nM.



Purity: 99.53%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-986143

Cat. No.: HY-145373

BMS-986143 is an orally active, reversible **BTK** inhibitor with an IC_{50} of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1, ITK with IC_{50}s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM,19 nM, 21 nM, respectively. BMS-986143 can be used for the research of autoimmune diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMX-IN-1

(BMX kinase inhibitor) Cat. No.: HY-80002

BMX-IN-1 is a selective, irreversible inhibitor of **bone marrow tyrosine kinase on chromosome X (BMX)** that targets Cys^{496} in the BMX ATP binding domain with an IC_{50} of 8 nM, also targets the related Bruton's tyrosine kinase **(BTK)** with an IC_{50} value of 10.4 nM, but is more...



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Branebrutinib

(BMS-986195) Cat. No.: HY-112161

Branebrutinib (BMS-986195) is a highly potent, selective covalent, irreversible inhibitor of Bruton's tyrosine kinase **(BTK)**, with an IC_{50} of 0.1 nM.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

BTK IN-1

(SNS062 analog) Cat. No.: HY-101941

BTK IN-1 (SNS062 analog) is a potent **BTK** inhibitor, with an IC_{50} of <100 nM.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BTK inhibitor 10

Cat. No.: HY-125997

BTK inhibitor 10 is a potent and orally active **Bruton kinase (BTK)** inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK inhibitor 13

Cat. No.: HY-130255

BTK inhibitor 13 (compound 8) is a potent and selective **Bruton's tyrosine kinase (BTK)** inhibitor with an IC_{50} of 1.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK inhibitor 17

Cat. No.: HY-131705

BTK inhibitor 17 is a potent and orally active irreversible **BTK** inhibitor with an IC_{50} of 2.1 nM. BTK inhibitor 17 can be used for rheumatoid arthritis research.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BTK inhibitor 18

Cat. No.: HY-132196

BTK inhibitor 18 is a potent, selective,orally active and covalent **Btk** inhibitor with a IC_{50} of 142 nM. BTK inhibitor 18 has anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BTK inhibitor 19

Cat. No.: HY-139881

BTK inhibitor 19 is a highly selective, covalent **BTK** inhibitor (IC_{50} = 2.7 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Btk inhibitor 2

(BGB-3111 analog) Cat. No.: HY-101766

Btk inhibitor 2 (BGB-3111 analog) is a **Bruton's tyrosine kinase** (**BTK**) inhibitor extracted from patent US 20170224688 A1.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BTK inhibitor 20

Cat. No.: HY-143730

BTK inhibitor 20 is a potent **BTK** inhibitor with an IC_{50} of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK-IN-10

Cat. No.: HY-147580

BTK-IN-10 is a potent **BTK** inhibitor with IC_{50}s of <5 nM for wild-type BTK or mutated BTK (C481S), respectively (WO2022012509A1; example 111).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK-IN-11

Cat. No.: HY-147581

BTK-IN-11 is a potent inhibitor of **BTK**. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK-IN-12

Cat. No.: HY-147582

BTK-IN-12 is a potent **BTK** inhibitor with IC_{50}s of 1.2 nM and 0.8 nM for wild-type BTK or mutated BTK (C481S), respectively (WO2022037649A1; compound 8).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK-IN-14

Cat. No.: HY-147584

BTK-IN-14 is a potent inhibitor of **BTK**. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK-IN-5

Cat. No.: HY-115876

BTK-IN-5 is a covalent **BTK** inhibitor for treating medical conditions such as cardiovascular diseases, respiratory diseases, inflammation, and diabetes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK-IN-6

Cat. No.: HY-142932

BTK-IN-6 is a potent inhibitor of Bruton's Tyrosine Kinase (**BTK**). BTK is a member of the Tec family of tyrosine kinases and plays an important role in the regulation of early B-cell development and mature B-cell activation and survival.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK-IN-7

Cat. No.: HY-143900

BTK-IN-7 is a potent and selective inhibitor of **BTK** (IC_{50}=4.0 nM). BTK-IN-7 has high selectivity in both enzymatic (**ITK** >250-fold, **EGFR** >2500-fold) and cellular levels(**ITK** >227-fold, **EGFR** 27-fold). BTK-IN-7 also has potent antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK-IN-8

Cat. No.: HY-145884

BTK-IN-8 is a potent selective peripheral covalent **BTK** inhibitor (IC_{50}=0.22 nM; K_d=0.91 nM). BTK-IN-8 has good whole blood CD69 cellular potency (IC_{50}=0.029 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK-IN-9

Cat. No.: HY-115944

BTK-IN-9 is a reversible **BTK** inhibitors with potent antiproliferative activity in mantle cell lymphoma. BTK-IN-9 specifically disturbs mitochondrial membrane potential and increases reactive oxygen species level in Z138 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CGI-1746

Cat. No.: HY-11999

CGI-1746 is a potent and highly selective inhibitor of the **Btk** with IC_{50} of 1.9 nM.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CHMFL-BTK-01

Cat. No.: HY-101521

CHMFL-BTK-01 (compound 9) is a highly selective irreversible **BTK** inhibitor, with an IC_{50} of 7 nM. CHMFL-BTK-01 (compound 9) potently inhibited BTK Y223 auto-phosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CHMFL-EGFR-202

Cat. No.: HY-101522

CHMFL-EGFR-202 is a potent, irreversible inhibitor of **epidermal growth factor receptor (EGFR) mutant kinase**, with IC_{50}s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CNX-500

Cat. No.: HY-100338

CNX-500 is a probe consisting of a covalent **Btk** inhibitor (CC-292) chemically linked to biotin. CNX-500 retains inhibitory activity against **Btk** (IC_{50} of 0.5 nM) and the ability to form a covalent bond with **Btk**.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

CNX-774

Cat. No.: HY-13943

CNX-774 is an orally active, irreversible and selective **BTK** inhibitor, with an IC_{50} of < 1 nM. CNX-774 specifically targets Cysteine 481 of Btk for covalent modification.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CTA056

Cat. No.: HY-110113

CTA056 is an **ITK** (IL-2-inducible T-cell kinase) inhibitor with an IC_{50} of 0.1 μM. CTA056 selectively targets malignant T cells and modulates oncomirs. CTA056 induces apoptosis and is a potential therapeutic agent for the treatment of T-cell leukemia and lymphoma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dihydrodiol-Ibrutinib

(PCI-45227)

Cat. No.: HY-100659

Dihydrodiol-Ibrutinib (PCI-45227) is a dihydrodiol active **metabolite** of Ibrutinib (HY-10997), has inhibitory activity towards **BTK** approximately 15 times lower than that of ibrutinib.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg

Edralbrutinib

(TG-1701)

Cat. No.: HY-137438

Edralbrutinib (TG-1701) is a potent **BTK** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-40

Cat. No.: HY-143901

EGFR-IN-40 (compound 3z) is a potent **BTK**, **EGFR**, and **ITK** inhibitor with IC_{50} values of 1.2 nM, 5.3 nM, and 46.1 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Elsubrutinib

(ABBV-105)

Cat. No.: HY-109143

Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (**BTK**) inhibitorThe IC_{50} of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fenebrutinib

(GDC-0853)

Cat. No.: HY-19834

Fenebrutinib (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (**Btk**) inhibitor with K_is of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk, and the C481S, C481R, T474I, T474M mutants.



Purity: 99.83%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

G-744

Cat. No.: HY-102036

G-744 is a highly potent, selective and orally active **Btk** inhibitor with an IC_{50} of 2 nM. G-744 is metabolically stable, well tolerated and efficacious to treat arthritis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GDC-0834

Cat. No.: HY-15427

GDC-0834 is a potent and selective **BTK** inhibitor. GDC-0834 inhibits BTK with an in vitro IC_{50} of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC_{50} of 1.1 and 5.6 μM in mouse and rat, respectively.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GDC-0834 Racemate

Cat. No.: HY-15427A

GDC-0834 Racemate is the racemate form of GDC-0834, which is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GDC-0834 S-enantiomer

Cat. No.: HY-15427B

GDC-0834 (S-enantiomer) is the S-enantiomer of GDC-0834. GDC-0834 is a potent and selective BTK inhibitor.



Purity: 95.11%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg

HZ-A-005

Cat. No.: HY-147784

HZ-A-005 is a potent, selective, and covalent Bruton's tyrosine kinase (**BTK**) inhibitor. HZ-A-005 markedly decreases tumor growth in xenograft mouse models.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ibrutinib

(PCI-32765)

Cat. No.: HY-10997

Ibrutinib (PCI-32765) is a selective, irreversible **Btk** inhibitor with an IC_{50} of 0.5 nM.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Ibrutinib deacryloylpiperidine

(IBT4A)

Cat. No.: HY-78727

Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC_{50} of 0.5 nM.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Ibrutinib dimer

Cat. No.: HY-136113

Ibrutinib dimer is a Dimer of Ibrutinib. Ibrutinib dimer is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC_{50} of 0.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ibrutinib Racemate

(PCI-32765 Racemate)

Cat. No.: HY-10997A

Ibrutinib Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversible **Btk** inhibitor with IC_{50} value of 0.5 nM.



Purity: 95.13%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ibrutinib-biotin

Cat. No.: HY-100342

Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker, extracted from patent WO2014059368A1 Compound 1-5, has an IC_{50} of 0.755-1.02 nM for **BTK**.



Purity: 99.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ibrutinib-d5

(PCI-32765-d5)

Cat. No.: HY-10997S

Ibrutinib D5 (PCI-32765 D5) is a deuterium labeled Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IBT6A

Cat. No.: HY-13036A

IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC_{50} of 0.5 nM.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

IBT6A hydrochloride

Cat. No.: HY-13036B

IBT6A hydrochloride is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC_{50} of 0.5 nM.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JAK3/BTK-IN-1

Cat. No.: HY-143716

JAK3/BTK-IN-1 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-2

Cat. No.: HY-143717

JAK3/BTK-IN-2 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-3

Cat. No.: HY-143718

JAK3/BTK-IN-3 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-4

Cat. No.: HY-143719

JAK3/BTK-IN-4 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-5

Cat. No.: HY-143720

JAK3/BTK-IN-5 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LFM-A13

Cat. No.: HY-18009

LFM-A13 is a potent **BTK**, **JAK2**, **PLK** inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with **IC_{50}**s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Luxeptinib

(CG-806)

Cat. No.: HY-139535

Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent **pan-FLT3/pan-BTK** inhibitor. Luxeptinib induces cell cycle arrest, **apoptosis** or **autophagy** in acute myeloid leukemia cells.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MT-802

Cat. No.: HY-122562

MT-802 is a potent **BTK** degrader based on **Cereblon** ligand, with a DC_{50} of 1 nM. MT-802 has potential to treat C481S mutant chronic lymphocytic leukemia (CLL).

Purity: 98.55%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

N-piperidine Ibrutinib hydrochloride

Cat. No.: HY-130983

N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent **BTK** inhibitor with IC_{50}s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively.



Purity: 95.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ONO-4059 analog

Cat. No.: HY-18951

ONO-4059 analog is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Orelabrutinib

(ICP-022)

Cat. No.: HY-129390

Orelabrutinib (ICP-022) is a potent, orally active, and irreversible **Bruton's tyrosine kinase (BTK)** inhibitor with potential antineoplastic activity.



Purity: 99.90%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PCI 29732

Cat. No.: HY-18010

PCI 29732 is a potent, orally active, reversible BTK inhibitor with K_i^{app} values of 8.2, 4.6, and 2.5 nM for BTK, Lck and Lyn, respectively. PCI 29732 shows only modest inhibitory activity against Itk, another Tec family kinase.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PCI-33380

Cat. No.: HY-100335

PCI-33380 is an irreversible and selective Bruton's Tyrosine Kinase **(BTK)** inhibitor (fluorescent probe).



Purity: 95.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

PF-06250112

Cat. No.: HY-117900

PF-06250112 is a potent, highly selective, orally bioavailable **BTK** inhibitor with an IC_{50} of 0.5 nM, shows inhibitory effect toward **BMX nonreceptor tyrosine kinase** and **TEC** with IC_{50}s of 0.9 nM and 1.2 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pirtobrutinib

(LOXO-305)

Cat. No.: HY-131328

Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation **BTK** inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models.



Purity: 99.88%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Poseltinib

(HM71224; LY3337641)

Cat. No.: HY-109010

Poseltinib, an orally active, selective and irreversible **Bruton's tyrosine kinase (BTK)** inhibitor (IC_{50} =1.95 nM), with 0.3, 2.3 and 2.4-fold selectivity for BTK over BMX, TEC and TXK, respectively.



Purity: 98.01%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

QL-X-138

Cat. No.: HY-124645

QL-X-138 is a potent and selective **BTK/MNK dual kinase** inhibitor, exhibits covalent binding to BTK and non-covalent binding to MNK. QL-X-138 shows IC_{50}s of 9.4 nM, 107.4 nM and 26 nM for BTK, MNK1 and MNK2 kinases respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

QL47

Cat. No.: HY-80003

QL47, a broad-spectrum **antiviral** agent, inhibits dengue virus and other RNA viruses. QL47 selectively inhibits eukaryotic translation. QL47 is a potent covalent inhibitor of **BTK** with an IC_{50} of 7 nM.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Remibrutinib

Cat. No.: HY-128757

Remibrutinib, is a potent and orally active **bruton tyrosine kinase (BTK)** inhibitor with an IC_{50} value of 1 nM. Remibrutinib inhibits BTK activity with an IC_{50} value of 0.023 μM in blood. Remibrutinib has the potential for Chronic urticaria (CU) treatment.



Purity: 98.90%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RET-IN-14

Cat. No.: HY-144170

RET-IN-14 (compound 49) is a potent **RET** inhibitor with IC_{50}s of <0.51 nM, 9.3 nM, 1.3 nM, 9.2 nM, 15 nM for RET (WT), RET (G810R), RET (V804M), BTK and BTK (C481S), respectively. RET-IN-14 has the potential for tumors research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rilzabrutinib

(PRN1008)

Cat. No.: HY-112166

Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton's Tyrosine Kinase **(BTK)**, with an IC_{50} of 1.3 nM.



Purity: 98.22%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RN486

Cat. No.: HY-18018

RN486 is a potent, selective and orally active **Btk** inhibitor with an IC_{50} of 4.0 nM and a K_d of 0.31 nM. RN486 is less active for other kinases. RN486 can be used for rheumatoid arthritis and systemic lupus erythematosus research.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

SJF620

Cat. No.: HY-133137

SJF620 is a PROTAC connected by ligands for **Cereblon** and **Btk** with a DC_{50} of 7.9 nM. SJF620 contains a Lenalidomide analog for recruiting CRBN.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

SJF620 hydrochloride

Cat. No.: HY-133137A

SJF620 hydrochloride is a PROTAC connected by ligands for **Cereblon** and **Btk** with a DC_{50} of 7.9 nM. SJF620 contains a Lenalidomide analog for recruiting CRBN.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Spebrutinib

(AVL-292; CC-292)

Cat. No.: HY-18012

Spebrutinib (AVL-292; CC-292) is a covalent, orally active, and highly selective with an IC_{50} of 0.5 nM.



Purity: 99.62%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Spebrutinib besylate

(AVL-292 benzenesulfonate; CC-292 besylate)

Cat. No.: HY-18012A

Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a potent inhibitor of **Btk** kinase activity (IC_{50}<0.5 nM, K_{inact}/K_I=7.69×10^4 M^{-1}s^{-1}) in biochemical assays.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Sunvozertinib

(DZD9008)

Cat. No.: HY-132842

Sunvozertinib (DZD9008) is a potent **ErbBs** (EGFR, Her2, especially mutant forms) and **BTK** inhibitor.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAK-020

Cat. No.: HY-132879

TAK-020 is a covalent **Btk** inhibitor, which becomes the clinical candidate.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Terreic acid

Cat. No.: HY-110013

Terreic acid, a quinone epoxide **antibiotic**, acts as an effective **Btk** inhibitor. Terreic acid blocks the interaction between PKC and the pleckstrin homology domain of Btk.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tirabrutinib

(ONO-4059; GS-4059)

Cat. No.: HY-15771

Tirabrutinib (ONO-4059) is a selective and novel inhibitor of BTK with IC_{50} 2.2 nM, Tirabrutinib binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.



Purity: 99.65%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tirabrutinib hydrochloride

(ONO-4059 hydrochloride; GS-4059 hydrochloride)

Cat. No.: HY-15771A

Tirabrutinib (ONO-4059) hydrochloride is a selective and novel inhibitor of BTK with IC_{50} 2.2 nM, Tirabrutinib binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TL-895

Cat. No.: HY-139481

TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible **BTK** inhibitor with an IC_{50} and a K_i of 1.5 nM and 11.9 nM, respectively. TL-895 is used be for JAKi-relapsed/refractory myelofibrosis, acute myeloid leukemia, COVID-19 and cancer research.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tolebrutinib

(SAR442168; PRN2246)

Cat. No.: HY-109192

Tolebrutinib (SAR442168) is a potent, selective, orally active and brain-penetrant inhibitor of **Bruton tyrosine kinase (BTK)**, with IC_{50}s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively.



Purity: 98.96%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Vecabrutinib

(SNS-062)

Cat. No.: HY-109078

Vecabrutinib (SNS-062) is a potent, noncovalent **BTK** and **ITK** inhibitor, with K_d values of 0.3 nM and 2.2 nM, respectively. Vecabrutinib shows an IC_{50} of 24 nM for **ITK**.



Purity: 99.85%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

XMU-MP-3

Cat. No.: HY-136531

XMU-MP-3 is a potent non-covalent **BTK** inhibitor with IC_{50}s of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation in the presence of 10 μM ATP, respectively. XMU-MP-3 also induces **apoptosis**.



Purity: 98.27%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Zanubrutinib

(BGB-3111)

Cat. No.: HY-101474A

Zanubrutinib (BGB-3111) is a selective **Bruton tyrosine kinase** (**Btk**) inhibitor.



Purity: 99.18%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Zanubrutinib D5

(BGB-3111 D5)

Cat. No.: HY-101474S

Zanubrutinib D5 (BGB-3111 D5) is deuterium labeled Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (Btk) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-Fms

CSF-1 receptor; colony stimulating factor 1 receptor; CSF-1R; CSF1R

c-FMS (CSF1R, CSF-1R) is a receptor protein-tyrosine kinase of the platelet-derived growth factor receptor (PDGFR) family. c-FMS is the cell surface receptor for IL-34 and CSF1. c-FMS has important roles in haematopoiesis, regulation of proliferation, cell survival and maturation of microglia and monocytes, as well as in controlling the overall immune response.

c-FMS is specifically expressed in osteoclasts and myelomonocytic-lineage cells, such as monocytes and macrophages, and the activation of c-FMS signaling promotes the proliferation or differentiation of these cells. It also promotes the production of inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL6).

c-Fms Inhibitors

AZD7507

Cat. No.: HY-117244

AZD7507 is a potent and orally active **CSF-1R** inhibitor, with antitumor activity.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BPR1R024

Cat. No.: HY-132935

BPR1R024 is an orally active and selective **CSF1R** inhibitor (IC_{50} = 0.53 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-Fms-IN-1

Cat. No.: HY-18791

c-Fms-IN-1 is a **FMS kinase** inhibitor with an IC_{50} of 0.0008 μM.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

c-Fms-IN-10

Cat. No.: HY-126297

c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase inhibitor of **FMS** (Colony stimulating factor-1 receptor, CSF-1R) with IC_{50} of 2 nM. c-Fms-IN-10 has anti-tumor activity.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

c-Fms-IN-2

Cat. No.: HY-18787

c-Fms-IN-2 is a **FMS kinase** inhibitor with an IC_{50} of 0.024 μM.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

c-Fms-IN-3

Cat. No.: HY-13075

c-Fms-IN-3 is a novel c-Fms kinase inhibitor with a potential as anti-inflammatory agent and antirheumatic agent.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

c-Fms-IN-6

Cat. No.: HY-111947

c-Fms-IN-6 is a potent inhibitor of **c-FMS**, with an IC_{50} of ≤10 nM for unphosphorylated c-FMS, also weakly inhibits unphosphorylated c-KIT and PDGFR (IC_{50} > 1 μM). Used in the research of autoimmune diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-Fms-IN-7

Cat. No.: HY-111948

c-Fms-IN-7 is a **cFMS** inhibitor extracted from patent WO2011079076A1, example159, has an IC_{50} of 18.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-Fms-IN-8

Cat. No.: HY-119942

c-Fms-IN-8 (compound 4a) is a **colony stimulating factor-1 receptor (CSF-1R, c-FMS)** Type II inhibitor, with an IC_{50} of 9.1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

c-Fms-IN-9

Cat. No.: HY-128680

c-Fms-IN-9 is a **c-FMS** inhibitor extracted from patent WO2014145023A1, Compound Example 7. c-Fms-IN-9 inhibits unphosphorylated c-FMS kinase (**uFMS**) and **uKIT** with IC_{50}s of <0.01 μM and 0.1-1 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

cFMS Receptor Inhibitor II

Cat. No.: HY-112451

cFMS Receptor Inhibitor II is a **CSF1R** kinase inhibitor. CSF-1 is a cytokine.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Chiauranib

(CS2164)

Cat. No.: HY-124526

Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CSF1R-IN-1

Cat. No.: HY-101774

CSF1R-IN-1 is a **CSF1R** inhibitor with an with an IC_{50} of 0.5 nM.



Purity: 98.75%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CSF1R-IN-2

Cat. No.: HY-111787

CSF1R-IN-2 (compound 5) is an oral-active inhibitor of **SRC**, **MET** and **c-FMS**, with IC_{50} values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CSF1R-IN-3

Cat. No.: HY-139990

CSF1R-IN-3 (compound 21) is a potent and orally active **CSF-1R** inhibitor (IC_{50}=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CSF1R-IN-4

Cat. No.: HY-144040

CSF1R-IN-4 is a potent inhibitor of **CSF1R**. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-4 affects the exchange of inflammatory factors between TAMs and glioma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CSF1R-IN-5

Cat. No.: HY-144041

CSF1R-IN-5 is a potent inhibitor of **CSF1R**. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-5 affects the exchange of inflammatory factors between TAMs and glioma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dovitinib

(CHIR-258; TKI258)

Cat. No.: HY-50905

Dovitinib (CHIR-258) is an orally active, potent **multi-targeted tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **CSF-1R**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Edicotinib

(JNJ-40346527; JNJ-527)

Cat. No.: HY-109086

Edicotinib (JNJ-40346527) is a potent, selective, brain penetrant and orally active **colony-stimulating factor-1 receptor (CSF-1R)** inhibitor with an IC_{50} of 3.2 nM.



Purity: 99.56%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GENZ-882706

(RA03546849)

Cat. No.: HY-101526

GENZ-882706 is a potent colony stimulating factor-1 receptor (**CSF-1R**) Inhibitor extracted from patent WO 2017015267A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GENZ-882706(Raceme)

(GENZ-882706 racemate)

Cat. No.: HY-101526R

GENZ-882706(Raceme) is the racemate of GENZ-882706.



Purity: 98.79%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GW2580

Cat. No.: HY-10917

GW2580 is an orally bioavailable and selective inhibitor of **c-Fms kinase** which completely inhibits human cFMS kinase in vitro at 0.06 μM. GW2580 acts as a competitive inhibitor of ATP binding to the cFMS kinase and inhibits colony-stimulating-factor-1 signaling.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

GW2580-d6

Cat. No.: HY-10917S

GW2580-d6 is the deuterium labeled GW2580. GW2580 is an orally bioavailable and selective inhibitor of **c-Fms kinase** which completely inhibits human cFMS kinase in vitro at 0.06 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IHMT-TRK-284

Cat. No.: HY-146697

IHMT-TRK-284 (Compound 34) is a potent, orally active **type II TRK kinase** inhibitor with IC_{50} values of 10.5, 0.7, and 2.6 nM to **TRKA, B**, and **C** respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JTE-952

Cat. No.: HY-122906

JTE-952 is a potent, oral active and selective Type II inhibitor of **colony stimulating factor-1 receptor** (**CSF-1R or cFMS**, type III receptor tyrosine kinase), with IC_{50} values of 13 nM and 261 nM for CSF1R and TrkA , respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Ki20227

Cat. No.: HY-10408

Ki20227 is an orally active and highly selective **c-Fms tyrosine kinase (CSF1R)** inhibitor with IC_{50}s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, **VEGFR2** (vascular endothelial growth factor receptor-2), **c-Kit** (stem cell factor receptor) and **PDGFRβ** (platelet-derived growth factor...



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Linifanib

(ABT-869; AL-39324)

Cat. No.: HY-50751

Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of **VEGFR** and **PDGFR** family with IC_{50}s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity.



Purity: 99.72%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

OSI-930

Cat. No.: HY-10204

OSI-930 is an orally selective inhibitor of **Kit**, **KDR** and **CSF-1R (c-Fms)** with IC_{50}s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits **Flt-1**, **c-Raf**, **Lck** and low activity against **PDGFRα/β**, **Flt-3** and **Abl**. OSI-930 has antitumor activity.



Purity: 98.13%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pazopanib Hydrochloride

(GW786034 (Hydrochloride))

Cat. No.: HY-12009

Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with an IC_{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pexidartinib

(PLX-3397)

Cat. No.: HY-16749

Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive **colony stimulating factor 1 receptor (CSF1R or M-CSFR)** and **c-Kit** inhibitor, with IC_{50}s of 20 and 10 nM, respectively.



Purity: 99.64%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Pexidartinib hydrochloride

(PLX-3397 hydrochloride) Cat. No.: HY-16749A

Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive **colony stimulating factor 1 receptor (CSF1R or M-CSFR)** and **c-Kit** inhibitor, with IC_{50}s of 20 and 10 nM, respectively.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 200 mg, 500 mg, 1 g

PF 477736

(PF 00477736) Cat. No.: HY-10032

PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of **Chk1**, with a K_i of 0.49 nM, it is also a **Chk2** inhibitor, with a K_i of 47 nM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PLX5622

Cat. No.: HY-114153

PLX5622 is a highly selective brain penetrant and orally active **CSF1R** inhibitor (IC_{50}=0.016 μM; K_i=5.9 nM). PLX5622 allows for extended and specific microglial elimination, preceding and during pathology development. PLX5622 demonstrates desirable PK properties in varies animals.



Purity: 99.95%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PLX5622 hemifumarate

Cat. No.: HY-114153A

PLX5622 hemifumarate is a highly selective brain penetrant and orally active **CSF1R** inhibitor (IC_{50}=0.016 μM; K_i=5.9 nM). PLX5622 hemifumarate allows for extended and specific microglial elimination, preceding and during pathology development.



Purity: 99.64%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PLX647

Cat. No.: HY-13838

PLX647 is an orally active, highly specific dual **FMS** and **KIT** kinase inhibitor, with IC_{50}s of 28 and 16 nM, respectively. PLX647 shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR (IC_{50}s=91 and 130 nM, respectively).



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PLX647 dihydrochloride

Cat. No.: HY-13838A

PLX647 dihydrochloride is an orally active, highly specific dual **FMS** and **KIT** kinase inhibitor, with IC_{50}s of 28 and 16 nM, reapectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PRN1371

Cat. No.: HY-101768

PRN1371 is a highly selective and potent **FGFR1-4** and **CSF1R** inhibitor with IC_{50}s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively.



Purity: 99.72%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Sotuletinib

(BLZ945) Cat. No.: HY-12768

Sotuletinib (BLZ945) is a potent, selective and brain-penetrant **CSF-1R (c-Fms)** inhibitor with an IC_{50} of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs.



Purity: 99.78%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vimseltinib

(DCC-3014) Cat. No.: HY-136256

Vimseltinib (DCC-3014) is a **c-FMS** (**CSF-IR**) and **c-Kit** dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC_{50}s of <0.01 μM and 0.1-1 μM, respectively.



Purity: 99.08%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

c-Kit

SCFR; CD117

c-Kit (Mast/stem cell growth factor receptor, SCFR or CD117) is a proteinthat in humans is encoded by the KIT gene. c-Kit (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. c-Kit is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. c-Kit is a receptor tyrosine kinase type III, which binds to stem cell factor. When c-Kit binds to stem cell factor (SCF) it forms adimer that activates its intrinsic tyrosine kinase activity, that in turn phosphorylates and activates signal transduction molecules that propagate the signal in the cell. Signalling through c-Kit plays a role in cell survival, proliferation, and differentiation.

c-Kit Inhibitors

AC710

Cat. No.: HY-13493

AC710 is a potent **PDGFR** inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amuvatinib

(MP470; HPK 56)

Cat. No.: HY-10206

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: 98.07%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amuvatinib hydrochloride

(MP470 hydrochloride; HPK 56 hydrochloride)

Cat. No.: HY-10206A

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

AST 487

(NVP-AST 487)

Cat. No.: HY-15002

AST 487 is a **RET** kinase inhibitor with IC_{50} of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits **Flt-3** with IC_{50} of 520 nM.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Avapritinib

(BLU-285)

Cat. No.: HY-101561

Avapritinib (BLU-285) is a highly potent, selective, and orally active **KIT** and **PDGFRA** activation loop mutant kinases inhibitor with IC_{50}s of 0.27 and 0.24 nM for **KIT D816V** and **PDGFRA D842V**, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD2932

Cat. No.: HY-18179

AZD2932 is a potent and multi-targeted kinase inhibitor **VEGFR2**, **PDGFβ**, **Flt-3** and **c-Kit** with IC_{50}s of 8, 4, 7 and 9 nM in cell assay, respectively.



Purity: 96.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD3229

Cat. No.: HY-112802

AZD3229 is a potent pan-**KIT** mutant inhibitor for the treatment of gastrointestinal stromal tumors.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD3229 Tosylate

Cat. No.: HY-112802A

AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bezuclastinib

(CGT9486; PLX 9486)

Cat. No.: HY-145557

Bezuclastinib (CGT9486; PLX 9486) is a potent inhibitor of **c-kit** and **c-kit D816V** ($0.0001<IC_{50}<1$ μM; extracted from patent WO2014100620 A2, compound P-2007). Bezuclastinib is a tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

c-Kit-IN-1

Cat. No.: HY-15240

c-Kit-IN-1 is a potent inhibitor of **c-Kit** and **c-Met** with IC_{50}s of <200 nM.



Purity: 98.72%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

c-Kit-IN-2

Cat. No.: HY-128602

c-Kit-IN-2 is a **c-KIT** inhibitor with an IC_{50} of 82 nM, shows superior antiproliferative activities against all the three GIST cell lines, GIST882, GIST430, and GIST48, with GI_{50}s of 3, 1, and 2 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-Kit-IN-5-1

Cat. No.: HY-18302

c-Kit-IN-5 is potent inhibitor of **c-Kit**, with IC_{50}s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cabozantinib

(XL184; BMS-907351)

Cat. No.: HY-13016

Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Cabozantinib-d4

(XL184-d4; BMS-907351-d4)

Cat. No.: HY-13016S1

Cabozantinib-d4 is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cabozantinib-d6

Cat. No.: HY-13016S

Cabozantinib-d6 (XL184-d6) is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Chiauranib

(CS2164)

Cat. No.: HY-124526

Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CHMFL-ABL/KIT-155

(CHMFL-ABL-KIT-155)

Cat. No.: HY-101034

CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active **type II ABL/c-KIT** dual kinase inhibitor (IC_{50}s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC_{50}=81 nM), CSF1R (IC_{50}=227 nM), DDR1 (IC_{50}=116 nM),...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CHMFL-KIT-033

Cat. No.: HY-128589

CHMFL-KIT-033 is a potent and selective inhibitor of **c-KIT T670I mutant** for gastrointestinal stromal tumors (GISTs), with an IC_{50} of 0.045 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dovitinib

(CHIR-258; TKI258)

Cat. No.: HY-50905

Dovitinib (CHIR-258) is an orally active, potent **multi-targeted tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **CSF-1R**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Dovitinib lactate

(CHIR-258 lactate; TKI-258 lactate)

Cat. No.: HY-10207

Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: 99.62%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dovitinib lactate hydrate

(TKI258 lactate hydrate; CHIR-258 lactate hydrate) Cat. No.: HY-B0062

Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dovitinib-D8

Cat. No.: HY-50905S

Dovitinib-D8 (CHIR-258-D8) is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Flumatinib

(HHGV678) Cat. No.: HY-13904

Flumatinib (HHGV678) is an orally available, selective inhibitor of **Bcr-Abl**. Flumatinib inhibits **c-Abl**, **PDGFRβ** and **c-Kit** with IC_{50}s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Flumatinib mesylate

(HHGV678 mesylate) Cat. No.: HY-13905

Flumatinib (HHGV678) mesylate is an orally active and selective inhibitor of **Bcr-Abl**. Flumatinib mesylate inhibits c-Abl, PDGFRβ and c-Kit with IC_{50} values of 1.2, 307.6 and 665.5 nM, respectively.



Purity: 99.97%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 500 mg

Flumatinib-d3

(HHGV678-d3) Cat. No.: HY-13904S

Flumatinib-d3 is deuterium labeled Flumatinib. Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HG-7-85-01

Cat. No.: HY-15814

HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of **Bcr-Abl**, **PDGFRα**, **Kit**, and **Src kinases**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IHMT-TRK-284

Cat. No.: HY-146697

IHMT-TRK-284 (Compound 34) is a potent, orally active **type II TRK kinase** inhibitor with IC_{50} values of 10.5, 0.7, and 2.6 nM to **TRKA**, **B**, and **C** respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imatinib

(STI571; CGP-57148B) Cat. No.: HY-15463

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits **BCR/ABL**, **v-Abl**, **PDGFR** and **c-kit** kinase activity.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

Imatinib D4

(STI571 D4; CGP-57148B D4) Cat. No.: HY-15463S1

Imatinib D4 (STI571 D4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imatinib Mesylate

(STI571 Mesylate; CGP-57148B Mesylate) Cat. No.: HY-50946

Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits **c-Kit**, **Bcr-Abl**, and **PDGFR** (IC_{50}=100 nM) tyrosine kinases.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

Imatinib-d8

(STI571-d8; CGP-57148B-d8) Cat. No.: HY-15463S

Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

ISCK03

Cat. No.: HY-101443

ISCK03 is a specific **SCF/c-Kit** inhibitor.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JNJ-38158471

Cat. No.: HY-18317

JNJ-38158471 is a well tolerated, orally available, highly selective **VEGFR-2** inhibitor, with an IC_{50} of 40 nM. JNJ-38158471 also inhibits **Ret** and **Kit** with IC_{50}s of 180 and 500 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KG5

Cat. No.: HY-15198

KG5 is an orally active dual **PDGFRβ** and **B-Raf** allosteric inhibitor. KG5 also inhibits **Flt3**, **KIT** and **c-Raf**. KG5 has anticancer, antiangiogenic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ki20227

Cat. No.: HY-10408

Ki20227 is an orally active and highly selective **c-Fms tyrosine kinase (CSF1R)** inhibitor with IC_{50}s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, **VEGFR2** (vascular endothelial growth factor receptor-2), **c-Kit** (stem cell factor receptor) and **PDGFRβ** (platelet-derived growth factor...



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Lenvatinib

(E7080) Cat. No.: HY-10981

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib mesylate

(E7080 mesylate) Cat. No.: HY-10981A

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib-d4

(E7080-d4) Cat. No.: HY-10981S

Lenvatinib-d4 (E7080-d4) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lenvatinib-d5

(E7080-d5) Cat. No.: HY-10981S1

Lenvatinib-d5 (E7080-d5) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Linifanib

(ABT-869; AL-39324) Cat. No.: HY-50751

Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of **VEGFR** and **PDGFR** family with IC_{50}s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity.



Purity: 99.72%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

M4205

Cat. No.: HY-132166

M4205 is a **c-KIT** inhibitor, with an IC_{50} of 10 nM for c-KIT V654A. M4205 has high activity on c-KIT mutations in exon 11, 13, 17.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Masitinib

(AB1010) Cat. No.: HY-10209

Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Masitinib mesylate

(AB-1010 mesylate) Cat. No.: HY-10209A

Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Midostaurin

(PKC412; CGP 41251) Cat. No.: HY-10230

Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits **PKCα/β/γ**, **Syk**, **Flk-1**, **Akt**, **PKA**, **c-Kit**, **c-Fgr**, **c-Src**, **FLT3**, **PDFRβ** and **VEGFR1/2** with IC_{50}s ranging from 22-500 nM.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Motesanib

(AMG 706) Cat. No.: HY-10228

Motesanib (AMG 706) is a potent ATP-competitive inhibitor of **VEGFR1/2/3** with IC_{50}< /b>s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret..



Purity: 99.99%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Motesanib Diphosphate

(AMG 706 Diphosphate) Cat. No.: HY-10229

Motesanib Diphosphate (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of **VEGFR1/2/3** with IC_{50}s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret.



Purity: 99.85%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Multi-kinase inhibitor 1

Cat. No.: HY-103032

Multi-kinase inhibitor 1 is a potent **multi-kinase** inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of **PDGF-R**, **c-Kit** and **Bcr-abl**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OSI-930

Cat. No.: HY-10204

OSI-930 is an orally selective inhibitor of **Kit**, **KDR** and **CSF-1R (c-Fms)** with IC_{50}s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits **Flt-1**, **c-Raf**, **Lck** and low activity against **PDGFRα/β**, **Flt-3** and **Abl**. OSI-930 has antitumor activity.



Purity: 98.13%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pazopanib

(GW786034) Cat. No.: HY-10208

Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with IC_{50}s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pazopanib Hydrochloride

(GW786034 (Hydrochloride)) Cat. No.: HY-12009

Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with an IC_{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pazopanib-d6

(GW786034-d6) Cat. No.: HY-10208S

Pazopanib-d6 (GW786034-d6) is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with IC_{50}s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD180970

Cat. No.: HY-103274

PD180970 is a highly potent and ATP-competitive **$p210^{Bcr-Abl}$ kinase** inhibitor, with an IC_{50} of 5 nM for inhibiting the autophosphorylation of **$p210^{Bcr-Abl}$**. PD180970 also inhibits **Src** and **KIT** kinase with IC_{50}s of 0.8 nM and 50 nM, respectively.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Pexidartinib

(PLX-3397) Cat. No.: HY-16749

Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive **colony stimulating factor 1 receptor (CSF1R or M-CSFR)** and **c-Kit** inhibitor, with IC_{50}s of 20 and 10 nM, respectively.



Purity: 99.64%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Pexidartinib hydrochloride

(PLX-3397 hydrochloride) Cat. No.: HY-16749A

Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive **colony stimulating factor 1 receptor (CSF1R or M-CSFR)** and **c-Kit** inhibitor, with IC_{50}s of 20 and 10 nM, respectively.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 200 mg, 500 mg, 1 g

PLX647

Cat. No.: HY-13838

PLX647 is an orally active, highly specific dual **FMS** and **KIT** kinase inhibitor, with IC_{50}s of 28 and 16 nM, respectively. PLX647 shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR (IC_{50}s=91 and 130 nM, respectively).



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PLX647 dihydrochloride

Cat. No.: HY-13838A

PLX647 dihydrochloride is an orally active, highly specific dual **FMS** and **KIT** kinase inhibitor, with IC_{50}s of 28 and 16 nM, reapectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ripretinib

(DCC-2618) Cat. No.: HY-112306

Ripretinib (DCC-2618) is an orally bioavailable, selective **KIT** and **PDGFRA** switch-control inhibitor.



Purity: 99.33%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sitravatinib

(MGCD516; MG-516) Cat. No.: HY-16961

Sitravatinib (MGCD516) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: 99.59%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Sitravatinib malate

(MGCD516 malate; MG-516 malate) Cat. No.: HY-16961A

Sitravatinib malate (MGCD516 malate) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

SU11652

Cat. No.: HY-112452

SU11652 is a potent **receptor tyrosine kinase (RTK)** inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including **VEGFR**, **FGFR**, **PDGFR**, and **Kit**. SU11652 can be uesd for spontaneous cancers expressing Kit mutations research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SU14813

Cat. No.: HY-10501

SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC_{50}s of 50, 2, 4, 15 nM for **VEGFR2**, **VEGFR1**, **PDGFRβ** and **KIT**.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SU14813 maleate

Cat. No.: HY-10501A

SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC_{50}s of 50, 2, 4, 15 nM for **VEGFR2**, **VEGFR1**, **PDGFRβ** and **KIT**.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tandutinib

(MLN518; CT53518)

Cat. No.: HY-10202

Tandutinib (MLN518) is a potent and selective inhibitor of the **FLT3** with an IC_{50} of 0.22 μM, and also inhibits **c-Kit** and **PDGFR** with IC_{50}s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML).



Purity: 99.48%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg

Tandutinib hydrochloride

(MLN518 hydrochloride; CT53518 hydrochloride)

Cat. No.: HY-10202A

Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the **FLT3** with an IC_{50} of 0.22 μM, and also inhibits **c-Kit** and **PDGFR** with IC_{50}s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML).



Purity: 98.84%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg

Telatinib

(Bay 57-9352)

Cat. No.: HY-10527

Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of **VEGFR2**, **VEGFR3**, **PDGFα**, and **c-Kit** with IC_{50}s of 6, 4, 15 and 1 nM, respectively.



Purity: 98.72%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Telatinib mesylate

(Bay 57-9352 mesylate)

Cat. No.: HY-10527C

Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active **VEGFR2**, **VEGFR3**, **PDGFα**, and **c-Kit** inhibitor with IC_{50}s of 6 nM, 4 nM, 15 nM and 1 nM, respectively.



Purity: 99.46%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Toceranib

(SU11654; PHA 291639E)

Cat. No.: HY-10330

Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



Purity: 96.25%
Clinical Data: Launched
Size: 10 mg, 50 mg

Toceranib phosphate

(SU11654 phosphate; PHA 291639E phosphate)

Cat. No.: HY-10330A

Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



Purity: 98.02%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg, 100 mg

Toceranib-d8

Cat. No.: HY-10330S

Toceranib-d8 (SU11654-d8) is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Tyrphostin AG1296

(AG1296)

Cat. No.: HY-13894

Tyrphostin AG1296 is a potent and selective inhibitor of **platelet-derived growth factor receptor (PDGFR)**, with an IC_{50} of 0.8 μM.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

VEGFR-IN-1

Cat. No.: HY-101219

VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC_{50}s of 0.02, 0.18, 0.24 7.3, and 7 μM for **KDR**, **Flt-1**, c-Kit, EGF-R, and c-Src, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vimseltinib

(DCC-3014)

Cat. No.: HY-136256

Vimseltinib (DCC-3014) is a **c-FMS** (**CSF-IR**) and **c-Kit** dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC_{50}s of <0.01 μM and 0.1-1 μM, respectively.



Purity: 99.08%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

c-Met/HGFR

c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymalorigin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.

c-Met/HGFR Inhibitors, Agonists & Activators

AC-386

Cat. No.: HY-143463

AC-386 is a highly potent **c-Met** inhibitor with IC_{50} value of 7.42 nM. AC-386 has antiproliferative activities against certain cancer cell lines. AC-386 can be used for researching anti-cancer resistance.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Altiratinib

(DCC-2701)

Cat. No.: HY-B0791

Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC_{50}s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for **MET**, **TIE2**, **VEGFR2**, **FLT3**, **Trk1**, **Trk2**, and **Trk3** respectively.



Purity: 98.06%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AMG-208

Cat. No.: HY-12035

AMG-208 is an orally active **c-Met/RON** dual selective inhibitor with an IC_{50} of 9 nM for c-Met. AMG-208 is a **CYP3A4** inhibitor with an IC_{50} of 32 μM. AMG-208 has anti-cancer activity.



Purity: 99.34%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

AMG-337

Cat. No.: HY-18696

AMG-337 is a potent and highly selective small molecule ATP-competitive MET kinase inhibitor. AMG 337 inhibits MET kinase activity with an IC50 of < 5nM in enzymatic assays.



Purity: 99.43%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

AMG-458

Cat. No.: HY-14723

AMG-458 is a potent, selective and orally bioavailable **c-Met** inhibitor, with K_i values of 1.2 nM and 2.0 nM for human and mouse c-Met, respectively.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Amuvatinib

(MP470; HPK 56)

Cat. No.: HY-10206

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: 98.07%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amuvatinib hydrochloride

(MP470 hydrochloride; HPK 56 hydrochloride)

Cat. No.: HY-10206A

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Antitumor agent-45

Cat. No.: HY-144394

Antitumor agent-45 (Compound 21) could induce and stimulate A549 cells apoptosis in G0/G1 and G2/M phase. Antitumor agent-45 (Compound 21) inhibits c-Met expression to regulate the growth of tumor cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BAY-474

Cat. No.: HY-133083

BAY-474 is a tyrosine-protein kinase **c-Met** inhibitor. BAY-474 acts as an epigenetics probe.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS 777607

(BMS 817378)

Cat. No.: HY-12076

BMS 777607 (BMS 817378) is a **Met-related** inhibitor for **c-Met**, **Axl**, **Ron** and **Tyro3** with IC_{50}s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity...



Purity: 99.04%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS-794833

Cat. No.: HY-10497

BMS-794833 is a **VEGFR2** and **Met** inhibitor extracted from patent WO2009094417, compound example 1; has IC_{50}s of 15 and 1.7 nM, respectively.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bozitinib

(PLB-1001; CBT-101; Vebreltinib)

Cat. No.: HY-125017

Bozitinib (PLB-1001) is a highly selective **c-MET** kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily.



Purity: 99.66%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BPI-9016M

Cat. No.: HY-114356

BPI-9016M is a potent, orally active, and selective dual **c-Met** and **AXL** tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

c-Kit-IN-1

Cat. No.: HY-15240

c-Kit-IN-1 is a potent inhibitor of **c-Kit** and **c-Met** with IC_{50}s of <200 nM.



Purity: 98.72%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

c-Met inhibitor 1

Cat. No.: HY-15735

c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

c-Met-IN-1

Cat. No.: HY-101031

c-met-IN-1 (compound 16) is a potent and selective **c-Met** inhibitor, with IC_{50} of 1.1 nM, with antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-Met-IN-10

Cat. No.: HY-146274

c-Met-IN-10 (compound 26a) is a highly potent **c-Met kinase** inhibitor with an IC_{50} value of 16 nM. c-Met-IN-10 has inhibitory activity against cancer cells A549, H460 and HT-29 with IC_{50}s of 0.56 ~ 1.59 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-Met-IN-11

Cat. No.: HY-147694

c-Met-IN-11 (compound 3) is a potent **c-MET** and **VEGFR-2** inhibitor, with IC_{50} values of 41.4 and 71.1 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-Met-IN-12

Cat. No.: HY-147695

c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II **c-Met** kinase inhibitor, with an IC_{50} of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against **AXL**, **Mer** and **TYRO3** kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-Met-IN-2

Cat. No.: HY-101773

c-Met-IN-2 is a potent, selective and orally available **c-Met** inhibitor, with an IC_{50} of 0.6 nM, with antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-Met-IN-9

Cat. No.: HY-115937

c-Met-IN-9, a 4-phenoxypyridine derivative, is a **c-Met kinas** inhibitor with an IC_{50} of 12 nM. c-Met-IN-9 induces cells **apoptosis**, and has antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-Met/HDAC-IN-2

Cat. No.: HY-143462

c-Met/HDAC-IN-2 is a highly potent **c-Met** and **HDAC** dual inhibitor with IC_{50}s of 18.49 nM and 5.40 nM for **HDAC1** and **c-Met**, respectively. c-Met/HDAC-IN-2 has antiproliferative activities against certain cancer cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cabozantinib

(XL184; BMS-907351)

Cat. No.: HY-13016

Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Cabozantinib-d4

(XL184-d4; BMS-907351-d4)

Cat. No.: HY-13016S1

Cabozantinib-d4 is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cabozantinib-d6

Cat. No.: HY-13016S

Cabozantinib-d6 (XL184-d6) is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Capmatinib

(INC280; INCB28060)

Cat. No.: HY-13404

Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive **c-Met** kinase inhibitor (IC_{50}=0.13 nM).



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

CEP-40783

(RXDX-106)

Cat. No.: HY-100946

CEP-40783 is a potent, selective and orally available inhibitor of **AXL** and **c-Met** with IC_{50} values of 7 nM and 12 nM, respectively.



Purity: 99.22%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Crizotinib

(PF-02341066)

Cat. No.: HY-50878

Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive **ALK** and **c-Met** inhibitor with IC_{50}s of 20 and 8 nM, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Crizotinib hydrochloride

(PF-02341066 hydrochloride)

Cat. No.: HY-50878A

Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual **ALK** and **c-Met** inhibitor with IC_{50}s of 20 and 8 nM, respectively.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Crizotinib-d5

(PF-02341066-d5)

Cat. No.: HY-50878S

Crizotinib-d5 (PF-02341066-d5) is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive **ALK** and **c-Met** inhibitor with IC_{50}s of 20 and 8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CSF1R-IN-2

Cat. No.: HY-111787

CSF1R-IN-2 (compound 5) is an oral-active inhibitor of **SRC**, **MET** and **c-FMS**, with IC_{50} values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DS-1205b free base

Cat. No.: HY-114357A

DS-1205b free base is a potent and selective inhibitor of **AXL kinase**, with an IC_{50} of 1.3 nM. DS-1205b free base also inhibits **MER**, **MET**, and **TRKA**, with IC_{50}s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

EGFR-IN-8

Cat. No.: HY-126320

EGFR-IN-8 is a dual **EGFR** and **c-Met** inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ensartinib

(X-396)

Cat. No.: HY-103714

Ensartinib (X-396) is a potent and dual **ALK/MET** inhibitor with IC_{50}s of <0.4 nM and 0.74 nM, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ensartinib dihydrochloride

(X-396 dihydrochloride)

Cat. No.: HY-103714A

Ensartinib dihydrochloride (X-396 dihydrochloride) is a potent and dual **ALK/MET** inhibitor with IC_{50}s of <0.4 nM and 0.74 nM, respectively.



Purity: 99.46%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Foretinib

(XL880; GSK1363089; GSK089; EXEL-2880)

Cat. No.: HY-10338

Foretinib is a multi-target tyrosine kinase inhibitor with IC_{50}s of 0.4 nM and 0.9 nM for **Met** and **KDR**.



Purity: 99.77%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fosgonimeton

(ATH-1017)

Cat. No.: HY-132814

Fosgonimeton (ATH-1017) is a **hepatocyte growth factor receptor** agonist (WO2017210489).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gemnelatinib

Cat. No.: HY-132816

Gemnelatinib is a **tyrosine kinase inhibitor** (WO2018077227, implementation example 1). Gemnelatinib can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glesatinib

(MGCD265)

Cat. No.: HY-19642

Glesatinib (MGCD265) is an orally active, potent **MET/SMO** dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glesatinib hydrochloride

(MGCD265 hydrochloride)

Cat. No.: HY-19642A

Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent **MET/SMO** dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).



Purity: 98.25%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Glumetinib

(SCC244)

Cat. No.: HY-116000

Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive **c-Met** inhibitor with an IC_{50} of 0.42 nM.



Purity: 98.15%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Golvatinib

(E-7050)

Cat. No.: HY-13068

Golvatinib (E-7050) is a potent dual inhibitor of both **c-Met** and **VEGFR2** kinases with IC_{50}s of 14 and 16 nM, respectively.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JNJ-38877605

Cat. No.: HY-50683

JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.



Purity: 99.95%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JNJ-38877618

Cat. No.: HY-111050

JNJ-38877618 is a potent, highly selective, orally bioavailable **Met** kinase inhibitor with IC_{50}s of 2 and 3 nM for wild type and mutant Met, respectively.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Meleagrin

Cat. No.: HY-N6797

Meleagrin is a roquefortine C-derived alkaloid produced by fungi of the genus Penicillium and has antimicrobial and anti-proliferative activities. Meleagrin is a class of **FabI** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Merestinib

(LY2801653)

Cat. No.: HY-15514

Merestinib (LY2801653) is a potent, orally bioavailable **c-Met** inhibitor (K_i=2 nM) with anti-tumor activities.



Purity: 99.99%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Merestinib dihydrochloride

(LY2801653 dihydrochloride)

Cat. No.: HY-15514A

Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable **c-Met** inhibitor (K_i=2 nM) with anti-tumor activities.



Purity: 99.36%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MET kinase-IN-2

Cat. No.: HY-131065

MET kinase-IN-2 is a potent, selective, orally bioavailable **MET kinase** inhibitor with an IC_{50} of 7.4 nM. MET kinase-IN-2 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MET kinase-IN-3

Cat. No.: HY-146884

MET kinase-IN-3 (compound 8) is an orally active and potent **MET** inhibitor, with an IC_{50} of 9.8 nM. MET kinase-IN-3 shows good and broad-spectrum antiproliferative activity against cancer cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MGCD-265 analog

Cat. No.: HY-10991

MGCD-265 analog is a potent and oral active inhibitor of **c-Met** and **VEGFR2** tyrosine kinases, with IC_{50}s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity.



Purity: 98.57%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

MK-2461

Cat. No.: HY-50703

MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met with a mean IC50 of 2.5 nM.



Purity: 99.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MK-8033

Cat. No.: HY-13299

MK-8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.



Purity: 95.02%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MK-8033 hydrochloride

Cat. No.: HY-13299A

MK8033 Hcl is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.



Purity: 99.70%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg

Multi-kinase-IN-1

Cat. No.: HY-146014

Multi-kinase-IN-1 (Compound 11k) is a potent **kinase** inhibitor with antitumor activity. Multi-kinase-IN-1 induces cell **apoptosis**, and can be studied for **colorectal cancer**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ningetinib

Cat. No.: HY-107145A

Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with **IC_{50}**s of 6.7, 1.9 and <1.0 nM for **c-Met**, **VEGFR2** and **Axl**, respectively.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ningetinib Tosylate

Cat. No.: HY-107145

Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with **IC_{50}**s of 6.7, 1.9 and <1.0 nM for **c-Met**, **VEGFR2** and **Axl**, respectively.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Norleual

Cat. No.: HY-P1415

Norleual, an angiotensin (Ang) IV analog, is a **hepatocyte growth factor (HGF)/c-Met** inhibitor with an **IC_{50}** of 3 pM. Norleual is an **AT4 receptor** antagonist and exhibits potent antiangiogenic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NPS-1034

Cat. No.: HY-100509

NPS-1034 is a dual inhibitor of **AXL** and **MET** with **IC_{50}**s of 10.3 and 48 nM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NVP-BVU972

Cat. No.: HY-15456

NVP-BVU972 is a selective and potent Met inhibitor (IC50 = 14 nM). Antitumor agents.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pamufetinib

(TAS-115)

Cat. No.: HY-12423

Pamufetinib (TAS-115) is a potent **VEGFR** and hepatocyte growth factor receptor (**c-Met/HGFR**)-targeted kinase inhibitor with **IC_{50}**s of 30 and 32 nM for rVEGFR2 and rMET, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Pamufetinib mesylate

(TAS-115 mesylate) Cat. No.: HY-12423A

Pamufetinib (TAS-115) mesylate is a potent **VEGFR**and hepatocyte growth factor receptor (**c-Met/HGFR**)-targeted kinase inhibitor, with **IC_{50}**s of 30 and 32 nM for rVEGFR2 and rMET, respectively.



Purity: 99.19%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-04217903

Cat. No.: HY-12017

PF-04217903 is a potent ATP-competitive **c-Met kinase** inhibitor with **K_i** of 4.8 nM for human c-Met. PF-04217903 shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties.



Purity: 99.95%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-04217903 methanesulfonate

Cat. No.: HY-12017A

PF-04217903 methanesulfonate is a potent ATP-competitive **c-Met kinase** inhibitor with **K_i** of 4.8 nM for human c-Met. PF-04217903 methanesulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties.



Purity: 99.87%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-04217903 phenolsulfonate

Cat. No.: HY-12017B

PF-04217903 phenolsulfonate is a potent ATP-competitive **c-Met kinase** inhibitor with **K_i** of 4.8 nM for human c-Met. PF-04217903 phenolsulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PHA-665752

Cat. No.: HY-11107

PHA-665752 is a selective, ATP-competitive, and active-site inhibitor of the catalytic activity of **c-Met** kinase (**K_i**=4 nM; **IC_{50}**=9 nM). PHA-665752 exhibits >50-fold selectivity for c-Met compared with a panel of diverse tyrosine and serine-threonine kinases.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

S49076

Cat. No.: HY-12965

S49076 is a novel, potent inhibitor of **MET**, **AXL/MER**, and **FGFR1/2/3** with **IC_{50}** values below 20 nM.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

SAR125844

Cat. No.: HY-16446

SAR125844 is a potent, highly selective, reversible and ATP-competitive **MET receptor tyrosine kinase (RTK)** inhibitor, with an **IC_{50}** of 4.2 nM. Shows inhibition of MET autophosphorylation in cell-based assays.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Savolitinib

(Volitinib; HMPL-504; AZD-6094) Cat. No.: HY-15959

Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable **c-Met** inhibitor with **IC_{50}** s of 5 nM and 3 nM for c-Met and p-Met, respectively.



Purity: 99.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SCR-1481B1

(c-Met inhibitor 2) Cat. No.: HY-18711A

SCR-1481B1 (c-Met inhibitor 2) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SGX-523

Cat. No.: HY-12019

SGX523 is a exquisitely selective and ATP-competitive **MET** inhibitor. SGX523 potently inhibits MET with an **IC_{50}** of 4 nM and is >1,000-fold selective versus other protein kinases. Antitumor activity.



Purity: 99.28%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

SRI 31215 TFA

Cat. No.: HY-114363A

SRI 31215 (TFA), a triplex inhibitor of **matriptase**, **hepsin** and **hepatocyte growth factor activator (HGFA)** with IC_{50}s of 0.69 μM, 0.65 μM, 0.3 μM, blocks pro-HGF activation and thus mimics the activity of HAI-1/2.



Purity: 98.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SU11274

(PKI-SU11274)

Cat. No.: HY-12014

SU11274 is a selective **Met** inhibitor with IC_{50} of 10 nM, but has no effects on PGDFRβ, EGFR or Tie2.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SYN1143

Cat. No.: HY-18307

SYN1143 is a potent, selective and orally active dual inhibitor of **c-Met/RON**, with IC_{50}s of 4 and 9 nM, respectively. SYN1143 has weak inhibitory activity on **Lck**, **Tie2**, **Src**, and **BTK** with IC_{50}s ranging from 160 to 710 nM.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Terevalefim

(ANG-3777)

Cat. No.: HY-137455

Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the **c-Met receptor**.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tivantinib

(ARQ 197)

Cat. No.: HY-50686

Tivantinib is a highly selective **c-Met** tyrosine kinase inhibitor with a K_i of 355 nM.



Purity: 99.67%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Tunlametinib

Cat. No.: HY-132844

Tunlametinib, an **antineoplastic** agent, is a **tyrosine kinase** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyrosine kinase inhibitor

Cat. No.: HY-10421

Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

X-376

Cat. No.: HY-16590

X-376 is a potent and highly specific **ALK** tyrosine kinase inhibitor (TKI) (IC_{50}=0.61 nM). X-376 is a less potent inhibitor of **MET** (IC_{50}=0.69 nM). X-376 displays potent anti-tumor activity.



Purity: 98.36%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

XL092

Cat. No.: HY-138696

XL092 is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including **MET**, **VEGFR2**, **AXL** and **MER**, with IC_{50}s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. XL092 exhibits anti-tumor activity.



Purity: 99.52%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Discoidin Domain Receptor

Discoidin domain receptors (DDRs) are members of the transmembrane receptor tyrosine kinase (RTK) superfamily which are distinguished from others by the presence of a discoidin motif in the extracellular domain and their utilization of collagens as internal ligands. Two types of DDRs, DDR1 and DDR2, have been identified with distinct expression profiles and ligand specificities.

Upon collagen binding, DDRs transduce cellular signaling involved in various cell functions, including cell adhesion, proliferation, differentiation, migration, and matrix homeostasis. Altered DDR function resulting from either mutations or overexpression has been implicated in several types of disease, including atherosclerosis, inflammation, cancer, and tissue fibrosis. DDRs have been considered as novel potential molecular targets for drug discovery and increasing efforts are being devoted to the identification of new small molecule inhibitors targeting the receptors.

Discoidin Domain Receptor Inhibitors

7rh
(DDR1-IN-2)

Cat. No.: HY-U00444

7rh (DDR1-IN-2) is a potent inhibitor of **discoidin domain receptor 1 (DDR1)**, with an IC_{50} of 13.1 nM, and also less potently inhibits DDR2, with an IC_{50} of 203 nM.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

DDR Inhibitor

Cat. No.: HY-W018931

DDR Inhibitor is a potent **discoidin domain receptor (DDR)** inhibitor, with an IC_{50} of 3.3 nM for DDR2, and shows 53% inhibition on DDR1 at 1.5 nM.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

DDR-TRK-1

Cat. No.: HY-100695

DDR-TRK-1 is a selective Discoidin Domain Receptor 1 **(DDR1)** inhibitor, with an IC_{50} value of 9.4 nM. DDR-TRK-1 also inhibits TRK family.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DDR1-IN-1

Cat. No.: HY-13979

DDR1-IN-1 is a potent and selective **DDR1 receptor tyrosine kinase** inhibitor with an IC_{50} of 105 nM; 4-fold less potent for DDR2 (IC_{50} = 413 nM).



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DDR1-IN-1 dihydrochloride

Cat. No.: HY-13979A

DDR1-IN-1 dihydrochloride is a potent and selective **DDR1 receptor tyrosine kinase** inhibitor with an IC_{50} of 105 nM; 4-fold less potent for DDR2 (IC_{50} = 413 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DDR1-IN-4

Cat. No.: HY-114173

DDR1-IN-4 (Compound 2.45) is a selective and potent **Discoidin Domain Receptor 1 (DDR1)** autophosphorylation inhibitor, with IC_{50} values of 29 nM and 1.9 μM for DDR1 and DDR2, respectively.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DDR1-IN-5

Cat. No.: HY-133669

DDR1-IN-5 is a selective **Discoidin Domain Receptor family, member 1 (DDR1)** inhibitor with an IC_{50} of 7.36 nM. DDR1-IN-5 inhibits auto-phosphorylation DDR1b (Y513) with an IC_{50} of 4.1 nM. DDR1-IN-5 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DDR1-IN-6

Cat. No.: HY-133670

DDR1-IN-6 is a selective **Discoidin Domain Receptor family, member 1 (DDR1)** inhibitor with an IC_{50} of 9.72 nM. DDR1-IN-6 inhibits auto-phosphorylation DDR1b (Y513) with an IC_{50} of 9.7 nM. DDR1-IN-6 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DDR2-IN-1

Cat. No.: HY-112545

DDR2-IN-1 is potent **DDR2** inhibitor with an IC_{50} of 26 nM. DDR2-IN-1, compound 129, can be used for osteoarthritis research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR1/DDR2 inhibitor 1

Cat. No.: HY-114311

FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of **fibroblast growth factor receptor 1 (FGFR1)** and **discoindin domain receptor 2 (DDR2)**, with IC_{50} values of 31.1 nM and 3.2 nM, respectively. Antitumor activity.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Merestinib

(LY2801653) Cat. No.: HY-15514

Merestinib (LY2801653) is a potent, orally bioavailable **c-Met** inhibitor (K_i=2 nM) with anti-tumor activities.



Purity: 99.99%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Merestinib dihydrochloride

(LY2801653 dihydrochloride) Cat. No.: HY-15514A

Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable **c-Met** inhibitor (K_i=2 nM) with anti-tumor activities.



Purity: 99.36%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML786 dihydrochloride

Cat. No.: HY-14979A

ML786 dihydrochloride is a potent and orally bioavailable **Raf** inhibitor, with IC_{50}s of 2.1, 4.2, and 2.5 nM for ^{V600E}**ΔB-Raf**, **wt B-Raf**, and **C-Raf**, respectively. ML786 dihydrochloride also inhibits **Abl-1**, **DDR2**, **EPHA2**, **KDR**, and **RET** (IC_{50}=<0.5, 7.0, 11, 6.2, 0.8 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sitravatinib

(MGCD516; MG-516) Cat. No.: HY-16961

Sitravatinib (MGCD516) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: 99.59%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Sitravatinib malate

(MGCD516 malate; MG-516 malate) Cat. No.: HY-16961A

Sitravatinib malate (MGCD516 malate) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

VU6015929

Cat. No.: HY-135401

VU6015929 is a potent, selective and orally active dual **discoidin domain receptor 1/2 (DDR1/2)** inhibitor with IC_{50}s of 4.67 nM and 7.39 nM, respectively. VU6015929 potently blocks collagen-induced **DDR1** activation and collagen-IV production.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

WRG-28

Cat. No.: HY-114169

WRG-28 is a selective, extracellularly acting **DDR2** allosteric inhibitor with an IC_{50} of 230 nM. WRG-28 uniquely inhibits receptor-ligand interactions via allosteric modulation of the receptor.



Purity: 99.42%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DYRK

Dual specificity tyrosine phosphorylation regulated kinase; Dual specificity tyrosine regulated kinase

<P>DYRKs (dual-specificity tyrosine-regulated kinases; dual-specificity tyrosine phosphorylation-regulated kinases) comprise a family of protein kinases within the CMGC group of the eukaryotic kinome. DYRKs contain five members in humans that are clustered into two classes based on their phylogenetic relationships: class I DYRKs, DYRK1A and DYRK1B and class II DYRKs, DYRK2, DYRK3, and DYRK4.

DYRK kinases are “dual specificity” kinases, as they can phosphorylate both tyrosine (Y) and serine/threonine (S/T) residues, although Y-phosphorylation is limited to their autophosphorylation activity. DYRK kinases phosphorylate a broad set of substrates that are involved in a wide range of cellular processes, and they are thought to fulfill essential biological functions both during development and in maintaining homeostasis during the adult life. Consequently, the aberrant regulation or expression of DYRK kinases has been associated with several human pathologies, including cancer.

DYRK Inhibitors

ARN25068

Cat. No.: HY-144290

ARN25068 is a sub-micromolar inhibitor of the three protein kinases, **GSK-3β**, **FYN** and **DYRK1A** to tackle tau hyperphosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ-Dyrk1B-33

Cat. No.: HY-117391

AZ-Dyrk1B-33 is a potent and selective **Dyrk1B kinase** inhibitor, with an IC_{50} of 7 nM.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ191

Cat. No.: HY-12277

AZ191 is a potent inhibitor that selectively inhibits **DYRK1B** with IC_{50} of 17 nM.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CK2/ERK8-IN-1

Cat. No.: HY-135906

CK2/ERK8-IN-1 is a dual **casein kinase 2 (CK2)** (K_i of 0.25 μM) and **ERK8** (MAPK15, ERK7) inhibitor with IC_{50}s of 0.50 μM. CK2/ERK8-IN-1 also binds to **PIM1**, **HIPK2** (**homeodomain-interacting protein kinase 2**), and **DYRK1A** with K_is of 8.65 μM, 15.25 μM, and 11.9 μM, respectively.

Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

CLK-IN-T3

Cat. No.: HY-115470

CLK-IN-T3 is a high potent, selective, and stable **CDC-like kinase (CLK)** inhibitor with IC_{50}s of 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases, respectively. CLK-IN-T3 has anti-cancer activity.



Purity: 98.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DYRK1-IN-1

Cat. No.: HY-132308

DYRK1-IN-1 is a highly selective and ligand-efficient **DYRK1A** inhibitor. DYRK1-IN-1 inhibits **DYRK1A** phosphorylation activity with an IC_{50} value of 220 nM. DYRK1-IN-1 can be used for the research of central nervous system penetrant **DYRK1A** chemical probe.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dyrk1A-IN-1

Cat. No.: HY-139830

Dyrk1A-IN-1 is a triple inhibitor of **Dyrk1A kinase** activity (IC_{50} = 119 nM) and the aggregation of tau and α-syn oligomers.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dyrk1A-IN-4

Cat. No.: HY-147066

Dyrk1A-IN-4 (compound 48) is a potent and orally active **DYRK1A** and **DYRK2** inhibitor with IC_{50}s of 2 nM and 6 nM, respectively. Dyrk1A-IN-4 has anticancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dyrk1A/α-synuclein-IN-1

Cat. No.: HY-144695

Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual **Dyrk1A** and **α-synuclein aggregation** inhibitor with IC_{50} values of 177 nM and 10.5 μM, respectively. Dyrk1A/α-synuclein-IN-1 has high predictive CNS penetration and neuroprotective effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dyrk1A/α-synuclein-IN-2

Cat. No.: HY-144696

Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual **Dyrk1A** and **α-synuclein aggregation** inhibitor with an IC_{50} of 7.8 μM for α-synuclein. Dyrk1A/α-synuclein-IN-2 has high predictive CNS penetration and neuroprotective effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DYRKs-IN-1

Cat. No.: HY-128758

DYRKs-IN-1 is a potent **DYRKs** (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC_{50}s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DYRKs-IN-1 hydrochloride

Cat. No.: HY-128758A

DYRKs-IN-1 hydrochloride is a potent **DYRKs** (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC_{50}s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 hydrochloride has antitumor activity.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

DYRKs-IN-2

Cat. No.: HY-128759

DYRKs-IN-2 (Example 132) is a potent **DYRKs** inhibitor with IC_{50}s of 30.6 nM and 12.8 nM for DYRK1B and DYRK1A, respectively. DYRKs-IN-2 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EHT 1610

Cat. No.: HY-111380

EHT 1610 is a strong inhibitor of **DYRK's** family kinases, with IC_{50}s of 0.36, 0.59 nM for DYRK1A and DYRK1B, respectively.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EHT 5372

Cat. No.: HY-111379

EHT 5372 is a highly potent and selective inhibitor of **DYRK's** family kinases with IC_{50}s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, 221 nM for **DYRK1A**, **DYRK1B** , DYRK2 DYRK3 CLK1, CLK2, CLK4, GSK-3α, GSK-3β.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GNF2133

Cat. No.: HY-142295

GNF2133 is a potent, selective and orally active **DYRK1A** inhibitor with IC_{50}s of 0.0062, >50 μM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GNF2133 hydrochloride

Cat. No.: HY-142295A

GNF2133 hydrochloride is a potent, selective and orally active **DYRK1A** inhibitor with IC_{50}s of 0.0062, >50 μM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GNF4877

Cat. No.: HY-129492

GNF4877 is a potent **DYRK1A** and **GSK3β** inhibitor with IC_{50}s of 6nM and 16nM, respectively, which leads to blockade of nuclear factor of activated T-cells (NFATc) nuclear export and increased β-cell proliferation (EC_{50} of 0.66μM for mouse β (R7T1) cells).



Purity: 98.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

GSK-626616

Cat. No.: HY-105309

GSK-626616 is a potent, orally bioavailable inhibitor of **DYRK3** (IC_{50}=0.7 nM). GSK-626616 inhibits other members of the DYRK family (e.g., DYRK1A and DYRK2) with similar potency, which is a potential therapy for the treatment of anemia.



Purity: 99.68%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Harmine hydrochloride

(Telepathine hydrochloride)

Cat. No.: HY-N0737

Harmine Hydrochloride (Telepathine Hydrochloride) is a natural **DYRK** inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of **5-HT_{2A} serotonin receptor**, with an K_i of 397 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Haspin-IN-1

Cat. No.: HY-146586

Haspin-IN-1 (compound 2a) is a **haspin** inhibitor with an IC_{50} of 119 nM. Haspin-IN-1 also inbibits **CLK1** and **DYRK1A** with IC_{50}s of 221 nM and 916.3 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Haspin-IN-2

Cat. No.: HY-146587

Haspin-IN-2 (compound 4) is a potent and selective **haspin** inhibitor with an IC_{50} of 50 nM. Haspin-IN-1 also inbibits **CLK1** and **DYRK1A** with IC_{50}s of 445 nM and 917 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ID-8

Cat. No.: HY-15838

ID-8 is an inhibitor of **dual-specificity tyrosine phosphorylation-regulated kinase (DYRK)**. ID-8 sustains embryonic stem cell (ESC) self-renewal and pluripotency. ID-8 enhances Wnt-mediated hESC survival and proliferation via inhibition of DYRKs.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

INDY

Cat. No.: HY-108476

INDY is a potent and ATP-competitive **Dyrk1A** and **Dyrk1B** inhibitor with IC_{50}s of 0.24 μM and 0.23 μM, respectively. INDY binds in the ATP pocket of the enzyme and has a K_i value of 0.18 μM for Dyrk1A.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

JH-XIV-68-3

Cat. No.: HY-144617

JH-XIV-68-3 is a selective macrocyclic inhibitor of **DYRK1A/B**. JH-XIV-68-3 displays selectivity for DYRK1A and close family member DYRK1B in biochemical and cellular assays. JH-XIV-68-3 demonstrates antitumor efficacy in head and neck squamous cell carcinoma (HNSCC) cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JH-XVII-10

Cat. No.: HY-144614

JH-XVII-10 is a potent, selective and orally active **DYRK1A** and **DYRK1B** inhibitor with IC_{50}s of 3 nM and 5 nM for **DYRK1A** and **DYRK1B**, respectively. JH-XVII-10 shows antitumor efficacy in neck squamous cell carcinoma (HNSCC) cell lines.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KH-CB20

Cat. No.: HY-12828A

KH-CB20, an E/Z mixture, is a potent and selective inhibitor of **CLK1** and the closely related isoform **CLK4**, with an IC_{50} of 16.5 nM for **CLK1**. KH-CB20 can also inhibit **DYRK1A** (IC_{50}=57.8 nM) and **CLK3** (IC_{50}=488 nM).



Purity: 99.66%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

LDN-192960

Cat. No.: HY-13455

LDN-192960 is an inhibitor of **Haspin** and **Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2)** with IC_{50}s of 10 nM and 48 nM, respectively.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

LDN-192960 hydrochloride

Cat. No.: HY-13455A

LDN-192960 hydrochloride is an inhibitor of **Haspin** and **Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2)** with IC_{50}s of 10 nM and 48 nM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

LDN-209929 dihydrochloride

Cat. No.: HY-110320

LDN-209929 dihydrochloride is a potent and selective **haspin kinase** inhibitor (IC_{50}=55 nM) with180-fold selectivity verses DYRK2 (IC_{50}=9.9 μM). LDN-209929 is a optimized analogue of LDN-192960 (HY-13455).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Leucettine L41

Cat. No.: HY-117049

Leucettine L41 is a potent inhibitor of **dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), DYRK2, CDC-like kinase 1 (CLK1), and CLK3** (IC_{50}s = 0.04, 0.035, 0.015, and 4.5 μM, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MBM-55S

Cat. No.: HY-101029A

MBM-55S is a potent **NIMA-related kinase 2 (Nek2)** inhibitor with an IC_{50} of 1 nM. MBM-55S shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC_{50}=5.4 nM) and DYRK1a (IC_{50}=6.5 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mirk-IN-1

(Dyrk1B/A-IN-1)

Cat. No.: HY-12838

Mirk-IN-1 is a potent inhibitor of Dyrk1B(Mirk kianse) and Dyrk1A with IC50 of 68±48 nM and 22±8 nM respectively. IC50 value: 68±48/22±8 nM (Dyrk1B/Dyrk1A) Target: Dyrk inhibitor Mirk-IN-1 had an EC50 of 1.9 ±0.2 mmol/L on SW620 cells.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Protein kinase inhibitors 1

Cat. No.: HY-U00439

Protein kinase inhibitors 1 is a novel inhibitor of **HIPK2** with an IC_{50} of 74 nM and K_d of 9.5 nM.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Protein kinase inhibitors 1 hydrochloride

Cat. No.: HY-U00439A

Protein kinase inhibitors 1 hydrochloride is a potent **HIPK2** inhibitor, with IC_{50}s of 136 and 74 nM for HIPK1 and HIPK2, and a K_d of 9.5 nM for HIPK2.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

T025

Cat. No.: HY-112296

T025 is an orally active and highly potent inhibitor of **Cdc2-like kinase (CLKs)**, with K_d values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell **apoptosis**.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

tBID

Cat. No.: HY-100464

tBID is a selective inhibitor of homeodomain-interacting protein kinase 2 (**HIPK2**) with an IC_{50} of 0.33 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

EGFR

Epidermal growth factor receptor; ErbB-1; HER1

The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All EGFR family members are characterized by a modular structure consisting of an extracellular ligand-binding domain, a single hydrophobic transmembrane region, and the intracellular part harbouring the highly conserved tyrosine kinase domain. The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ten growth factors and their ErbB specificities are: EGF, amphiregulin (AR), and TGF bind ErbB-1; betacellulin, and epiregulin bind both ErbB-1 and ErbB-4; the neuregulins (also called heregulins and Neu differentiation factors) NRG-1 and NRG-2 bind ErbB-3 and ErbB-4; and NRG-3 and NRG-4 bind ErbB-4. No known ligand binds ErbB-2. The three best characterized signaling pathways induced through ErbBs are Ras-mitogen-activated protein kinase (Ras-MAPK), phosphatidylinositol 3 kinase-protein kinase B (PI3K-PKB/Akt), and phospholipase C-protein kinase C (PLC-PKC) pathways.

(E)-AG 556

((E)-Tyrphostin AG 556) Cat. No.: HY-101041

(E)-AG 556 is a highly selective **EGFR** inhibitor and also blocks LPS-induced TNF-α production.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E)-AG 99

((E)-Tyrphostin 46; (E)-Tyrphostin AG 99) Cat. No.: HY-100962

(E)-AG 99 ((E)-Tyrphostin 46) is a potent **EGFR** inhibitor.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

(E/Z)-AG490

((E/Z)-Tyrphostin AG490; (E/Z)-Tyrphostin B42) Cat. No.: HY-107459

(E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a **tyrosine kinase** inhibitor that inhibits **EGFR**, **Stat-3** and **JAK2/3**.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E/Z)-CP-724714

Cat. No.: HY-W008914

(E/Z)-CP-724714 is a racemic compound of (E)-CP-724714 and (Z)-CP-724714 isomers. CP-724714 is a potent and selective orally active ErbB2 (HER2) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

(Rac)-JBJ-04-125-02

Cat. No.: HY-135805A

(Rac)-JBJ-04-125-02 is the racemate of JBJ-04-125-02. JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active **EGFR** inhibitor with an IC_{50} of 0.26 nM for $EGFR^{L858R/T790M}$.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg

(Rac)-Pyrotinib

((Rac)-SHR-1258) Cat. No.: HY-104065A

(Rac)-Pyrotinib ((Rac)-SHR-1258) is the racemate of Pyrotinib. Pyrotinib is a potent and selective EGFR/HER2 dual inhibitor.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

(S)-Sunvozertinib

((S)-DZD9008) Cat. No.: HY-132842A

(S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against **EGFR** exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC_{50}=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively).



Purity: 99.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AEE788

(NVP-AEE 788) Cat. No.: HY-10045

AEE788 is an inhibitor of the **EGFR** and **ErbB2** with IC_{50} values of 2 and 6 nM, respectively.



Purity: 98.39%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AEE788-d5

Cat. No.: HY-10045S

AEE788-d5 is the deuterium labeled AEE788. AEE788 is an inhibitor of the **EGFR** and **ErbB2** with IC_{50} values of 2 and 6 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Afatinib

(BIBW 2992) Cat. No.: HY-10261

Afatinib (BIBW 2992) is an irreversible **EGFR** family inhibitor with IC_{50}s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Afatinib D6

(BIBW 2992 D6) Cat. No.: HY-10261S

Afatinib D6 (BIBW 2992 D6) is deuterium labeled Afatinib. Afatinib (BIBW 2992) is an irreversible EGFR family inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Afatinib dimaleate

(BIBW 2992MA2) Cat. No.: HY-10261A

Afatinib dimaleate is an irreversible **EGFR** family inhibitor with IC_{50}s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Afatinib impurity 11

Cat. No.: HY-133780

Afatinib impurity 11 is an impurity of Afatinib. Afatinib is an irreversible **EGFR** family inhibitor with IC_{50}s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Afatinib-d4

(BIBW 2992-d4) Cat. No.: HY-10261S1

Afatinib-d4 (BIBW 2992-d4) is the deuterium labeled Afatinib. Afatinib (BIBW 2992) is an irreversible **EGFR** family inhibitor with IC_{50}s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Afatinib-d6 dimaleate

(BIBW 2992MA2-d6) Cat. No.: HY-10261AS

Afatinib-d6 dimaleate (BIBW 2992MA2-d6) is the deuterium labeled Afatinib dimaleate. Afatinib dimaleate is an irreversible **EGFR** family inhibitor with IC_{50}s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AG 555

(Tyrphostin AG 555) Cat. No.: HY-15336

AG 555 (Tyrphostin AG 555), a potent antiretroviral drug, is a potent and selective inhibitor of **EGFR** and blocks **Cdk2** activation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 250 mg

AG-1478

(Tyrphostin AG-1478; NSC 693255) Cat. No.: HY-13524

AG-1478 (Tyrphostin AG-1478) is a selective **EGFR** tyrosine kinase inhibitor with IC_{50} of 3 nM. AG-1478 has antiviral effects against **HCV** and **encephalomyocarditis virus (EMCV)**.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AG-1478 hydrochloride (Tyrphostin AG-1478 hydrochloride; NSC 693255 hydrochloride)

Cat. No.: HY-13524A

AG-1478 hydrochloride (Tyrphostin AG-1478 hydrochloride) is a selective **EGFR** tyrosine kinase inhibitor with IC_{50} of 3 nM. AG-1478 hydrochloride has antiviral effects against **HCV** and **encephalomyocarditis virus (EMCV)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AG-494

(Tyrphostin AG 494) Cat. No.: HY-101042

AG-494 (Tyrphostin AG 494) is a potent and selective **EGFR** tyrosine kinase inhibitor (IC_{50}=0.7 μM). AG-494 inhibits the autophosphorylation of EGFR, ErbB2, HER1-2 and PDGF-R with IC_{50}s 1.1, 39, 45 and 6 μM, respectively.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

AG-825

(Tyrphostin AG-825) Cat. No.: HY-15844

AG-825 (Tyrphostin AG-825) is a selective and ATP-competitive **ErbB2** inhibitor which suppresses tyrosine phosphorylation, with an IC_{50} of 0.35 μM. AG-825 displays anti-cancer activity. AG825 significantly accelerates apoptosis of human neutrophils.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AG1557

Cat. No.: HY-12806

AG1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (**EGFR**) tyrosine kinase, has a **pIC$_{50}$** value of 8.194.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AG490

(Tyrphostin AG490; Tyrphostin B42) Cat. No.: HY-12000

AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits **EGFR**, **Stat-3** and **JAK2/3**.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Alflutinib

(Furmonertinib; AST2818) Cat. No.: HY-112870

Alflutinib is a potent inhibitor of **EGFR**. Alflutinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Alflutinib has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alflutinib mesylate

(Furmonertinib mesylate; AST2818 mesylate) Cat. No.: HY-112870A

Alflutinib (Furmonertinib) mesylate is is a potent inhibitor of **EGFR**. Alflutinib (Furmonertinib) mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation.



Purity: 99.96%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Allitinib

(AST-1306; ALS 1306) Cat. No.: HY-15375

Allitinib (AST-1306) is an orally active and irreversible **EGFR** and **ErbB2** inhibitor with **IC$_{50}$**s of 0.5 and 3 nM, respectively. Allitinib also inhibits **ErbB4** with an IC$_{50}$ of 0.8 nM. Allitinib is an anilino-quinazoline compound and has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Allitinib tosylate

(AST-1306 (TsOH)) Cat. No.: HY-13427

Allitinib tosylate (AST-1306 (TsOH)) is an orally active and irreversible **EGFR** and **ErbB2** inhibitor with **IC$_{50}$**s of 0.5 and 3 nM, respectively. Allitinib tosylate also inhibits **ErbB4** with an IC$_{50}$ of 0.8 nM.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Almonertinib

(HS-10296) Cat. No.: HY-112823

Almonertinib (HS-10296) is an orally available, irreversible, third-generation **EGFR tyrosine kinase** inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Almonertinib hydrochloride

(HS-10296 hydrochloride) Cat. No.: HY-112823B

Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation **EGFR tyrosine kinase** inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations.



Purity: 98.03%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Almonertinib mesylate

(HS-10296 mesylate) Cat. No.: HY-112823A

Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation **EGFR** tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ARRY-380 analog

Cat. No.: HY-10531

ARRY-380 analog, an inhibitor of **EGFR (ErbB1)**, is extracted from patent WO2015153959A2, compound 249. ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2.



Purity: 96.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ARRY-380 analog-d3

Cat. No.: HY-10531S

ARRY-380 analog-d3 is the deuterium labeled ARRY-380 analog. ARRY-380 analog, an inhibitor of **EGFR (ErbB1)**, is extracted from patent WO2015153959A2, compound 249. ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg

ASK120067

Cat. No.: HY-138751

ASK120067 is a potent and orally active inhibitor of **$EGFR^{T790M}$** (IC_{50}:0.3 nM) with selectivity over $EGFR^{WT}$ (IC_{50}:6.0 nM). ASK120067 is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC).



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AST5902 trimesylate

Cat. No.: HY-138627A

AST5902 trimesylate is the principal metabolite of Alflutinib (AST2818) both in vitro and in vivo. AST5902 trimesylate exerts antineoplastic activity. Alflutinib is an **EGFR** inhibitor.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Astragaloside VI

Cat. No.: HY-N6577

Astragaloside VI could activate **EGFR/ERK** signalling pathway to improve wound healing.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 5 mg

AV-412

(MP412)

Cat. No.: HY-10346

AV-412 (MP412) is an **EGFR** inhibitor with **IC_{50}**s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, $EGFR^{L858R}$, $EGFR^{T790M}$, $EGFR^{L858R/T790M}$ and ErbB2, respectively.



Purity: 99.17%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AV-412 free base

(MP-412 free base)

Cat. No.: HY-10346A

AV-412 free base (MP-412 free base) is an **EGFR** inhibitor with **IC_{50}**s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, $EGFR^{L858R}$, $EGFR^{T790M}$, $EGFR^{L858R/T790M}$ and ErbB2, respectively.



Purity: 98.07%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Avitinib

(Abivertinib; AC0010)

Cat. No.: HY-19816

Avitinib (AC0010) is an irreversible, mutant-selective **EGFR** inhibitor that effectively inhibits EGFR T790M resistance mutations in non-small cell lung cancer (NSCLC). Abivertinib is also a novel **BTK** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Avitinib maleate

(Abivertinib maleate; AC0010 maleate)

Cat. No.: HY-19816A

Avitinib (Abivertinib) maleate is a pyrrolopyrimidine-based irreversible epidermal growth factor receptor (**EGFR**) inhibitor with an **IC_{50}** of 7.68 nM.



Purity: 99.17%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZ-5104

Cat. No.: HY-B0793

AZ-5104 is an active, demethylated metabolite of AZD 9291. AZ-5104 is an **EGFR** inhibitor with **IC_{50}**s of 1, 6, 1, 25 and 7 nM for $EGFR^{L858R/T790M}$, $EGFR^{L858R}$, $EGFR^{L861Q}$, EGFR and ErbB4, respectively.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

AZ7550

Cat. No.: HY-B0794

AZ7550 is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an **IC_{50}** of 1.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ7550 hydrochloride

Cat. No.: HY-B0794A

AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an IC_{50} of 1.6 μM.



Purity: 98.66%
Clinical Data: Phase 1
Size: 5 mg, 10 mg

AZ7550 Mesylate

(AZ7550 trimesylate salt)

Cat. No.: HY-B0794B

AZ7550 Mesylate is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an IC_{50} of 1.6 μM.



Purity: 99.34%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg

BAY 2476568

Cat. No.: HY-134877

BAY 2476568 is a potent and selective **EGFR** inhibitor, with IC_{50}s of < 0.2 nM for wild-type EGFR and several mutations (EGFRR ex20insSVD, EGFRR ex20insASV, EGFRR ex20insNPG).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Befotertinib

(D-0316)

Cat. No.: HY-137433

Befotertinib (D-0316) is the third-generation **EGFR tyrosine kinase** inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC).



Purity: 99.96%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BGB-102

(JNJ-26483327)

Cat. No.: HY-15732

BGB-102 is a potent multi-kinase inhibitor against **EGFR**, **HER2**, and **HER4** with IC_{50}s of 9.6 nM, 18 nM and 40.3 nM, respectively.



Purity: 97.10%
Clinical Data: Phase 1
Size: 5 mg

BI-4020

Cat. No.: HY-129550

BI-4020 is a fourth-generation, orally active, and non-covalent **EGFR** tyrosine kinase inhibitor.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BLU-945

Cat. No.: HY-144680

receptor (**EGFR**). EGFR is a member of the erbB receptor family, which includes transmembrane protein tyrosine kinase receptors. BLU-945 effectively inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

BMS-599626

(AC480)

Cat. No.: HY-10251

BMS-599626 (AC480) is a selective and orally bioavailable **HER1** and **HER2** inhibitor, with IC_{50}s of 20 and 30 nM, respectively. BMS-599626 displays ~8-fold less potent to HER4 (IC_{50}=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

BMS-599626 Hydrochloride

(AC480 Hydrochloride)

Cat. No.: HY-12010

BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable **HER1** and **HER2** inhibitor, with IC_{50}s of 20 and 30 nM, respectively.



Purity: 99.87%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 50 mg, 100 mg

BMS-690514

Cat. No.: HY-10333

BMS-690514 is a potent and orally active inhibitor of **EGFR** and **VEGFR**; has IC_{50}s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Butein

(2′,3,4,4′-tetrahydroxy Chalcone)

Cat. No.: HY-16558

Butein is a cAMP-specific **PDE** inhibitor with an IC_{50} of 10.4 μM for **PDE4**. Butein is a specific protein tyrosine kinase inhibitor with IC_{50}s of 16 and 65 μM for **EGFR** and **p60**$^{c\text{-}src}$ in HepG2 cells.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Canertinib

(CI-1033; PD-183805)

Cat. No.: HY-10367

Canertinib (CI-1033;PD-183805) is a potent and irreversible **EGFR** inhibitor; inhibits cellular **EGFR** and **ErbB2** autophosphorylation with IC_{50}s of 7.4 and 9 nM.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Canertinib dihydrochloride

(CI-1033 dihydrochloride; PD-183805 dihydrochloride)

Cat. No.: HY-10367A

Canertinib dihydrochloride (CI-1033 dihydrochloride) is a potent and irreversible **EGFR** inhibitor; inhibits cellular **EGFR** and **ErbB2** autophosphorylation with IC_{50}s of 7.4 and 9 nM.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

CCT365623 hydrochloride

Cat. No.: HY-124674A

CCT365623 hydrochloride is an orally active **lysyl oxidase (LOX)** inhibitor, with an IC_{50} of 0.89 μM. CCT365623 hydrochloride suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 hydrochloride is extremely well tolerated, and has good pharmacokinetic properties.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cetuximab

(C225)

Cat. No.: HY-P9905

Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (**EGFR**), with a K_d of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.



Purity: 99.70%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

CGP52411

(DAPH)

Cat. No.: HY-103442

CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive **EGFR** inhibitor with an IC_{50} of 0.3 μM.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

CHMFL-EGFR-202

Cat. No.: HY-101522

CHMFL-EGFR-202 is a potent, irreversible inhibitor of **epidermal growth factor receptor (EGFR) mutant kinase**, with IC_{50}s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chrysophanol

(Chrysophanic acid)

Cat. No.: HY-13595

Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of **EGFR** and suppresses activation of **AKT** and **mTOR/p70S6K**.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

CL-387785

(EKI-785; WAY-EKI 785)

Cat. No.: HY-10325

CL-387785(EKI785; WAY-EKI 785) is an irreversible inhibitor of **EGFR** with IC_{50} of 370 pM.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CNX-2006

Cat. No.: HY-13897

CNX-2006 is a mutant-selective and irreversible **EGFR** inhibitor with an IC_{50} below 20 nM for EGFR^{T790M}.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CP-724714

Cat. No.: HY-14674

CP-724714 is a potent, selective and orally active **ErbB2 (HER2)** tyrosine kinase inhibitor, with an IC_{50} of 10 nM. CP-724714 displays a marked selectivity against EGFR kinase (IC_{50}=6400 nM). CP-724714 potently inhibits ErbB2 receptor autophosphorylation in intact cells.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CUDC-101

Cat. No.: HY-10223

CUDC-101 is a potent inhibitor of **HDAC**, **EGFR**, and **HER2** with IC_{50}s of 4.4, 2.4, and 15.7 nM, respectively.



Purity: 99.19%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cyasterone

Cat. No.: HY-N0211

Cyasterone, a natural **EGFR** inhibitor, mainly isolated from Ajuga decumbens Thunb (Labiatae). Cyasterone manifests anti-proliferation effect by induced **apoptosis** and cell cycle arrests. Cyasterone may serves as a therapeutic anti-tumor agent against human tumors.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Dacomitinib

(PF-00299804; PF-299804)

Cat. No.: HY-13272

Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the **ERBB** family of kinases with IC_{50}s of 6 nM, 45.7 nM and 73.7 nM for **EGFR**, **ERBB2**, and **ERBB4**, respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dacomitinib-d10

(PF-00299804-d10; PF-299804-d10)

Cat. No.: HY-13272S3

Dacomitinib-d10 is deuterium labeled Dacomitinib. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dacomitinib-d10 dihydrochloride (PF-00299804-d10 dihydrochloride; PF-299804-d10 dihydrochloride)

Cat. No.: HY-13272S2

Dacomitinib-d10 (PF-00299804-d10) dihydrochloride is the deuterium labeled Dacomitinib dihydrochloride.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dacomitinib-d3

(PF-00299804-d3; PF-299804-d3)

Cat. No.: HY-13272S

Dacomitinib-d3 (PF-00299804-d3) is the deuterium labeled Dacomitinib. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the **ERBB** family of kinases with IC_{50}s of 6 nM, 45.7 nM and 73.7 nM for **EGFR**, **ERBB2**, and **ERBB4**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dacomitinib-d5

(PF-00299804-d5; PF-299804-d5)

Cat. No.: HY-13272S1

Dacomitinib-d5 (PF-00299804-d5) is the deuterium labeled Dacomitinib. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the **ERBB** family of kinases with IC_{50}s of 6 nM, 45.7 nM and 73.7 nM for **EGFR**, **ERBB2**, and **ERBB4**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Daphnetin

(7,8-Dihydroxycoumarin)

Cat. No.: HY-N0281

Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative isolated from plants of the Genus Daphne, is a **protein kinase** inhibitor, with **IC_{50}s** of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively.



Purity: 99.21%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

DBPR112

Cat. No.: HY-128778

DBPR112 is an orally active furanopyrimidine-based **EGFR** inhibitor with IC_{50}s of 15 nM and 48 nM for $EGFR^{WT}$ and $EGFR^{L858R/T790M}$, respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy.



Purity: 98.07%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride; Delphinidin 3-O-β-glucoside chloride)

Cat. No.: HY-108052

Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in bilberry extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL).



Purity: 99.83%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Disitamab vedotin (RC48)

Cat. No.: HY-P9985

Disitamab vedotin (RC48) is an antibody-drug conjugate **(ADC)** comprising a monoclonal antibody against human epidermal growth factor receptor 2 **(HER2)** conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.

Disitamab vedotin

Purity: 97.40%
Clinical Data: Launched
Size: 1 mg, 5 mg

Dosimertinib

Cat. No.: HY-142283

Dosimertinib is a highly potent, selective, and orally efficacious deuterated **EGFR** targeting clinical candidate for the treatment of non-small-cell lung cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DP-C-4

Cat. No.: HY-141481

DP-C-4 is a **Cereblon**-based dual **PROTAC** for simultaneous degradation of **EGFR** and **PARP**.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

EAI045

Cat. No.: HY-100213

EAI045 is an allosteric and the fourth-generation inhibitor of mutant **EGFR** with IC_{50}s of 1.9, 0.019, 0.19 and 0.002 μM for EGFR, $EGFR^{L858R}$, $EGFR^{T790M}$ and $EGFR^{L858R/T790M}$ at 10 μM ATP, respectively.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

EGFR mutant-IN-1

Cat. No.: HY-125841

EGFR mutant-IN-1, a 5-methylpyrimidopyridone derivative, is a potent and selective $EGFR^{L858R/T790M/C797S}$ mutant inhibitor with an IC_{50} of 27.5 nM, while being a significantly less potent for $EGFR^{WT}$ (IC_{50} >1.0 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR Protein Tyrosine Kinase Substrate

Cat. No.: HY-P2503

EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-1

Cat. No.: HY-19617

EGFR-IN-1 (compound 24) is an orally active and irreversible **L858R/T790M mutant selective EGFR** inhibitor. EGFR-IN-1 potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-1 hydrochloride

Cat. No.: HY-19617A

EGFR-IN-1 hydrochloride is an orally active and irreversible **L858R/T790M mutant selective EGFR** inhibitor. EGFR-IN-1 hydrochloride potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-1 TFA

Cat. No.: HY-19617B

EGFR-IN-1 TFA is an orally active and irreversible **L858R/T790M mutant selective EGFR** inhibitor. EGFR-IN-1 TFA potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EGFR-IN-11

Cat. No.: HY-130616

EGFR-IN-11 is a fourth-generation **EGFR**-tyrosine kinase inhibitor (**EGFR-TKI**) with an IC_{50} of 18 nM for triple mutant $EGFR^{L858R/T790M/C797S}$.
EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EGFR-IN-12

Cat. No.: HY-17499

EGFR-IN-12 is a 4,6-disubstituted pyrimidine and is a potent, ATP-competitive, irreversible and highly selective **EGFR** inhibitor with an $IC_{50}$of 21 nM. EGFR-IN-12 also inhibits mutant $EGFR^{L858R}$ and $EGFR^{L861Q}$ with IC_{50}s of 63 nM and 4 nM, respectively.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

EGFR-IN-15

Cat. No.: HY-138746

EGFR-IN-15 (compound I-005) is a **EGFR** inhibitor with an IC_{50} of 4 nM. EGFR-IN-15 can be used for oncological diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-16

Cat. No.: HY-137786

EGFR-IN-16 (compound 3) is a potent **EGFR** inhibitor with pIC_{50} of 4.85 and 4.74 for EGFR and HER-2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-17

Cat. No.: HY-115716

EGFR-IN-17 is a potent and selective inhibitor of the **epidermal growth factor receptor** (IC_{50} 0.0002 μM) to overcome C797S-mediated resistance.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-18

Cat. No.: HY-139884

EGFR-IN-18 potently inhibits enzymatic activity in L858R/T790M/C797S mutant **EGFR** (4.9 nM), with a significantly lower activity for wild-type **EGFR** (47 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-2

Cat. No.: HY-100520

EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation **EGFR** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-21

Cat. No.: HY-142678

EGFR-IN-21 is a potent **EGFR** inhibtior with an IC_{50} of 0.38 nM. EGFR-IN-21 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-22

Cat. No.: HY-142679

EGFR-IN-22 is a potent **EGFR** inhibitor with IC_{50}s of 4.91 nM and 0.54 nM for **wild type EGFR** and $EGFR^{L858R/T790M/C797S}$, respectively (CN112538072A, compound 243).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-23

Cat. No.: HY-142680

EGFR-IN-23 is a potent **EGFR** TKI (tyrosine kinase inhibitor) with an IC_{50} of 8.05 nM for BaF3/EGFR-DEL19/T790M/C797S cell (WO2021244502A1, compound 8).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-24

Cat. No.: HY-142512

EGFR-IN-24, a potent EGFR inhibitor, shows inhibition against EGFR(del19/T790M/C797S) and EGFR(L858R/T790M/C797S), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-25

Cat. No.: HY-142517

EGFR-IN-25 is a potent **EGFR** inhibitor with IC_{50}s of 9 nM and 60 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and A431 cells (WT), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-27

Cat. No.: HY-142519

EGFR-IN-27 is a potent EGFR inhibitor with IC_{50}s of <50 nM for EGFR Del, L858R, Del/T790M, L858R/T790M, Del/T790M/C797S, and L858R/T790M/C797S, respectively (WO2021249324A1, compound 511).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-28

Cat. No.: HY-142681

EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-29

Cat. No.: HY-143729

EGFR-IN-29 is a potent **EGFR** inhibitor, example J-022, extracted from Patent WO2021160087.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-30

Cat. No.: HY-144044

EGFR-IN-30 is a potent **EGFR** inhibitor with IC_{50}s of 1-10 nM, <1 nM for EGFR (WT), EGFR (L858R/T790M/C797S), respectively. EGFR-IN-30 has potential for cell proliferative diseases, such as cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-31

Cat. No.: HY-144048

EGFR-IN-31 is a potent inhibitor of **EGFR**. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-32

Cat. No.: HY-144049

EGFR-IN-32 is a potent inhibitor of **EGFR**. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-33

Cat. No.: HY-144050

EGFR-IN-33 is a potent inhibitor of **EGFR**. EGFR-IN-33 is an anti-tumor drug with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-34

Cat. No.: HY-144051

EGFR-IN-34 is a potent inhibitor of **EGFR**. EGFR-IN-34 is an anti-tumor drug with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-35

Cat. No.: HY-144052

EGFR-IN-35 is a potent inhibitor of **EGFR**. EGFR-IN-35 is an anti-tumor drug with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-36

Cat. No.: HY-144053

EGFR-IN-36 is a potent **EGFR** inhibitor with IC_{50}s of 19.09 nM, 120.01 nM, 2.35 nM for EGFR (WT), HER2 (WT), HER2 (A775_G776insYVMA), respectively. EGFR-IN-36 has potential for wild and/or mutant EGFR and/or HER2 kinase mediated tumors research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-37

Cat. No.: HY-144054

EGFR-IN-37 is a potent inhibitor of **EGFR**. EGFR-IN-37 is an anti-tumor drug with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-38

Cat. No.: HY-144055

EGFR-IN-38 is a potent inhibitor of **EGFR**. EGFR-IN-38 is an anti-tumor drug with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-39

Cat. No.: HY-144056

EGFR-IN-39 is a potent inhibitor of **EGFR**. EGFR-IN-39 is an anti-tumor drug with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-40

Cat. No.: HY-143901

EGFR-IN-40 (compound 3z) is a potent **BTK**, **EGFR**, and **ITK** inhibitor with IC_{50} values of 1.2 nM, 5.3 nM, and 46.1 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-42

Cat. No.: HY-145823

EGFR-IN-42 (Compound 17b) is a potent inhibitor of **EGFR** with single-digit nanomolar activity. EGFR-IN-42 connects tamoxifen or endoxifen with the EGFR-inhibitor gefitinib via a covalent linkage. EGFR-IN-42 retains both ER antagonist activity and EGFR inhibition.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-43

Cat. No.: HY-145824

EGFR-IN-43 (Compound 17c) is a potent inhibitor of **EGFR** with single-digit nanomolar activity. EGFR-IN-43 connects tamoxifen or endoxifen with the EGFR-inhibitor gefitinib via a covalent linkage. EGFR-IN-43 retains both ER antagonist activity and EGFR inhibition.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-44

Cat. No.: HY-145844

EGFR-IN-44 (Compound 6a) is a potent, orally active **EGFR** tyrosine kinase inhibitor with an IC_{50} of 4.11 nM. EGFR-IN-44 induces cell **apoptosis** and shows an oral bioavailability value of 33.57%. EGFR-IN-44 can be studied for non-small-cell lung cancers.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-45

Cat. No.: HY-145867

EGFR-IN-45 is a potent epidermal growth factor receptor (**EGFR**) pan inhibitor, with IC_{50}s of 0.4 μM and 1.6 μM for **EGFR** and **CDK2**, respectively. EGFR-IN-45 also inhibit Topo I and Topo II. EGFR-IN-45 arrests cancer cells in the pre-G1 phase and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-46

Cat. No.: HY-144794

EGFR-IN-46 is a potent **EGFR** and **FAK** dual inhibitor with IC_{50}s of 20.17 nM, 14.25 nM, respectively. EGFR-IN-46 significantly inhibits the growth of cancer cells. EGFR-IN-46 induces cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-47

Cat. No.: HY-143337

EGFR-IN-47 is a potent and orally active $EGFR^{L858R/T790M/C797S}$ inhibitor with an IC_{50} of 0.01 μM. EGFR-IN-47 induces cell cycle attest and cell **apoptosis**. EGFR-IN-47 has the potential for the research of NSCLC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-48

Cat. No.: HY-143445

EGFR-IN-48 is a potent and orally active **EGFR** inhibitor with IC_{50}s of 0.193 nM, 0.251 nM, 10.4 nM for $EGFR^{d19/TM/CS}$, $EGFR^{LR/TM/CS}$, $EGFR^{WT}$, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-49

Cat. No.: HY-146782

EGFR-IN-49 is a potent and selective **EGFR** inhibitor with IC_{50}s of 65.0 nM and 13.6 nM for $EGFR^{T790M}$ and $EGFR^{T790M/L858R}$, respectively. EGFR-IN-49 induces late **apoptosis** in a dose-dependent manner.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-5

Cat. No.: HY-111415

EGFR-IN-5 is a **EGFR** inhibitor with IC_{50}s of 10.4, 1.1, 34, 7.2 nM for EGFR, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, and $EGFR^{L858R/T790M/C797S}$, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EGFR-IN-51

Cat. No.: HY-146471

EGFR-IN-51 (Compound 6) is a potent **EGFR** inhibitor with IC_{50} values of 0.493, 102.60 and 461.63 μM against EGFR, **EGFR L858R-TK** and **EGFR T790M-TK**, respectively. EGFR-IN-51 shows cytotoxic activity against cancer cell lines and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-52

Cat. No.: HY-146472

EGFR-IN-52 (Compound 4) is a potent **EGFR** inhibitor with IC_{50} values of 0.358, 86.02 and 432.67 μM against EGFR, **EGFR L858R-TK** and **EGFR T790M-TK**, respectively. EGFR-IN-52 shows cytotoxic activity against cancer cell lines and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-53

Cat. No.: HY-146473

EGFR-IN-53 (Compound 7) is a potent **EGFR** inhibitor with an IC_{50} of 8.264 μM. EGFR-IN-53 shows cytotoxic activity against cancer cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-54

Cat. No.: HY-146474

EGFR-IN-54 (Compound 3c) is a potent **EGFR** inhibitor with an IC_{50} of 1.623 μM. EGFR-IN-54 shows cytotoxic activity against cancer cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-55

Cat. No.: HY-146132

EGFR-IN-55 (Compound 8a) is a potent **EGFR** inhibitor with IC_{50} values of 70 nM and 3.9 nM against $EGFR^{WT}$ and $EGFR^{L858R/T790M}$, respectively. EGFR-IN-55 arrests NCI-H1975 cells in G0/G1 phase and shows anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-56

Cat. No.: HY-146136

EGFR-IN-56 (Compound 13a) is a potent **EGFR** inhibitor with IC_{50} values of 541.7 nM and 132.1 nM against $EGFR^{T790M}$ and $EGFR^{T790M/L858R}$, respectively. EGFR-IN-56 blocks cancer cells in G2/M phase and induce into late **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-57

Cat. No.: HY-146138

EGFR-IN-57 (Compound 25a) is a potent, orally active **EGFR-TK** inhibitor with an IC_{50} of 0.054 μM. EGFR-IN-57 also inhibits **VEGFR-2**, **CK2α**, **topoisomerase IIβ** and **tubulin polymerization** with IC_{50} values of 0.087, 0.171, 0.13 and 3.61 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-7

Cat. No.: HY-128862

EGFR-IN-7 (compound 34) is a selective and potent **EGFR kinase** inhibitor extracted from patent WO2019015655A1, has IC_{50}s of 7.92 nM and 0.218 nM for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) respectively, and shows anti-tumor activity.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

EGFR-IN-8

Cat. No.: HY-126320

EGFR-IN-8 is a dual **EGFR** and **c-Met** inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EGFR-IN-9

Cat. No.: HY-18213

EGFR-IN-9 (Compound 8) is a potent **EGFR kinase** inhibitor with IC_{50}s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR/BRAF-IN-1

Cat. No.: HY-115933

EGFR/BRAF-IN-1 (compound 21), a 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivative, is a potent **EGFR/BRAF** inhibitor with an IC_{50} of 45 nM for $BRAF^{V600E}$. EGFR/BRAF-IN-1 inhibits cancer cell proliferation (GI_{50}=35 nM). EGFR/BRAF-IN-1 shows good antioxidant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR/CSC-IN-1

Cat. No.: HY-132883

EGFR/CSC-IN-1 is a potential **EGFR** (IC_{50} 10.52 nM) and cancer stem cell (CSC) dual inhibitor for triple-negative breast cancer treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR/ErbB-2/ErbB-4 inhibitor-2

Cat. No.: HY-112420

EGFR/ErbB-2/ErbB-4 inhibitor-2 (Compound 5) is a **EGFR** and **ErbB** inhibitor with IC_{50}s of 0.017 μM, 0.08 μM, 1.91 μM.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EGFR/HER2-IN-2

Cat. No.: HY-115951

EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual inhibitor of **EGFR** and **HER2** with IC_{50} values of 5.02 μM and 0.83 μM against EGFR and HER2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR/HER2-IN-3

Cat. No.: HY-115952

EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual inhibitor of **EGFR** and **HER2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EMI1

Cat. No.: HY-138072

EMI1 is an **EGFR ex19del/T790M/C797S** and **EGFR L858R/T790M/C797S** inhibitor. EMI1 can be used for the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

EMI48

Cat. No.: HY-131066

EMI48, the derivative of EMI1, displays greater potency toward mutant **EGFR** than EMI1. EMI48 inhibits **EGFR** triple mutants.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EMI56

Cat. No.: HY-131067

EMI56, the derivative of EMI1, displays greater potency toward mutant **EGFR** than EMI1. EMI56 inhibits **EGFR** triple mutants.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Epertinib

(S-22611)

Cat. No.: HY-107367

Epertinib (S-22611) is a potent, oral, reversible, and selective tyrosine kinase inhibitor of **EGFR**, **HER2** and **HER4**, with IC_{50}s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib shows potent antitumor activity.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 1 mg

Epertinib hydrochloride

(S-22611 hydrochloride)

Cat. No.: HY-107367A

Epertinib hydrochloride (S-22611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of **EGFR**, **HER2** and **HER4**, with IC_{50}s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib hydrochloride shows potent antitumor activity.



Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Epitinib

(HMPL-813)

Cat. No.: HY-139300

Epitinib is an orally active and selective **epidermal growth factor receptor tyrosine kinase** inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Epitinib succinate

(HMPL-813 succinate)

Cat. No.: HY-139300A

Epitinib succinate is an orally active and selective **epidermal growth factor receptor tyrosine kinase** inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib succinate can be used for the research of cancer.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Erlotinib

(CP-358774; NSC 718781; OSI-774)

Cat. No.: HY-50896

Erlotinib (CP-358774) is a directly acting **EGFR** tyrosine kinase inhibitor, with an IC_{50} of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC_{50} of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Erlotinib Hydrochloride (CP-358774 hydrochloride; NSC 718781 hydrochloride; OSI-774 hydrochloride)

Cat. No.: HY-12008

Erlotinib Hydrochloride (CP-358774 Hydrochloride) inhibits purified **EGFR** kinase with an IC_{50} of 2 nM.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Erlotinib mesylate (CP-358774 mesylate; NSC 718781 mesylate; OSI-774 mesylate)

Cat. No.: HY-12008A

Erlotinib mesylate (CP-358774 mesylate) inhibits purified **EGFR** kinase with an IC_{50} of 2 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Erlotinib-13C6

(CP-358774-13C6; NSC 718781-13C6; OSI-774-13C6) Cat. No.: HY-50896S1

Erlotinib-13C6 (CP-358774-13C6) is a 13C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC_{50} of 2 nM for human EGFR.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Erlotinib-d6

(CP-358774-d6; NSC 718781-d6; OSI-774-d6) Cat. No.: HY-50896S

Erlotinib D6 (CP-358774 D6) is a deuterium labeled Erlotinib (CP-358774). Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC_{50} of 2 nM for human EGFR.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Erlotinib-d6 hydrochloride (CP-358774-d6 hydrochloride; NSC 718781-d6 hydrochloride; OSI-774-d6 hydrochloride)

Cat. No.: HY-12008S

Erlotinib D6 hydrochloride (CP-358774 D6 hydrochloride) a deuterium labeled Erlotinib Hydrochloride. Erlotinib Hydrochloride inhibits purified EGFR kinase with an IC_{50} of 2 nM.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 1 mg

Falnidamol

(BIBX 1382) Cat. No.: HY-10322

Falnidamol (BIBX 1382) is an orally active, selective **EGFR tyrosine kinase** inhibitor with an **IC_{50}** of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC_{50}=3.4 μM) and a range of other related tyrosine kinases (IC_{50}>10 μM).



Purity: 97.03%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

FIIN-3

Cat. No.: HY-18603

FIIN-3 is an irreversible inhibitor of **FGFR** with an **IC_{50}** of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Gefitinib

(ZD1839) Cat. No.: HY-50895

Gefitinib (ZD1839) is a potent, selective and orally active **EGFR tyrosine kinase** inhibitor with an **IC_{50}** of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC_{50} of 54 nM) and that blocks EGF-stimulated **EGFR** autophosphorylation in tumor cells.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Gefitinib hydrochloride

(ZD-1839 hydrochloride) Cat. No.: HY-50895A

Gefitinib hydrochloride (ZD1839 hydrochloride) is a potent, selective and orally active **EGFR tyrosine kinase** inhibitor with an **IC_{50}** of 33 nM.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Gefitinib N-oxide

Cat. No.: HY-100636

Gefitinib N-oxide is the N-oxide derivative of Gefitinib. Gefitinib is an **EGFR tyrosine kinase** inhibitor, with **IC_{50}** of 2-37 nM in NR6wtEGFR cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gefitinib-based PROTAC 3

Cat. No.: HY-123921

Gefitinib-based PROTAC 3, conjugating an **EGFR** binding element to a **von Hippel-Lindau** ligand via a linker, induces **EGFR** degradation with **DC_{50}**s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Gefitinib-d3

Cat. No.: HY-50895S2

Gefitinib-d3 (ZD1839-d3) is the deuterium labeled Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active **EGFR tyrosine kinase** inhibitor with an **IC_{50}** of 33 nM.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Gefitinib-d6

(ZD1839-d6) Cat. No.: HY-50895S1

Gefitinib-d6 (ZD1839-d6) is the deuterium labeled Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active **EGFR tyrosine kinase** inhibitor with an IC_{50} of 33 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gefitinib-d8

(ZD1839-d8) Cat. No.: HY-50895S

Gefitinib D8 (ZD1839 D8) is a deuterium labeled Gefitinib. Gefitinib is an **EGFR tyrosine kinase** inhibitor, with IC_{50} of 2-37 nM in NR6wtEGFR cells.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Genistein

(NPI 031L) Cat. No.: HY-14596

Genistein, a soy isoflavone, is a multiple **tyrosine kinases** (e.g., **EGFR**) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering **apoptosis**, the cell cycle, and angiogenesis and inhibiting metastasis.



Purity: 99.84%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg, 500 mg

Genistein-d4

(NPI 031L-d4) Cat. No.: HY-14596S

Genistein-d4 (NPI 031L-d4) is the deuterium labeled Genistein. Genistein, a soy isoflavone, is a multiple **tyrosine kinases** (e.g.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HER2-IN-5

Cat. No.: HY-143733

HER2-IN-5 is a potent and orally active **HER-2** inhibitor, example 10, extracted from patent WO2021164697.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HER2-IN-7

Cat. No.: HY-143874

HER2-IN-7 is a potent inhibitor of **HER2**. Deregulation of ErbB family signalling modulates proliferation, invasion, metastasis, angiogenesis, and tumour cell survival.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HER2-IN-8

Cat. No.: HY-144097

HER2-IN-8 is a **HER-2** inhibitor extracted from patent WO2021179274A1 compound 107. HER2-IN-8 can be used for the research of cancer and inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HKI-357

Cat. No.: HY-103443

HKI-357 is an irreversible dual inhibitor of **EGFR** and **ERBB2** with IC_{50}s of 34 nM and 33 nM, respectively. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.



Purity: 99.65%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Icotinib

(BPI-2009) Cat. No.: HY-15164A

Icotinib (BPI-2009) is a potent and specific **EGFR** inhibitor with an IC_{50} of 5 nM; also inhibits mutant $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, $EGFR^{T790M}$ and $EGFR^{L861Q}$.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Icotinib Hydrochloride

(BPI-2009H) Cat. No.: HY-15164

Icotinib Hydrochloride (BPI-2009) is a potent and specific **EGFR** inhibitor with an IC_{50} of 5 nM; also inhibits mutant $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, $EGFR^{T790M}$ and $EGFR^{L861Q}$.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

JBJ-02-112-05

Cat. No.: HY-135914

JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active **EGFR** inhibitor with an IC_{50} of 15 nM for $EGFR^{L858R/T790M}$.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JBJ-04-125-02

Cat. No.: HY-135805

JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active **EGFR** inhibitor with an IC_{50} of 0.26 nM for $EGFR^{L858R/T790M}$. JBJ-04-125-02 can inhibit cancer cell proliferation and $EGFR^{L858R/T790M/C797S}$ signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

JCN037

(JGK037)

Cat. No.: HY-136430

JCN037 (JGK037) is non-covalent and BBB-penetrant **EGFR** tyrosine kinase inhibitor, with IC_{50} values of 2.49 nM, 3.95 nM, 4.48 nM for EGFR, p-wtEGFR and pEGFRv, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JND3229

Cat. No.: HY-119944

JND3229 is a highly potent and fourth-generation $EGFR^{C797S}$ reversible inhibitor with IC_{50} value of 5.8 nM, and also potently suppressed $EGFR^{L858R/T790M}$ and $EGFR^{WT}$ with IC_{50} values of 30.5 and 6.8 nM.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JNJ28871063 hydrochloride

Cat. No.: HY-103441

JNJ28871063 hydrochloride is an orally active, highly selective and ATP competitive **pan-ErbB kinase** inhibitor with IC_{50} values of 22 nM, 38 nM, and 21 nM for ErbB1, ErbB2, and ErbB4, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Khellin

Cat. No.: HY-B1394

Khellin is a furochromone that can be isolated from Ammi visnuga L.. Khellin is an **EGFR** inhibitor with an IC_{50} of 0.15 μM. Khelline has anti-proliferative activity in vitro. Khellin has antispasmodic and coronary vasodilator effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lapatinib

(GW572016; GW2016)

Cat. No.: HY-50898

Lapatinib (GW572016) is a potent inhibitor of the **ErbB-2** and **EGFR** tyrosine kinase domains with IC_{50} values against purified **EGFR** and **ErbB-2** of 10.2 and 9.8 nM, respectively.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g

Lapatinib ditosylate (GW572016 ditosylate monohydrate; GW2016 ditosylate monohydrate)

Cat. No.: HY-50898B

Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the **ErbB-2** and **EGFR** tyrosine kinase domains with IC_{50} values against purified **EGFR** and **ErbB-2** of 10.2 and 9.8 nM, respectively.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Lapatinib ditosylate

(GW572016 ditosylate; GW2016 ditosylate)

Cat. No.: HY-50898A

Lapatinib ditosylate (GW572016 ditosylate) is a potent inhibitor of the **ErbB-2** and **EGFR** tyrosine kinase domains with IC_{50} values against purified **EGFR** and **ErbB-2** of 10.2 and 9.8 nM, respectively.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g

Lapatinib-d4-1

(GW572016-d4-1; GW2016-d4-1)

Cat. No.: HY-50898S3

Lapatinib-d4-1 is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lapatinib-d5

(GW572016-d5; GW2016-d5) Cat. No.: HY-50898S2

Lapatinib-d5 is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lapatinib-d7 dihydrochloride

(GW572016-d7 dihydrochloride; GW2016-d7 dihydrochloride) Cat. No.: HY-50898S1

Lapatinib-d7 (GW572016-d7) dihydrochloride is the deuterium labeled Lapatinib dihydrochloride. Lapatinib (GW572016) dihydrochloride is a potent inhibitor of the **ErbB-2** and **EGFR** tyrosine kinase domains with IC_{50} values against purified **EGFR** and **ErbB-2** of 10.2 and 9.8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lapatinib-d7 ditosylate

Cat. No.: HY-50898BS

Lapatinib-d7 (GW572016-d7) ditosylate is the deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the **ErbB-2** and **EGFR** tyrosine kinase domains with IC_{50} values against purified **EGFR** and **ErbB-2** of 10.2 and 9.8 nM, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Lavendustin A

(RG-14355) Cat. No.: HY-18963

Lavendustin A (RG-14355), isolated from Streptomyces Griseolavendus, is a potent, specific and ATP-competitive inhibitor of **tyrosine kinase**, with an IC_{50} of 11 ng/mL for EGFR-associated tyrosine kinase.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Lavendustin C

Cat. No.: HY-W013857

Lavendustin C is a potent **Ca^{2+} calmodulin-dependent kinase II (CaMK II)** inhibitor with an IC_{50} of 0.2 μM. Lavendustin C inhibits **EGFR**-associated tyrosine kinase (IC_{50}=0.012 μM) and **pp60$^{c\text{-}src(+)}$** kinase (IC_{50}=0.5 μM) .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lazertinib

(YH25448; GNS-1480) Cat. No.: HY-109061

Lazertinib (YH25448) is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation **EGFR** tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer.



Purity: 99.73%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LDC0496

Cat. No.: HY-146262

LDC0496 is a potent and selective **EGFR** inhibitor. LDC0496 possesses intense inhibitory potency toward EGFR and Her2 exon20 insertion mutations, as well as selectivity over wild type EGFR and within the kinome.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lifirafenib

(BGB-283) Cat. No.: HY-18957

Lifirafenib (BGB-283) is a novel and potent **Raf** Kinase and **EGFR** inhibitor with IC_{50} values of 23 and 29 nM for recombinant $BRaf^{V600E}$ and EGFR, respectively.



Purity: 98.02%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mal-amido-PEG8-Val-Ala-PAB-SG3200

Cat. No.: HY-139957

Mal-amido-PEG8-Val-Ala-PAB-SG3200 is a site-specific **antibody-drug conjugate** that binds **HER2** (extracted from patent WO2016166300A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Margetuximab

Cat. No.: HY-P99030

Margetuximab (MGAH22) is a chimeric anti-**HER2** monoclonal antibody optimized Fc domain, with an EC_{50} value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer.

Margetuximab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mavelertinib

(PF-06747775)

Cat. No.: HY-12972

Mavelertinib is a selective, orally available and irreversible **EGFR tyrosine kinase inhibitor (EGFR TKI)**, with IC_{50}s of 5, 4, 12 and 3 nM for Del, L858R, and double mutants T790M/L858R and T790M/Del, respectively.



Purity: 99.21%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MC-Val-Cit-PAB-Amide-TLR7 agonist 4

Cat. No.: HY-145960

MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a **HER2-TLR7** and **HER2-TLR8** immune agonist conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methyl 2,5-dihydroxycinnamate

Cat. No.: HY-101006

Methyl 2,5-dihydroxycinnamate is an erbstatin analog and a stable, potent inhibitor of EGFR kinase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mobocertinib

(TAK-788; AP32788)

Cat. No.: HY-135815

Mobocertinib (TAK-788) is a potent and orally active inhibitor of **EGFR** and **HER2** oncogenic mutants, including exon 20 insertions, with selectivity over WT EGFR. Antitumor activity.



Purity: 99.60%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg, 100 mg, 500 mg

Mobocertinib succinate

(TAK-788 succinate; AP32788 succinate)

Cat. No.: HY-135815A

Mobocertinib succinate (TAK-788 succinate) is a potent and orally active inhibitor of **EGFR** and **HER2** oncogenic mutants, including exon 20 insertions, with selectivity over WT EGFR. Antitumor activity.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 500 mg

MTX-211

Cat. No.: HY-107364

MTX-211 is a dual inhibitor of **EGFR** and **PI3K**, used for the treatment of cancer and other diseases.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Mubritinib

(TAK-165)

Cat. No.: HY-13501

Mubritinib (TAK-165) is a potent and selective **EGFR2/HER2** inhibitor with an IC_{50} of 6 nM.



Purity: 99.91%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Mutant EGFR inhibitor

Cat. No.: HY-13984

Mutant EGFR inhibitor is a potent and selective mutant **EGFR** inhibitor extracted from patent WO 2013014448 A1; inhibits $EGFR^{L858R}$, $EGFR^{Exon\ 19\ deletion}$ and $EGFR^{T790M}$.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Mutated EGFR-IN-1

(Osimertinib analog)

Cat. No.: HY-78869

Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated **EGFR**, such as L858R EGFR, ExonI9 deletion activating mutant and T790M resistance mutant.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mutated EGFR-IN-2

Cat. No.: HY-128860

Mutated EGFR-IN-2 (compound 91) is a mutant-selective **EGFR** inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC_{50}=1nM) and ex19del/T790M), and can suppress activity...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mutated EGFR-IN-3

Cat. No.: HY-130608

Mutated EGFR-IN-3 (compound 3) is a potent, ATP-competitive and highly selective allosteric dibenzodiazepinone inhibitor of the **EGFR(L858R/T790M)** and **EGFR(L858R/T790M/C797S)** mutants with IC_{50} values of 12 nM and 13 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Naquotinib

(ASP8273)

Cat. No.: HY-19729

Naquotinib (ASP8273) is an orally available, mutant-selective and irreversible **EGFR** inhibitor; with IC_{50}s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Naquotinib mesylate

(ASP8273 (mesylate))

Cat. No.: HY-19803

Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective and irreversible **EGFR** inhibitor; with IC_{50}s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.



Purity: 98.02%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nazartinib

(EGF816)

Cat. No.: HY-12872

Nazartinib (EGF816) is a covalent mutant-selective **EGFR** inhibitor, with K_i and K_{inact} of 31 nM and 0.222 min^{-1} on EGFR(L858R/790M) mutant, respectively.



Purity: 99.48%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nazartinib mesylate

(EGF816 mesylate)

Cat. No.: HY-12872A

Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective **EGFR** inhibitor, with K_i and K_{inact} of 31 nM and 0.222 min^{-1} on EGFR(L858R/790M) mutant, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Neratinib

(HKI-272)

Cat. No.: HY-32721

Neratinib (HKI-272) is an orally available, irreversible **tyrosine kinase** inhibitor with IC_{50}s of 59 nM and 92 nM for HER2 and EGFR, respectively.



Purity: 99.59%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Neratinib-d6

Cat. No.: HY-32721S

Neratinib-d6 (HKI-272-d6) is the deuterium labeled Neratinib. Neratinib (HKI-272) is an orally available, irreversible **tyrosine kinase** inhibitor with IC_{50}s of 59 nM and 92 nM for HER2 and EGFR, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Nimotuzumab

Cat. No.: HY-P9968

Nimotuzumab is a humanized IgG1 monoclonal antibody targeting **EGFR** with a K_D of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands.

Nimotuzumab

Purity: 96.30%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NRC-2694

Cat. No.: HY-19909

NRC-2694 is an epidermal growth factor receptor (**EGFR**) antagonist with anti-cancer and anti-proliferative properties.



Purity: 99.71%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

NSC 228155

Cat. No.: HY-101084

NSC 228155 is an activator of **EGFR**, binds to the extracellular region of **EGFR** and enhance tyrosine phosphorylation of EGFR.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NSC114126

Cat. No.: HY-144445

NSC114126 is a potent and orally active inhibitor of EGFR tyrosine kinase (**EGFR-TK**). NSC114126 has strong antiproliferative activities. NSC114126 has the potential for the research of cancer diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC381467

Cat. No.: HY-144444

NSC381467 is a potent and orally active inhibitor of EGFR tyrosine kinase (**EGFR-TK**). NSC381467 has strong antiproliferative activities. NSC381467 has the potential for the research of cancer diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC81111

Cat. No.: HY-144441

NSC81111 is a potent and orally active **EGFR-TK** inhibitor with an IC_{50} of 0.15 nM. NSC81111 has anticaner effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

O-Desmethyl gefitinib

Cat. No.: HY-100064

O-Desmethyl gefitinib is an active metabolite of Gefitinib in human plasma. The formation of O-desmethyl gefitinib is dependent on CYP2D6 activity. O-desmethyl gefitinib inhibits **EGFR** with an IC_{50} of 36 nM in subcellular assays.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

O-Desmethyl gefitinib D8

Cat. No.: HY-100064S

O-Desmethyl gefitinib D8 is a deuterium labeled O-Desmethyl gefitinib. O-Desmethyl gefitinib is an active metabolite of Gefitinib in human plasma. The formation of O-desmethyl gefitinib is dependent on CYP2D6 activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

O-Desmethyl gefitinib-d6

Cat. No.: HY-100064S1

O-Desmethyl Gefitinib-d6 is the deuterium labeled O-Desmethyl gefitinib. O-Desmethyl gefitinib is an active metabolite of Gefitinib in human plasma. The formation of O-desmethyl gefitinib is dependent on CYP2D6 activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Olafertinib

Cat. No.: HY-19815

Olafertinib is a third-generation **EGFR** TKI, with GI_{50} values of 5 nM (EGFR L858R/T790M), 10 nM (EGFR del19) and 689 nM (EGFR WT), respectively. Olafertinib has the potential for NSCLC research.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Olmutinib

(HM61713, BI 1482694)

Cat. No.: HY-19730

Olmutinib (HM61713; BI-1482694) is an orally active and irreversible third **EGFR tyrosine kinase** inhibitor that binds to a cysteine residue near the kinase domain. Olmutinib is used for NSCLC.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Oritinib

(SH-1028)

Cat. No.: HY-139920

Oritinib (SH-1028), an irreversible third-generation **EGFR TKI**, overcomes T790M-mediated resistance in non-small cell lung cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oritinib mesylate

(SH-1028 mesylate)

Cat. No.: HY-139920A

Oritinib (SH-1028) mesylate is a selective, orally active, and pyrimidine-based irreversible inhibitor of **EGFR** with an IC_{50} of 18 nM. Oritinib (SH-1028) mesylate exhibits potent activity against EGFR sensitive and resistant (T790 M) mutations.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Osimertinib

(AZD-9291; Mereletinib) Cat. No.: HY-15772

Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective **EGFR** inhibitor with an apparent **IC_{50}** of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Osimertinib dimesylate

(AZD-9291 dimesylate; Mereletinib dimesylate) Cat. No.: HY-79077

Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective **EGFR** inhibitor with **IC_{50}**s of 12 and 1 nM against $EGFR^{L858R}$ and $EGFR^{L858R/T790M}$, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Osimertinib mesylate

(AZD-9291 mesylate; Mereletinib mesylate) Cat. No.: HY-15772A

Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective **EGFR** inhibitor with an apparent **IC_{50}** of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Osimertinib-d6

(AZD-9291-d6; Mereletinib-d6) Cat. No.: HY-15772S

Osimertinib D6 (AZD-9291 D6) is a deuterium labeled osimertinib. Osimertinib is a covalent, orally active, irreversible, and mutant-selective **EGFR** inhibitor with an apparent **IC_{50}** of 12 nM against L858R and 1 nM against L858R/T790M.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 1 mg

pan-HER-IN-1

Cat. No.: HY-144676

pan-HER-IN-1 (Compound C5) is an irreversible, orally active pan-**HER** inhibitor with **IC_{50}** values of 0.38, 1.6, 2.2 and 3.5 nM against **EGFR**, **HER4**, $EGFR^{T790M/L858R}$ and **HER2**, respectively. pan-HER-IN-1 induces **apoptosis** and shows antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

pan-HER-IN-2

Cat. No.: HY-144677

pan-HER-IN-2 (Compound C6) is a reversible, orally active pan-**HER** inhibitor with **IC_{50}** values of 0.72, 2.0, 8.2 and 75.1 nM against **EGFR**, **HER4**, $EGFR^{T790M/L858R}$ and **HER2**, respectively. pan-HER-IN-2 induces **apoptosis** and shows antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Panitumumab

(ABX-EGF) Cat. No.: HY-P99041

Panitumumab (ABX-EGF) is a fully human IgG2 anti-**EGFR** monoclonal antibody. Panitumumab has an anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD 174265

Cat. No.: HY-112411

PD 174265 is a potent, cell-permeable, reversible, and selective inhibitor of **EGFR** with an **IC_{50}** of 450 pM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD-089828

Cat. No.: HY-112345

PD-089828 is an ATP competitive inhibitor of **FGFR-1**, **PDGFR-β** and **EGFR** (**IC_{50}**s=0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of **c-Src** tyrosine kinase (**IC_{50}**=0.18 μM). PD-089828 also inhibits **MAPK** with an **IC_{50}** of 7.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD-161570

Cat. No.: HY-100434

PD-161570 is a potent and ATP-competitive **human FGF-1 receptor** inhibitor with an **IC_{50}** of 39.9 nM and a **K_i** of 42 nM. PD-161570 also inhibits the **PDGFR**, **EGFR** and **c-Src tyrosine kinases** with **IC_{50}** values of 310 nM, 240 nM, and 44 nM, respectively.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD153035

(SU-5271; AG1517; ZM 252868)

Cat. No.: HY-14346

PD153035 (SU-5271; AG1517; ZM 252868) is a potent **EGFR** inhibitor with K_i and IC_{50} of 6 and 25 pM, respectively.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PD153035 Hydrochloride (SU-5271 Hydrochloride; AG1517 Hydrochloride; ZM 252868 Hydrochloride)

Cat. No.: HY-12013

PD153035 Hydrochloride (SU-5271 Hydrochloride) is a potent **EGFR** inhibitor with K_i and IC_{50} of 6 and 25 pM, respectively.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PD158780

Cat. No.: HY-18609

PD158780 is a potent **EGFR** family inhibitor with IC_{50}s of 8 pM, 49, 52, 52 nM for EGFR, ErbB2, ErbB3, and ErbB4, respectively.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

PD168393

Cat. No.: HY-13896

PD168393 is a potent, selective and cell-permeable inhibitor of **EGFR tyrosine kinase** and **ErbB2**. PD168393 irreversiblely inactivates EGF receptor (IC_{50}=0.7 nM) and is inactive against insulin receptor, PDGFR, FGFR and PKC.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

PDZ1i

(113B7)

Cat. No.: HY-124813

PDZ1i is a potent, BBB-penetrated and specific **MDA-9/Syntenin** inhibitor. PDZ1i inhibits crucial GBM (glioblastoma multiforme) signaling involving **FAK** and **EGFRvIII**. PDZ1i reduces **MMP** secretion. PDZ1i can improve survival of brain tumor-bearing mice and reduce tumor invasion.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pelitinib

(EKB-569; WAY-EKB 569)

Cat. No.: HY-32718

Pelitinib (EKB-569;WAY-EKB 569) is an irreversible inhibitor of **EGFR** with an IC_{50} of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC_{50}s of 282, 800, and 1255 nM, respectively.



Purity: 98.80%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pelitinib-d6

Cat. No.: HY-32718S

Pelitinib-d6 (EKB-569-d6) is the deuterium labeled Pelitinib. Pelitinib (EKB-569) is an irreversible inhibitor of **EGFR** with an IC_{50} of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC_{50}s of 282, 800, and 1255 nM, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Pertuzumab

Cat. No.: HY-P9912

Pertuzumab, a humanized IgG1 monoclonal antibody, is a **HER2** dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

Purity: 99.10%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Pertuzumab (PBS)

Cat. No.: HY-P9912A

Pertuzumab (PBS), a humanized monoclonal antibody, is a **HER2** dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-06459988

Cat. No.: HY-19985

PF-06459988 is an irreversible inhibitor of T790M-Containing EGFR Mutants.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-6274484

Cat. No.: HY-101450

PF-6274484 is a potent **EGFR** inhibitor with K_is of 0.14 nM and 0.18 nM for EGFR-L858R/T790M and WT EGFR, respectively. PF-6274484 inhibits EGFR-L858R/T790M autophosphorylation in H1975 tumor cells and EGFR WT in A549 tumor cells with IC_{50}s of 6.6 and 5.8 nM, respectively.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PKI-166

Cat. No.: HY-117155

PKI-166 is a potent, selective and orally bioavailable **EGFR tyrosine kinase** inhibitor, with an IC_{50} of 0.7 nM.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

PKI-166 hydrochloride

Cat. No.: HY-110328

PKI-166 hydrochloride is a potent, selective and orally active **EGFR tyrosine kinase** inhibitor, with an IC_{50} of 0.7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

pp60 (v-SRC) Autophosphorylation Site, Phosphorylated

Cat. No.: HY-P2548

pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. pp60 (v-SRC) Autophosphorylation Site, Phosphorylated can be used for the screening of EGFR Kinase inhibitors via phosphorylated-substrate quantification.

RRLIEDNE-{pTyr}-TARG

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC EGFR degrader 2

Cat. No.: HY-144304

PROTAC EGFR degrader 2 is a potent PROTAC **EGFR** degrader. PROTAC EGFR degrader 2 exhibits excellent antiproliferative activity with IC_{50} of 4.0 nM and good EGFR degradation activity with DC50 of 36.51 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC EGFR degrader 3

Cat. No.: HY-144605

PROTAC EGFR degrader 3 is a potent **PROTAC EGFR** degrader. PROTAC EGFR degrader 3 shows excellent cellular activity against the H1975 and HCC827 cells with high selectively. PROTAC EGFR degrader 3 shows that the lysosome is involved in the degradation process of EGFR mutant degradation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pyrotinib

(SHR-1258)

Cat. No.: HY-104065

Pyrotinib (SHR-1258) is a potent and selective **EGFR/HER2** dual inhibitor with IC_{50}s of 13 and 38 nM, respectively.



Purity: 99.61%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Pyrotinib dimaleate

(SHR-1258 dimaleate)

Cat. No.: HY-104065B

Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective **EGFR/HER2** dual inhibitor with IC_{50}s of 13 and 38 nM, respectively.



Purity: 99.63%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Rezivertinib

(BPI-7711)

Cat. No.: HY-109189

Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RG13022

(Tyrphostin RG13022)

Cat. No.: HY-101429

RG13022 is a **tyrosine kinase** inhibitor; inhibits the autophosphorylation reaction of the EGF receptor with an IC_{50} of 4 μM.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RG14620

(Tyrphostin RG14620) Cat. No.: HY-101426

RG14620 is an **EGFR** inhibitor with an IC_{50} of 3 μM.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rociletinib

(CO-1686; AVL-301; CNX-419) Cat. No.: HY-15729

Rociletinib (CO-1686) is an orally delivered kinase inhibitor that specifically targets the mutant forms of **EGFR** including T790M, and the K_i values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.



Purity: 99.79%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rociletinib hydrobromide (CO-1686 hydrobromide; AVL-301 hydrobromide; CNX-419 hydrobromide)

Cat. No.: HY-15729A

Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of **EGFR** including T790M, and the K_i values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.



Purity: 98.04%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RTC-5

(TRC-382) Cat. No.: HY-123952

RTC-5 (TRC-382) is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an **EGFR** driven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sapitinib

(AZD-8931) Cat. No.: HY-13050

Sapitinib (AZD-8931) is a reversible, ATP competitive **EGFR** inhibitor of with IC_{50}s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SC209

Cat. No.: HY-144880

SC209, an **ADC cytotoxin** extracted from patent WO2021247798, is used in synthesis of anti-**EGFR** antibody-drug conjugate ADC. SC209 is a metabolite of STRO-002.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Selatinib

Cat. No.: HY-116437

Selatinib is a reversible and orally active dual **EGFR** and **ErbB2** inhibitor with IC_{50}s of 13 nM and 22.5 nM, respectively. Selatinib has anticancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Simotinib

Cat. No.: HY-101820

Simotinib is a selective, specific, and orally bioavailable **EGFR** tyrosine kinase inhibitor, with an IC_{50} of 19.9 nM. Antineoplastic activities.



Purity: 99.70%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Simotinib hydrochloride

Cat. No.: HY-101820A

Simotinib hydrochloride is a selective, specific, and orally bioavailable **EGFR** tyrosine kinase inhibitor, with an IC_{50} of 19.9 nM. Antineoplastic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SU5204

Cat. No.: HY-126319

SU5204, a tyrosine kinase inhibitor, has IC_{50}s of 4 and 51.5 μM for **FLK-1 (VEGFR-2)** and **HER2**, respectively.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sulforaphene

Cat. No.: HY-N2450

Sulforaphene, isolated from radish seeds, exhibits an ED_{50} against velvetleaf seedlings approximately 2 x 10^{-4} M. Sulforaphene promotes cancer cells apoptosis and inhibits migration via inhibiting **EGFR**, **p-ERK1/2**, **NFκB** and other signals.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Sunvozertinib

(DZD9008)

Cat. No.: HY-132842

Sunvozertinib (DZD9008) is a potent **ErbBs** (EGFR, Her2, especially mutant forms) and **BTK** inhibitor.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAK-285

Cat. No.: HY-15196

TAK-285 is a potent, selective, ATP-competitive and orally active **HER2** and **EGFR(HER1)** inhibitor with **IC_{50}** of 17 nM and 23 nM, respectively. TAK-285 is >10-fold selectivity for **HER1/2** than HER4, and less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc.



Purity: 98.04%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tarlox-TKI

Cat. No.: HY-43533

Tarlox-TKI, the active metabolite of Tarloxotinib, is an irreversible pan-**ErbB** TKI (Tarlox-TKI).



Purity: 96.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Tarloxotinib bromide

(TH-4000)

Cat. No.: HY-17632

Tarloxotinib bromide (TH-4000) is an irreversible **EGFR/HER2** inhibitor.



Purity: 99.26%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAS0728

Cat. No.: HY-111553

TAS0728 is a potent, selective, orally active, irreversible and covalent-binding **HER2** inhibitor, binds to HER2 at C805, inhibits its kinase activity, with an **IC_{50}** of 13 nM.



Purity: 99.15%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TAS6417

(CLN-081)

Cat. No.: HY-112299

TAS6417 (CLN-081) is a highly effective, orally active and **pan-mutation-selective EGFR** tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with **IC_{50}** values ranging from 1.1-8.0 nM.



Purity: 98.77%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tephrosin

(Deguelinol I; Hydroxydeguelin)

Cat. No.: HY-N1166

Tephrosin is a natural rotenoid which has potent antitumor activities. Tephrosin induces degradation of of **EGFR** and **ErbB2** by inducing internalization of the receptors.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tesevatinib

(XL-647; EXEL-7647; KD-019)

Cat. No.: HY-13314

Tesevatinib (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits **EGFR**, **ErbB2**, **KDR**, **Flt4** and **EphB4** kinase with **IC_{50}**s of 0.3, 16, 1.5, 8.7, and 1.4 nM.



Purity: 99.21%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg

Tezatabep matraxetan

Cat. No.: HY-139565

Tezatabep matraxetan is a radiolabeled polypeptide used for diagnosis and research of cancer characterized by overexpression of **HER2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Theliatinib

(Xiliertinib; HMPL-309) Cat. No.: HY-104066

Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective **EGFR** inhibitor with a K_i of 0.05 nM and an IC_{50} of 3 nM. Theliatinib has an IC_{50} of 22 nM for **EGFR T790M/L858R mutant**.



Purity: 99.88%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Trastuzumab

(Anti-Human HER2, Humanized Antibody) Cat. No.: HY-P9907

Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

Trastuzumab

Purity: 99.80%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Trastuzumab deruxtecan

(DS-8201; DS-8201a) Cat. No.: HY-138298A

Trastuzumab deruxtecan (DS-8201a) is an anti-**human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC)**.

Trastuzumab deruxtecan

Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trastuzumab deruxtecan (solution)

(DS-8201 (solution); DS-8201a (solution)) Cat. No.: HY-138298

Trastuzumab deruxtecan (DS-8201a) (solution) is an anti-**human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC)**.

Trastuzumab deruxtecan

Purity: 98.75%
Clinical Data: Launched
Size: 5 mg (10 mg × mL * 500 µL in Aqµeoµs solµtion)

Trastuzumab emtansine

(Ado-Trastuzumab emtansine; PRO132365; T-DM 1) Cat. No.: HY-P9921

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine).

Trastuzumab emtansine

Purity: ≥99.40%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Tucatinib

(Irbinitinib; ARRY-380; ONT-380) Cat. No.: HY-16069

Tucatinib (Irbinitinib) is a potent, orally active and selective **HER2** inhibitor with an IC_{50} of 8 nM.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Tucatinib hemiethanolate (Irbinitinib hemiethanolate; ARRY-380 hemiethanolate; ONT-380 hemiethanolate)

Cat. No.: HY-16069A

Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective **HER2** inhibitor with an IC_{50} of 8 nM.



Purity: 99.45%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tuxobertinib

(BDTX-189) Cat. No.: HY-136789

Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric **EGFR** and **HER2** oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. Tuxobertinib shows K_Ds of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity.



Purity: 99.94%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TX1-85-1

Cat. No.: HY-100848

TX1-85-1 is an irreversible **Her3 (ErbB3)** inhibitor with an IC_{50} of 23 nM. TX1-85-1 is also the first selective **Her3 ligand**, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Tyrphostin 23

(Tyrphostin A23; RG-50810; AG 18) Cat. No.: HY-15644

Tyrphostin 23 (Tyrphostin A23) is an **EGFR** inhibitor with an IC_{50} and K_i of 35 and 11 µM, respectively.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tyrphostin 25

(AG82; Tyrphostin A 25; Tyrphostin AG 82; RG-50875)

Cat. No.: HY-101958

Tyrphostin 25 (AG82) is a specific inhibitor of the **EGFR tyrosine kinase**. Tyrphostin 25 is also a **GPR35** agonist with an IC_{50} of 0.94 μM and an EC_{50} of 5.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyrphostin 8

Cat. No.: HY-W174279

Tyrphostin 8 is a **tyrosine kinase**, with an IC_{50} of 560 μM for **EGFR kinase**. Tyrphostin 8 is also a **GTPase** inhibitor. Tyrphostin 8 can inhibit the protein **serine/threonine phosphatase calcineurin** (IC_{50}=21 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyrphostin AG 112

Cat. No.: HY-112474

Tyrphostin AG 112 is an **EGFR phosphorylation** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyrphostin AG 528

(Tyrphostin B66; AG 528)

Cat. No.: HY-100499

Tyrphostin AG 528 is an inhibitor of **EGFR** and **ErbB2** with IC_{50}s of 4.9 and 2.1 μM, respectively. Tyrphostin AG 528 (Tyrphostin B66) is a protein tyrosine kinase inhibitor, with IC_{50}s of 4.9 μM for **epidermal growth factor receptors (EGFR)** and 2.1 μM for **ErbB2**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyrphostin AG 879

(AG 879)

Cat. No.: HY-20878

Tyrphostin AG 879 (AG 879) is a tyrosine kinase inhibitor that inhibits **TrKA** phosphorylation (IC_{50} of 10 μM), but not TrKB and TrKC.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyrphostin AG30

(AG30)

Cat. No.: HY-118532

Tyrphostin AG30 (AG30) is a potent and selective **EGFR tyrosine kinase** inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Varlitinib

(ASLAN001; ARRY-334543)

Cat. No.: HY-10530

Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-**EGFR** inhibitor with IC_{50}s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.



Purity: 96.66%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

VEGFR-IN-1

Cat. No.: HY-101219

VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC_{50}s of 0.02, 0.18, 0.24 7.3, and 7 μM for **KDR**, **Flt-1**, c-Kit, EGF-R, and c-Src, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WHI-P154

Cat. No.: HY-13895

WHI-P154 is a potent **EGFR** inhibitor, and also modestly blocks **JAK3**, with IC_{50}s of 4 nM and 1.8 μM, respectively.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

WHI-P180

(Janex 3)

Cat. No.: HY-15769

WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits **RET**, **KDR** and **EGFR** with IC_{50}s of 5 nM, 66 nM and 4 μM, respectively.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

WHI-P180 hydrochloride

(Janex 3 hydrochloride;)

Cat. No.: HY-15769A

WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits **RET**, **KDR** and **EGFR** with IC_{50}s of 5 nM, 66 nM and 4 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WZ-3146

Cat. No.: HY-12001

WZ3146 is a mutant selective **EGFR** inhibitor with IC_{50}s of 2, 2, 5, 14 and 66 nM for $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, $EGFR^{E746\_A750}$, $EGFR^{E746\_A750/T790M}$ and EGFR, respectively.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

WZ4002

Cat. No.: HY-12026

WZ4002 is a mutant selective **EGFR** inhibitor with IC_{50}s of 2, 8, 3 and 2 nM for $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, $EGFR^{E746\_A750}$ and $EGFR^{E746\_A750/T790M}$, respectively.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

WZ8040

Cat. No.: HY-12029

WZ8040 is an irreversible mutated **EGFR T790M** inhibitor and inhibits **EGFR phosphorylation**. WZ8040 displays 100-fold greater activity against the mutated EGFR than the normal.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

ZD-4190

Cat. No.: HY-U00002

ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (**VEGFR2**) and of epidermal growth factor receptor (**EGFR**) signalling, used for the treatment of cancer.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Zorifertinib

(AZD3759)

Cat. No.: HY-18750

Zorifertinib (AZD3759) is a potent, orally active, central nervous system-penetrant, **EGFR** inhibitor. At K_m ATP concentrations, the IC_{50}s are 0.3, 0.2, and 0.2 nM for $EGFR^{wt}$, $EGFR^{L858R}$, and $EGFR^{exon\ 19Del}$, respectively.



Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

β-Hydroxyisovalerylshikonin

Cat. No.: HY-N4201

Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermium radix, acts as a potent inhibitor of **protein tyrosine kinases (PTK)**, with IC_{50}s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ephrin Receptor

The Eph receptor tyrosine kinase (RTK) family comprises the largest group of surface receptors and are categorized into EphA or EphB subclasses based on sequence homology and preferential binding to their ephrin-A and ephrin-B ligands, respectively.

In humans, nine EphA (EphA1-8,10) and five EphB (EphB1-4,6) receptors are expressed, along with five ephrin-A and three ephrin-B ligands. Unlike most RTKs, Eph receptors interact with ligands that are often membrane-bound, allowing both “forward signaling” in the receptor-bound cell and “reverse signaling” in the ephrin-bound cell. In addition to “forward signaling,” Eph receptors can signal in the absence of ligand binding and kinase activation through cross-talk with other RTKs, such as HER2.

Eph receptor tyrosine kinases and their ligands, the ephrins, play key roles in the regulation of migration and cell adhesion during development, thereby influencing cell fate, morphogenesis and organogenesis. By now, many Eph receptors and ephrins have also been found to play important roles in the progression of cancer. Therefore, the Eph/ephrin system is considered a promising therapeutic target.

123C4

Cat. No.: HY-P0177

123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase **EPHA4**, with a K_i value of 0.65 μM.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

ALW-II-41-27

(Eph receptor tyrosine kinase inhibitor)

Cat. No.: HY-18007

ALW-II-41-27 is a **Eph** family tyrosine kinase inhibitor with an IC_{50} of 11 nM for Eph2.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Eph inhibitor 2

Cat. No.: HY-131005

Eph inhibitor 2 (Example 35) is a **Eph** family tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EphA2 agonist 1

Cat. No.: HY-147637

EphA2 agonist 1 (Compound 7bg) is a potent **EphA2 receptor** agonist. EphA2 agonist 1 shows great potency and selectivity toward EphA2 overexpressed glioblastoma cells and stimulates EphA2 phosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EphA2 agonist 2

Cat. No.: HY-146141

EphA2 agonist 2 (Lead compound) is a selective **EphA2** agonist with antitumor activities. EphA2 agonist 2 can cross the BBB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JI-101

Cat. No.: HY-16265

JI-101 is an orally available multi-kinase inhibitor of **VEGFR2**, **PDGFRβ** and **EphB4** with potent anti-cancer activity.



Purity: 99.43%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

KYL peptide

Cat. No.: HY-P2264

KYL peptide, an antagonistic peptide, selectively targets **EphA4 receptor**. KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML786 dihydrochloride

Cat. No.: HY-14979A

ML786 dihydrochloride is a potent and orally bioavailable **Raf** inhibitor, with IC_{50}s of 2.1, 4.2, and 2.5 nM for ^{V600E}**ΔB-Raf**, **wt B-Raf**, and **C-Raf**, respectively. ML786 dihydrochloride also inhibits **Abl-1**, **DDR2**, **EPHA2**, **KDR**, and **RET** (IC_{50}=<0.5, 7.0, 11, 6.2, 0.8 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NVP-BHG712

(BHG712)

Cat. No.: HY-13258A

NVP-BHG712 is an oral active **EphB4 kinase autophosphorylation** inhibitor, with IC_{50} values of 3.3 nM and 3.0 nM for EphA2 and EphB4, respectively.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-BHG712 isomer

Cat. No.: HY-13258

NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tesevatinib

(XL-647; EXEL-7647; KD-019)

Cat. No.: HY-13314

Tesevatinib (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits **EGFR**, **ErbB2**, **KDR**, **Flt4** and **EphB4** kinase with IC_{50}s of 0.3, 16, 1.5, 8.7, and 1.4 nM.



Purity: 99.21%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg

UniPR129

Cat. No.: HY-123607

UniPR129 is a potent **Eph/ephrin** antagonist. UniPR129 has the potential for the research of cancer disease.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UniPR505

Cat. No.: HY-146375

UniPR505 (Compound 14) is an **EphA2** antagonist with an IC_{50} of 0.95 μM. UniPR505 displays anti-angiogenic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAK

PTK2 protein tyrosine kinase 2; PTK2; Focal adhesion kinase

FAK (Focal Adhesion Kinase or PTK2) is a non-receptor and non-membrane associated protein tyrosine kinase that is activated at the sites of cell-matrix adhesions and integrin clustering by auto-phosphorylation (at Tyr397), Src, and other tyrosine kinases. FAK mediates integrin-based cell signaling by transferring signals regulating cell migration, adhesion, and survival from the extracellular matrix to the cytoplasm.

FAK is overexpressed in many tumors, including those derived from the head and neck, colon, breast, prostate, liver, and thyroid. Furthermore, FAK overexpression is highly correlated with an invasive phenotype in these tumors. Inhibition of FAK signaling by overexpression of dominant-negative fragments of FAK reduces invasion of glioblastomas and ovarian cancer cells. FAK therefore represents an important target for the development of anti-neoplastic and anti-metastatic drugs.

FAK Inhibitors

ALK inhibitor 1

Cat. No.: HY-15357

ALK inhibitor 1 (compound 17) is a potent pyrimidin **ALK** inhibitor. ALK inhibitor 1 is a potent inhibitor of **testis-specific serine/threonine kinase 2** (**TSSK2**; **IC_{50}**=31 nM) and **focal adhesion kinase** (**FAK**; **IC_{50}**=2 nM).



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

ALK inhibitor 2

Cat. No.: HY-15358

ALK inhibitor 2 (compound 18) is a potent pyrimidin **ALK** inhibitor. ALK inhibitor 2 is a potent inhibitor of **testis-specific serine/threonine kinase 2** (**TSSK2**; **IC_{50}**=37 nM) and **focal adhesion kinase** (**FAK**; **IC_{50}**=5 nM).



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

AMP-945

Cat. No.: HY-145652

AMP-945 is an inhibitor of the enzyme focal adhesion kinase (**FAK**).



Purity: 98.96%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Batatasin III

Cat. No.: HY-122965

Batatasin III, a stilbenoid, inhibits cancer migration and invasion by suppressing epithelial to **mesenchymal transition (EMT)** and **FAK-AKT** signals. Batatasin III has anti-cancer activities.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

BI-3663

Cat. No.: HY-111546

BI-3663 is a highly selective **PTK2/FAK** PROTAC (**DC_{50}**=30 nM), with **Cereblon** ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an **IC_{50}** of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 (HY-124625) linked to Pomalidomide (HY-10984) with a linker.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

BI-4464

Cat. No.: HY-124625

BI-4464 is a highly selective ATP competitive inhibitor of **PTK2/FAK**, with an **IC_{50}** of 17 nM. A PTK2 ligand for PROTAC.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CEP-37440

Cat. No.: HY-15841

CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).



Purity: 99.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Chloropyramine hydrochloride

Cat. No.: HY-B1305

Chloropyramine hydrochloride is a **histamine receptor H1** antagonist which can also inhibit the biochemical function of **VEGFR-3** and **FAK**.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Conteltinib

(CT-707)

Cat. No.: HY-109084

Conteltinib (CT-707) is a multi-kinase inhibitor targeting FAK, ALK, and Pyk2. Conteltinib exerts significant inhibitory effect on **FAK** with an **IC_{50}** of 1.6 nM.



Purity: 99.47%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Defactinib

(VS-6063; PF-04554878)

Cat. No.: HY-12289

Defactinib (VS-6063; PF-04554878) is a novel **FAK** inhibitor with potential antiangiogenic and antineoplastic activities.



Purity: 99.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Defactinib hydrochloride

(VS-6063 hydrochloride; PF 04554878 hydrochloride) Cat. No.: HY-12289A

Defactinib hydrochloride (VS-6063 hydrochloride; PF 04554878 hydrochloride) is a novel **FAK** inhibitor, which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.



Purity: 98.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EGFR-IN-46

Cat. No.: HY-144794

EGFR-IN-46 is a potent **EGFR** and **FAK** dual inhibitor with IC_{50}s of 20.17 nM, 14.25 nM, respectively. EGFR-IN-46 significantly inhibits the growth of cancer cells. EGFR-IN-46 induces cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAK inhibitor 2

Cat. No.: HY-128580

FAK inhibitor 2 is a potent **focal adhesion kinase (FAK)** inhibitor with an IC_{50} of 0.07 nM, with antitumor and anti-angiogenesis activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAK inhibitor 5

Cat. No.: HY-18928

FAK inhibitor 5 (compound 2) is a novel allosteric **FAK** inhibitor, with IC_{50} values in the low micromolar range.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAK inhibitor 6

Cat. No.: HY-146203

Compound 26F not only optimized the effective inhibitory enzyme (ic_{50}= 28.2 nm), but also showed relatively less cytotoxicity (ic_{50}= 3.32 μ M) And induced MDA-MB-231 cell apoptosis in a dose-dependent manner, effectively blocking MDA-MB-231 cells in g0/g1 phase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAK PROTAC B5

Cat. No.: HY-143458

FAK PROTAC B5 (Compound B5) is a **FAK PROTAC** degrader with an IC_{50} value of 14.9 nM. FAK PROTAC B5 presents strong FAK degradation activity, antiproliferative activity, outstanding plasma stability and moderate membrane permeability. FAK PROTAC B5 inhibits cell migration and invasion.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAK-IN-1

Cat. No.: HY-145108

FAK-IN-1 is a **FAK** inhibitor with anticancer activities (WO2020231726 (Example 27)).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAK-IN-2

Cat. No.: HY-144448

FAK-IN-2 is a potent and orally active focal adhesion kinase (**FAK**) inhibitor, with anticancer activity (FAK IC_{50}= 35 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAK-IN-3

Cat. No.: HY-143407

FAK-IN-3 (Compound 36) is a potent inhibitor of focal adhesion kinase (**FAK**). FAK-IN-3 not only decreases migration and invasion of PA-1 cells, but also reduces expression of MMP-2 and MMP-9. FAK-IN-3 inhibits tumor growth and metastasis, and no obvious adverse effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAK-IN-4

Cat. No.: HY-146065

FAK-IN-4 (Compound 7d) is potential **FAK** inhibitor with anticancer activities. FAK-IN-4 induces cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAK-IN-5

Cat. No.: HY-147520

FAK-IN-5 (Compound 8l) is a **FAK signaling** inhibitor. FAK-IN-5 induces cell **apoptosis** and **autophagy**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fangchinoline

Cat. No.: HY-N1372A

Fangchinoline is isolated from Stephania tetrandra with extensive biological activities, such as enhancing immunity, anti-inflammatory sterilization and anti-atherosclerosis.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

GSK215

Cat. No.: HY-132296

GSK215 is a potent and selective **PROTAC focal adhesion kinase (FAK)** degrader. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK2256098

Cat. No.: HY-100498

GSK2256098 is a selective **FAK** kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells.



Purity: 99.74%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Harringtonolide

Cat. No.: HY-N10335

Harringtonolide is a potent **RACK1** inhibitor (IC_{50}=39.66 μM in A375 cells). Harringtonolide inhibits the epithelial-mesenchymal transition (EMT) process and cell proliferation by affecting the interaction between **FAK** and **RACK1**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Masitinib

(AB1010)

Cat. No.: HY-10209

Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

NAMI-A

Cat. No.: HY-19376

NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases, inhibits the adhesion and migration. In vitro: NAMI-A can significantly affect tumor cells with metastatic ability.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Nitidine chloride

Cat. No.: HY-N0498

Nitidine chloride, a potential **anti-malarial** lead compound derived from Zanthoxylum nitidum (Roxb) DC, exerts potent anticancer activity through diverse pathways, including inducing **apoptosis**, inhibiting **STAT3** signaling cascade, **DNA topoisomerase 1 and 2A**, **ERK** and...



Purity: 99.61%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

NVP-TAE 226

(TAE226)

Cat. No.: HY-13203

NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual **FAK** and **IGF-1R** inhibitor with IC_{50}s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits **Pyk2** and **insulin receptor (InsR)** with IC_{50}s of 3.5 nM and 44 nM, respectively.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PDZ1i

(113B7)

Cat. No.: HY-124813

PDZ1i is a potent, BBB-penetrated and specific **MDA-9/Syntenin** inhibitor. PDZ1i inhibits crucial GBM (glioblastoma multiforme) signaling involving **FAK** and **EGFRvIII**. PDZ1i reduces **MMP** secretion. PDZ1i can improve survival of brain tumor-bearing mice and reduce tumor invasion.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Petunidin chloride

Cat. No.: HY-126410

Petunidin chloride is an O-methylated anthocyanidin derived from delphinidin.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

PF-431396

Cat. No.: HY-10460

PF-431396 is an orally active dual **focal adhesion kinase (FAK)** and **proline-rich tyrosine kinase 2 (PYK2)** inhibitor, with IC_{50} values of 2 nM and 11 nM, respectively.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

PF-562271

(VS-6062)

Cat. No.: HY-10459

PF-562271 (VS-6062) is a potent, ATP-competitive and reversible **FAK** and **Pyk2** kinase inhibitor with IC_{50}s of 1.5 nM and 13 nM, respectively.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PF-562271 besylate

(VS-6062 besylate)

Cat. No.: HY-10458

PF-562271 (VS-6062) besylate is a potent ATP-competitive, reversible inhibitor of **FAK** and **Pyk2** kinase, with an IC_{50} of 1.5 nM and 13 nM, respectively.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PF-562271 hydrochloride

(VS-6062(hydrochloride))

Cat. No.: HY-20403

PF-562271 (VS-6062) hydrochloride is a potent, ATP-competitive and reversible **FAK** and **Pyk2** kinase inhibitor with IC_{50}s of 1.5 nM and 13 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-573228

Cat. No.: HY-10461

PF-573228 is a potent and selective **FAK** inhibitor with IC_{50} of 4 nM for purified recombinant catalytic fragment of FAK.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

PND-1186

(VS-4718; SR-2516)

Cat. No.: HY-13917

PND-1186 (VS-4718) is a potent, highly-specific and reversible inhibitor of **FAK** with an IC_{50} of 1.5 nM. PND-1186 selectively promotes tumor cell **apoptosis**.



Purity: 99.80%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PND-1186 hydrochloride

(VS-4718 hydrochloride; SR-2516 hydrochloride)

Cat. No.: HY-13917A

PND-1186 hydrochloride (VS-4718 hydrochloride) is a potent, highly-specific and reversible inhibitor of **FAK** with an IC_{50} of 1.5 nM. PND-1186 hydrochloride selectively promotes tumor cell **apoptosis**.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PROTAC FAK degrader 1

Cat. No.: HY-119932

PROTAC FAK degrader 1 is a selective and potent **von Hippel-Lindau**-based **focal adhesion kinase** (**FAK**) degrader with an IC_{50} of 6.5 nM, DC_{50} of 3 nM.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

SU6656

Cat. No.: HY-B0789

SU6656 is a **Src family kinases** inhibitor with IC_{50}s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.



Purity: 96.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ULK1-IN-2

Cat. No.: HY-143466

ULK1-IN-2 (compound 3s) is a potent **ULK1** inhibitor. ULK1-IN-2 shows highest cytotoxic effect against cancer cell lines, with IC_{50} of 1.94 μM in A549. ULK1-IN-2 can induce apoptosis and simultaneously block autophagy, and can be used to study NSCLC (Non-small cell lung cancer).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Y15

(FAK Inhibitor 14)

Cat. No.: HY-12444

Y15 is a potent and specific inhibitor of focal adhesion kinase (**FAK**) that inhibits its autophosphorylation activity, decreases the viability of cancer cells, and blocks tumor growth.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

YH-306

Cat. No.: HY-120213

YH-306 is an antitumor agent. YH-306 suppresses colorectal tumour growth and metastasis via **FAK** pathway. YH-306 significantly inhibits the migration and invasion of colorectal cancer cells. YH-306 potently suppresses uninhibited proliferation and induces cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR

Fibroblast growth factor receptor

FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins. Some of these receptors are involved in pathological conditions. A point mutation in FGFR3 can lead to achondroplasia. Five distinct membrane FGFR have been identified in vertebrates and all of them belong to the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). The fibroblast growth factor family constitutes one of the most important groups of paracrine factors that act during development. They are responsible for determining certain cells to become mesoderm, for the production of blood vessels, for limb outgrowth, and for the growth and differentiation of numerous cell types.

(Z)-Orantinib

((Z)-SU6668; (Z)-TSU-68)

Cat. No.: HY-10517A

(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of **Flk1/KDR**, **PDGFRβ**, and **FGFR1**, with IC_{50}s of 2.1, 0.008, and 1.2 μM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

2,5-Dihydroxybenzoic acid

Cat. No.: HY-W001179

2,5-Dihydroxybenzoic acid is a derivative of benzoic and a powerful inhibitor of **fibroblast growth factors**.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

2,5-Dihydroxybenzoic acid-d3

Cat. No.: HY-W001179S

2,5-Dihydroxybenzoic acid-d3 is the deuterium labeled 2,5-Dihydroxybenzoic acid.
2,5-Dihydroxybenzoic acid is a derivative of benzoic and a powerful inhibitor of **fibroblast growth factors**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 50 mg

3-Methylthienyl-carbonyl-JNJ-7706621

Cat. No.: HY-141685

3-Methylthienyl-carbonyl-JNJ-7706621 is a potent and selective inhibitor of **cyclin-dependent kinase (CDK)**, with IC_{50}s of 6.4 nM and 2 nM for **CDK1/cyclinB** and **CDK2/cyclinA**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alofanib

(RPT835)

Cat. No.: HY-17601

Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (**FGFR2**). Anticancer and antiangiogenic activity.



Purity: 98.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Aprutumab

(BAY 1179470)

Cat. No.: HY-P99007

Aprutumab (BAY 1179470) is a fully human **FGFR2** monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research.

Aprutumab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ARQ 069

Cat. No.: HY-101544

ARQ 069, an analog of ARQ 523, inhibits **FGFR** in an enantiospecific manner. ARQ 069 targets the unphosphorylated, inactive forms of FGFR1/FGFR2 kinases (IC_{50}s of 0.84 μM and 1.23 μM, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ASP5878

Cat. No.: HY-19983

ASP5878 is an oral active inhibitor of **FGFR 1, 2, 3, and 4**, with IC_{50} values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity.



Purity: 99.86%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD4547

Cat. No.: HY-13330

AZD4547 is a potent inhibitor of the **FGFR** family with IC_{50}s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for **FGFR1**, **FGFR2**, **FGFR3**, and **FGFR4**, respectively.



Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Bemarituzumab

Cat. No.: HY-P99010

Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against **FGFR2b** (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research.

Bemarituzumab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BLU9931

Cat. No.: HY-12823

BLU9931 is a potent, highly selective, and irreversible **fibroblast growth factor receptor 4 (FGFR4)** inhibitor with an IC_{50} of 3 nM and a K_d of 6 nM. BLU9931 has significant antitumor activity.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BO-264

Cat. No.: HY-135960

BO-264 is a highly potent and orally active **transforming acidic coiled-coil 3 (TACC3)** inhibitor with an IC_{50} of 188 nM and a K_d of 1.5 nM. BO-264 specifically blocks the function of **FGFR3-TACC3** fusion protein.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg, 250 mg

CP-547632

Cat. No.: HY-13302

CP-547632 is an orally active, ATP-competitive and potent **VEGFR-2** and **FGF** kinases inhibitor with IC_{50}s of 11 nM and 9 nM, respectively. CP-547632 is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 has antitumor efficacy.



Purity: 98.71%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CP-547632 hydrochloride

Cat. No.: HY-13302B

CP-547632 hydrochloride is an orally active, ATP-competitive and potent **VEGFR-2** and **FGF** kinases inhibitor with IC_{50}s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs).



Purity: 98.24%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CP-547632 TFA

Cat. No.: HY-13302C

CP-547632 TFA is an orally active, ATP-competitive and potent **VEGFR-2** and **FGF** kinases inhibitor with IC_{50}s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CPL304110

Cat. No.: HY-131908

CPL304110 is a potent, orally active and selective inhibitor of **fibroblast growth factor receptors FGFR (1-3)**, with IC_{50} values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectively.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Derazantinib

(ARQ-087)

Cat. No.: HY-19981

Derazantinib (ARQ-087) is an orally bioavailable, ATP competitive tyrosine kinase inhibitor; exhibits potent activity against **FGFR1-3** chondrocytes with IC_{50}s of 4.5, 1.8, and 4.5 nM, respectively.



Purity: 99.18%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Derazantinib Racemate

(ARQ-087 Racemate)

Cat. No.: HY-19981A

Derazantinib Racemate (ARQ-087 Racemate) is the racemate of Derazantinib. Derazantinib is an orally bioavailable, ATP competitive tyrosine kinase inhibitor; exhibits potent activity against **FGFR1-3** chondrocytes with IC_{50}s of 4.5, 1.8, and 4.5 nM, respectively.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg

Dovitinib

(CHIR-258; TKI258)

Cat. No.: HY-50905

Dovitinib (CHIR-258) is an orally active, potent **multi-targeted tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **CSF-1R**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Dovitinib lactate

(CHIR-258 lactate; TKI-258 lactate)

Cat. No.: HY-10207

Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: 99.62%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dovitinib lactate hydrate

(TKI258 lactate hydrate; CHIR-258 lactate hydrate)

Cat. No.: HY-B0062

Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dovitinib-D8

Cat. No.: HY-50905S

Dovitinib-D8 (CHIR-258-D8) is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E7090

Cat. No.: HY-101466

E7090 is an orally available, potent, and selective **FGFR** inhibitor with IC_{50}s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for **FGFR1/FGFR2/FGFR3/FGFR4**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E7090 succinate

Cat. No.: HY-101466A

E7090 succinate is an orally available, selective and potent inhibitor of **FGFR1, FGFR2** and **FGFR3** tyrosine kinase activities, with IC_{50} values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ENMD-2076

Cat. No.: HY-10987A

ENMD-2076 is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ENMD-2076 Tartrate

Cat. No.: HY-10987

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 98.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

EOC317

(ACTB-1003)

Cat. No.: HY-16025

EOC317 (ACTB-1003) is an oral kinase inhibitor with IC_{50}s of 6, 2 and 4 nM for **FGFR1**, **VEGFR2** and **Tie-2**.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Erdafitinib

(JNJ-42756493)

Cat. No.: HY-18708

Erdafitinib (JNJ-42756493) is a potent and orally available **FGFR** family inhibitor; inhibits FGFR1/2/3/4 with IC_{50}s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.



Purity: 99.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ferulic acid

(Coniferic acid)

Cat. No.: HY-N0060

Ferulic acid is a novel fibroblast growth factor receptor 1 (**FGFR1**) inhibitor with IC_{50}s of 3.78 and 12.5 μM for **FGFR1** and **FGFR2**, respectively.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g, 5 g

Ferulic acid sodium

(Coniferic acid sodium)

Cat. No.: HY-N0060A

Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (**FGFR1**) inhibitor with IC_{50}s of 3.78 and 12.5 μM for **FGFR1** and **FGFR2**, respectively.



Purity: ≥99.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g, 5 g

FGFR-IN-1

Cat. No.: HY-145043

FGFR-IN-1 is a potent **FGFR** inhibitor with an IC_{50} of <100 nM for FGFR1, FGFR2, and FGFR3, respectively (patent US20130338134A1, example 219).



Purity: 99.35%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FGFR-IN-2

Cat. No.: HY-142921

FGFR-IN-2 (compound 1) is a potent **FGFR** inhibitor with IC_{50}s of 7.3 nM, 4.3 nM, 7.6 nM, 11 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FGFR-IN-2 has the potential for cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR-IN-3

Cat. No.: HY-147683

FGFR-IN-3 (compound 6) is an orally active, potent and BBB-penetrated **FGFR** (fibroblast growth factor receptor) modulator. FGFR-IN-3 shows neuroprotective activity. FGFR-IN-3 can be used for neurodegenerative diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR-IN-4

Cat. No.: HY-147619

FGFR-IN-4 is a potent inhibitor of **FGFR**. Fibroblast growth factor receptor (FGFR) is a tyrosine kinase receptor that binds to fibroblast growth factor ligands. FGFR-IN-4 has the potential for the research of cancer diseases (extracted from patent WO2022033532A1, compound 20).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR-IN-5

Cat. No.: HY-147620

FGFR-IN-5 is a potent inhibitor of **FGFR**. Fibroblast growth factor receptor (FGFR) is a tyrosine kinase receptor that binds to fibroblast growth factor ligands. FGFR-IN-5 has the potential for the research of cancer diseases (extracted from patent WO2022042612A1, compound 3).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR-IN-7

Cat. No.: HY-147684

FGFR-IN-7 (compound 17) is an orally active, potent and BBB-penetrated **FGFR** (fibroblast growth factor receptor) modulator. FGFR-IN-7 shows neuroprotective activity. FGFR-IN-7 improves brain exposure and reduced risk of phospholidosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR1 inhibitor-2

Cat. No.: HY-139376

FGFR1 inhibitor-2 is a **FGFR1** inhibitor (IC_{50} is 4.55 μM in MDA-MB-231 cells). FGFR1 inhibitor-2 can be used for the research of metastatic triple-negative breast cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR1/DDR2 inhibitor 1

Cat. No.: HY-114311

FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of **fibroblast growth factor receptor 1 (FGFR1)** and **discoindin domain receptor 2 (DDR2)**, with IC_{50} values of 31.1 nM and 3.2 nM, respectively. Antitumor activity.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FGFR2-IN-2

Cat. No.: HY-145231

FGFR2-IN-2 (Compound 38) is a selective **FGFR2** inhibitor with IC_{50}s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR3-IN-1

Cat. No.: HY-147713

FGFR3-IN-1 (compound 1) is a **fibroblast growth factor receptor (FGFR)** inhibitor, with IC_{50}s of 40 nM, 5.1 nM, and 12 nM for **FGFR1**, **2**, and **3**, respectively. FGFR3-IN-1 can be used for the research of bladder cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR3-IN-2

Cat. No.: HY-147714

FGFR3-IN-2 (compound 18b) is a potent and selective **FGFR3** inhibitor, with IC_{50}s of 4.1 nM and 570 nM for **FGFR3** and **VEGFR2**, respectively. FGFR3-IN-2 can be used for the research of bladder cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR3-IN-3

Cat. No.: HY-147715

FGFR3-IN-3 (compound 40a) is a potent and pan-**FGFR** inhibitor, with IC_{50}s of 2.1 nM, 3.1 nM, 4.3 nM and 74 nM for **FGFR1**, **2**, **3**, and **4**, respectively. FGFR3-IN-3 can be used for the research of bladder cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR4-IN-1

Cat. No.: HY-100631

FGFR4-IN-1 is a potent inhibiotr of **FGFR4** with IC_{50} of 0.7 nM.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FGFR4-IN-10

Cat. No.: HY-146541

FGFR4-IN-10 (compound 5a) is a potent and selective **FGFR4** inhibitor with an IC_{50} value of 70.7 nM. FGFR4-IN-10 shows no inhibition against other FGFR family members, i.e. FGFR1, FGFR2 and FGFR3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR4-IN-11

Cat. No.: HY-147515

FGFR4-IN-11 (Compound 30) is a potent, selective, covalent **FGFR4** inhibitor with an IC_{50} of 2.1 nM. FGFR4-IN-11 significantly inhibits the FGF19/FGFR4 signaling pathway and shows antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR4-IN-12

Cat. No.: HY-147793

FGFR4-IN-12 (Compound A34) is a potent inhibitor of **FGFR4**. FGFR4-IN-12 exhibits improved FGFR4 inhibitory capability and selectivity and excellent anti-proliferative activities against FGFR4-dependent HCC cell lines. FGFR4-IN-12 has the potential for the research of cancer diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR4-IN-4

Cat. No.: HY-129181

FGFR4-IN-4 (compound 693) is a **FGFR4** inhibitor with anti-tumor activity, extracted from patent WO2018113584A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR4-IN-5

Cat. No.: HY-131704

FGFR4-IN-5 is a potent and selective covalent **FGFR4** inhibitor with an IC_{50} of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FGFR4-IN-6

Cat. No.: HY-143881

FGFR4-IN-6 (Compound 9ka) is a covalently reversible **FGFR4** inhibitor with an IC_{50} value of 5.4 nM. FGFR4-IN-6 also exhibits good oral pharmacokinetic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR4-IN-7

Cat. No.: HY-115902

FGFR4-IN-7 (Compound C3) is a covalent reversible **FGFR4** inhibitor with an IC_{50} value of 0.42 μM. FGFR4-IN-7 induces **apoptosis** via the FGFR4 signaling pathway blockage. FGFR4-IN-7 can be used for the research of hepatocellular carcinoma (HCC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR4-IN-8

Cat. No.: HY-145836

FGFR4-IN-8 (Compound 7v) is an ATP-competitive, highly selective covalent inhibitor of wild-type and gatekeeper mutant **FGFR4**. FGFR4-IN-8 exhibits excellent potency against FGFR4, FGFR4^{V550M} and FGFR4^{C552S} with IC_{50}s of 0.5, 0.25, 1.6, 931 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR4-IN-9

Cat. No.: HY-144759

FGFR4-IN-9 (Compound 6O) is a selective **FGFR4** inhibitor with an IC_{50} of 75.3 nM. FGFR4-IN-9 effectively inhibits both the growth and angiogenesis of HCC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FIIN-1

(FGFR irreversible inhibitor-1)

Cat. No.: HY-15813

FIIN-1 is a potent, irreversible, selective **FGFR** inhibitor. FIIN-1 binds to **FGFR1/2/3/4** and **Flt1/4** with K_ds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC_{50}s of FIIN-1 are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FIIN-2

Cat. No.: HY-18602

FIIN-2 is an irreversible inhibitor of **FGFR** with an IC_{50} of 3.1, 4.3, 27, and 45 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

FIIN-3

Cat. No.: HY-18603

FIIN-3 is an irreversible inhibitor of **FGFR** with an IC_{50} of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Fisogatinib

(BLU-554)

Cat. No.: HY-100492

Fisogatinib (BLU-554) is a potent, highly selective and orally active **fibroblast growth factor receptor 4 (FGFR4)** inhibitor with an IC_{50} of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on **FGFR4** signalling.



Purity: 99.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Formononetin

(Biochanin B; Flavosil; Formonetol)

Cat. No.: HY-N0183

Formononetin is a potent **FGFR2** inhibitor with an IC_{50} of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Futibatinib

(TAS-120)

Cat. No.: HY-100818

Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible **FGFR** inhibitor, with IC_{50}s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively.



Purity: 99.46%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Gandotinib

(LY2784544)

Cat. No.: HY-13034

Gandotinib (LY2784544) is a potent **JAK2** inhibitor with IC_{50} of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC_{50} of 4, 25, 32, 44, and 95 nM.



Purity: 99.82%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Gunagratinib

(ICP-192)

Cat. No.: HY-132817

Gunagratinib (ICP-192) is a low toxicity and orally active **pan-FGFR** (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits **FGFR** activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Heparan Sulfate

Cat. No.: HY-101916

Heparan sulfate, a complex and linear polysaccharide, exists as part of glycoproteins named heparan sulfate proteoglycans, which are expressed abundantly on the cell surface and in the extracellular matrix.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Infigratinib

(BGJ-398; NVP-BGJ398)

Cat. No.: HY-13311

Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the **FGFR** family with IC_{50}s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for **FGFR1**, **FGFR2**, **FGFR3**, and **FGFR4**, respectively.



Purity: 99.70%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Infigratinib phosphate

(BGJ-398 phosphate; NVP-BGJ398 phosphate)

Cat. No.: HY-13311A

Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the **FGFR** family with IC_{50} of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for **FGFR1**, **FGFR2**, **FGFR3**, and **FGFR4**, respectively.



Purity: 97.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

JK-P3

Cat. No.: HY-108933

JK-P3 is a potent and pan **VEGFR2** inhibitor, with IC_{50}s of 7.83 μM, 27 μM and 5.18 μM for VEGFR2, FGFR1 and FGFR3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KHS101 hydrochloride

Cat. No.: HY-10996A

KHS101 hydrochloride could selectively induce a neuronal differentiation phenotype and interacts with transforming acidic coiled-coil-containing protein 3 **(TACC3)**.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KW-2449

Cat. No.: HY-10339

KW-2449 is a multi-targeted kinase inhibitor of **FLT3**, **ABL**, **ABL**^{T315I} and **Aurora kinase** with IC_{50}s of 6.6, 14, 4 and 48 nM, respectively.



Purity: 99.85%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib

(E7080)

Cat. No.: HY-10981

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib mesylate

(E7080 mesylate)

Cat. No.: HY-10981A

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib-d4

(E7080-d4)

Cat. No.: HY-10981S

Lenvatinib-d4 (E7080-d4) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lenvatinib-d5

(E7080-d5)

Cat. No.: HY-10981S1

Lenvatinib-d5 (E7080-d5) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lucitanib

(E-3810)

Cat. No.: HY-15391

Lucitanib (E-3810) is a novel dual inhibitor of **VEGFR** and **FGFR**, potently and selectively inhibits **VEGFR1**, **VEGFR2**, **VEGFR3**, **FGFR1** and **FGFR2** with IC_{50}s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.



Purity: 98.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY2874455

Cat. No.: HY-13304

LY2874455 is a **pan-FGFR** inhibitor with IC_{50}s of 2.8, 2.6, 6.4, 6 nM for **FGFR1**, **FGFR2**, **FGFR3**, **FGFR4**, respectively.



Purity: 98.06%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Masitinib

(AB1010)

Cat. No.: HY-10209

Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Masitinib mesylate

(AB-1010 mesylate)

Cat. No.: HY-10209A

Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

MAX-40279

Cat. No.: HY-145723

MAX-40279 is a dual and potent inhibitor of **FLT3** kinase and **FGFR** kinase. MAX-40279 has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAX-40279 hemiadipate

Cat. No.: HY-145723C

MAX-40279 hemiadipate is a dual and potent inhibitor of **FLT3** kinase and **FGFR** kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAX-40279 hemifumarate

Cat. No.: HY-145723B

MAX-40279 hemifumarate is a dual and potent inhibitor of **FLT3** kinase and **FGFR** kinase. MAX-40279 hemifumarate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).



Purity: 99.56%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAX-40279 hydrochloride

Cat. No.: HY-145723A

MAX-40279 hydrochloride is a dual and potent inhibitor of **FLT3** kinase and **FGFR** kinase. MAX-40279 hydrochloride has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nintedanib

(BIBF 1120)

Cat. No.: HY-50904

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Nintedanib esylate

(BIBF 1120 esylate)

Cat. No.: HY-11106

Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Nintedanib-13C,d3

(BIBF 1120-13C,d3) Cat. No.: HY-50904S1

Nintedanib-13C,d3 is the 13C- and deuterium labeled. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nintedanib-d3

(BIBF 1120-d3) Cat. No.: HY-50904S

Nintedanib-d3 (BIBF 1120-d3) is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nintedanib-d8

(BIBF 1120-d8) Cat. No.: HY-50904S2

Nintedanib-d8 is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ODM-203

Cat. No.: HY-119367

ODM-203 is a potent **FGFR** and **VEGFR** families inhibitor with IC_{50}s of 11, 16, 6, 35 nM towards recombinant FGFR1, FGFR2, FGFR3 and FGFR4 as well as 26, 9, 5 nM towards VEGFR1, VEGFR2 and VEGFR3, respectively. ODM-203 exhibits strong anti-tumor activity and induces anti-tumor immunity.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Orantinib

(SU6668; TSU-68) Cat. No.: HY-10517

Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with K_is of 2.1 μM, 8 nM and 1.2 μM for **Flt-1**, **PDGFRβ** and **FGFR1**, respectively.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pazopanib

(GW786034) Cat. No.: HY-10208

Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with IC_{50}s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pazopanib Hydrochloride

(GW786034 (Hydrochloride)) Cat. No.: HY-12009

Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with an IC_{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pazopanib-d6

(GW786034-d6) Cat. No.: HY-10208S

Pazopanib-d6 (GW786034-d6) is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with IC_{50}s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD-089828

Cat. No.: HY-112345

PD-089828 is an ATP competitive inhibitor of **FGFR-1**, **PDGFR-β** and **EGFR** (IC_{50}s=0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of **c-Src** tyrosine kinase (IC_{50}=0.18 μM). PD-089828 also inhibits **MAPK** with an IC_{50} of 7.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD-161570

Cat. No.: HY-100434

PD-161570 is a potent and ATP-competitive **human FGF-1 receptor** inhibitor with an IC_{50} of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the **PDGFR**, **EGFR** and **c-Src tyrosine kinases** with IC_{50} values of 310 nM, 240 nM, and 44 nM, respectively.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD-166866

Cat. No.: HY-101296

PD166866 is a selective **FGFR1** tyrosine kinase inhibitor with an IC_{50} of 52.4 nM.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PD173074

Cat. No.: HY-10321

PD173074 is a potent **FGFR1** inhibitor with an IC_{50} of 25 nM and also inhibits **VEGFR2** with an IC_{50} of 100-200 nM, showing 1000-fold selectivity for FGFR1 over PDGFR and c-Src.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Pemigatinib

(INCB054828)

Cat. No.: HY-109099

Pemigatinib (INCB054828) is an orally active, selective **FGFR** inhibitor with IC_{50}s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 500 mg

PF 477736

(PF 00477736)

Cat. No.: HY-10032

PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of **Chk1**, with a K_i of 0.49 nM, it is also a **Chk2** inhibitor, with a K_i of 47 nM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Picrasidine Q

Cat. No.: HY-N9507

Picrasidine Q, an alkaloid component extracted from Angelica keiskei species, has the capacity of anti-cell transformation and anti-cancer. Picrasidine Q induces cell **apoptosis** and G1 phase arrest in human esophageal cancer cell lines, and directly inhibits **FGFR2** kinase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Ponatinib

(AP24534)

Cat. No.: HY-12047

Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ponatinib hydrochloride

(AP24534 hydrochloride)

Cat. No.: HY-108766

Ponatinib (AP24534) hydrochloride is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: >98%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg, 100 mg

Ponatinib-d8

(AP24534-d8)

Cat. No.: HY-12047S

Ponatinib D8 (AP24534 D8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 1 mg

PP58

Cat. No.: HY-18622

PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits **PDGFR**, **FGFR** and **Src** family activities with nanomolar IC_{50} values.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

PRN1371

Cat. No.: HY-101768

PRN1371 is a highly selective and potent **FGFR1-4** and **CSF1R** inhibitor with IC_{50}s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively.



Purity: 99.72%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

R1530

Cat. No.: HY-13737

R1530 is a highly potent, orally active, dual-acting **mitosis/angiogenesis** inhibitor, with anti-tumor and anti-angiogenic activities. R1530 is a multikinase inhibitor which binds to 31 kinases with K_d values of <500 nM.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Roblitinib

(FGF-401)

Cat. No.: HY-101568

Roblitinib (FGF-401) is an orally active and highly selective **FGFR4** inhibitor with an IC_{50} of 1.9 nM. Roblitinib has antitumor activity.



Purity: 99.33%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Rogaratinib

(BAY1163877)

Cat. No.: HY-100019

Rogaratinib (BAY1163877) is a potent and selective **fibroblast growth factor receptor** (**FGFR**) inhibitor.



Purity: 99.86%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

S49076

Cat. No.: HY-12965

S49076 is a novel, potent inhibitor of **MET**, **AXL/MER**, and **FGFR1/2/3** with IC_{50} values below 20 nM.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

SM1-71

Cat. No.: HY-136848

SM1-71 (compound 5) is a potent **TAK1** inhibitor, with a K_i of 160 nM, it also can covalently inhibit **MKNK2**, **MAP2K1/2/3/4/6/7**, **GAK**, **AAK1**, **BMP2K**, **MAP3K7**, **MAPKAPK5**, **GSK3A/B**, **MAPK1/3**, **SRC**, **YES1**, **FGFR1**, **ZAK (MLTK)**, **MAP3K1**, **LIMK1** and **RSK2**.



Purity: 96.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SNIPER(TACC3)-11

Cat. No.: HY-145895

SNIPER(TACC3)-11 is a potent **FGFR3-TACC3** degrader. SNIPER(TACC3)-11 reduces FGFR3-TACC3 protein levels and suppressed the growth of FGFR3-TACC3 positive cancer cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SSR128129E

(SSR)

Cat. No.: HY-15599

SSR128129E is an orally available and allosteric **FGFR** inhibitor with an IC_{50} of 1.9 μM for FGFR1.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SSR128129E free acid

(SSR free acid)

Cat. No.: HY-15599A

SSR128129E free acid is an orally available and allosteric **FGFR** inhibitor with an IC_{50} of 1.9 μM for FGFR1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SU 5402

Cat. No.: HY-10407

SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC_{50} of 20 nM, 30 nM, and 510 nM for **VEGFR2**, **FGFR1**, and **PDGFRβ**, respectively.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SU11652

Cat. No.: HY-112452

SU11652 is a potent **receptor tyrosine kinase (RTK)** inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including **VEGFR**, **FGFR**, **PDGFR**, and **Kit**. SU11652 can be uesd for spontaneous cancers expressing Kit mutations research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SU4984

Cat. No.: HY-118203

SU4984 is a protein tyrosine kinase inhibitor, with an IC_{50} of 10-20 μM for **fibroblast growth factor receptor 1 (FGFR1)**. SU4984 is also inhibits **platelet-derived growth factor receptor**, and **insulin receptor**. SU4984 can be used for the research of cancer.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sulfatinib

(HMPL-012)

Cat. No.: HY-12297

Sulfatinib (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against **VEGFR1/2/3**, **FGFR1** and **CSF1R** with IC_{50}s of in a range of 1 to 24 nM.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

SUN11602

Cat. No.: HY-101493

SUN11602 is a novel aniline compound with basic fibroblast growth factor-like activity.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SUN13837

Cat. No.: HY-147681

SUN13837 is an orally active, potent and BBB-penetrated **FGFR** (fibroblast growth factor receptor) modulator. SUN13837 shows neuroprotective activity. SUN13837 can be used for neurodegenerative diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Surfen dihydrochloride

(Aminoquincarbamide dihydrochloride)

Cat. No.: HY-122704A

Surfen dihydrochloride is a potent **HS (heparan sulfate)** antagonist. Surfen binds to glycosaminoglycans. Surfen neutralizes the anticoagulant activity of both unfractionated and low molecular weight heparins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TG 100572

Cat. No.: HY-10184

TG 100572 is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TG 100572 Hydrochloride

Cat. No.: HY-10185

TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

TG 100801

Cat. No.: HY-10186

TG 100801 is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: 98.60%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg

TG 100801 Hydrochloride

Cat. No.: HY-10187

TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Tyrosine kinase-IN-1

Cat. No.: HY-100315

Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 4, 20, 4, 2 nM for **KDR**, **Flt-1**, **FGFR1** and **PDGFRα**, respectively.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zoligratinib

(Debio 1347; CH5183284) **Cat. No.:** HY-19957

Zoligratinib (Debio 1347) is an orally available and selective **FGFR** inhibitor with **IC_{50}**s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.



Purity: 99.73%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FLT3

Cluster of differentiation antigen 135; CD135; Fms like tyrosine kinase 3

FLT3 (Fms-like tyrosine kinase 3, CD135) is a protein that in humans is encoded by the FLT3 gene. FLT3 is a cytokine receptor which belongs to the receptor tyrosine kinase class III. FLT3 is the receptor for the cytokine Flt3 ligand (FLT3L). FLT-3 is expressed on the surface of many hematopoietic progenitor cells. Signalling of FLT3 is important for the normal development of haematopoietic stem cells and progenitor cells. The FLT3 gene is one of the most frequently mutated genes in acute myeloid leukemia (AML). Besides, high levels of wild-type FLT3 have been reported for blast cells of some AML patients without FLT3 mutations. These high levels may be associated with worse prognosis. Signaling through FLT3 plays a role in cell survival, proliferation, and differentiation. FLT3 is important for lymphocyte (B cell and T cell) development, but not for the development of other blood cells. Two cytokines that down modulate FLT3 activity are TNF-Alpha and TGF-Beta.

FLT3 Inhibitors

(E/Z)-Zotiraciclib

((E/Z)-TG02; (E/Z)-SB1317) Cat. No.: HY-15166

(E/Z)-Zotiraciclib ((E/Z)-TG02) is a potent inhibitor of **CDK2**, **JAK2**, and **FLT3**. (E/Z)-Zotiraciclib ((E/Z)-TG02) can be used for the research of cancer.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(E/Z)-Zotiraciclib citrate

((E/Z)-TG02 citrate; (E/Z)-SB1317 citrate) Cat. No.: HY-15166B

(E/Z)-Zotiraciclib citrate is a potent **CDK2**, **JAK2**, and **FLT3** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

(E/Z)-Zotiraciclib hydrochloride

((E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride) Cat. No.: HY-15166A

(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent **CDK2**, **JAK2**, and **FLT3** inhibitor.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

(R)-3-Hydroxy Midostaurin

((R)-CGP52421) Cat. No.: HY-108263B

(R)-3-Hydroxy Midostaurin ((R)-CGP52421) is a potent kinases inhibitor. (R)-3-Hydroxy Midostaurin is a major metabolite of midostaurin (PKC412; HY-10230) undergoing by the hepatic CYP3A4 enzyme. (R)-3-Hydroxy Midostaurin has the potential for acute myeloid leukemia (AML).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-3-Hydroxy Midostaurin

((S)-CGP52421) Cat. No.: HY-108263A

(S)-3-Hydroxy Midostaurin ((S)-CGP52421) is a potent kinases inhibitor with **IC_{50}** values of <400 nM for 13 kinases (VEGFR-2, TRK-A, FLT3, et).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Z)-SU5614

Cat. No.: HY-18952A

(Z)-SU5614 is a potent **FLT3** inhibitor and selectively induces growth arrest, apoptosis, and cell cycle arrest in Ba/F3 and AML cell lines expressing a constitutively activated FLT3.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

3-Hydroxy Midostaurin

(CGP52421) Cat. No.: HY-108263

3-Hydroxy Midostaurin (CGP 52421), a metabolite of PKC412, effectively inhibits **FMS-like tyrosine kinase-3 (FLT3)** autophosphorylation with **IC_{50}**s of approximately 132 nM and 9.8 μM in culture medium and plasma, respectively. 3-Hydroxy Midostaurin is less selective but more cytotoxic than PKC412.



Purity: 97.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

4SC-203

Cat. No.: HY-19897

4SC-203 is a potent **multikinase** inhibitor with potential antineoplastic activity. 4SC-203 selectively FLT3/STK1, FLT3 mutated forms, and VEGFRs.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

5'-Fluoroindirubinoxime

(5'-FIO) Cat. No.: HY-103464

5'-Fluoroindirubinoxime (5'-FIO, compound 13), an Indirubin (HY-N0117) derivative, is a potent **FLT3** inhibitor, with an **IC_{50}** of 15 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

AC710

Cat. No.: HY-13493

AC710 is a potent **PDGFR** inhibitor with **K_d**s of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AKN-028

Cat. No.: HY-118304

AKN-028 is an orally active and potent **FLT3 tyrosine kinase** inhibitor (IC_{50} = 6nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Altiratinib

(DCC-2701)

Cat. No.: HY-B0791

Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC_{50}s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for **MET**, **TIE2**, **VEGFR2**, **FLT3**, **Trk1**, **Trk2**, and **Trk3** respectively.



Purity: 98.06%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AMG 925

Cat. No.: HY-15889

AMG 925 is a potent, selective, and orally available **FLT3/CDK4** dual inhibitor with IC_{50}s of 2±1 nM and 3±1 nM, respectively.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

AMG 925 HCl

Cat. No.: HY-15889A

AMG 925 HCl is a potent, selective, and orally available **FLT3/CDK4** dual inhibitor with IC_{50}s of 2±1 nM and 3±1 nM, respectively.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Amuvatinib

(MP470; HPK 56)

Cat. No.: HY-10206

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: 98.07%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amuvatinib hydrochloride

(MP470 hydrochloride; HPK 56 hydrochloride)

Cat. No.: HY-10206A

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

AST 487

(NVP-AST 487)

Cat. No.: HY-15002

AST 487 is a **RET** kinase inhibitor with IC_{50} of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits **Flt-3** with IC_{50} of 520 nM.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT9283

Cat. No.: HY-50514

AT9283 is a multi-targeted kinase inhibitor with potent activity against **Aurora A/B**, **JAK2/3**, **Abl (T315I)** and **Flt3** (IC_{50}s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo.



Purity: 99.70%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

ATH686

Cat. No.: HY-15003

ATH686 is a potent, selective and ATP-competitive **FLT3** inhibitor. ATH686 target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3 mutants via induction of **apoptosis** and cell cycle inhibition. ATH686 has antileukemic effects.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AZD2932

Cat. No.: HY-18179

AZD2932 is a potent and multi-targeted kinase inhibitor **VEGFR2**, **PDGFβ**, **Flt-3** and **c-Kit** with IC_{50}s of 8, 4, 7 and 9 nM in cell assay, respectively.



Purity: 96.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BPR1J-097

Cat. No.: HY-13537

BPR1J-097 is a novel potent **FLT3** inhibitor with an IC_{50} of 11nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BPR1J-097 Hydrochloride

Cat. No.: HY-13537A

BPR1J-097 Hydrochloride is a novel and potent **FLT3** inhibitor with an IC_{50} of 11nM.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

BPR1K871

(DBPR114)

Cat. No.: HY-100865

BPR1K871 is a potent and selective dual **FLT3/AURKA** inhibitor with IC_{50}s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

BSc5371

Cat. No.: HY-111545

BSc5371 is a potent and irreversible **FLT3** inhibitor, with K_ds of 1.3, 0.83, 1.5, 5.8 and 2.3 nM for mutant FLT3(D835H), FLT3(ITD, D835V), FLT3(ITD, F691L), FLT3-ITD and wild type FLT3wt, respectively. BSc5371 is cytotoxic to FLT3-dependent cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CA-4948

Cat. No.: HY-135317

CA-4948 is a potent **IRAK4/FLT3** inhibtor with anti-tumor activity.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cabozantinib

(XL184; BMS-907351)

Cat. No.: HY-13016

Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Cabozantinib-d4

(XL184-d4; BMS-907351-d4)

Cat. No.: HY-13016S1

Cabozantinib-d4 is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cabozantinib-d6

Cat. No.: HY-13016S

Cabozantinib-d6 (XL184-d6) is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CCT241736

Cat. No.: HY-18161

CCT241736 is a potent and orally bioavailable dual **FLT3** and **Aurora kinase** inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC_{50}, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants including FLT3-ITD (K_d, 38 nM) and FLT3(D835Y) (K_d, 14 nM).



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cenisertib

(AS-703569; R-763)

Cat. No.: HY-13072

Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of **Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3**.



Purity: 99.64%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CHIR-124

Cat. No.: HY-13263

CHIR-124 is a potent and selective **Chk1** inhibitor with IC_{50} of 0.3 nM, and also potently targets **PDGFR** and **FLT3** with IC_{50}s of 6.6 nM and 5.8 nM.



Purity: 96.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Crenolanib

(CP-868596)

Cat. No.: HY-13223

Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases **FLT3** and **PDGFRα/β** with K_ds of 0.74 nM and 2.1 nM/3.2 nM, respectively.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Crotonoside

(Isoguanosine)

Cat. No.: HY-N0071

Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits **FLT3** and **HDAC3/6**, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the treatment of AML.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Dovitinib

(CHIR-258; TKI258)

Cat. No.: HY-50905

Dovitinib (CHIR-258) is an orally active, potent **multi-targeted tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **CSF-1R**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Dovitinib lactate

(CHIR-258 lactate; TKI-258 lactate)

Cat. No.: HY-10207

Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: 99.62%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dovitinib lactate hydrate

(TKI258 lactate hydrate; CHIR-258 lactate hydrate)

Cat. No.: HY-B0062

Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dovitinib-D8

Cat. No.: HY-50905S

Dovitinib-D8 (CHIR-258-D8) is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E6201

(ER-806201)

Cat. No.: HY-15496

E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of **MEK1** and **FLT3**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ENMD-2076

Cat. No.: HY-10987A

ENMD-2076 is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ENMD-2076 Tartrate

Cat. No.: HY-10987

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 98.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

FLT3-IN-10

Cat. No.: HY-134481

FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (**FLT3**). FLT3-IN-10 has the potential for the treatment of FLT3-mutated acute myeloid leukemia (AML).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FLT3-IN-11

Cat. No.: HY-143894

FLT3-IN-11 (compound 30) is a potent, selective and orally active **FLT3 kinase** inhibitor with **IC_{50}**s of 7.22 nM and 4.95 nM for **wild-type FLT3** and **FLT3-D835Y**, respectively. FLT3-IN-11 high selectivity for FLT3 over c-KIT (>1000-fold).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3-IN-12

Cat. No.: HY-143895

FLT3-IN-12 is a potent, selective and orally active **FLT3 kinase** inhibitor with **IC_{50}**s of 1.48 nM and 2.87 nM for **FLT3-WT** and **FLT3-D835Y**, respectively. FLT3-IN-12 possesses high selectivity over c-KIT (>1000-fold).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3-IN-14

Cat. No.: HY-144777

FLT3-IN-14 is a potent **FLT3** inhibitor with **IC_{50}**s of 5.6 nM and 1.4 nM for FLT3-WT and FLT3-ITD. FLT3-IN-14 reduces the phosphorylation of FLT3 (Y591), induces cell cycle arrest at G1 phase and **apoptosis**. FLT3-IN-14 significantly reduces the tumor growth in an MV4-11 xenograft mouse model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3-IN-15

Cat. No.: HY-146886

FLT3-IN-15 is a highly potent and orally active **FLT3** inhibitor with **IC_{50}**s of 0.87 nM and 0.32 nM for FLT3 and FLT3/D835Y, respectively. FLT3-IN-15 can be used for researching acute myeloid leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3-IN-2

Cat. No.: HY-18744

FLT3-IN-2 is a FLT3 inhibitor with IC50 of 1 μM, detailed information refer to WO 2012158957 A2 and WO 2007013896.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FLT3-IN-3

Cat. No.: HY-112145

FLT3-IN-3 is a potent **FLT3** inhibitor with **IC_{50}**s of 13 and 8 nM for **FLT3 WT** and **FLT3 D835Y**, respectively.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FLT3-IN-4

Cat. No.: HY-128571

FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (**FLT3**; **IC_{50}**=7 nM) inhibitor for treating acute myelogenous leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FLT3-IN-6

Cat. No.: HY-128572

FLT3-IN-6 is a potent and selective inhibitor of **FLT3-ITD** (FLT3 mutation) with an **IC_{50}** of 1.336 nM.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FLT3/CDK4-IN-1

Cat. No.: HY-115904

FLT3/CDK4-IN-1 is a potent, high selective and orally active **FLT3/CDK4** dual inhibitor (**IC_{50}**=11 and 7 nM for FLT3 and CDK4, respectively). FLT3/CDK4-IN-1 has antiproliferative activities against certain cancer cells. FLT3/CDK4-IN-1 has good antitumor effect in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3/D835Y-IN-1

Cat. No.: HY-143434

FLT3/D835Y-IN-1 (compound 13a) is a orally active, potent and selective **FLT3** and **FLT3/D835Y** inhibitor, with IC_{50} values of 0.26 nM and 0.18 nM, respectively. FLT3/D835Y-IN-1 also blocks tumor growth, has anticancer efficacy, and can be used to research for AML (acute myeloid leukemia).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3/ITD-IN-1

Cat. No.: HY-144709

FLT3/ITD-IN-1 (Compound 1) is a potent FLT3 internal tandem duplications (**FLT3-ITD**) inhibitor with IC_{50} values of 38.2 nM and 144.1 nM against **FLT3** and FLT3-ITD, respectively. FLT3/ITD-IN-1 displays excellent antiproliferative activities against acute myeloid leukemia cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3/ITD-IN-2

Cat. No.: HY-144710

FLT3/ITD-IN-2 (Compound 17) is a potent FLT3 internal tandem duplications (**FLT3-ITD**) inhibitor with IC_{50} values of 0.3, 0.4 and 1.0 nM against **$FLT3^{D835Y}$**, **FLT3** and FLT3-ITD, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3/ITD-IN-3

Cat. No.: HY-144711

FLT3/ITD-IN-3 (Compound 19) is a potent FLT3 internal tandem duplications (**FLT3-ITD**) inhibitor with IC_{50} values of 0.3, 0.4 and 0.9 nM against **$FLT3^{D835Y}$**, **FLT3** and FLT3-ITD, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3/ITD-IN-4

Cat. No.: HY-146680

FLT3/ITD-IN-4 (Compound 16) is a selective FMS-like tyrosine kinase 3 internal tandem duplications (**FLT3-ITD**) inhibitor with an IC_{50} of 2.3 nM. FLT3/ITD-IN-4 can be used for acute myeloid leukemia research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3/TrKA-IN-1

Cat. No.: HY-146749

FLT3/TrKA-IN-1 is a potent **FLT3/TrKA** dual kinase inhibitor with the IC_{50}s of 43.8 nM, 97.2 nM, 92.5 nM and 23.6 nM for FLT3, FLT3-ITD, FLT3-TKD and TrKA, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FN-1501

Cat. No.: HY-111361

FN-1501 is a potent inhibitor of **FLT3** and **CDK**, with IC_{50}s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fostamatinib

(R788)

Cat. No.: HY-13038A

Fostamatinib (R788) is the oral prodrug of the active compound R406. R406 is an orally available and competitive **Syk/FLT3** inhibitor with a K_i of 30 nM and an IC_{50} of 41 nM. R406 also inhibits Lyn (IC_{50}=63 nM) and Lck (IC_{50}=37 nM).



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fostamatinib Disodium

(R788(Disodium))

Cat. No.: HY-13038

Fostamatinib Disodium (R788 Disodium) is the oral prodrug of the active compound R406. R406 is an orally available and competitive **Syk/FLT3** inhibitor with a K_i of 30 nM and an IC_{50} of 41 nM. R406 also inhibits Lyn (IC_{50}=63 nM) and Lck (IC_{50}=37 nM).



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fostamatinib disodium hexahydrate

(R788 disodium hexahydrate)

Cat. No.: HY-13038B

Fostamatinib (R788) disodium hexahydrate is the oral prodrug of the active compound R406. R406 is an orally available and competitive **Syk/FLT3** inhibitor with a K_i of 30 nM and an IC_{50} of 41 nM. R406 also inhibits Lyn (IC_{50}=63 nM) and Lck (IC_{50}=37 nM).



Purity: 98.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fostamatinib-d9

(R788-d9) Cat. No.: HY-13038AS

Fostamatinib-d9 (R788-d9) is the deuterium labeled Fostamatinib. Fostamatinib (R788) is the oral prodrug of the active compound R406. R406 is an orally available and competitive **Syk/FLT3** inhibitor with a K_i of 30 nM and an IC_{50} of 41 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

G-749

Cat. No.: HY-12333

G-749 is a potent, oral active and ATP competitive **FLT3** inhibitor, with IC_{50}s of 0.4 nM and 0.6 nM for FLT3 wild type and FLT3-D835Y, respectively. G-749 can be used for the research of drug resistance for acute myeloid leukemia (AML).



Purity: 98.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Gandotinib

(LY2784544) Cat. No.: HY-13034

Gandotinib (LY2784544) is a potent **JAK2** inhibitor with IC_{50} of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC_{50} of 4, 25, 32, 44, and 95 nM.



Purity: 99.82%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Gilteritinib

(ASP2215) Cat. No.: HY-12432

Gilteritinib (ASP2215) is a potent and ATP-competitive **FLT3/AXL** inhibitor with IC_{50}s of 0.29 nM/0.73 nM, respectively.



Purity: 99.55%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Gilteritinib hemifumarate

(ASP2215 hemifumarate) Cat. No.: HY-12432A

Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive **FLT3/AXL** inhibitor with IC_{50} of 0.29 nM/0.73 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Gilteritinib-d3

(ASP2215-d3) Cat. No.: HY-12432S

Gilteritinib-d3 (ASP2215-d3) is the deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive **FLT3/AXL** inhibitor with IC_{50}s of 0.29 nM/0.73 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gilteritinib-d8

(ASP2215-d8) Cat. No.: HY-12432S1

Gilteritinib-d8 is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HM43239

Cat. No.: HY-145015

HM43239 is an orally active and selective **FLT3** inhibitor with IC_{50}s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HP1142

Cat. No.: HY-145691

HP1142 is a potent and selective inhibitor of **FLT3** receptor tyrosine kinase (FLT3/ITD mutation). HP1142 is a benzoimidazole scaffold-based compound. HP1142 has the potential for the research of FLT3/ITD leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HP1328

Cat. No.: HY-145690

HP1328 is a potent inhibitor of **FLT3** receptor tyrosine kinase (FLT3/ITD mutation). HP1328 is a benzoimidazole scaffold-based compound. HP1328 significantly reduces the leukemia burden and prolongs the survival of mice with FLT3/ITD leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hypothemycin

Cat. No.: HY-107417

Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for **VEGFR2/VEGFR1**, **MEK1/MEK2**, **FLT-3**, **PDGFRβ/PDGFRα**, and **ERK1/ERK2**, respectively.



Purity: 96.10%
Clinical Data: No Development Reported
Size: 1 mg

JAK2-IN-7

Cat. No.: HY-131906

JAK2-IN-7 is a selective **JAK2** inhibitor with IC_{50}s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3^{V617F} cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JAK2/FLT3-IN-1

Cat. No.: HY-130247

JAK2/FLT3-IN-1 is a potent and orally active dual **JAK2/FLT3** inhibitor with IC_{50} values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK2/FLT3-IN-1 TFA

Cat. No.: HY-130247A

JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual **JAK2/FLT3** inhibitor with IC_{50} values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

JNJ-47117096 hydrochloride

(MELK-T1 hydrochloride)

Cat. No.: HY-12420

JNJ-47117096 hydrochloride is potent and selective **MELK** inhibitor, with an IC_{50} of 23 nM, also effectively inhibits **Flt3**, with an IC_{50} of 18 nM.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

K783-0308

Cat. No.: HY-115906

K783-0308 is a potent and selective dual inhibitor of **FLT3** and **MNK2** with IC_{50} values of 680 and 406 nM, respectively. K783-0308 inhibits the growth of MOLM-13 (IC_{50}=10.5 μM) and MV-4-11 (IC_{50}=10.4 μM) cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KG5

Cat. No.: HY-15198

KG5 is an orally active dual **PDGFRβ** and **B-Raf** allosteric inhibitor. KG5 also inhibits **Flt3**, **KIT** and **c-Raf**. KG5 has anticancer, antiangiogenic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KW-2449

Cat. No.: HY-10339

KW-2449 is a multi-targeted kinase inhibitor of **FLT3**, **ABL**, **ABL^{T315I}** and **Aurora kinase** with IC_{50}s of 6.6, 14, 4 and 48 nM, respectively.



Purity: 99.85%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LBW242

Cat. No.: HY-15519

LBW242, a 3-mer and Smac mimetic, is a potent and orally active proapoptotic **IAP** inhibitor. LBW242 shows effects on mutant FLT3-expressing cells. LBW242 has activity against multiple myeloma, and potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lestaurtinib

(CEP-701; KT-5555)

Cat. No.: HY-50867

Lestaurtinib (CEP-701;KT-5555) is an ATP-competitive multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases. Lestaurtinib inhibits **JAK2**, **FLT3** and **TrkA** with IC_{50}s of 0.9, 3 and less than 25 nM, respectively.



Purity: 99.92%
Clinical Data: Phase 3
Size: 5 mg

Linifanib

(ABT-869; AL-39324)

Cat. No.: HY-50751

Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of **VEGFR** and **PDGFR** family with IC_{50}s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity.



Purity: 99.72%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

LT-850-166

Cat. No.: HY-139619

LT-850-166 is a potent **FLT3** inhibitor with the capacity of overcoming a variety of FLT3 mutations.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Luxeptinib

(CG-806)

Cat. No.: HY-139535

Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent **pan-FLT3/pan-BTK** inhibitor. Luxeptinib induces cell cycle arrest, **apoptosis** or **autophagy** in acute myeloid leukemia cells.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MAX-40279

Cat. No.: HY-145723

MAX-40279 is a dual and potent inhibitor of **FLT3** kinase and **FGFR** kinase. MAX-40279 has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAX-40279 hemiadipate

Cat. No.: HY-145723C

MAX-40279 hemiadipate is a dual and potent inhibitor of **FLT3** kinase and **FGFR** kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAX-40279 hemifumarate

Cat. No.: HY-145723B

MAX-40279 hemifumarate is a dual and potent inhibitor of **FLT3** kinase and **FGFR** kinase. MAX-40279 hemifumarate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).



Purity: 99.56%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAX-40279 hydrochloride

Cat. No.: HY-145723A

MAX-40279 hydrochloride is a dual and potent inhibitor of **FLT3** kinase and **FGFR** kinase. MAX-40279 hydrochloride has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Merestinib

(LY2801653)

Cat. No.: HY-15514

Merestinib (LY2801653) is a potent, orally bioavailable **c-Met** inhibitor (K_i=2 nM) with anti-tumor activities.



Purity: 99.99%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Merestinib dihydrochloride

(LY2801653 dihydrochloride)

Cat. No.: HY-15514A

Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable **c-Met** inhibitor (K_i=2 nM) with anti-tumor activities.



Purity: 99.36%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MRX-2843

(UNC2371)

Cat. No.: HY-101549

MRX-2843 (UNC2371) is an orally active, ATP-competitive dual **MERTK** and **FLT3** tyrosine kinases inhibitor (TKI) with enzymatic IC_{50}s of 1.3 nM for MERTK and 0.64 nM for FLT3, respectively.



Purity: 99.70%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

OTS447

Cat. No.: HY-144869

OTS447 is a potent **FLT3** inhibitor with an IC_{50} of 21 nM (WO2012016082A1, compound 335).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pacritinib

(SB1518)

Cat. No.: HY-16379

Pacritinib (SB1518) is a potent inhibitor of both wild-type **JAK2** (IC_{50}=23 nM) and **JAK2**^{V617F} mutant (IC_{50}=19 nM). Pacritinib also inhibits **FLT3** (IC_{50}=22 nM) and its mutant **FLT3**^{D835Y} (IC_{50}=6 nM).



Purity: 99.93%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PDGFRα/FLT3-ITD-IN-1

Cat. No.: HY-145902

PDGFRα/FLT3-ITD-IN-1 (Compound 12d) is a potent inhibitor of **PDGFRα/FLT3** with IC_{50}s of more than 0.036 and 0.003 μM, respectively. PDGFRα/FLT3-ITD-IN-1 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PDGFRα/FLT3-ITD-IN-2

Cat. No.: HY-145903

PDGFRα/FLT3-ITD-IN-2 (Compound 13d) is a potent inhibitor of **PDGFRα/FLT3** with IC_{50}s of more than 20 and 1.654 μM, respectively. PDGFRα/FLT3-ITD-IN-2 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PDGFRα/FLT3-ITD-IN-3

Cat. No.: HY-145904

PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of **PDGFRα/FLT3** with IC_{50}s of 0.153 and 0.004 μM, respectively. PDGFRα/FLT3-ITD-IN-3 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF 477736

(PF 00477736)

Cat. No.: HY-10032

PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of **Chk1**, with a K_i of 0.49 nM, it is also a **Chk2** inhibitor, with a K_i of 47 nM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PROTAC FLT-3 degrader 1

Cat. No.: HY-114323

PROTAC FLT-3 degrader 1 is a **von Hippel-Lindau**-based PROTAC **FLT-3** internal tandem duplication (**ITD**) degrader with an IC_{50} 0.6 nM. Anti-proliferative activity; apoptosis induction.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Quizartinib

(AC220)

Cat. No.: HY-13001

Quizartinib (AC220) is an orally active, highly selective and potent second-generation type II **FLT3 tyrosine kinase** inhibitor, with a K_d of 1.6 nM. Quizartinib inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC_{50}s of 4.2 and 1.1 nM, respectively.



Purity: 99.01%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

R406

Cat. No.: HY-12067

R406 is an orally available and competitive **Syk/FLT3** inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk kinase activity in vitro with an IC_{50} of 41 nM, measured at an ATP concentration corresponding to its K_m value.



Purity: 96.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

R406 free base

Cat. No.: HY-11108

R406 free base is an orally available and competitive **Syk/FLT3** inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk kinase activity in vitro with an IC_{50} of 41 nM, measured at an ATP concentration corresponding to its K_m value.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rebastinib

(DCC-2036) Cat. No.: HY-13024

Rebastinib (DCC-2036) is an orally active, non-ATP-competitive **Bcr-Abl** inhibitor for **Abl1^{WT}** and **Abl1^{T315I}** with **IC_{50}**s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.



Purity: 99.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ripretinib

(DCC-2618) Cat. No.: HY-112306

Ripretinib (DCC-2618) is an orally bioavailable, selective **KIT** and **PDGFRA** switch-control inhibitor.



Purity: 99.33%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SEL24-B489

Cat. No.: HY-120758

SEL24-B489 is a potent, type I, orally active, dual **PIM** and **FLT3-ITD** inhibitor, with **K_d** values of 2 nM for PIM1, 2 nM for PIM2 and 3 nM for PIM3, respectively.
.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sitravatinib

(MGCD516; MG-516) Cat. No.: HY-16961

Sitravatinib (MGCD516) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with **IC_{50}**s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: 99.59%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Sitravatinib malate

(MGCD516 malate; MG-516 malate) Cat. No.: HY-16961A

Sitravatinib malate (MGCD516 malate) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with **IC_{50}**s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

SKLB4771

(FLT3-IN-1) Cat. No.: HY-12960

SKLB4771 is a novel potent and selective Flt3 inhibitor with IC50 of 10 nM; against FLT3-ITD-expressing MV4-11 cells with IC50 of 6 nM. IC50 value: 10 nM (in vitro) Target: in vitro: SKLB4771 inhibited FLT3 phosphorylation in a dose-dependent manner.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sorafenib

(Bay 43-9006) Cat. No.: HY-10201

Sorafenib (Bay 43-9006) is a potent and orally active **Raf** inhibitor with **IC_{50}**s of 6 nM and 20 nM for **Raf-1** and **B-Raf**, respectively. Sorafenib is a multikinase inhibitor with **IC_{50}**s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for **VEGFR2**, **VEGFR3**, **PDGFRβ**, **FLT3** and **c-Kit**, respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Sorafenib Tosylate

(Bay 43-9006 Tosylate) Cat. No.: HY-10201A

Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active **Raf** inhibitor with **IC_{50}**s of 6 nM and 20 nM for **Raf-1** and **B-Raf**, respectively.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Sorafenib-13C,d3

Cat. No.: HY-10201S2

Sorafenib-13C,d3 is the 13C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active **Raf** inhibitor with **IC_{50}**s of 6 nM and 20 nM for **Raf-1** and **B-Raf**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sorafenib-d3

(Bay 43-9006-d3; Donafenib) Cat. No.: HY-10201S

Sorafenib-d3 (Bay 43-9006-d3) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC_{50}s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.



Purity: 99.57%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sorafenib-d4

(Bay 43-9006-d4)

Cat. No.: HY-10201S1

Sorafenib-d4 (Bay 43-9006-d4) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC_{50}s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TAK-659

Cat. No.: HY-100867

TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of **spleen tyrosine kinase (SYK)** and **fms related tyrosine kinase 3 (FLT3)**, with an IC_{50} of 3.2 nM and 4.6 nM for SYK and FLT3, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

TAK-659 hydrochloride

Cat. No.: HY-100867A

TAK-659 hydrochloride is a highly potent, selective, reversible and orally available dual inhibitor of **spleen tyrosine kinase (SYK)** and **fms related tyrosine kinase 3 (FLT3)**, with an IC_{50} of 3.2 nM and 4.6 nM for SYK and FLT3, respectively.



Purity: 99.91%
Clinical Data: Phase 2
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tandutinib

(MLN518; CT53518)

Cat. No.: HY-10202

Tandutinib (MLN518) is a potent and selective inhibitor of the **FLT3** with an IC_{50} of 0.22 μM, and also inhibits **c-Kit** and **PDGFR** with IC_{50}s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML).



Purity: 99.48%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg

Tandutinib hydrochloride

(MLN518 hydrochloride; CT53518 hydrochloride)

Cat. No.: HY-10202A

Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the **FLT3** with an IC_{50} of 0.22 μM, and also inhibits **c-Kit** and **PDGFR** with IC_{50}s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML).



Purity: 98.84%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg

TCS 359

Cat. No.: HY-13907

TCS 359, a 2-acylaminothiophene-3-carboxamide, is a potent and selective **FLT3** inhibitor with an IC_{50} of 42 nM. TCS 359 inhibits MV4-11 cell proliferation with an IC_{50} of 340 nM.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

TG101209

Cat. No.: HY-10410

TG101209 is a selective **JAK2** inhibitor with IC_{50} of 6 nM, less potent to **Flt3** and **RET** with IC_{50} of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tyrphostin AG1296

(AG1296)

Cat. No.: HY-13894

Tyrphostin AG1296 is a potent and selective inhibitor of **platelet-derived growth factor receptor (PDGFR)**, with an IC_{50} of 0.8 μM.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UNC2025

Cat. No.: HY-12344

UNC2025 is a potent, ATP-competitive and highly orally active **Mer/Flt3** inhibitor with IC_{50} values of 0.74 nM and 0.8 nM, respectively. UNC2025 is >45-fold selectivity for MERTK relative to Axl (IC_{50}= 122 nM; K_i = 13.3 nM).



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UNC2025 hydrochloride

Cat. No.: HY-12344A

UNC2025 hydrochloride is a potent, ATP-competitive, and highly orally active **Mer/Flt3** inhibitor with IC_{50} values of 0.74 nM and 0.8 nM, respectively. UNC2025 hydrochloride is >45-fold selectivity for MERTK relative to Axl (IC_{50}= 122 nM; K_i = 13.3 nM).



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UNC4203

Cat. No.: HY-124502

UNC4203 is a potent, orally available and highly selective **MERTK** inhibitor, with IC_{50}s of 1.2 nM, 140 nM, 42 nM and 90 nM for MERTK, AXL, TYRO3 and FLT3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UNC5293

Cat. No.: HY-132200

UNC5293 is a **MERTK**-selective and potent inhibitor (K_i=190 pM). UNC5293 inhibits MERTK (IC_{50}=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IGF-1R

Insulin-like growth factor-1 receptor

IGF-1R (Insulin-like growth factor 1 receptor), a receptor tyrosine kinase, is activated upon binding to the ligands IGF-1 or IGF-2 leading to cell growth, survival and migration of both normal and cancerous cells.

IGF-1R can initiate the activation of the PI3K/AKT/mTOR signaling and Ras/Raf/MEK/MAPK pathways resulting in the activation of multiple transcription factors such as ELK-1, CREB and AP-1 to modulate cell proliferation, survival, differentiation, motility, invasion and angiogenesis. IGF-1R overexpression or increased IGF-1R kinase activity is associated with a broad range of human cancers and therefore the IGF-1R is widely considered as a very promising target for cancer treatment.

IGF-1R Inhibitors & Agonists

AG1024

(Tyrphostin AG 1024) Cat. No.: HY-10253

AG1024 (Tyrphostin AG 1024) is a reversible, competitive and selective **IGF-1R** inhibitor with an IC_{50} of 7 μM. AG1024 inhibits phosphorylation of **IR** (IC_{50}=57 μM). AG1024 induces **apoptosis** and has anti-cancer activity.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZ12253801

Cat. No.: HY-125102

AZ12253801 is an ATP-competitive **IGF-1R** tyrosine kinase inhibitor that shows 10-fold selectivity over the insulin receptor. AZ12253801 inhibits IGF-1R–driven proliferation in 3T3 mouse fibroblasts (transfected with human IGF-1R) with an IC_{50} of 17 nmol/L.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ7550

Cat. No.: HY-B0794

AZ7550 is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an IC_{50} of 1.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ7550 hydrochloride

Cat. No.: HY-B0794A

AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an IC_{50} of 1.6 μM.



Purity: 98.66%
Clinical Data: Phase 1
Size: 5 mg, 10 mg

AZ7550 Mesylate

(AZ7550 trimesylate salt) Cat. No.: HY-B0794B

AZ7550 Mesylate is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an IC_{50} of 1.6 μM.



Purity: 99.34%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg

AZD-3463

(ALK/IGF1R inhibitor) Cat. No.: HY-15609

AZD-3463 (ALK/IGF1R inhibitor) is an orally active **ALK/IGF1R** inhibitor, with a K_i of 0.75 nM for ALK. AZD3463 induces **apoptosis** and **autophagy** in neuroblastoma cells.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS-536924

Cat. No.: HY-10262

BMS-536924 is an orally active, competitive and selective **insulin-like growth factor receptor (IGF-1R)** kinase and **insulin receptor (IR)** inhibitor with IC_{50}s of 100 nM and 73 nM, respectively. BMS-536924 has anti-cancer activity.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS-754807

Cat. No.: HY-10200

BMS-754807 is a potent and reversible **IGF-1R/IR** inhibitor (IC_{50}=1.8 and 1.7 nM, respectively; K_i=<2 nM for both). BMS-754807 also shows potent activities against Met, RON, TrkA, TrkB, AurA, and AurB with IC_{50} values of 6, 44, 7, 4, 9, and 25 nM, respectively.



Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ceritinib

(LDK378) Cat. No.: HY-15656

Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive **ALK** tyrosine kinase inhibitor with an IC_{50} of 200 pM. Ceritinib (LDK378) also inhibits **IGF-1R**, **InsR**, and **STK22D** with IC_{50} values of 8, 7, and 23 nM, respectively. Ceritinib (LDK378) shows great antitumor potency.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ceritinib D7

(LDK378 D7) Cat. No.: HY-15656S

Ceritinib D7 (LDK378 D7) is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ceritinib dihydrochloride

(LDK378 dihydrochloride)

Cat. No.: HY-15656A

Ceritinib dihydrochloride (LDK378 dihydrochloride) is a selective, orally bioavailable and ATP-competitive **ALK** tyrosine kinase inhibitor with an IC_{50} of 200 pM.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ginsenoside Rg5

Cat. No.: HY-N0908

Ginsenoside Rg5 is the main component of Red ginseng. Ginsenoside blocks binding of **IGF-1** to its receptor with an IC_{50} of ~90 nM. Ginsenoside Rg5 also inhibits the mRNA expression of **COX-2** via suppression of the DNA binding activities of **NF-κB p65**.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GSK1838705A

Cat. No.: HY-13020

GSK1838705A is a potent and reversible **IGF-IR** and the **insulin receptor** inhibitor with IC_{50}s of 2.0 and 1.6 nM, respectively. It also inhibits **ALK** with an IC_{50} of 0.5 nM.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK1904529A

Cat. No.: HY-10524

GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of **insulin-like growth factor-1 receptor (IGF-1R)** and **insulin receptor (IR)**, with IC_{50}s of 27 and 25 nM, respectively.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

I-OMe-Tyrphostin AG 538

(I-OMe-AG 538)

Cat. No.: HY-135680

I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of **IGF-1R** (insulin-like growth factor-1 receptor tyrosine kinase).



Purity: 99.34%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IGF-1R inhibitor-2

Cat. No.: HY-145110

IGF-1R inhibitor-2 (example 121) is an insulin-like growth factor-1 receptor (**IGF-1R**) inhibitor. Downregulation of IGF-1R can reverse the transformed phenotype of tumor cells and potentially render them susceptible to apoptosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Indirubin Derivative E804

Cat. No.: HY-18785

Indirubin Derivative E804 is a potent inhibitor of Insulin-like Growth Factor 1 Receptor **(IGF1R)**, with an IC_{50} of 0.65 μM for IGF1R.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Linsitinib

(OSI-906)

Cat. No.: HY-10191

Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the **IGF-1 receptor** and **insulin receptor (IR)** with IC_{50}s of 35 and 75 nM, respectively.



Purity: 99.83%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Linsitinib-d3

(OSI-906-d3)

Cat. No.: HY-10191S

Linsitinib-d3 (OSI-906-d3) is the deuterium labeled Linsitinib. Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the **IGF-1 receptor** and **insulin receptor (IR)** with IC_{50}s of 35 and 75 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NBI-31772

Cat. No.: HY-110135

NBI-31772 is the potent and nonselective inhibitor of **IGFBP** with a K_i value of 47 nM. NBI-31772 has the potential for the research of IGF-responsive diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NBI-31772 hydrate

Cat. No.: HY-110135A

NBI-31772 hydrate is a potent inhibitor of interaction between **insulin-like growth factor (IGF)** and **IGF-binding proteins (IGFBPs)**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

NVP-ADW742

(ADW742; GSK 552602A; ADW)

Cat. No.: HY-10252

NVP-ADW742 (ADW742) is an orally active, selective **IGF-1R tyrosine kinase** inhibitor with an IC_{50} of 0.17 μM. NVP-ADW742 inhibits **insulin receptor (InsR)** with an IC_{50} of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/**proapoptotic** biologic sequelae in tumor cells.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-AEW541

(AEW541)

Cat. No.: HY-50866

NVP-AEW541 (AEW541) is a potent inhibitor of **IGF-1R** with IC_{50} of 0.15 μM, also inhibits **InsR**, with IC_{50} of 0.14 μM.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

NVP-TAE 226

(TAE226)

Cat. No.: HY-13203

NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual **FAK** and **IGF-1R** inhibitor with IC_{50}s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits **Pyk2** and **insulin receptor (InsR)** with IC_{50}s of 3.5 nM and 44 nM, respectively.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Picropodophyllin

(AXL1717; Picropodophyllin; PPP)

Cat. No.: HY-15494

Picropodophyllin (AXL1717) is a selective **insulin-like growth factor-1 receptor (IGF-1R)** inhibitor with an IC_{50} of 1 nM.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Picropodophyllotoxin-d6

Cat. No.: HY-15494S1

Picropodophyllotoxin-d6 is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PQ401

Cat. No.: HY-13686

PQ401 is a potent inhibitor of **IGF-IR** signaling. PQ401 inhibits IGF-I-stimulated IGF-IR autophosphorylation with an IC_{50} of 12.0 μM in a series of studies in MCF-7 cells. PQ401 is effective at inhibiting IGF-I-stimulated growth of MCF-7 cells (IC_{50}, 6 μM).



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Ugodotin

Cat. No.: HY-139591

Ugodotin is an antibody-drug conjugate. Ugodotin can binds **IGF-1R** with antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

XL228

Cat. No.: HY-15749

XL228 is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 5, 3.1, 1.6, 6.1, 2 nM for **Bcr-Abl**, **Aurora A**, **IGF-1R**, **Src** and **Lyn**, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Insulin Receptor

Insulin receptor (IR), a phylogenetically ancient tyrosine kinase receptor, is a large cell surface glycoprotein that concentrates insulin at the site of action and also initiates responses to insulin. The receptor is a disulfide-linked oligomer comprised of two alpha and two beta subunits. The insulin receptor exists in two isoforms, IR-A and IR-B, expressed in different relative abundance in the various organs and tissues. The two IR isoforms have similar binding affinity for insulin but different affinity for insulin-like growth factor (IGF)-2 and proinsulin, which are bound by IR-A but not IR-B.

The insulin receptor has a crucial role in controlling glucose homeostasis, regulating lipid, protein and carbohydrate metabolism, and modulating brain neurotransmitter levels. Insulin receptor dysfunction has been associated with many diseases, including diabetes, cancer and Alzheimer's disease.

AG1024

(Tyrphostin AG 1024)

Cat. No.: HY-10253

AG1024 (Tyrphostin AG 1024) is a reversible, competitive and selective **IGF-1R** inhibitor with an IC_{50} of 7 μM. AG1024 inhibits phosphorylation of **IR** (IC_{50}=57 μM). AG1024 induces **apoptosis** and has anti-cancer activity.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AGL-2263

Cat. No.: HY-112720

AGL-2263 is an **insulin receptor** and **insulin-like growth factor (IGF) receptor** inhibitor.



Purity: 97.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AVJ16

Cat. No.: HY-144873

AVJ16 is a member of the insulin-like growth factor 2 mRNA-binding protein family. AVJ16 regulates protein translation by binding to the mRNAs of certain genes.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-536924

Cat. No.: HY-10262

BMS-536924 is an orally active, competitive and selective **insulin-like growth factor receptor (IGF-1R)** kinase and **insulin receptor (IR)** inhibitor with IC_{50}s of 100 nM and 73 nM, respectively. BMS-536924 has anti-cancer activity.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS-754807

Cat. No.: HY-10200

BMS-754807 is a potent and reversible **IGF-1R/IR** inhibitor (IC_{50}=1.8 and 1.7 nM, respectively; K_i=<2 nM for both). BMS-754807 also shows potent activities against Met, RON, TrkA, TrkB, AurA, and AurB with IC_{50} values of 6, 44, 7, 4, 9, and 25 nM, respectively.



Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ceritinib

(LDK378)

Cat. No.: HY-15656

Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive **ALK** tyrosine kinase inhibitor with an IC_{50} of 200 pM. Ceritinib (LDK378) also inhibits **IGF-1R**, **InsR**, and **STK22D** with IC_{50} values of 8, 7, and 23 nM, respectively. Ceritinib (LDK378) shows great antitumor potency.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ceritinib D7

(LDK378 D7)

Cat. No.: HY-15656S

Ceritinib D7 (LDK378 D7) is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ceritinib dihydrochloride

(LDK378 dihydrochloride)

Cat. No.: HY-15656A

Ceritinib dihydrochloride (LDK378 dihydrochloride) is a selective, orally bioavailable and ATP-competitive **ALK** tyrosine kinase inhibitor with an IC_{50} of 200 pM.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DA-JC4

Cat. No.: HY-P3255

DA-JC4 is a dual **GLP-1/GIP receptor** agonist and can be used for the research of neurological disease and insulin signaling pathways.

Purity: 96.57%
Clinical Data: No Development Reported
Size: 5 mg

Demethylasterriquinone B1

(DAQ B1; L-783281; Dimethylasterriquinone)

Cat. No.: HY-107586

Demethylasterriquinone B1 is a selective **insulin receptor** activator. Demethylasterriquinone B1 stimulates tyrosine phosphorylation of the **IR β** subunit, and the activation of **PIK3** and **AKT**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GIP (1-30) amide, porcine

Cat. No.: HY-P2541

GIP (1-30) amide, porcine is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42). GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GIP (1-30) amide, porcine TFA

Cat. No.: HY-P2541A

GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42). GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

Purity: 98.55%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

GIP (1-30) amide,human

Cat. No.: HY-P2080

GIP (1-30) amide,human is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GIP (1-30) amide,human acetate

Cat. No.: HY-P2080B

GIP (1-30) amide,human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions.

Purity: 98.26%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GIP (3-42), human

Cat. No.: HY-P2542

GIP (3-42), human acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo.

Purity: 98.24%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GIP, human

(Gastric Inhibitory Peptide (GIP), human)

Cat. No.: HY-P0276

GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GIP, human TFA

(Gastric Inhibitory Peptide (GIP), human TFA)

Cat. No.: HY-P0276A

GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of **glucose-dependent insulin secretion** and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion.

Purity: 96.24%
Clinical Data: No Development Reported
Size: 1 mg

GSK1838705A

Cat. No.: HY-13020

GSK1838705A is a potent and reversible **IGF-IR** and the **insulin receptor** inhibitor with IC_{50}s of 2.0 and 1.6 nM, respectively. It also inhibits **ALK** with an IC_{50} of 0.5 nM.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK1904529A

Cat. No.: HY-10524

GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of **insulin-like growth factor-1 receptor (IGF-1R)** and **insulin receptor (IR)**, with IC_{50}s of 27 and 25 nM, respectively.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

HNMPA

Cat. No.: HY-101962

HNMPA is a membrane impermeable **insulin receptor tyrosine kinase** inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

HNMPA-(AM)3

Cat. No.: HY-124097

HNMPA-(AM)3 is a cell-permeable and selective **insulin receptor tyrosine kinase** inhibitor analog of HNMPA. HNMPA-(AM)3 greatly inhibits the ability of prothoracicotropic hormone (PTTH) to activate ERK phosphorylation and stimulate ecdysteroidogenesis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Insulin (human)

Cat. No.: HY-P0035

Insulin (human) is a polypeptide hormone that regulates the level of glucose.

Insulin (human)

Purity: 96.90%
Clinical Data: Launched
Size: 25 mg, 50 mg, 100 mg

Insulin glargine

Cat. No.: HY-108719

Insulin glargine is a long-acting insulin analog. Insulin glargine can be used for the diabetes mellitus.

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Insulin levels modulator

Cat. No.: HY-112819

Insulin levels modulator could be used to treat diabetes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Insulin(cattle)

(Insulin from bovine pancreas)

Cat. No.: HY-P1156

Insulin cattle (Insulin from bovine pancreas) is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.

Insulin(cattle)

Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Kaempferitrin

(Lespedin; Lespenephryl)

Cat. No.: HY-N0628

Kaempferitrin is a natural flavonoid, possesses antinociceptive, anti-inflammatory, anti-diabetic, antitumoral and chemopreventive effects, and activates **insulin** signaling pathway.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

KU14R

Cat. No.: HY-15481

KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Linsitinib

(OSI-906)

Cat. No.: HY-10191

Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the **IGF-1 receptor** and **insulin receptor (IR)** with IC_{50}s of 35 and 75 nM, respectively.



Purity: 99.83%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Linsitinib-d3

(OSI-906-d3)

Cat. No.: HY-10191S

Linsitinib-d3 (OSI-906-d3) is the deuterium labeled Linsitinib. Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the **IGF-1 receptor** and **insulin receptor (IR)** with IC_{50}s of 35 and 75 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MID-1

Cat. No.: HY-115461

MID-1 is a disruptor of **MG53-IRS-1** (Mitsugumin 53-insulin receptor substrate-1) interaction.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MSDC 0160

(Mitoglitazone; CAY10415) Cat. No.: HY-100550

MSDC 0160 (Mitoglitazone) is a mitochondrial target of thiazolidinediones (mTOT)-modulating **insulin sensitizer** and a modulator of **mitochondrial pyruvate carrier (MPC)**. MSDC 0160 is a thiazolidinedione (TZD) with antidiabetic and neuroprotective activities.



Purity: 99.40%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

MSDC-0602K

(Azemiglitazone potassium) Cat. No.: HY-108022A

MSDC-0602K (Azemiglitazone potassium), a **PPARγ**-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC_{50} of 18.25 μM. MSDC-0602K modulates the mitochondrial pyruvate carrier (MPC).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

NT219

Cat. No.: HY-145935

NT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 (**IRS1/2**) and **STAT3**. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NVP-ADW742

(ADW742; GSK 552602A; ADW) Cat. No.: HY-10252

NVP-ADW742 (ADW742) is an orally active, selective **IGF-1R tyrosine kinase** inhibitor with an IC_{50} of 0.17 μM. NVP-ADW742 inhibits **insulin receptor (InsR)** with an IC_{50} of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/**proapoptotic** biologic sequelae in tumor cells.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-AEW541

(AEW541) Cat. No.: HY-50866

NVP-AEW541 (AEW541) is a potent inhibitor of **IGF-1R** with IC_{50} of 0.15 μM, also inhibits **InsR**, with IC_{50} of 0.14 μM.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

NVP-TAE 226

(TAE226) Cat. No.: HY-13203

NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual **FAK** and **IGF-1R** inhibitor with IC_{50}s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits **Pyk2** and **insulin receptor (InsR)** with IC_{50}s of 3.5 nM and 44 nM, respectively.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

OI338

Cat. No.: HY-142663

OI338 is an orally available, ultralong-acting insulin analogue.

OI338

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Peonidin 3-O-glucoside chloride

Cat. No.: HY-W040127

Peonidin 3-O-glucoside chloride, an anthocyanin, act as an insulin secretagogue. Peonidin 3-O-glucoside chloride can increase glucose uptake in HepG2 cells. Peonidin 3-O-glucoside chloride has the potential for type-2 diabetes comorbidities research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rhoifolin

Cat. No.: HY-N0755

Rhoifolin is a flavone glycoside isolated from Citrus grandis (L.) Osbeck leaves. Rhoifolin is beneficial for diabetic complications through enhanced adiponectin secretion, tyrosine phosphorylation of **insulin receptor-β** and **glucose transporter 4 (GLUT 4)** translocation.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

S961

Cat. No.: HY-P2093

S961 is an high-affinity and selective **insulin receptor (IR)** antagonist with IC_{50}s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

S961 acetate

Cat. No.: HY-P2093B

S961 acetate is an high-affinity and selective **insulin receptor** (**IR**) antagonist with **IC_{50}**s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.

Purity: 99.52%
Clinical Data: No Development Reported
Size: 5 mg

S961 TFA

Cat. No.: HY-P2093A

S961 TFA is an high-affinity and selective **insulin receptor** (**IR**) antagonist with **IC_{50}**s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.

Purity: 97.60%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

SU4984

Cat. No.: HY-118203

SU4984 is a protein tyrosine kinase inhibitor, with an **IC_{50}** of 10-20 μM for **fibroblast growth factor receptor 1 (FGFR1)**. SU4984 is also inhibits **platelet-derived growth factor receptor**, and **insulin receptor**. SU4984 can be used for the research of cancer.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Itk

Interleukin-2 inducible T-cell kinase; IL2 inducible T-cell kinase

Itk (Interleukin-2-inducible T-cell kinase) is a Tec family tyrosine kinase that mediates signaling processes after T cell receptor engagement. Activation of Itk requires recruitment to the membrane via its pleckstrin homology domain, phosphorylation of Itk by the Src kinase, Lck, and binding of Itk to the SLP-76/LAT adapter complex. After activation, Itk phosphorylates and activates phospholipase C-gamma1 (PLC-gamma1), leading to production of two second messengers, DAG and IP3. IP3 and DAG stimulate the release of calcium ions from the endoplasmic reticulum and activate Protein Kinase C, respectively. In addition, Itk regulates the development of Th2 cells and their subsequent cytokine secretion, thereby modulating the immune response.

Studies have shown that ITK is involved in the pathogenesis of autoimmune diseases as well as in carcinogenesis. The loss of ITK or its activity either by mutation or by the use of inhibitors led to a beneficial outcome in experimental models of asthma, inflammatory bowel disease and multiple sclerosis among others. In humans, biallelic mutations in the ITK gene locus result in a monogenetic disorder leading to T cell dysfunction, etc. These findings put ITK in the strong focus as a target for drug development.

Itk Inhibitors

BMS-509744

Cat. No.: HY-11092

BMS-509744 is a potent, selective and ATP competitive **Itk** inhibitor with an IC_{50} of 19 nM.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

EGFR-IN-40

Cat. No.: HY-143901

EGFR-IN-40 (compound 3z) is a potent **BTK**, **EGFR**, and **ITK** inhibitor with IC_{50} values of 1.2 nM, 5.3 nM, and 46.1 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GNE-4997

Cat. No.: HY-16984

GNE-4997 is a potent and selective **interleukin-2-inducible T-cell kinase (ITK)** inhibitor with a K_i of 0.09 nM, and the correlation between the basicity of solubilizing elements in GNE-4997 and off-target antiproliferative effects reduces cytotoxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ITK antagonist

Cat. No.: HY-13232

ITK antagonist (compound 10 n) is a potent, orally active and selective **ITK** (Interleukin-2 inducible T-cell kinase) antagonist (IC_{50}=1 and 20 nM in different assays). ITK antagonist inhibits insulin receptor kinase (IRK) with an IC_{50} of 160 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ITK inhibitor 2

Cat. No.: HY-128726

ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (**ITK**) inhibitor extracted from patent WO2011065402A1, compound 4, with an IC_{50} of 2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ITK inhibitor 5

Cat. No.: HY-146671

ITK inhibitor 5 (compound 27) is a potent and selective **ITK** inhibitor with IC_{50}s of 5.6, 25 nM for ITK, BTK, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ITK inhibitor 6

Cat. No.: HY-146672

ITK inhibitor 6 (compound 43) is a potent and selective **ITK** inhibitor with IC_{50}s of 4 nM, 133 nM, 320 nM, 2360 nM, 155 nM for ITK, BTK, JAK3, EGFR, LCK, respectively. ITK inhibitor 6 inhibits phosphorylation of PLCγ1 and ERK1/2. ITK inhibitor 6 shows antiproliferative activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ITK/TRKA-IN-1

Cat. No.: HY-141864

ITK/TRKA-IN-1 is a dual inhibitor of **IL-2-inducible T-cell kinase (ITK)** and **tropomyosin receptor kinase A (TRKA)** with an IC_{50} value of 1.0 nM and 96 % inhibition, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-06465469

Cat. No.: HY-108691

PF-06465469 is a covalent inhibitor of **ITK** with an IC_{50} of 2nM.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

PRN694

Cat. No.: HY-12680

PRN694 is an irreversible, highly selective and potent covalent **interleukin-2-inducible T-cell kinase (ITK)** and **resting lymphocyte kinase (RLK)** dual inhibitor with IC_{50}s of 0.3 nM and 1.4 nM, respectively.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Vecabrutinib

(SNS-062) Cat. No.: HY-109078

Vecabrutinib (SNS-062) is a potent, noncovalent **BTK** and **ITK** inhibitor, with K_d values of 0.3 nM and 2.2 nM, respectively. Vecabrutinib shows an IC_{50} of 24 nM for **ITK**.



Purity: 99.85%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PDGFR

Platelet-derived growth factor receptor

PDGFR (Platelet-derived growth factor receptors) are cell surface tyrosine kinase receptors for members of the platelet-derived growth factor (PDGF) family. PDGF subunits -A and -B are important factors regulating cell proliferation, cellular differentiation, cell growth, development and many diseases including cancer. There are two forms of the PDGFR: PDGFR alpha and PDGFR beta.

PDGFR Inhibitors

(Z)-Orantinib

((Z)-SU6668; (Z)-TSU-68) Cat. No.: HY-10517A

(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of **Flk1/KDR**, **PDGFRβ**, and **FGFR1**, with IC_{50}s of 2.1, 0.008, and 1.2 μM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

10Z-Hymenialdisine

((Z)-Hymenialdisine; Hymenialdisine) Cat. No.: HY-N6794

10Z-Hymenialdisine ((Z)-Hymenialdisine) is a natural bioactive pyrrole alkaloid. 10Z-Hymenialdisine is a pan kinase inhibitor, and has anticancer activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AC710

Cat. No.: HY-13493

AC710 is a potent **PDGFR** inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AC710 Mesylate

Cat. No.: HY-13493A

AC710 Mesylate is a potent **PDGFR** inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AG 1295

Cat. No.: HY-101957

AG 1295 is a selective **platelet-derived growth factor receptor (PDGFR)** tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR whereas not affects the autophosphorylation of the EGF receptor.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AG 370

Cat. No.: HY-116111

AG 370, an indole tyrphostin, is a potent **PDGF**-induced mitogenesis inhibitor (IC_{50} of 20 μM). AG 370 displays weak inhibition of the EGF receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amuvatinib

(MP470; HPK 56) Cat. No.: HY-10206

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: 98.07%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amuvatinib hydrochloride

(MP470 hydrochloride; HPK 56 hydrochloride) Cat. No.: HY-10206A

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Avapritinib

(BLU-285) Cat. No.: HY-101561

Avapritinib (BLU-285) is a highly potent, selective, and orally active **KIT** and **PDGFRA** activation loop mutant kinases inhibitor with IC_{50}s of 0.27 and 0.24 nM for **KIT D816V** and **PDGFRA D842V**, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Axitinib

(AG-013736) Cat. No.: HY-10065

Axitinib is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 0.1, 0.2, 0.1-0.3, 1.6 nM for **VEGFR1**, **VEGFR2**, **VEGFR3** and **PDGFRβ**, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Axitinib 13CD3

(AG-013736 13CD3)

Cat. No.: HY-10065S

Axitinib 13CD3 (AG-013736 13CD3) is a 13C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 0.1, 0.2, 0.1-0.3, 1.6 nM for **VEGFR1**, **VEGFR2**, **VEGFR3** and **PDGFRβ**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

AZD2932

Cat. No.: HY-18179

AZD2932 is a potent and multi-targeted kinase inhibitor **VEGFR2**, **PDGFβ**, **Flt-3** and **c-Kit** with IC_{50}s of 8, 4, 7 and 9 nM in cell assay, respectively.



Purity: 96.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cediranib

(AZD2171)

Cat. No.: HY-10205

Cediranib (AZD2171) is a highly potent, orally available **VEGFR** tyrosine kinase inhibitor with IC_{50}s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.



Purity: 99.58%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Cediranib maleate

(AZD-2171 maleate)

Cat. No.: HY-13049

Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available **VEGFR** inhibitor with IC_{50}s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.



Purity: 99.74%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Chiauranib

(CS2164)

Cat. No.: HY-124526

Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CHIR-124

Cat. No.: HY-13263

CHIR-124 is a potent and selective **Chk1** inhibitor with IC_{50} of 0.3 nM, and also potently targets **PDGFR** and **FLT3** with IC_{50}s of 6.6 nM and 5.8 nM.



Purity: 96.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CP-673451

Cat. No.: HY-12050

CP-673451 is a potent and selective inhibitor of **PDGFR** with IC_{50}s of 10 and 1 nM for PDGFRα and PDGFRβ, respectively.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Crenolanib

(CP-868596)

Cat. No.: HY-13223

Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases **FLT3** and **PDGFRα/β** with K_ds of 0.74 nM and 2.1 nM/3.2 nM, respectively.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DMPQ dihydrochloride

Cat. No.: HY-108627

DMPQ dihydrochloride is a potent and selective inhibitor of human **platelet-derived growth factor receptor β (PDGFRβ)** with an IC_{50} of 80 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dovitinib

(CHIR-258; TKI258)

Cat. No.: HY-50905

Dovitinib (CHIR-258) is an orally active, potent **multi-targeted tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **CSF-1R**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Dovitinib lactate

(CHIR-258 lactate; TKI-258 lactate) Cat. No.: HY-10207

Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: 99.62%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dovitinib lactate hydrate

(TKI258 lactate hydrate; CHIR-258 lactate hydrate) Cat. No.: HY-B0062

Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dovitinib-D8

Cat. No.: HY-50905S

Dovitinib-D8 (CHIR-258-D8) is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ENMD-2076

Cat. No.: HY-10987A

ENMD-2076 is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ENMD-2076 Tartrate

Cat. No.: HY-10987

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 98.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

Famitinib

(SHR1020) Cat. No.: HY-108713

Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of **c-kit**, **VEGFR-2** and **PDGFRβ** with IC_{50} values of 2.3 nM, 4.7 nM and 6.6 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Flumatinib

(HHGV678) Cat. No.: HY-13904

Flumatinib (HHGV678) is an orally available, selective inhibitor of **Bcr-Abl**. Flumatinib inhibits **c-Abl**, **PDGFRβ** and **c-Kit** with IC_{50}s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Flumatinib mesylate

(HHGV678 mesylate) Cat. No.: HY-13905

Flumatinib (HHGV678) mesylate is an orally active and selective inhibitor of **Bcr-Abl**. Flumatinib mesylate inhibits c-Abl, PDGFRβ and c-Kit with IC_{50} values of 1.2, 307.6 and 665.5 nM, respectively.



Purity: 99.97%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 500 mg

Flumatinib-d3

(HHGV678-d3) Cat. No.: HY-13904S

Flumatinib-d3 is deuterium labeled Flumatinib. Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GZD856

Cat. No.: HY-101489

GZD856 formic is a potent and orally active **PDGFRα/β** inhibitor, with IC_{50}s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a **Bcr-Abl**^{T315I} inhibitor, with IC_{50}s of 19.9 and 15.4nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GZD856 formic

Cat. No.: HY-101489A

GZD856 formic is a potent and orally active **PDGFRα/β** inhibitor, with IC_{50}s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a **Bcr-Abl^{T315I}** inhibitor, with IC_{50}s of 19.9 and 15.4nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HG-7-85-01

Cat. No.: HY-15814

HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of **Bcr-Abl**, **PDGFRα**, **Kit**, and **Src kinases**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hypothemycin

Cat. No.: HY-107417

Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for **VEGFR2/VEGFR1**, **MEK1/MEK2**, **FLT-3**, **PDGFRβ/PDGFRα**, and **ERK1/ERK2**, respectively.



Purity: 96.10%
Clinical Data: No Development Reported
Size: 1 mg

IHMT-TRK-284

Cat. No.: HY-146697

IHMT-TRK-284 (Compound 34) is a potent, orally active **type II TRK kinase** inhibitor with IC_{50} values of 10.5, 0.7, and 2.6 nM to **TRKA, B**, and **C** respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ilorasertib

(ABT-348)

Cat. No.: HY-16018

Ilorasertib (ABT-348) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits **Aurora C**, **Aurora B**, and **Aurora A** with IC_{50}s of 1 nM, 7 nM, 120 nM, respectively.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 50 mg, 100 mg

Ilorasertib hydrochloride

(ABT-348 hydrochloride)

Cat. No.: HY-16018A

Ilorasertib (ABT-348 hydrochloride) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits **Aurora C**, **Aurora B**, and **Aurora A** with IC_{50}s of 1 nM, 7 nM, 120 nM, respectively.



Purity: 99.67%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Imatinib

(STI571; CGP-57148B)

Cat. No.: HY-15463

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits **BCR/ABL**, **v-Abl**, **PDGFR** and **c-kit** kinase activity.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

Imatinib D4

(STI571 D4; CGP-57148B D4)

Cat. No.: HY-15463S1

Imatinib D4 (STI571 D4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imatinib Mesylate

(STI571 Mesylate; CGP-57148B Mesylate)

Cat. No.: HY-50946

Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits **c-Kit**, **Bcr-Abl**, and **PDGFR** (IC_{50}=100 nM) tyrosine kinases.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

Imatinib-d8

(STI571-d8; CGP-57148B-d8)

Cat. No.: HY-15463S

Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

JI-101

Cat. No.: HY-16265

JI-101 is an orally available multi-kinase inhibitor of **VEGFR2**, **PDGFRβ** and **EphB4** with potent anti-cancer activity.



Purity: 99.43%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

JNJ-10198409

Cat. No.: HY-W011266

JNJ-10198409 is a relatively selective, orally active, and ATP competitive **PDGF-RTK** (platelet-derived growth factor receptor tyrosine kinase) inhibitor (IC_{50}=2 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

KG5

Cat. No.: HY-15198

KG5 is an orally active dual **PDGFRβ** and **B-Raf** allosteric inhibitor. KG5 also inhibits **Flt3**, **KIT** and **c-Raf**. KG5 has anticancer, antiangiogenic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ki20227

Cat. No.: HY-10408

Ki20227 is an orally active and highly selective **c-Fms tyrosine kinase (CSF1R)** inhibitor with IC_{50}s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, **VEGFR2** (vascular endothelial growth factor receptor-2), **c-Kit** (stem cell factor receptor) and **PDGFRβ** (platelet-derived growth factor...



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Lenvatinib

(E7080)

Cat. No.: HY-10981

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib mesylate

(E7080 mesylate)

Cat. No.: HY-10981A

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib-d4

(E7080-d4)

Cat. No.: HY-10981S

Lenvatinib-d4 (E7080-d4) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lenvatinib-d5

(E7080-d5)

Cat. No.: HY-10981S1

Lenvatinib-d5 (E7080-d5) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Linifanib

(ABT-869; AL-39324)

Cat. No.: HY-50751

Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of **VEGFR** and **PDGFR** family with IC_{50}s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity.



Purity: 99.72%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Masitinib

(AB1010)

Cat. No.: HY-10209

Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Masitinib mesylate

(AB-1010 mesylate) Cat. No.: HY-10209A

Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Methylnissolin

(Astrapterocarpan) Cat. No.: HY-N2484

Methylnissolin (Astrapterocarpan), isolated from Astragalus membranaceus, inhibits **platelet-derived growth factor (PDGF)**-BB-induced cell proliferation with an IC_{50} of 10 μM.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Multi-kinase inhibitor 1

Cat. No.: HY-103032

Multi-kinase inhibitor 1 is a potent **multi-kinase** inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of **PDGF-R**, **c-Kit** and **Bcr-abl**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Multi-kinase-IN-1

Cat. No.: HY-146014

Multi-kinase-IN-1 (Compound 11k) is a potent **kinase** inhibitor with antitumor activity. Multi-kinase-IN-1 induces cell **apoptosis**, and can be studied for **colorectal cancer**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-(p-Coumaroyl) Serotonin

Cat. No.: HY-129440

N-(p-Coumaroyl) Serotonin is a polyphenol isolated from the seeds of safflower and has antioxidative, anti-atherogenic and anti-inflammatory properties. N-(p-Coumaroyl) Serotonin inhibits PDGF-induced on **phosphorylation of PDGF receptor** and Ca^{2+} release from sarcoplasmic reticulum.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 5 mg

Nintedanib

(BIBF 1120) Cat. No.: HY-50904

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Nintedanib esylate

(BIBF 1120 esylate) Cat. No.: HY-11106

Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Nintedanib-13C,d3

(BIBF 1120-13C,d3) Cat. No.: HY-50904S1

Nintedanib-13C,d3 is the 13C- and deuterium labeled. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nintedanib-d3

(BIBF 1120-d3) Cat. No.: HY-50904S

Nintedanib-d3 (BIBF 1120-d3) is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nintedanib-d8

(BIBF 1120-d8) Cat. No.: HY-50904S2

Nintedanib-d8 is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NVP-ACC789

(ACC-789; ZK202650) Cat. No.: HY-19624

NVP-ACC789 is an inhibitor of human **VEGFR-1**, **VEGFR-2** (mouse **VEGFR-2**), **VEGFR-3** and **PDGFR-β** with IC_{50}s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Orantinib

(SU6668; TSU-68) Cat. No.: HY-10517

Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with K_is of 2.1 μM, 8 nM and 1.2 μM for **Flt-1**, **PDGFRβ** and **FGFR1**, respectively.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pazopanib

(GW786034) Cat. No.: HY-10208

Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with IC_{50}s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pazopanib Hydrochloride

(GW786034 (Hydrochloride)) Cat. No.: HY-12009

Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with an IC_{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pazopanib-d6

(GW786034-d6) Cat. No.: HY-10208S

Pazopanib-d6 (GW786034-d6) is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with IC_{50}s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD-089828

Cat. No.: HY-112345

PD-089828 is an ATP competitive inhibitor of **FGFR-1**, **PDGFR-β** and **EGFR** (IC_{50}s=0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of **c-Src** tyrosine kinase (IC_{50}=0.18 μM). PD-089828 also inhibits **MAPK** with an IC_{50} of 7.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD-161570

Cat. No.: HY-100434

PD-161570 is a potent and ATP-competitive **human FGF-1 receptor** inhibitor with an IC_{50} of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the **PDGFR**, **EGFR** and **c-Src tyrosine kinases** with IC_{50} values of 310 nM, 240 nM, and 44 nM, respectively.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PDGFR Tyrosine Kinase Inhibitor III

(PDGF Receptor Tyrosine Kinase Inhibitor III) Cat. No.: HY-112412

PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PDGFR-IN-1

Cat. No.: HY-144653

PDGFR-IN-1 (compound 7m) is a potent and orally active **PDGFR** (platelet-derived growth factor receptor) inhibitor, with IC_{50} values of 2.4 and 0.9 nM for **PDGFRα** and **PDGFRβ**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PDGFRα kinase inhibitor 1

Cat. No.: HY-111507

PDGFRα kinase inhibitor 1 is a highly selective type II **PDGFRα** kinase inhibitor with IC_{50}s of 132 nM and 6115 nM for PDGFRα and PDGFRβ, respectively.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PDGFRα/FLT3-ITD-IN-1

Cat. No.: HY-145902

PDGFRα/FLT3-ITD-IN-1 (Compound 12d) is a potent inhibitor of **PDGFRα/FLT3** with IC_{50}s of more than 0.036 and 0.003 μM, respectively.
PDGFRα/FLT3-ITD-IN-1 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PDGFRα/FLT3-ITD-IN-2

Cat. No.: HY-145903

PDGFRα/FLT3-ITD-IN-2 (Compound 13d) is a potent inhibitor of **PDGFRα/FLT3** with IC_{50}s of more than 20 and 1.654 μM, respectively.
PDGFRα/FLT3-ITD-IN-2 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PDGFRα/FLT3-ITD-IN-3

Cat. No.: HY-145904

PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of **PDGFRα/FLT3** with IC_{50}s of 0.153 and 0.004 μM, respectively. PDGFRα/FLT3-ITD-IN-3 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ponatinib

(AP24534)

Cat. No.: HY-12047

Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ponatinib hydrochloride

(AP24534 hydrochloride)

Cat. No.: HY-108766

Ponatinib (AP24534) hydrochloride is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: >98%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg, 100 mg

Ponatinib-d8

(AP24534-d8)

Cat. No.: HY-12047S

Ponatinib D8 (AP24534 D8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 1 mg

PP121

Cat. No.: HY-10372

PP121 is a multi-targeted kinase inhibitor with IC_{50}s of 10, 60, 12, 14, 2 nM for **mTOR**, **DNK-PK**, **VEGFR2**, **Src**, **PDGFR**, respectively.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PP58

Cat. No.: HY-18622

PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits **PDGFR**, **FGFR** and **Src** family activities with nanomolar IC_{50} values.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Regorafenib

(BAY 73-4506)

Cat. No.: HY-10331

Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1**, respectively.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib Hydrochloride

(BAY 73-4506 hydrochloride)

Cat. No.: HY-13308

Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with IC_{50}s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib monohydrate

(BAY 73-4506 monohydrate) Cat. No.: HY-10331A

Regorafenib monohydrate (BAY 73-4506 monohydrate) is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with IC_{50}s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib-13C,d3

(BAY 73-4506-13C,d3) Cat. No.: HY-10331S1

Regorafenib-13C,d3 is the 13C- and deuterium labeled. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Regorafenib-d3

(BAY 73-4506-d3) Cat. No.: HY-10331S

Regorafenib D3 (BAY 73-4506 D3) is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ripretinib

(DCC-2618) Cat. No.: HY-112306

Ripretinib (DCC-2618) is an orally bioavailable, selective **KIT** and **PDGFRA** switch-control inhibitor.



Purity: 99.33%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sennoside B

Cat. No.: HY-N0366

Sennoside B is an anthraquinone glycoside, found in large quantities in leaves and pods of Senna (Cassia angustifolia). Sennoside B can inhibit PDGF-stimulated cell proliferation by binding to PDGF-BB and its receptor and by down-regulating the PDGFR-beta signaling pathway.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Seralutinib

(GB002; PK10571) Cat. No.: HY-109190

Seralutinib (GB002) is an inhaled **PDGFRα and PDGFRβ** inhibitor. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension.



Purity: 99.77%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SU 5402

Cat. No.: HY-10407

SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC_{50} of 20 nM, 30 nM, and 510 nM for **VEGFR2**, **FGFR1**, and **PDGFRβ**, respectively.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SU11652

Cat. No.: HY-112452

SU11652 is a potent **receptor tyrosine kinase (RTK)** inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including **VEGFR**, **FGFR**, **PDGFR**, and **Kit**. SU11652 can be uesd for spontaneous cancers expressing Kit mutations research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SU14813

Cat. No.: HY-10501

SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC_{50}s of 50, 2, 4, 15 nM for **VEGFR2**, **VEGFR1**, **PDGFRβ** and **KIT**.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SU14813 maleate

Cat. No.: HY-10501A

SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC_{50}s of 50, 2, 4, 15 nM for **VEGFR2**, **VEGFR1**, **PDGFRβ** and **KIT**.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SU16f

Cat. No.: HY-108628

SU16f is a potent and selective **PDGFRβ** inhibitor with IC_{50}s of 10 nM, 140 nM, 2.29 μM for PDGFRβ, PDGFR1, PDGFR2, respectively.



Purity: ≥99.0%
Clinical Data:
Size: 1 mg, 5 mg

SU4312

Cat. No.: HY-100349

SU4312 is the racemate of (Z)-SU4312 and (E)-SU4312. (Z)-SU4312 inhibits PDGFR and FLK-1 with IC_{50}s of 19.4 and 0.8 μM, respectively. (E)-SU4312 inhibits PDGFR, FLK-1, EGFR, HER-2, and IGF-1R with IC_{50}s of 24.2, 5.2, 18.5, 16.9 and 10.0 μM, respectively.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

SU4984

Cat. No.: HY-118203

SU4984 is a protein tyrosine kinase inhibitor, with an IC_{50} of 10-20 μM for **fibroblast growth factor receptor 1 (FGFR1)**. SU4984 is also inhibits **platelet-derived growth factor receptor**, and **insulin receptor**. SU4984 can be used for the research of cancer.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sunitinib

(SU 11248)

Cat. No.: HY-10255A

Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 80 nM and 2 nM for **VEGFR2** and **PDGFRβ**, respectively.



Purity: 98.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Sunitinib Malate

(SU 11248 Malate)

Cat. No.: HY-10255

Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 80 nM and 2 nM for **VEGFR2** and **PDGFRβ**, respectively.



Purity: 99.47%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Sunitinib-d10

(SU 11248-d10)

Cat. No.: HY-10255AS

Sunitinib D10 (SU 11248 D10) is a deuterium labeled Sunitinib. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 80 nM and 2 nM for **VEGFR2** and **PDGFRβ**, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sunitinib-d4

Cat. No.: HY-10255AS1

Sunitinib-d4 (SU 11248-d4) is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 80 nM and 2 nM for **VEGFR2** and **PDGFRβ**, respectively.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 1 mg, 25 mg

TAK-593

Cat. No.: HY-15506

TAK-593 is a potent **VEGFR** and **PDGFR** family inhibitor with IC_{50}s of 3.2, 0.95, 1.1, 4.3 and 13 nM for VEGFR1, VEGFR2, VEGFR3, PDFGRα and PDFGRβ, respectively.



Purity: 99.62%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tandutinib

(MLN518; CT53518)

Cat. No.: HY-10202

Tandutinib (MLN518) is a potent and selective inhibitor of the **FLT3** with an IC_{50} of 0.22 μM, and also inhibits **c-Kit** and **PDGFR** with IC_{50}s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML).



Purity: 99.48%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg

Tandutinib hydrochloride

(MLN518 hydrochloride; CT53518 hydrochloride)

Cat. No.: HY-10202A

Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the **FLT3** with an IC_{50} of 0.22 μM, and also inhibits **c-Kit** and **PDGFR** with IC_{50}s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML).



Purity: 98.84%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg

Telatinib

(Bay 57-9352)

Cat. No.: HY-10527

Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of **VEGFR2**, **VEGFR3**, **PDGFα**, and **c-Kit** with IC_{50}s of 6, 4, 15 and 1 nM, respectively.



Purity: 98.72%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Telatinib mesylate

(Bay 57-9352 mesylate)

Cat. No.: HY-10527C

Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active **VEGFR2**, **VEGFR3**, **PDGFα**, and **c-Kit** inhibitor with IC_{50}s of 6 nM, 4 nM, 15 nM and 1 nM, respectively.



Purity: 99.46%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TG 100572

Cat. No.: HY-10184

TG 100572 is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TG 100572 Hydrochloride

Cat. No.: HY-10185

TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

TG 100801

Cat. No.: HY-10186

TG 100801 is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: 98.60%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg

TG 100801 Hydrochloride

Cat. No.: HY-10187

TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Toceranib

(SU11654; PHA 291639E)

Cat. No.: HY-10330

Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



Purity: 96.25%
Clinical Data: Launched
Size: 10 mg, 50 mg

Toceranib phosphate

(SU11654 phosphate; PHA 291639E phosphate)

Cat. No.: HY-10330A

Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



Purity: 98.02%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg, 100 mg

Toceranib-d8

Cat. No.: HY-10330S

Toceranib-d8 (SU11654-d8) is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Trapidil

(AR-12008)

Cat. No.: HY-B1016

Trapidil is a vasodilator, is an antiplatelet drug with specific platelet-derived growth factor.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tyrosine kinase-IN-1

Cat. No.: HY-100315

Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 4, 20, 4, 2 nM for **KDR**, **Flt-1**, **FGFR1** and **PDGFRα**, respectively.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyrphostin AG1296

(AG1296)

Cat. No.: HY-13894

Tyrphostin AG1296 is a potent and selective inhibitor of **platelet-derived growth factor receptor (PDGFR)**, with an IC_{50} of 0.8 μM.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyrphostin AG1433

(SU1433; AG1433)

Cat. No.: HY-119757

Tyrphostin AG1433 (SU1433) is a **tyrosine kinases** inhibitor. AG1433 is also a selective **PDGFRβ** and **VEGFR-2 (Flk-1/KDR)** inhibitor with IC_{50}s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vorolanib

(CM082; X-82)

Cat. No.: HY-109019

Vorolanib (CM082) is an orally active, potent multikinase **VEGFR/PDGFR** inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895).



Purity: 99.80%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zeteletinib

(BOS-172738; DS-5010)

Cat. No.: HY-139590

Zeteletinib (BOS-172738; DS-5010) is an orally active, selective **RET kinase** inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zeteletinib hemiadipate

(BOS-172738 hemiadipate; DS-5010 hemiadipate)

Cat. No.: HY-139590A

Zeteletinib (BOS-172738; DS-5010) hemiadipate is an orally active, selective **RET kinase** inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PKA

Protein kinase A

PKA (Protein kinase A) is a Ser/Thr phosphoryl transferase that transfers the γ-phosphate group of ATP to protein substrates. PKA phosphorylates more than 100 cytoplasmic and membrane associated targets. PKA mediates a myriad of cellular signaling events and its activity is tightly regulated both in space and time.

PKA is an evolutionarily conserved negative regulator of the hedgehog (Hh) signal transduction pathway. PKA is known to be required for the proteolytic processing event that generates the repressor forms of the Ci and Gli transcription factors that keep target genes off in the absence of Hh.

PKA Inhibitors, Antagonists & Activators

6-Bnz-cAMP sodium salt

Cat. No.: HY-103322

6-Bnz-cAMP sodium salt is a cell-permeable cAMP analog. 6-Bnz-cAMP selectively activates cAMP-dependent PKA but not Epac signaling pathways.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

8-Bromo-cAMP sodium salt

(8-Br-Camp sodium salt) Cat. No.: HY-12306

8-Bromo-cAMP sodium salt (8-Br-Camp sodium salt), a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (**PKA**).



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

8-CPT-Cyclic AMP sodium

(8-CPT-cAMP sodium; 8-(p-Chlorophenylthio)-cAMP sodium) Cat. No.: HY-111673

8-CPT-Cyclic AMP (8-CPT-cAMP) sodium is a selective activator of **cyclic AMP-dependent protein kinase (PKA)**. 8-CPT-Cyclic AMP sodium is also a potent inhibitor of the cyclic GMP-specific phosphodiesterase **(PDE VA)** with an IC_{50} of 0.9 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

A-3 hydrochloride

Cat. No.: HY-125957

A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various **kinases**. It against PKA (K_i=4.3 μM), casein kinase II (K_i=5.1 μM) and myosin light chain kinase (MLCK) (K_i=7.4 μM).



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

AT13148

Cat. No.: HY-16071

AT13148 is an orally active and ATP-competitive, multi-**AGC kinase** inhibitor with IC_{50}s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.



Purity: 99.42%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT7867

Cat. No.: HY-12059

AT7867 is a potent ATP-competitive inhibitor of **Akt1/Akt2/Akt3** and **p70S6K/PKA** with IC_{50}s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT7867 dihydrochloride

Cat. No.: HY-12059A

AT7867 dihydrochloride is a potent ATP-competitive inhibitor of **Akt1/Akt2/Akt3** and **p70S6K/PKA** with IC_{50}s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bilobetin

Cat. No.: HY-N2118

Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Bucladesine calcium

(Dibutyryl cAMP calcium salt; DBcAMP calcium salt) Cat. No.: HY-B0764A

Bucladesine calcium salt (Dibutyryl-cAMP calcium salt;DC2797 calcium salt) is a cell-permeable cyclic AMP (cAMP) analog and selectively activates cAMP dependent protein kinase (**PKA**) by increasing the intracellular level of cAMP.



Purity: 95.73%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Bucladesine sodium

(Dibutyryl cAMP sodium salt; DBcAMP sodium salt) Cat. No.: HY-B0764

Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective **PKA** activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a **phosphodiesterase (PDE)** inhibitor.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

CCG215022

Cat. No.: HY-18991

CCG215022 is a G protein-coupled receptor kinases (**GRKs**) inhibitor with **IC_{50}**s of 0.15±0.07 μM, 0.38±0.06 μM and 3.9±1 μM for **GRK2**, **GRK5** and **GRK1**, respectively.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

CREBtide

Cat. No.: HY-P1595

CREBtide, a synthetic 13 amino acid peptide, has been reported as a **PKA** substrate.

KRREILSRRPSYR

Purity: 98.89%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Daphnetin

(7,8-Dihydroxycoumarin)

Cat. No.: HY-N0281

Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative isolated from plants of the Genus Daphne, is a **protein kinase** inhibitor, with **IC_{50}s** of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively.



Purity: 99.21%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Fasudil

(HA-1077; AT877)

Cat. No.: HY-10341A

Fasudil (HA-1077; AT877), is a nonspecific **RhoA/ROCK** inhibitor and also has inhibitory effect on protein kinases, with an **K_i** of 0.33 μM for ROCK1, **IC_{50}**s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Fasudil Hydrochloride

(HA-1077 Hydrochloride; AT-877 Hydrochloride)

Cat. No.: HY-10341

Fasudil Hydrochloride (HA-1077 Hydrochloride; AT877 Hydrochloride), is a nonspecific **RhoA/ROCK** inhibitor and also has inhibitory effect on protein kinases, with an **K_i** of 0.33 μM for ROCK1, **IC_{50}**s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

Gliotoxin

(Aspergillin)

Cat. No.: HY-N6727

Gliotoxin is a secondary metabolite, the most abundant mycotoxin secreted by A. fumigatus, inhibits the phagocytosis of macrophages and the immune functions of other immune cells .



Purity: 99.51%
Clinical Data: No Development Reported
Size: 5 mg

H-8 dihydrochloride

Cat. No.: HY-112465

H-8 (dihydrochloride) is a cell-permeable, reversible and ATP-competitive **PKA** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

H-89

Cat. No.: HY-15979

H-89 is a potent and selective inhibitor of cyclic AMP-dependent protein kinase (**protein kinase A**) with **IC_{50}** of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase, and others kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

H-89 dihydrochloride

Cat. No.: HY-15979A

H-89 dihydrochloride is a potent and selective inhibitor of protein kinase A (**PKA**) with an **IC_{50}** of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

HA-100

Cat. No.: HY-100984

HA-100 is a potent **protein kinase** inhibitor, with **IC_{50}**s of 4 μM, 8 μM, 12 μM and 240 μM for **cGMP-dependent protein kinase (PKG)**, **cAMP-dependent protein kinase (PKA)**, **protein kinase C (PKC)** and **MLC-kinase**, respectively. HA-100 also used as a **ROCK** inhibitor.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HA-100 hydrochloride

Cat. No.: HY-100984A

HA-100 hydrochloride is a potent **protein kinase** inhibitor, with IC_{50}s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (**PKG**), cAMP-dependent protein kinase (**PKA**), protein kinase C (**PKC**) and **MLC-kinase**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hu7691

Cat. No.: HY-132302

Hu7691 is an orally active, selective **Akt** inhibitor with IC_{50}s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 inhibits tumor growth and enables decrease of cutaneous toxicity in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hu7691 free base

Cat. No.: HY-132302A

Hu7691 free base is an orally active, selective **Akt** inhibitor with IC_{50}s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 free base inhibits tumor growth and enables decrease of cutaneous toxicity in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Jaspamycin

(7-CN-7-C-Ino)

Cat. No.: HY-111759

Jaspamycin (7-CN-7-C-Ino) is a potent activator of **PKA**, binding to the R site (PKAR), with an EC_{50} of 6.5 nM and K_d of 8 nM in Trypanosoma brucei. Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα. **Anti-parasite** activity.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

K-252a

(SF2370; Antibiotic K 252a; Antibiotic SF 2370)

Cat. No.: HY-N6732

K-252a, a staurosporine analog, inhibits **protein kinase**, with IC_{50} values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca^{2+}/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Kemptide

Cat. No.: HY-P0248

Kemptide is a synthetic heptapeptide that acts as a specific substrate for cAMP-dependent protein kinase (**PKA**).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Kemptide Phospho-Ser5

Cat. No.: HY-P0291

Kemptide (Phospho-Ser5) is a phosphate acceptor peptide that serves as a specific substrate for cAMP-dependent protein kinase (PKA).

LRRA-pSer-LG

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

KT5720

Cat. No.: HY-N6789

KT5720 is a cell-permeable, potent, specific, reversible, ATP-competitive inhibitor of **protein kinase A (PKA)**, with a K_i of 60 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 50 μg, 100 μg

KT5823

Cat. No.: HY-N6791

KT5823, a selective the cGMP-dependent protein kinase (**PKG**) inhibitor with an K_i value of 0.23 μM, it also inhibits **PKA** and **PKC** with K_i values of 10 μM and 4 μM, respectively.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 100 μg

Malantide

Cat. No.: HY-P1597

Malantide is a synthetic dodecapeptide derived from the site phosphorylated by **cAMP-dependent protein kinase (PKA)** on the β-subunit of phosphorylase kinase.

RTKRSGSVYEPLKI

Purity: 98.56%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Malantide TFA

Cat. No.: HY-P1597A

Malantide TFA is a synthetic dodecapeptide derived from the site phosphorylated by **cAMP-dependent protein kinase (PKA)** on the β-subunit of phosphorylase kinase.

RTKRSGSVYEPLKI (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Metadoxine

Cat. No.: HY-B1898

Metadoxine blocks adipocyte differentiation in association with inhibition of the protein kinase A-cAMP response element binding protein **(PKA-CREB)** pathway.



Purity: 99.38%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

PF-4950834

Cat. No.: HY-122011

PF-4950834 is a potent, selective, orally bioavailable, ATP-competitive **rho kinase** inhibitor with IC_{50} values of 8.35 nM and 33.12 nM against ROCK2 and ROCK1, respectively. PF-4950834 inhibits neutrophil migration.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PKA Inhibitor Fragment (6-22) amide

(PKI-(6-22)-amide)

Cat. No.: HY-P1290

PKA Inhibitor Fragment (6-22) amide is an inhibitor of cAMP-dependent **protein kinase A (PKA)**, with a K_i of 2.8 nM. PKA Inhibitor Fragment (6-22) amide can significantly reverse low-level morphine antinociceptive tolerance in mice.

TYADFIASGRTGRRNAI-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PKA Inhibitor Fragment (6-22) amide TFA

(PKI-(6-22)-amide TFA)

Cat. No.: HY-P1290A

PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent **protein kinase A (PKA)**, with a K_i of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse low-level morphine antinociceptive tolerance in mice.

TYADFIASGRTGRRNAI-NH_2 (TFA salt)

Purity: 96.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PKA-IN-1

Cat. No.: HY-115732

PKA-IN-1 is a potent and selective cyclic AMP-dependent protein kinase (PKA) catalytic subunit (**cAK**) inhibitor with an IC_{50} of 0.03 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PKI 14-22 amide,myristoylated

Cat. No.: HY-P1291

PKI 14-22 amide,myristoylated is a potent **cAMP-dependent PKA** inhibitor. PKI 14-22 amide,myristoylated reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion.

Myristoyl-GRTGRRNAI-NH_2

Purity: 99.65%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PKI 14-22 amide,myristoylated TFA

Cat. No.: HY-P1291A

PKI 14-22 amide,myristoylated TFA is a potent **cAMP-dependent PKA** inhibitor. PKI 14-22 amide,myristoylated TFA reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion.

Myristoyl-GRTGRRNAI-NH_2 (TFA salt)

Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PKI(5-24)

Cat. No.: HY-P0222

PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of **PKA** (cAMP-dependent protein kinase), with a K_i of 2.3 nM. PKI(5-24) corresponds to residues 5-24 in the naturally occurring heat-stable protein kinase inhibitor.

TTYADFIASGRTGRRNAIHD

Purity: 98.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PKI(5-24) TFA

Cat. No.: HY-P0222A

PKI(5-24) TFA is a potent, competitive, and synthetic peptide inhibitor of **PKA** (cAMP-dependent protein kinase), with a K_i of 2.3 nM. PKI(5-24) TFA corresponds to residues 5-24 in the naturally occurring heat-stable protein kinase inhibitor.

TTYADFIASGRTGRRNAIHD (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rp-8-CPT-cAMPS

Cat. No.: HY-120994A

Rp-8-CPT-cAMPS, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent **PKA I** and **II**. Rp-8-CPT-cAMPS preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rp-8-CPT-cAMPS sodium

Cat. No.: HY-120994

Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent **PKA I** and **II**. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rp-cAMPS

Cat. No.: HY-100530A

Rp-cAMPS, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent **PKA I and II** (K_is of 12.5 μM and 4.5 μM, respectively) antagonist. Rp-cAMPS is resistant to hydrolysis by phosphodiesterases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rp-cAMPS sodium salt

Cat. No.: HY-100530D

Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent **PKA I and II** (K_is of 12.5 μM and 4.5 μM, respectively) antagonist. Rp-cAMPS sodium salt is resistant to hydrolysis by phosphodiesterases.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rp-cAMPS triethylammonium salt

Cat. No.: HY-100530

Rp-cAMPS triethylammonium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent **PKA I and II** (K_is of 12.5 μM and 4.5 μM, respectively) antagonist. Rp-cAMPS triethylammonium salt is resistant to hydrolysis by phosphodiesterases.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

Sp-8-CPT-cAMPS

Cat. No.: HY-120994B

Sp-8-CPT-cAMPS, a cAMP analog, is a potent and selective activator of the cAMP-dependent **protein kinas A (PKA I and PKA II)**. Sp-8-CPT-cAMPS selects site A of RI compares to site A of RII by 153-fold and site B of RII compares to site B of RI by 59-fold.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sp-cAMPS

Cat. No.: HY-100530B

Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent **PKA I** and **PKA II**. Sp-cAMPS is also a potent, competitive **phosphodiesterase (PDE3A)** inhibitor with a K_i of 47.6 μM. Sp-cAMPS binds the **PDE10 GAF domain** with an EC_{50} of 40 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sp-cAMPS sodium salt

Cat. No.: HY-100530C

Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent **PKA I** and **PKA II**. Sp-cAMPS sodium salt is also a potent, competitive **phosphodiesterase (PDE3A)** inhibitor with a K_i of 47.6 μM. Sp-cAMPS sodium salt binds the **PDE10 GAF domain** with an EC_{50} of 40 μM.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

STAD 2

Cat. No.: HY-P2261

STAD 2 is a potent and selective disruptor of **PKA-RII**, with a K_d of 6.2 nM. STAD 2 disrupts interactions between PKA and **AKAP** in an isoform-selective manner. STAD 2 displays antimalarial activity through a PKA-independent mechanism.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Staurosporine

(Antibiotic AM-2282; STS; AM-2282)

Cat. No.: HY-15141

Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC_{50}s of 6 nM, 15 nM, 2 nM, and 3 nM for **PKC**, **PKA**, **c-Fgr**, and **Phosphorylase kinase** respectively. Staurosporine also inhibits **TAOK2** with an IC_{50} of 3 μM. Staurosporine is an apoptosis inducer.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

UCN-02

(7-epi-Hydroxystaurosporine) **Cat. No.:** HY-108262

UCN-02 (7-epi-Hydroxystaurosporine) is a selective **protein kinase C (PKC)** inhibitor produced by Streptomyces strain N-12, with IC_{50}s of 62 nM and 250 nM for PKC and protein kinase A (PKA), respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Warangalone

(Scandenolone) **Cat. No.:** HY-N1074

Warangalone is an anti-malarial compound which can inhibit the growth of both strains of parasite **3D7** (chloroquine sensitive) and **K1** (chloroquine resistant) with IC_{50}s of 4.8 μg/mL and 3.7 μg/mL, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

Pyk2

Proline-rich tyrosine kinase 2

Proline-rich tyrosine kinase 2 (Pyk2) is a cytoplasmic, non-receptor tyrosine kinase implicated in multiple signaling pathways. It is a negative regulator of osteogenesis and considered a viable drug target for osteoporosis treatment.

Pyk2 and focal adhesion kinase (FAK) comprise the focal adhesion kinase subfamily of non-receptor tyrosine kinases. PYK2 and FAK are large multidomain proteins containing an N-terminal FERM domain, a central catalytic domain, and a C-terminal segment containing dual proline rich (PR) subdomains and a focal adhesion targeting (FAT) region.

Pyk2, a non-receptor tyrosine kinase of the FAK family, is up-regulated in more than 60% of the tumors of hepatocellular carcinoma (HCC) patients.

Pyk2 Inhibitors

NVP-TAE 226

(TAE226)

Cat. No.: HY-13203

NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual **FAK** and **IGF-1R** inhibitor with IC_{50}s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits **Pyk2** and **insulin receptor (InsR)** with IC_{50}s of 3.5 nM and 44 nM, respectively.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-431396

Cat. No.: HY-10460

PF-431396 is an orally active dual **focal adhesion kinase (FAK)** and **proline-rich tyrosine kinase 2 (PYK2)** inhibitor, with IC_{50} values of 2 nM and 11 nM, respectively.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

PF-4618433

Cat. No.: HY-18312

PF-4618433 is a potent and selective **PYK2** inhibitor, with an IC_{50} of 637 nM. PF-4618433 may be suitable for the research of osteoporosis, craniofacial and appendicular skeletal defects and for targeted bone regeneration.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-562271

(VS-6062)

Cat. No.: HY-10459

PF-562271 (VS-6062) is a potent, ATP-competitive and reversible **FAK** and **Pyk2** kinase inhibitor with IC_{50}s of 1.5 nM and 13 nM, respectively.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PF-562271 besylate

(VS-6062 besylate)

Cat. No.: HY-10458

PF-562271 (VS-6062) besylate is a potent ATP-competitive, reversible inhibitor of **FAK** and **Pyk2** kinase, with an IC_{50} of 1.5 nM and 13 nM, respectively.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PF-562271 hydrochloride

(VS-6062(hydrochloride))

Cat. No.: HY-20403

PF-562271 (VS-6062) hydrochloride is a potent, ATP-competitive and reversible **FAK** and **Pyk2** kinase inhibitor with IC_{50}s of 1.5 nM and 13 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET

RET (REarranged during Transfection) is a transmembrane receptor tyrosine kinase that is activated by a complex consisting of a soluble glial cell line-derived neurotrophic factor (GDNF) family ligand (GFL) and a glycosyl phosphatidylinositol-anchored co-receptor, GDNF family receptors alpha (GFRalpha).

RET signalling is crucial for the development of the enteric nervous system. RET regulates the development of sympathetic, parasympathetic, motor, and sensory neurons, and is necessary for the postnatal maintenance of dopaminergic neurons. RET also plays a role as a driver oncogene in a variety of human cancers. Fusion of RET with several partner genes has been detected in papillary thyroid, lung, colorectal, pancreatic, and breast cancers, and tyrosine kinase inhibitors (TKIs) for RET (particularly RET-specific inhibitors) show promising effects against such cancers.

RET Inhibitors & Agonists

AD80

Cat. No.: HY-101963

AD80, a multikinase inhibitor, inhibits **RET**, **RAF**,**SRC**and **S6K**, with greatly reduced mTOR activity.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Amuvatinib

(MP470; HPK 56)

Cat. No.: HY-10206

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: 98.07%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amuvatinib hydrochloride

(MP470 hydrochloride; HPK 56 hydrochloride)

Cat. No.: HY-10206A

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

AST 487

(NVP-AST 487)

Cat. No.: HY-15002

AST 487 is a **RET** kinase inhibitor with IC_{50} of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits **Flt-3** with IC_{50} of 520 nM.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BBT594

(NVP-BBT594)

Cat. No.: HY-18840

BBT594 is a potent **receptor tyrosine kinase RET inhibitor**, used for cancer treatment.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BT-13

Cat. No.: HY-124401

BT-13 is a potent and selective **glial cell line-derived neurotrophic factor (GDNF) receptor RET** agonist independently of GFLs, promoting neurite growth from sensory neurons in vitro and attenuates experimental neuropathy in the Rat.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Enbezotinib

Cat. No.: HY-145565

Enbezotinib, an inhibitor of **RET**, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3/ITD-IN-4

Cat. No.: HY-146680

FLT3/ITD-IN-4 (Compound 16) is a selective FMS-like tyrosine kinase 3 internal tandem duplications (**FLT3-ITD**) inhibitor with an IC_{50} of 2.3 nM. FLT3/ITD-IN-4 can be used for acute myeloid leukemia research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK3179106

Cat. No.: HY-100459

GSK3179106 is an orally active and selective **RET** kinase inhibitor with IC_{50}s of 0.4 nM, 0.2 nM for human RET and rat RET, respectively. GSK3179106 has the potential for irritable bowel syndrome (IBS) through the attenuation of post-inflammatory and stress-induced visceral hypersensitivity.



Purity: 99.40%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Ilorasertib

(ABT-348)

Cat. No.: HY-16018

Ilorasertib (ABT-348) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits **Aurora C**, **Aurora B**, and **Aurora A** with IC_{50}s of 1 nM, 7 nM, 120 nM, respectively.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 50 mg, 100 mg

Ilorasertib hydrochloride

(ABT-348 hydrochloride) Cat. No.: HY-16018A

Ilorasertib (ABT-348 hydrochloride) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits **Aurora C**, **Aurora B**, and **Aurora A** with IC_{50}s of 1 nM, 7 nM, 120 nM, respectively.



Purity: 99.67%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

JNJ-38158471

Cat. No.: HY-18317

JNJ-38158471 is a well tolerated, orally available, highly selective **VEGFR-2** inhibitor, with an IC_{50} of 40 nM. JNJ-38158471 also inhibits **Ret** and **Kit** with IC_{50}s of 180 and 500 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lenvatinib

(E7080) Cat. No.: HY-10981

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib mesylate

(E7080 mesylate) Cat. No.: HY-10981A

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib-d4

(E7080-d4) Cat. No.: HY-10981S

Lenvatinib-d4 (E7080-d4) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lenvatinib-d5

(E7080-d5) Cat. No.: HY-10981S1

Lenvatinib-d5 (E7080-d5) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML786 dihydrochloride

Cat. No.: HY-14979A

ML786 dihydrochloride is a potent and orally bioavailable **Raf** inhibitor, with IC_{50}s of 2.1, 4.2, and 2.5 nM for ^{V600E}**ΔB-Raf**, **wt B-Raf**, and **C-Raf**, respectively. ML786 dihydrochloride also inhibits **Abl-1**, **DDR2**, **EPHA2**, **KDR**, and **RET** (IC_{50}=<0.5, 7.0, 11, 6.2, 0.8 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF 477736

(PF 00477736) Cat. No.: HY-10032

PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of **Chk1**, with a K_i of 0.49 nM, it is also a **Chk2** inhibitor, with a K_i of 47 nM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pralsetinib

(BLU-667) Cat. No.: HY-112301

Pralsetinib (BLU-667) is a highly potent, selective **RET** inhibitor. Pralsetinib (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC_{50}s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Pz-1

Cat. No.: HY-U00437

Pz-1 is a potent **RET** and **VEGFR2** inhibitor with IC_{50}s of less than 1 nM for both wild type kinases.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Regorafenib

(BAY 73-4506) Cat. No.: HY-10331

Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with **IC_{50}**s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1**, respectively.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib Hydrochloride

(BAY 73-4506 hydrochloride) Cat. No.: HY-13308

Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with **IC_{50}**s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib monohydrate

(BAY 73-4506 monohydrate) Cat. No.: HY-10331A

Regorafenib monohydrate (BAY 73-4506 monohydrate) is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with **IC_{50}**s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib-13C,d3

(BAY 73-4506-13C,d3) Cat. No.: HY-10331S1

Regorafenib-13C,d3 is the 13C- and deuterium labeled. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Regorafenib-d3

(BAY 73-4506-d3) Cat. No.: HY-10331S

Regorafenib D3 (BAY 73-4506 D3) is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET V804M-IN-1

Cat. No.: HY-136534

RET V804M-IN-1 (compound 5) is a wt-RET -selective inhibitors of **RETV804M** kinase, with an **IC_{50}** of 20 nM.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RET-IN-1

Cat. No.: HY-112950

RET-IN-1 is a **RET kinase** inhibitor extracted from patent WO2018071447A1, Compound Example 552, has **IC_{50s}** of 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-10

Cat. No.: HY-143615

RET-IN-10 is a potent inhibitor of **RET**. RET loss of function mutations leads to Hirschsprung's disease, while its gain of function mutations is associated with a variety of human tumors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-11

Cat. No.: HY-144131

RET-IN-11 is a potent and selective **RET** inhibitor with **IC_{50}**s of 6.20 nM, 18.68 nM for **RET** and **RET^{V804M}**, respectively. RET-IN-11 shows anti-proliferation and migration activity in CCDC6-RET-driven LC-2/ad cells. RET-IN-11 induces cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-12

Cat. No.: HY-144030

RET-IN-12 (compound 2) is a **RET** inhibitor, with **IC_{50}** values of 0.3 nM and 1 nM for RET(WT) and RET(V804M), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-13

Cat. No.: HY-144029

RET-IN-13 (compound 1), a quinoline compound, is a potent **RET** inhibitor with IC_{50}s of 0.5 nM, 0.9 nM for RET (WT) and RET (V804M), respectively. RET-IN-13 has the potential for tumors or intestinal diseases related to abnormal activation of RET research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-14

Cat. No.: HY-144170

RET-IN-14 (compound 49) is a potent **RET** inhibitor with IC_{50}s of <0.51 nM, 9.3 nM, 1.3 nM, 9.2 nM, 15 nM for RET (WT), RET (G810R), RET (V804M), BTK and BTK (C481S), respectively. RET-IN-14 has the potential for tumors research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-15

Cat. No.: HY-144422

RET-IN-15 is a **rearranged during transfection (RET) kinase** inhibitor extracted from patent WO2021115457A1 compound 51. RET-IN-15 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-16

Cat. No.: HY-146710

RET-IN-16 is a potent and selective **RET** inhibitor with IC_{50}s of 3.98 nM, 8.42 nM, 15.05 nM, 7.86 nM, 5.43 nM and 8.86 nM for **RET(WT)**, **RET(M918T)**, **RET(V804L)**, **RET(V804M)**, **RET-CCDC6** and **RET-KIF5B**, respectively. RET-IN-16 has anticancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-17

Cat. No.: HY-147563

RET-IN-17 is a potent inhibitor of **RET**. RET-IN-17 has the potential for the research of pain associated with IBS and other gastrointestinal disorders and for the research of cancers with constitutive RET kinase activity (extracted from patent WO2016038552A1, compound 1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-18

Cat. No.: HY-147564

RET-IN-18 is a pyridone compound. is a potent inhibitor of **RET**. RET-IN-18 is a potent inhibitor of **RET**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-3

Cat. No.: HY-133553

RET-IN-3 (compound 34) is a selective **RETV804M** kinase inhibitor, with an IC_{50} of 19 nM.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RET-IN-4

Cat. No.: HY-132193

RET-IN-4 is a potent, selective and orally active **RET** inhibitor with IC_{50}s of 1.29 nM, 1.97 nM, and 0.99 nM for **RET (WT)**, **RET (V804M)**, and **RET (M918T)**, respectively. RET-IN-4 exhibits better kinases selectivity against JAK2 (IC_{50} of 4.4 nM) and FLT3 (IC_{50} of 30.8 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-5

Cat. No.: HY-145023

RET-IN-5 is a potent **RET (rearranged during transfection)** inhibitor with an IC_{50}s of 0.4 nM and 135.1 nM for RET and VEGFR2, respectively (WO2021213476A1, compound 18).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-6

Cat. No.: HY-145024

RET-IN-6 is a potent **RET (rearranged during transfection)** inhibitor with an IC_{50} of 4.57 nM (CN113461670A, compound 321).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-7

Cat. No.: HY-141896

RET-IN-7 demonstrates potent in vitro **RET** kinase inhibition and robust in vivo efficacy in RET-driven tumor xenografts upon multiday dosing in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-8

Cat. No.: HY-143545

RET-IN-8 is a **rearranged during transfection (RET) kinase** inhibitor extracted from patent WO2021093720A1 compound I-1. RET-IN-8 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RET-IN-9

Cat. No.: HY-143546

RET-IN-9 is a potent inhibitor of **RET**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RPI-1

Cat. No.: HY-101246

RPI-1 is a specific, orally available 2-indolinone Ret tyrosine kinase inhibitor. RPI-1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Selpercatinib

(LOXO-292)

Cat. No.: HY-114370

Selpercatinib (LOXO-292) is a **RET kinase** inhibitor extracted from patent WO2018071447A1, Compound Example 163, has an IC_{50} of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), respectively. Antineoplastic activity.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SPP-86

Cat. No.: HY-110193

SPP-86 is a potent and selective cell permeable inhibitor of **RET tyrosine kinase**, with an IC_{50} of 8 nM. SPP-86 inhibits RET-induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK signaling, also inhibits RET-induced estrogen receptorα (ERα) phosphorylation in MCF7 cells.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

TG101209

Cat. No.: HY-10410

TG101209 is a selective **JAK2** inhibitor with IC_{50} of 6 nM, less potent to **Flt3** and **RET** with IC_{50} of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

trans-Pralsetinib

(trans-BLU-667)

Cat. No.: HY-112301A

trans-Pralsetinib (trans-BLU-667) is a **rearranged during transfection (RET)** inhibitor extracted from patent US20170121312A1, Compound Example 129.



Purity: 96.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vepafestinib

Cat. No.: HY-132846

Vepafestinib (compound 6) is a RET inhibitor (extracted from patent WO2019039439).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WF-47-JS03

Cat. No.: HY-133551

WF-47-JS03 is a potent and selective **RET** kinase inhibitor with IC_{50}s of 1.7 nM and 5.3 nM for KIF5B-RET transfected Ba/F3 cells and CCDC6-RET transfected LC-2/ad lung cancer cells, respectively.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WHI-P180 hydrochloride

(Janex 3 hydrochloride;) Cat. No.: HY-15769A

WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits **RET**, **KDR** and **EGFR** with IC_{50}s of 5 nM, 66 nM and 4 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zeteletinib

(BOS-172738; DS-5010) Cat. No.: HY-139590

Zeteletinib (BOS-172738; DS-5010) is an orally active, selective **RET kinase** inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zeteletinib hemiadipate

(BOS-172738 hemiadipate; DS-5010 hemiadipate) Cat. No.: HY-139590A

Zeteletinib (BOS-172738; DS-5010) hemiadipate is an orally active, selective **RET kinase** inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ROS

The transmembrane proto-oncogene receptor tyrosine kinase (RTK) ROS is one of the last two remaining orphan receptor tyrosine kinases. Its normal expression pattern is tightly spatiotemporally restricted during development. The ectopic expression, as well as the production of variable mutant forms of ROS kinase, has been reported in a number of cancers, such as glioblastoma multiforme, and non-small cell lung cancer, suggesting a role for ROS kinase in deriving such tumors. It is thought also that the c-ROS gene may have a role in some cardiovascular diseases, and the fact that homozygous male mice targeted against the c-ROS gene are healthy but infertile has inspired researchers to think about ROS inhibition as a method for the development of new male contraceptives.

ROS1 is a transmembrane receptor tyrosine kinase proto-oncogene that has been shown to have rearrangements with several genes in glioblastoma, non-small-cell lung cancer (NSCLC), and other neoplasms, including intrachromosomal fusion with GOPC due to microdeletions at 6q22.1. ROS1 fusion events are important findings in these tumors, as they are potentially targetable alterations with newer tyrosine kinase inhibitors.

AChE/BChE-IN-9

Cat. No.: HY-146399

AChE/BChE-IN-9 (Compound 7a) is a potent, orally active **AChE** and **BChE** inhibitor with IC_{50} values of 5.74 μM and 14.05 μM against hAChE and eqBChE, respectively. AChE/BChE-IN-9 is also an efficacious antioxidant with an IC_{50} of 57.35 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AChE/BChE/BACE-1-IN-1

Cat. No.: HY-147658

AChE/BChE/BACE-1-IN-1 (Compound 4k) is an orally active inhibitor of **AChE**, **BChE**, and **BACE-1** with IC_{50} values of 0.058, 0.082 and 0.115 μM against hAChE, hBChE and hBACE-1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AChE/BChE/BACE-1-IN-2

Cat. No.: HY-147659

AChE/BChE/BACE-1-IN-2 (Compound 4o) is an orally active inhibitor of **AChE**, **BChE**, and **BACE-1** with IC_{50} values of 0.069, 0.127 and 0.097 μM against hAChE, hBChE and hBACE-1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK/ROS1-IN-1

Cat. No.: HY-130794

ALK/ROS1-IN-1 (compound 2e) is a potent and selective anti crizotinib-resistant **ALK/ROS1** dual inhibitor, with IC_{50}s of 0.174 μM and 0.530 μM for ALK and ROS1 enzyme, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anti-inflammatory agent 21

Cat. No.: HY-146421

Anti-inflammatory agent 21 (compound 9o) is an orally active and low cytotoxic anti-inflammatory agent, with an IC_{50} value of 0.76 μM for **NO**. Anti-inflammatory agent 21 acts via accumulation **ROS** and blocks the **NF-κB/MAPK** signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antibacterial agent 69

Cat. No.: HY-144252

Antimicrobial agent 69 is a novel structural antimicrobial regulator and has been used to fight deadly multidrug-resistant bacterial infections, and its < b > MICs < / b > value is 2.978 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antibacterial agent 70

Cat. No.: HY-144255

Antibacterial agent 70 is a new dihydropyrimidinone imidazole hybrid antibacterial agent, and its < b > MIC < / b > value is 0.5 μg/mL.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anticancer agent 15

Cat. No.: HY-139860

Anticancer agent 15 is capable of significantly increasing the cellular level of **ROS** and inducing melanoma cancer cell death via necroptosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anticancer agent 42

Cat. No.: HY-146516

Anticancer agent 42 (compound 10d) is an orally active anticancer agent, and shows a potent antitumor activity against MDA-MB-231 cell with an IC_{50} of 0.07 μM. Anticancer agent 42 can exert its anticancer activity by activating apoptotic pathway and **p53** expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anticancer agent 56

Cat. No.: HY-146444

Anticancer agent 56 (compound 4d) is a potent anti-cancer agent with drug-likeness properties, possessing anticancer activity against several cancer cell lines (IC_{50}<3 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anticancer agent 58

Cat. No.: HY-146461

Anticancer agent 58 (compound 16) has inhibitory activity against kinds of cancer cell lines, especially in A549 and T24 with IC_{50}s of 0.6 μM and 0.7 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anticancer agent 59

Cat. No.: HY-146462

Anticancer agent 59 (compound 11) has inhibitory activity against kinds of cancer cell lines, especially in A549 with IC_{50} of 0.2 μM. Anticancer agent 59 induces **apoptosis** and an increase of Ca^{2+} and **ROS** in cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anticancer agent 65

Cat. No.: HY-146105

Anticancer agent 65 (compound 4c) shows excellent activity in cancer cell lines, especially A549 cells, with an IC_{50} of 1.07 μM. Anticancer agent 65 induces S-phase arrest in A549 cells and increases the expression level of p53 and p21.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antimicrobial agent-2

Cat. No.: HY-146460

Antimicrobial agent-2 (compound V-a) is a broad-spectrum antimicrobial agent, possessing inhibitory activity against various Gram-positive and -negative bacteria.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antiproliferative agent-4

Cat. No.: HY-146354

Antiproliferative against-4 (compound 2y) has excellent anti-proliferative activity against certain cancer cell lines. Antiproliferative against-4 reduces the mitochondrial membrane potential, and increases the **apoptosis** rate and the level of **ROS** on EC109.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antiproliferative agent-5

Cat. No.: HY-146390

Antiproliferative against-5 (compound 4o) can significantly and irreversibly inhibit proliferation of gastric cancer cells. Antiproliferative against-5 causes the G2/M phase arrest, and induces **ROS** accumulation and activation of **autophagy**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antiproliferative agent-7

Cat. No.: HY-146103

Antiproliferative against-7 (compound 8f) is a potent anti-proliferative agent. Antiproliferative against-7 has antiproliferative activity against cancer cell lines MCF-7, MDA-MB-231, HCT-116 and FR-2 with IC_{50}s of 3.5 μM, 15.54 μM, 30.43 μM and 34.8 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antitumor agent-55

Cat. No.: HY-146038

Antitumor agent-55 (compound 5q) is a potent antitumor agent. Antitumor agent-55 effectively inhibits PC3, with an IC_{50} of 0.91 μM. Antitumor agent-55 effectively inhibits the colony formation, suppresses the cell migration in PC3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antitumor agent-57

Cat. No.: HY-146048

Antitumor agent-57 (Compound 3o) is an NQO1-directed antitumor agent. Antitumor agent-57 inhibits tumor cell growth, triggers **ROS** generation and induces cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antitumor agent-60

Cat. No.: HY-146432

Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting **RAS-RAF** signaling pathway and binding to **CRAF** with a K_d value of 3.93 μM. Antitumor agent-60 induces **apoptosis** by blocking cell cycle at G2/M phase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apogossypolone

(ApoG2)

Cat. No.: HY-19551

Apogossypolone (ApoG2) is an orally active **Bcl-2 family proteins** inhibitor with K_i values of 35, 25 and 660 nM for Bcl-2, Mcl-1 and Bcl-X_L, respectively. Apogossypolone shows antitumor activities, induces cell **apoptosis** and **autophagy**. Apogossypolone also has antifungal activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Capillarisin

Cat. No.: HY-121192

Capillarisin, as a constituent from Artemisiae Capillaris herba, is found to exert anti-inflammatory and antioxidant properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Capsanthin

Cat. No.: HY-125711

Capsanthin is a carotenoid that has been found in C. annuum. Capsanthin has antioxidantantitumor and anti-inflammatory effects.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chol-CTPP

Cat. No.: HY-144825

Chol-CTPP is a ligand with dual targeting effect on blood-brain barrier (BBB) and **glioma** cells. Lip-CTPP can be gained by Chol-CTPP and another mitochondria targeting ligand (Chol-TPP).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cinnamtannin B-1

Cat. No.: HY-130237

Cinnamtannin B-1 is a proanthocyanidin with multiple biological functions, including antioxidant effects. Cinnamtannin B-1 inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced osteoporosis in vivo.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Crizotinib

(PF-02341066)

Cat. No.: HY-50878

Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive **ALK** and **c-Met** inhibitor with IC_{50}s of 20 and 8 nM, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Crizotinib hydrochloride

(PF-02341066 hydrochloride)

Cat. No.: HY-50878A

Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual **ALK** and **c-Met** inhibitor with IC_{50}s of 20 and 8 nM, respectively.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Crizotinib-d5

(PF-02341066-d5)

Cat. No.: HY-50878S

Crizotinib-d5 (PF-02341066-d5) is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive **ALK** and **c-Met** inhibitor with IC_{50}s of 20 and 8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Derrone

Cat. No.: HY-N3737

Derrone, a prenylated isoflavones, is an **Aurora kinase** inhibitor, with IC_{50} values of 6 and 22.3 μM against **Aurora B** and **Aurora A**, respectively. Derrone shows anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DPP-4 inhibitor 3

Cat. No.: HY-146455

DPP-4 inhibitor 3 (Compound 5a) is a potent **dipeptidyl peptidase IV (DPP-IV)** inhibitor with an IC_{50} of 0.75 nM. DPP-4 inhibitor 3 shows excellent antioxidant and insulinotropic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Entrectinib

(NMS-E628; RXDX-101)

Cat. No.: HY-12678

Entrectinib (NMS-E628) is a potent, orally available, and CNS-active **pan-Trk**, **ROS1**, and **ALK** inhibitor. Entrectinib inhibits TrkA, TrkB, TrkC, ROS1 and ALK with IC_{50} values of 1, 3, 5, 12 and 7 nM, respectively. Antitumor activity.



Purity: 99.32%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

F-1

Cat. No.: HY-112801

F-1 is a potent **ALK** and **ROS1** dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC_{50}s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALK^{WT}, $ROS1^{WT}$, ALK^{L1196M} and ALK^{G1202R}, respectively.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fascaplysin

Cat. No.: HY-112328

Fascaplysin is an antimicrobial and cytotoxic red pigment, that can come from the marine sponge (Fascaplysinopsis sp.). Fascaplysin has been synthesized in seven steps from indole (65% yield).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GGTI-2154

Cat. No.: HY-16229

GGTI-2154 is a potent and selective inhibitor of **geranylgeranyltransferase I (GGTase I)**, with an IC_{50} of 21 nM. GGTI-2154 shows more than 200-fold selectivity for GGTase I over FTase (IC50=5600 nM). GGTI-2154 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GGTI-2154 hydrochloride

Cat. No.: HY-16229A

GGTI-2154 hydrochloride is a potent and selective inhibitor **geranylgeranyltransferase I (GGTase I)**, with an IC_{50} of 21 nM. GGTI-2154 hydrochloride shows more than 200-fold selectivity for GGTase I over FTase (IC50=5600 nM). GGTI-2154 hydrochloride can be used for the research of cancer.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GGTI-2418

Cat. No.: HY-16231

GGTI-2418 is a highly potent, competitive, and selective **geranylgeranyltransferase I** (**GGTase I**) inhibitor. GGTI-2418 inhibits **GGTase I** and FTase activities with IC_{50}s of 9.5 nM and 53 μM, respectively.



Purity: 98.04%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Iruplinalkib

(WX-0593)

Cat. No.: HY-145574

Iruplinalkib (WX-0593) is a potent, selective, and orally active inhibitor of **ALK** and **ROS1** tyrosine kinase. Iruplinalkib (WX-0593) shows favorable safety and promising antitumor activity in advanced NSCLC with ALK or ROS1 rearrangement.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lorlatinib

(PF-06463922)

Cat. No.: HY-12215

Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive **ROS1/ALK** inhibitor. Lorlatinib has K_is of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK^{L1196M}, respectively. Lorlatinib has anticancer activity.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lorlatinib-13C,d3

(PF-06463922-13C,d3)

Cat. No.: HY-12215S

Lorlatinib-13C,d3 (PF-06463922-13C,d3) is the 13C- and deuterium labeled Lorlatinib. Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive **ROS1/ALK** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Malvidin-3-galactoside chloride

Cat. No.: HY-N6623

Malvidin-3-galactoside chloride, an anthocyanin monomer, induces hepatocellular carcinoma (HCC) cells cycle arrest and **apoptosis**. Malvidin-3-galactoside chloride inhibits the production and accumulation of **ROS**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MAO-B-IN-7

Cat. No.: HY-146762

MAO-B-IN-7 is a potent and blood-brain barrier permeable **MAO-B** and **AChE** inhibitor with IC_{50}s of 41 nM, 87 nM and 0.3 μM for human AChE, electric eel AChE and MAO-B, respectively. MAO-B-IN-7 can effectively alleviate oxidative stress and neuroinflammatory damage.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Merestinib

(LY2801653)

Cat. No.: HY-15514

Merestinib (LY2801653) is a potent, orally bioavailable **c-Met** inhibitor (K_i=2 nM) with anti-tumor activities.



Purity: 99.99%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Merestinib dihydrochloride

(LY2801653 dihydrochloride)

Cat. No.: HY-15514A

Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable **c-Met** inhibitor (K_i=2 nM) with anti-tumor activities.



Purity: 99.36%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MitoPQ

(MitoParaquat)

Cat. No.: HY-130278

MitoPQ is a **mitochondria**-targeted redox cycler. MitoPQ produces superoxide by redox cycling at the flavin site of complex I, selectively increasing superoxide production within mitochondria. MitoPQ can be used in antioxidant study.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nampt-IN-8

Cat. No.: HY-147795

Nampt-IN-8 (Compound 10d) is an **NAMPT** inhibitor with an IC_{50} of 0.183 μM. Nampt-IN-8 is also a relatively good NQO1 substrate. Nampt-IN-8 induces cell **apoptosis** and **ROS**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NF-κB/PON1-IN-1

Cat. No.: HY-146058

NF-κB/PON1-IN-1 (Compound 16) is a **NF-κB/PON1** pathway inhibitor. NF-κB/PON1-IN-1 has **antioxidant** (IC_{50} = 45.76 μM) and hepatoprotective activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nrf2 activator-4

Cat. No.: HY-146086

Nrf2 activator-4 (Compound 20a) is a highly potent, orally active **Nrf2** activator with an EC_{50} of 0.63 μM. Nrf2 activator-4 suppresses **reactive oxygen species** against oxidative stress in microglia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nrf2-ARE/hMAO-B/QR2 modulator 1

Cat. No.: HY-144635

Nrf2-ARE/hMAO-B/QR2 modulator 1 is a Resveratrol-based multitarget-directed ligands with IC_{50}s of 8.05, 9.83 and 0.57 μM for **hMAO-B**, **NRF2** and **QR2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nrf2/HO-1-IN-1

Cat. No.: HY-146971

Nrf2/HO-1-IN-1 is a potent **Nrf2/HO-1** pathway inhibitor, with an IC_{50} value of 0.38 μM for **NO**. Nrf2/HO-1-IN-1 can significantly reduce the level of **ROS** in cells. Nrf2/HO-1-IN-1 can be used for researching anti-inflammatory.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Orniplabin

(SMTP-7)

Cat. No.: HY-122311

Orniplabin (SMTP-7) is a low-molecular-weight compound that enhances plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

p38 MAPK-IN-3

Cat. No.: HY-144697

p38 MAPK-IN-3 (Compound 2c) is a **p38α MAPK** inhibitor. p38 MAPK-IN-3 has antitumor activities and induces **apoptosis** and **ROS**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Phyltetralin

Cat. No.: HY-121397

Phyltetralin (Compound 10) is a natural product than can be isolated from the hexane-ethyl acetate extract of Phyllanthus amarus leaves. Phyltetralin possesses immunosuppressive effects on different lineages of innate immune system.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kα-IN-6

Cat. No.: HY-147767

PI3Kα-IN-6 (Compound 5b) is a **PI3Kα** inhibitor. PI3Kα-IN-6 exhibits anticancer potential and no toxicity in normal cells. PI3Kα-IN-6 increases generation of **ROS**, reduces mitochondrial membrane potential (MMP) and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Repotrectinib

(TPX-0005)

Cat. No.: HY-103022

Repotrectinib (TPX-0005) is a potent **ROS1** (IC_{50}=0.07 nM) and **TRK** (IC_{50}=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib potently inhibits WT **ALK** (IC_{50}=1.01 nM). Repotrectinib has anti-cancer activity.



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

SMTIN-T140

Cat. No.: HY-147696

SMTIN-T140 (compound 6a) is a potent **TRAP1** (tumor-necrosis-factor-receptor associated protein 1) inhibitor, with an IC_{50} of 1.646 μM. SMTIN-T140 shows anticancer activity. SMTIN-T140 leads to mitochondrial dysfunction, increases mitochondrial ROS production and activates **AMPK**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Taletrectinib

(DS-6051b; AB-106)

Cat. No.: HY-131003

Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective **ROS1/NTRK** inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC_{50}s of 0.207, 0.622, 2.28, and 0.98 nM, respectively.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Taletrectinib free base

(DS-6051b free base; AB-106 free base)

Cat. No.: HY-131003A

Taletrectinib (DS-6051b) free base is a potent, orally active, and next-generation selective **ROS1/NTRK** inhibitor. Taletrectinib free base potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC_{50}s of 0.207, 0.622, 2.28, and 0.98 nM, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Topo I-IN-1

Cat. No.: HY-145859

Topo I-IN-1 (Compound 14d) is a potent **Topo I** inhibitor with antitumor activity and DNA intercalative capability. Topo I-IN-1 induces cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Topoisomerase I/II inhibitor 3

Cat. No.: HY-146504

Topoisomerase I/II inhibitor 3 (compound 7) is a potent **topoisomerase I (Topo I)** and **II (Topo II)** dual inhibitor. Topoisomerase I/II inhibitor 3 can inhibit cell proliferation, invasion and migration, and induce **apoptosis** by inhibiting **PI3K**/Akt/mTOR signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tubulin polymerization-IN-6

Cat. No.: HY-146505

Tubulin polymerization-IN-6 (compound 5f) is a potent **tubulin polymerization** inhibitor, with an IC_{50} of 1.09 μM. Tubulin polymerization-IN-6 inhibits cell migration and tube formation and contributes to the anti-angiogenesis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR-2-IN-19

Cat. No.: HY-146367

VEGFR-2-IN-19 (Compound 15b) is a potent **VEGFR2** inhibitor. VEGFR-2-IN-19 induces cell **apoptosis** and increases intracellular **reactive oxygen species** level. VEGFR-2-IN-19 can be used as an anticancer agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WY-135

Cat. No.: HY-111416

WY-135 is an **ALK** (IC_{50}=1.4 nM) and **ROS1** (IC_{50}=1.1 nM) dual inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZC0101

Cat. No.: HY-147772

ZC0101 is a potent, orally active **IDO1** and **TrxR** dual inhibitor with IC_{50} values of 0.084 μM and 7.98 μM, respectively. ZC0101 effectively induces **apoptosis** and **ROS** accumulation in cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Carotene

(Provitamin A; beta-Carotene)

Cat. No.: HY-N0411

β-Carotene (Provitamin A), a carotenoid compound, is a naturally-occurring vitamin A precursor. β-Carotene is a modulator of **reactive oxygen species (ROS)**, with antioxidant and antiinflammatory activities.

Purity: ≥98.0%
Clinical Data: Launched
Size: 50 mg, 100 mg

β-Nor-lapachone

Cat. No.: HY-146067

β-Nor-lapachone is a **Candida glabrata** antibiofilm agent. β-Nor-lapachone can stimulate **ROS** production, inhibits efflux activity, adhesion, biofilm formation and the metabolism of mature biofilms of Candida glabrata. β-Nor-lapachone has antifungal activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Src

Src family kinase (SFK) is a family of non-receptor tyrosine kinases including nine members: Src, Yes, Fyn, and Fgr, forming the SrcA subfamily, Lck, Hck, Blk, and Lyn in the SrcB subfamily, and Frk in its own subfamily. In immune cells, Src-family kinases (SFKs) have been implicated as critical regulators of a large number of intracellular signaling pathways. Src-family kinases (SFKs) occupy a proximal position in numerous signaling transduction cascades including those emanating from the T and B cell antigen receptors, Fc receptors, growth factor receptors, cytokine receptors, and integrins. In addition to these positive regulatory roles, Src-family kinases (SFKs) can also function as negative regulators of cellular signaling by phosphorylating immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on inhibitory receptors, resulting in recruitment and activation of inhibitory molecules such as the phosphatases SHP-1 and SH2 containing 5′ inositol phosphatase (SHIP-1).

Src Inhibitors & Activators

1-Naphthyl PP1
(1-NA-PP 1) Cat. No.: HY-13941

1-Naphthyl PP1 (1-NA-PP 1) is a selective inhibitor of **src** family kinases. 1-Naphthyl PP1 inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC_{50}s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

1-Naphthyl PP1 hydrochloride
(1-NA-PP 1 hydrochloride) Cat. No.: HY-13941B

1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) is a selective inhibitor of **src** family kinases. 1-Naphthyl PP1 hydrochloride inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC_{50}s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

1-NM-PP1
(PP1 Analog II) Cat. No.: HY-13942

1-NM-PP1, a cell-permeable PP1 analog, is a potent **Src family kinases** inhibitor with IC_{50}s of 4.3 nM and 3.2 nM for v-Src-as1 and c-Fyn-as1, respectively.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

7-Hydroxy-4-chromone
(7-Hydroxychromone) Cat. No.: HY-N6596

7-Hydroxychromone is a **Src kinase** inhibitor with an IC_{50} of <300 μM.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

A 419259
(RK-20449) Cat. No.: HY-15764

A 419259 is a broad-spectrum pyrrolo-pyrimidine inhibitor, designed to enhance selectivity towards the Src family with IC_{50} of 9 nM, <3 nM and <3 nM for **Src**, **Lck** and **Lyn**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

A 419259 trihydrochloride
(RK 20449 trihydrochloride) Cat. No.: HY-15764A

A 419259 trihydrochloride is a **Src family kinases** inhibitor with IC_{50}s of 9 nM, 3 nM and 3 nM for **Src**, **Lck** and **Lyn**, respectively.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

A-770041
Cat. No.: HY-11011

A-770041 is selective and orally active Src-family Lck inhibitor; A-770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300-fold selective against Fyn, the other Src family kinase involved in T-cell signaling.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH
Cat. No.: HY-P1200

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC_{50}≈1 μM).
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH is an inhibitor for **src SH3-SH2**:phosphoprotein interactions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA
Cat. No.: HY-P1200A

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC_{50}≈1 μM).
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA is an inhibitor for **src SH3-SH2**:phosphoprotein interactions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AD80
Cat. No.: HY-101963

AD80, a multikinase inhibitor, inhibits **RET**, **RAF**,**SRC**and **S6K**, with greatly reduced mTOR activity.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AMG-47a

Cat. No.: HY-18303

AMG-47a is a potent and orally active **lymphocyte-specific protein tyrosine kinase (Lck)** inhibitor, with an IC_{50} of 0.2 nM. AMG-47a also inhibits **VEGF2**, **p38α**, **Jak3** and **MLR** and **IL-2** with IC_{50}s of 1 nM, 3 nM, 72 nM, 30 nM and 21 nM, respectively.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Antiallergic agent-1

Cat. No.: HY-115723

Antiallergic agent-1, a **Src-family kinase** inhibitor, may serve as a new valuable lead compound for future antiallergic drug discovery.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD0424

Cat. No.: HY-112314

AZD0424 is an orally active, and dual selective **Src/Abl** kinase inhibitor with potential antineoplastic activity. AZD0424 induces **apoptosis** and cell cycle arrest in lymphoma cells.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

AZM475271

(M475271)

Cat. No.: HY-13561

AZM475271 is a potent and selective Src kinase inhibitor with IC50 of 5 nM; no inhibitory activity on Flt3, KDR, Tie-2.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Bafetinib

(INNO-406; NS-187)

Cat. No.: HY-50868

Bafetinib is a potent and orally active **Lyn/Bcr-Abl** tyrosine kinase inhibitor. Bafetinib augments the activities of several proapoptotic Bcl-2 homology (BH)3-only proteins (Bim, Bad, Bmf and Bik) and induces apoptosis in Ph^+ leukemia cells via Bcl-2 family-regulated intrinsic apoptosis pathway.



Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bosutinib

(SKI-606)

Cat. No.: HY-10158

Bosutinib is a dual **Src/Abl** inhibitor with IC_{50}s of 1.2 nM and 1 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Bosutinib D8

(SKI-606 D8)

Cat. No.: HY-10158S

Bosutinib D8 (SKI-606 D8) is a deuterium labeled Bosutinib. Bosutinib is a dual **Src/Abl** inhibitor with IC_{50}s of 1.2 nM and 1 nM, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

Caffeic acid-pYEEIE

Cat. No.: HY-P1377

Caffeic acid-pYEEIE, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Caffeic acid-pYEEIE TFA

Cat. No.: HY-P1377A

Caffeic acid-pYEEIE TFA, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

CGP77675

Cat. No.: HY-W062835

CGP77675 is an orally active and potent inhibitor of **Src** family kinases.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CGP77675 hydrate

Cat. No.: HY-W062835A

CGP77675 hydrate is an orally active and potent inhibitor of **Src** family kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CH6953755

Cat. No.: HY-135299

CH6953755 is a potent, orally active and selective **YES1** kinase (a member of the SRC family) inhibitor with an IC_{50} of 1.8 nM. CH6953755 inhibits YES1 kinase, leading to antitumor activity against YES1 Gene -amplified cancers in vitro and in vivo.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CHMFL-ABL-053

Cat. No.: HY-101268

CHMFL-ABL-053 (Compound 18a) is a potent, selective, and orally available **BCR-ABL**, **SRC** and **p38** kinase inhibitor with IC_{50} values of 70, 90 and 62 nM against ABL1, SRC and p38, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CSF1R-IN-2

Cat. No.: HY-111787

CSF1R-IN-2 (compound 5) is an oral-active inhibitor of **SRC**, **MET** and **c-FMS**, with IC_{50} values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Damnacanthal

Cat. No.: HY-108485

Damnacanthal is an anthraquinone isolated from the root of Morinda citrifolia. Damnacanthal is a highly potent, selective inhibitor of **p56^{lck} tyrosine kinase** activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Damnacanthal-d3

Cat. No.: HY-108485S

Damnacanthal-d3 is the deuterium labeled Damnacanthal. Damnacanthal is an anthraquinone isolated from the root of Morinda citrifolia. Damnacanthal is a highly potent, selective inhibitor of **p56^{lck} tyrosine kinase** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dasatinib

(BMS-354825)

Cat. No.: HY-10181

Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual **Src/Bcr-Abl** inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Dasatinib hydrochloride

(BMS-354825 hydrochloride)

Cat. No.: HY-10181A

Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual **Src/Bcr-Abl** inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively.



Purity: 98.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Dasatinib monohydrate

(BMS-354825 monohydrate)

Cat. No.: HY-10181B

Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual **Src/Bcr-Abl** inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Dasatinib-d8

(BMS-354825-d8)

Cat. No.: HY-10181S

Dasatinib D8 is a deuterium labeled Dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

DC-Srci-6649

Cat. No.: HY-139890

DC-Srci-6649 is a **c-Src** kinase inhibitor that inhibits the phosphorylation and locks c-Src in the inactive state.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DGY-06-116

Cat. No.: HY-136605

DGY-06-116 is an irreversible covalent, selective **Src** inhibitor with an **IC_{50}** of 3nM. DGY-06-116 inhibits FGFR1 with an IC_{50} of 8340 nM.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

eCF506

Cat. No.: HY-112096

eCF506 is a highly potent and orally bioavailable inhibitor of the non-receptor tyrosine kinase **Src** with an **IC_{50}** of less than 0.5 nM.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ENMD-2076

Cat. No.: HY-10987A

ENMD-2076 is a multi-targeted kinase inhibitor with **IC_{50}**s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ENMD-2076 Tartrate

Cat. No.: HY-10987

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with **IC_{50}**s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 98.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

EPQpYEEIPIYL

Cat. No.: HY-P3279

EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Fenlean

Cat. No.: HY-123506

Fenlean, a natural squamosamide derivative, is a **Src tyrosine kinase** inhibitor. Fenlean can inhibit over-activated microglia and protect dopaminergic neurons. Fenlean can attenuate neuroinflammation in Parkinson's disease models.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK2646264

Cat. No.: HY-112809

GSK2646264 (Compound 44) is a potent and selective **spleen tyrosine kinase (SYK)** inhibitor with a **pIC_{50}** of 7.1.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Hck-IN-1

Cat. No.: HY-125028

Hck-IN-1 (compound B9), a diphenylpyrazolo compound, is a selective **Nef-dependent Hck** inhibitor with **IC_{50}**s of 2.8 μM, >20 μM for Nef:Hck complex and Hck, respectively.



Purity: 98.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HG-7-85-01

Cat. No.: HY-15814

HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of **Bcr-Abl**, **PDGFRα**, **Kit**, and **Src kinases**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

iHCK-37

(ASN05260065)

Cat. No.: HY-139147

iHCK-37 (ASN05260065) is a potent and specific **Hck** inhibitor with a K_i value of 0.22 μM. iHCK-37 blocks HIV-1 viral replication with an EC_{50} value of 12.9 μM. iHCK-37 is used for chronic myeloid leukemia (CML) research.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KB SRC 4

Cat. No.: HY-108488

KB SRC 4 is a potent, and highly selective **c-Src** inhibitor, with a K_i of 44 nM and a K_d of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KX1-004

Cat. No.: HY-18237

KX1-004 is a potent and non-ATP competitive **Src-PTK** inhibitor with an IC_{50} of 40 μM. KX1-004 protects the cochlea from hazardous noise and prevents noise-induced hearing loss (NIHL).



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lavendustin C

Cat. No.: HY-W013857

Lavendustin C is a potent **Ca^{2+} calmodulin-dependent kinase II (CaMK II)** inhibitor with an IC_{50} of 0.2 μM. Lavendustin C inhibits **EGFR**-associated tyrosine kinase (IC_{50}=0.012 μM) and **pp60**$^{c\text{-}src(+)}$ kinase (IC_{50}=0.5 μM) .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lck Inhibitor

Cat. No.: HY-12072

Lck Inhibitor is a potent, orally active **Lck (lymphocyte specific kinase)** inhibitor with IC_{50}s of 7, 2.1, 4.2 and 200 nM for Lck, Lyn, Src and Syk kinases, respectively. Lck Inhibitor shows >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lck inhibitor 2

Cat. No.: HY-10644

Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lck-IN-1

Cat. No.: HY-138202

Lck-IN-1 is a potent lymphocyte protein tyrosine kinase **(Lck)** inhibitor extracted from patent WO2007013673A1, example 48.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lyn peptide inhibitor

Cat. No.: HY-P1111

Lyn peptide inhibitor is a potent and cell-permeable inhibitor of **Lyn-coupled IL-5 receptor** signaling pathway, while keeping other signals intact.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lyn peptide inhibitor TFA

Cat. No.: HY-P1111A

Lyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of **Lyn-coupled IL-5 receptor** signaling pathway, while keeping other signals intact.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Masitinib

(AB1010)

Cat. No.: HY-10209

Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Masitinib mesylate

(AB-1010 mesylate) Cat. No.: HY-10209A

Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

MNS

(NSC 170724; 5-(2-Nitrovinyl)benzodioxole) Cat. No.: HY-78263

MNS (NSC 170724), the beta-nitrostyrene derivative, is a potent **tyrosine kinase** inhibitor and a broad-spectrum antiplatelet agent.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Multi-kinase-IN-1

Cat. No.: HY-146014

Multi-kinase-IN-1 (Compound 11k) is a potent **kinase** inhibitor with antitumor activity. Multi-kinase-IN-1 induces cell **apoptosis**, and can be studied for **colorectal cancer**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Osteogenic Growth Peptide (10-14)

(OGP(10-14); Historphin) Cat. No.: HY-107024

Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PD-089828

Cat. No.: HY-112345

PD-089828 is an ATP competitive inhibitor of **FGFR-1**, **PDGFR-β** and **EGFR** (IC_{50}s=0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of **c-Src** tyrosine kinase (IC_{50}=0.18 μM). PD-089828 also inhibits **MAPK** with an IC_{50} of 7.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD-161570

Cat. No.: HY-100434

PD-161570 is a potent and ATP-competitive **human FGF-1 receptor** inhibitor with an IC_{50} of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the **PDGFR**, **EGFR** and **c-Src tyrosine kinases** with IC_{50} values of 310 nM, 240 nM, and 44 nM, respectively.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD166326

Cat. No.: HY-118144

PD166326 is a pyridopyrimidine-type inhibitor of **receptor tyrosine kinases**, with IC_{50}s of 6 nM and 8 nM for **Src** and **Abl**, respectively. PD166326 exhibits antileukemic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD173955

Cat. No.: HY-10395

PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PKC.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

PD180970

Cat. No.: HY-103274

PD180970 is a highly potent and ATP-competitive **$p210^{Bcr\text{-}Abl}$ kinase** inhibitor, with an IC_{50} of 5 nM for inhibiting the autophosphorylation of **$p210^{Bcr\text{-}Abl}$**. PD180970 also inhibits **Src** and **KIT** kinase with IC_{50}s of 0.8 nM and 50 nM, respectively.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Pelitinib

(EKB-569; WAY-EKB 569) Cat. No.: HY-32718

Pelitinib (EKB-569;WAY-EKB 569) is an irreversible inhibitor of **EGFR** with an IC_{50} of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC_{50}s of 282, 800, and 1255 nM, respectively.



Purity: 98.80%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pelitinib-d6

Cat. No.: HY-32718S

Pelitinib-d6 (EKB-569-d6) is the deuterium labeled Pelitinib. Pelitinib (EKB-569) is an irreversible inhibitor of **EGFR** with an IC_{50} of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC_{50}s of 282, 800, and 1255 nM, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

PF 477736

(PF 00477736)

Cat. No.: HY-10032

PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of **Chk1**, with a K_i of 0.49 nM, it is also a **Chk2** inhibitor, with a K_i of 47 nM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ponatinib

(AP24534)

Cat. No.: HY-12047

Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ponatinib hydrochloride

(AP24534 hydrochloride)

Cat. No.: HY-108766

Ponatinib (AP24534) hydrochloride is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: >98%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg, 100 mg

Ponatinib-d8

(AP24534-d8)

Cat. No.: HY-12047S

Ponatinib D8 (AP24534 D8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 1 mg

PP1

(AGL 1872; EI 275)

Cat. No.: HY-13804

PP1 is a potent, and **Src** family-selective tyrosine kinase inhibitor with IC_{50} of 5 and 6 nM for Lck and Fyn, respectively.



Purity: 98.62%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PP121

Cat. No.: HY-10372

PP121 is a multi-targeted kinase inhibitor with IC_{50}s of 10, 60, 12, 14, 2 nM for **mTOR**, **DNK-PK**, **VEGFR2**, **Src**, **PDGFR**, respectively.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PP2

(AGL 1879)

Cat. No.: HY-13805

PP2 is a reversible and ATP-competitive **Src** family kinases inhibitor with IC_{50}s of 4 and 5 nM for **Lck** and **Fyn**, respectively.



Purity: 98.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PP58

Cat. No.: HY-18622

PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits **PDGFR**, **FGFR** and **Src** family activities with nanomolar IC_{50} values.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Rebastinib

(DCC-2036)

Cat. No.: HY-13024

Rebastinib (DCC-2036) is an orally active, non-ATP-competitive **Bcr-Abl** inhibitor for **Abl1**^{WT} and **Abl1**^{T315I} with IC_{50}s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.



Purity: 99.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

RK-24466

(KIN 001-51)

Cat. No.: HY-108318

RK-24466 (KIN 001-51) is a potent and selective **Lck** inhibitor; inhibits Lck (64-509) and LckCD isoforms with IC_{50}s of less than 1 and 2 nM, respectively.



Purity: 98.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Saracatinib

(AZD0530)

Cat. No.: HY-10234

Saracatinib (AZD0530) is a potent **Src** family inhibitor with IC_{50}s of 2.7 to 11 nM for **c-Src**, **Lck**, **c-YES**, **Lyn**, **Fyn**, **Fgr**, and **Blk**. Saracatinib shows high selectivity over other tyrosine kinases.



Purity: 99.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Scutellarein

(6-Hydroxyapigenin; 4',5,6,7-Tetrahydroxyflavone)

Cat. No.: HY-N0752

Scutellarin, a main active ingredient extracted from Erigeron breviscapus (Vant.) Hand-Mazz., has been wildly used to treat acute cerebral infarction and paralysis induced by cerebrovascular diseases.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Secretin, canine

Cat. No.: HY-P1784

Secretin, canine is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine can regulates gastric chief cell function and paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SM1-71

Cat. No.: HY-136848

SM1-71 (compound 5) is a potent **TAK1** inhibitor, with a K_i of 160 nM, it also can covalently inhibit **MKNK2**, **MAP2K1/2/3/4/6/7**, **GAK**, **AAK1**, **BMP2K**, **MAP3K7**, **MAPKAPK5**, **GSK3A/B**, **MAPK1/3**, **SRC**, **YES1**, **FGFR1**, **ZAK (MLTK)**, **MAP3K1**, **LIMK1** and **RSK2**.



Purity: 96.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Squarunkin A hydrochloride

Cat. No.: HY-127002A

Squarunkin A hydrochloride is a potent and selective **UNC119-cargo interaction** inhibitor (IC_{50} of 10 nM for inhibiting the **UNC119A-myristoylated Src N-terminal peptide interaction**). Squarunkin A hydrochloride interferes with the activation of **Src kinase** in cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Src Inhibitor 1

(Src Kinase Inhibitor 1; Src-I1)

Cat. No.: HY-101053

Src Inhibitor 1 is a potent, ATP-competitive and selective dual site **Src** tyrosine kinase inhibitor with IC_{50} values of 44 nM for Src and 88nM for Lck.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Src Inhibitor 3

Cat. No.: HY-130254

Src Inhibitor 3 is a potent, orally active **c-terminal Src kinase (CSK)** with IC_{50} values below 3 nM and 4 nM in CSK HTRF and Caliper assay, respectively. Src Inhibitor 3 shows the ability to increase T cell proliferation induced by T cell receptor signaling.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SU6656

Cat. No.: HY-B0789

SU6656 is a **Src family kinases** inhibitor with IC_{50}s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.



Purity: 96.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

T338C Src-IN-1

Cat. No.: HY-16905

T338C Src-IN-1 is a potent mutant-Src T338C inhibitor; exhibited the most potent inhibition of T338C(IC50=111 nM) relative to WT c-Src (10-fold increase).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

T338C Src-IN-2

Cat. No.: HY-16906

T338C Src-IN-2 is a potent mutant c-Src T338C kinase inhibitor with IC50 of 317 nM; also inhibits T338C/V323A and T338C/V323S with IC50 of 57 nM/19 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TG 100572

Cat. No.: HY-10184

TG 100572 is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TG 100572 Hydrochloride

Cat. No.: HY-10185

TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

TG 100801

Cat. No.: HY-10186

TG 100801 is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: 98.60%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg

TG 100801 Hydrochloride

Cat. No.: HY-10187

TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Tirbanibulin

(KX2-391; KX-01)

Cat. No.: HY-10340

Tirbanibulin (KX2-391) is an inhibitor of **Src** that targets the peptide substrate site of Src, with GI_{50} of 9-60 nM in cancer cell lines.



Purity: 99.33%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tirbanibulin dihydrochloride

(KX2-391 dihydrochloride; KX-01 dihydrochloride)

Cat. No.: HY-10340A

Tirbanibulin (dihydrochloride) (KX2-391 (dihydrochloride)) is an inhibitor of **Src** that targets the peptide substrate site of Src, with GI_{50} of 9-60 nM in cancer cell lines.



Purity: 96.24%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tirbanibulin Mesylate

(KX2-391 Mesylate; KX01 Mesylate)

Cat. No.: HY-10340B

Tirbanibulin Mesylate (KX2-391 Mesylate) is an inhibitor of **Src** that targets the peptide substrate site of Src, with GI_{50} of 9-60 nM in cancer cell lines.



Purity: 99.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TL02-59

Cat. No.: HY-112852

TL02-59 is an orally active, selective Src-family kinase **Fgr** inhibitor with an IC_{50} of 0.03 nM. TL02-59 inhibits **Lyn** and **Hck** with IC_{50}s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TL02-59 dihydrochloride

Cat. No.: HY-112852A

TL02-59 dihydrochloride is an orally active, selective Src-family kinase **Fgr** inhibitor with an IC_{50} of 0.03 nM. TL02-59 dihydrochloride inhibits **Lyn** and **Hck** with IC_{50}s of 0.1 nM and 160 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tolimidone

(MLR-1023)

Cat. No.: HY-59047

Tolimidone is a potent and selective allosteric activator of **Lyn kinase** with an EC_{50} of 63 nM.



Purity: 99.98%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg

Tyrosine Kinase Peptide 1

Cat. No.: HY-P2547

Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay.

KVEKIGEGTYGVVYK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UM-164

(DAS-DFGO-II)

Cat. No.: HY-112182

UM-164 (DAS-DFGO-II) is a highly potent inhibitor of **c-Src** with a K_d of 2.7 nM. UM-164 also potently inhibits **p38α** and **p38β**.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

WH-4-023

(Dual LCK/SRC inhibitor)

Cat. No.: HY-12299

WH-4-023 is a potent and selective dual **Lck/Src** inhibitor with IC_{50} of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and KDR.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

XL228

Cat. No.: HY-15749

XL228 is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 5, 3.1, 1.6, 6.1, 2 nM for **Bcr-Abl**, **Aurora A**, **IGF-1R**, **Src** and **Lyn**, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

YH-306

Cat. No.: HY-120213

YH-306 is an antitumor agent. YH-306 suppresses colorectal tumour growth and metastasis via **FAK** pathway. YH-306 significantly inhibits the migration and invasion of colorectal cancer cells. YH-306 potently suppresses uninhibited proliferation and induces cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Hydroxyisovalerylshikonin

Cat. No.: HY-N4201

Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermium radix, acts as a potent inhibitor of **protein tyrosine kinases (PTK)**, with IC_{50}s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Syk

Spleen tyrosine kinase

Syk (Spleen tyrosine kinase) is a cytosolic non-receptor protein tyrosine kinase (PTK) that is expressed at high levels, both in hematopoietic cells (such as mast cells, B lymphocytes, T lymphocytes, neutrophils, dendritic cells, and macrophages) and in non-hematopoietic cells.

Syk mediates key signal transduction pathways following the activation of immune cell receptors. Syk associates with different receptors on the surface of various cells such as B cells, mast cells, monocytes, macrophages, and neutrophils, and even osteoclasts and breast cancer cells. Following the engagement of these receptors with their ligands, SYK is activated and orchestrates diverse cellular responses, including cytokine production (in T cells and monocytes) and phagocytosis (in macrophages).

Syk Inhibitors

BAY 61-3606

Cat. No.: HY-76474

BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective **Syk** inhibitor with a K_i of 7.5 nM and an IC_{50} of 10 nM. BAY 61-3606 reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BAY 61-3606 dihydrochloride

Cat. No.: HY-14985

BAY 61-3606 dihydrochloride is an orally available, ATP-competitive, reversible and highly selective **Syk** inhibitor with a K_i of 7.5 nM an IC_{50} of 10 nM. BAY 61-3606 dihydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Cerdulatinib

(PRT062070; PRT2070)

Cat. No.: HY-15999

Cerdulatinib (PRT062070) is a selective **Tyk2** inhibitor with an IC_{50} of 0.5 nM. Cerdulatinib (PRT062070) also is a dual **JAK** and **SYK** inhibitor with IC_{50}s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively.



Purity: 99.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Cerdulatinib hydrochloride

(PRT062070 hydrochloride; PRT2070 hydrochloride)

Cat. No.: HY-15999A

Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual **SYK** and **JAK**, with IC_{50}s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for **SYK** and **Tyk2**, **JAK1**, **2**, **3**, respectively.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cevidoplenib

Cat. No.: HY-109082

Cevidoplenib is an orally available inhibitor of **spleen tyrosine kinase (Syk)**, with potential anti-inflammatory and immunomodulating activities.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cevidoplenib dimesylate

Cat. No.: HY-109082A

Cevidoplenib is an orally available inhibitor of **spleen tyrosine kinase (Syk)**, with potential anti-inflammatory and immunomodulating activities.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Entospletinib

(GS-9973)

Cat. No.: HY-15968

Entospletinib (GS-9973) is an orally bioavailable, selective **Syk** inhibitor with an IC_{50} of 7.7 nM.



Purity: 99.86%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Fostamatinib

(R788)

Cat. No.: HY-13038A

Fostamatinib (R788) is the oral prodrug of the active compound R406. R406 is an orally available and competitive **Syk/FLT3** inhibitor with a K_i of 30 nM and an IC_{50} of 41 nM. R406 also inhibits Lyn (IC_{50}=63 nM) and Lck (IC_{50}=37 nM).



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fostamatinib Disodium

(R788(Disodium))

Cat. No.: HY-13038

Fostamatinib Disodium (R788 Disodium) is the oral prodrug of the active compound R406. R406 is an orally available and competitive **Syk/FLT3** inhibitor with a K_i of 30 nM and an IC_{50} of 41 nM. R406 also inhibits Lyn (IC_{50}=63 nM) and Lck (IC_{50}=37 nM).



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fostamatinib disodium hexahydrate

(R788 disodium hexahydrate)

Cat. No.: HY-13038B

Fostamatinib (R788) disodium hexahydrate is the oral prodrug of the active compound R406. R406 is an orally available and competitive **Syk/FLT3** inhibitor with a K_i of 30 nM and an IC_{50} of 41 nM. R406 also inhibits Lyn (IC_{50}=63 nM) and Lck (IC_{50}=37 nM).



Purity: 98.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fostamatinib-d9

(R788-d9)

Cat. No.: HY-13038AS

Fostamatinib-d9 (R788-d9) is the deuterium labeled Fostamatinib. Fostamatinib (R788) is the oral prodrug of the active compound R406. R406 is an orally available and competitive **Syk/FLT3** inhibitor with a K_i of 30 nM and an IC_{50} of 41 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK143

Cat. No.: HY-12736

GSK143 is an orally active and highly selective **spleen tyrosine kinase (SYK)** inhibitor with a pIC_{50} of 7.5. GSK143 inhibits phosphorylated Erk (pErk: pIC_{50}=7.1). GSK143 reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK143 dihydrochloride

Cat. No.: HY-12736A

GSK143 dihydrochloride is an orally active and highly selective **spleen tyrosine kinase (SYK)** inhibitor with a pIC_{50} of 7.5. GSK143 dihydrochloride inhibits phosphorylated Erk (pErk: pIC_{50}=7.1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK2646264

Cat. No.: HY-112809

GSK2646264 (Compound 44) is a potent and selective **spleen tyrosine kinase (SYK)** inhibitor with a pIC_{50} of 7.1.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Gusacitinib

(ASN-002)

Cat. No.: HY-103018

Gusacitinib (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (**SYK**) and janus kinase (**JAK**) with IC_{50} values of 5-46 nM. Gusacitinib has anti-cancer activity in both solid and hematological tumor types.



Purity: 99.41%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Lanraplenib

(GS-9876)

Cat. No.: HY-109091

Lanraplenib (GS-9876) is a highly selective and orally active **SYK** inhibitor (IC_{50}=9.5 nM) in development for the treatment of inflammatory diseases.



Purity: 98.22%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lanraplenib monosuccinate

(GS-9876 monosuccinate)

Cat. No.: HY-109091A

Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active **SYK** inhibitor (IC_{50}=9.5 nM) in development for the treatment of inflammatory diseases.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Lanraplenib succinate

(GS-9876 succinate)

Cat. No.: HY-109091B

Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active **SYK** inhibitor (IC_{50}=9.5 nM) in development for the treatment of inflammatory diseases.



Purity: 98.21%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MNS

(NSC 170724; 5-(2-Nitrovinyl)benzodioxole)

Cat. No.: HY-78263

MNS (NSC 170724), the beta-nitrostyrene derivative, is a potent **tyrosine kinase** inhibitor and a broad-spectrum antiplatelet agent.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

OXSI-2

Cat. No.: HY-112386

OXSI-2 is a bioavailable, cell-permeable **Syk** inhibitor with an EC_{50} of 313 nM and an IC_{50} of 14 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Piceatannol

(Astringenin; trans-Piceatannol) Cat. No.: HY-13518

Piceatannol is a well-known **Syk** inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI).



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

PRT-060318

(PRT318) Cat. No.: HY-12974

PRT-060318 (PRT318) is a novel selective inhibitor of the tyrosine kinase **Syk** with an IC_{50} of 4 nM.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PRT062607

(P505-15; PRT-2607; BIIB-057) Cat. No.: HY-15322

PRT062607(P505-15; PRT-2607; BIIB-057) is a highly specific and potent inhibitor of Syk with IC50 of 1-2 nM; >80-fold selective for Syk than Fgr, Lyn, FAK, Pyk2 and Zap70.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

PRT062607 Hydrochloride

(P505-15 Hydrochloride) Cat. No.: HY-15323

PRT062607 Hydrochloride (P505-15 Hydrochloride) is a highly specific and potent inhibitor of purified **Syk** (IC_{50} 1-2 nM).



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

R112

Cat. No.: HY-16420

R112 is an ATP-competitive inhibitor of Syk kinase with a Ki of 96 nM. R112 inhibits Syk kinase activity with an IC50 of 226 nM.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

R406

Cat. No.: HY-12067

R406 is an orally available and competitive **Syk/FLT3** inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk kinase activity in vitro with an IC_{50} of 41 nM, measured at an ATP concentration corresponding to its K_m value.



Purity: 96.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

R406 free base

Cat. No.: HY-11108

R406 free base is an orally available and competitive **Syk/FLT3** inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk kinase activity in vitro with an IC_{50} of 41 nM, measured at an ATP concentration corresponding to its K_m value.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RO9021

Cat. No.: HY-16902

RO9021 is an orally bioavailable, novel ATP-competitive inhibitor of **SYK**, with an average IC_{50} of 5.6 nM.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Sovleplenib

(HMPL-523) Cat. No.: HY-145598

Sovleplenib (HMPL-523) is a highly potent, orally available and selective **SYK** inhibitor with an IC_{50} of 25 nM. Anti-tumor activity. Sovleplenib can be used for the research of immune thrombocytopenia (ITP).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SRX3207

Cat. No.: HY-136198

SRX3207 is an orally active and first-in-class dual **Syk/PI3K** inhibitor, with IC_{50} values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression.



Purity: 98.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Syk Inhibitor II

Cat. No.: HY-112390A

Syk Inhibitor II is a potent, high selective and ATP-competitive **Syk** inhibitor with an IC_{50} of 41 nM. Syk Inhibitor II inhibits **5-HT** release from RBL-cells with an IC_{50} of 460 nM. Syk Inhibitor II shows less potent against other kinases and has anti-allergic effect.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Syk Kinase Peptide Substrate

Cat. No.: HY-P2505

Syk Kinase Peptide Substrate is a Syk kinase peptide substrate.

KEDPDYEWPSAK-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Syk Kinase Peptide Substrate, Biotin labeled

Cat. No.: HY-P2504

Syk Kinase Peptide Substrate, Biotin labeled is a biotin-labled Syk kinase peptide substrate.

Biotin-KEDPDYEWPSAK-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Syk-IN-1

Cat. No.: HY-12657

Syk-IN-1 (compound 4) is a potent **Syk** inhibitor, with an IC_{50} of 35 nM.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Syk-IN-3

Cat. No.: HY-130680

Syk-IN-3, a potent spleen tyrosine kinase (Syk) inhibitor, extracted from patent WO2011075515A1, compound example 152, has an $IC_{50<sub/>}$ of 1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Syk-IN-4

Cat. No.: HY-131341

Syk-IN-4 is a potent, selective and orally bioavailable **SYK** inhibitor with an IC_{50} of 0.31 nM. SYK has emerged as a potential target for autoimmunity and hematological cancers.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SYK/JAK-IN-1

Cat. No.: HY-145029

SYK/JAK-IN-1 is dual **SYK/JAK** inhibitor with IC_{50}s of <5 nM for SYK and JAK2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TAK-659

Cat. No.: HY-100867

TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of **spleen tyrosine kinase (SYK)** and **fms related tyrosine kinase 3 (FLT3)**, with an IC_{50} of 3.2 nM and 4.6 nM for SYK and FLT3, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

TAK-659 hydrochloride

Cat. No.: HY-100867A

TAK-659 hydrochloride is a highly potent, selective, reversible and orally available dual inhibitor of **spleen tyrosine kinase (SYK)** and **fms related tyrosine kinase 3 (FLT3)**, with an IC_{50} of 3.2 nM and 4.6 nM for SYK and FLT3, respectively.



Purity: 99.91%
Clinical Data: Phase 2
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAS05567

Cat. No.: HY-120214

TAS05567 is a potent, highly selective, ATP-competitive and orally active **Syk** inhibitor with an IC_{50} of 0.37 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TAM Receptor

Tyro3; Axl; Mer

TAM receptors, comprising of Tyro3, Axl and Mertk receptors, are receptor tyrosine kinases (RTKs) that are expressed by multiple immune cells including NK cells. The TAM family of receptors and their ligands Gas6 and Protein S (PROS1) are required for the optimal phagocytosis of apoptotic cells in the mature immune, nervous, and reproductive systems.

TAMs are three homologous type I receptor-tyrosine kinases that are activated by endogenous ligands, PROS1 and GAS6. These ligands can either activate TAMs as soluble factors, or, in turn, opsonize phosphatidylserine (PS) on apoptotic cells (ACs) and serve as bridging molecules between ACs and TAMs. Abnormal expression and activation of TAMs have been implicated in promoting proliferation and survival of cancer cells, as well as in suppressing anti-tumor immunity.

TAM Receptor Inhibitors

2-D08

Cat. No.: HY-114166

2-D08 is a cell permeable, mechanistically unique inhibitor of protein **SUMOylation**. 2-D08 also inhibits **Axl** with an IC_{50} of 0.49 nM.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Axl-IN-3

Cat. No.: HY-144706

Axl-IN-3 is a potent, selective and orally active **AXL kinase** inhibitor with an IC_{50} of 41.5 nM. Axl-IN-3 has lower inhibition of other kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Axl-IN-4

Cat. No.: HY-144708

Axl-IN-4 (Compound 24) is an **AXL kinase** inhibitor with an IC_{50} of 28.8 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Axl-IN-5

Cat. No.: HY-146596

Axl-IN-5 (compound 1) is a **AXL** inhibitor with an IC_{50} of 283 nM. Axl-IN-5 has anticancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Axl-IN-6

Cat. No.: HY-146615

Axl-IN-6 (compound 14) is an orally active and potent **AXL** inhibitor. Axl-IN-6 is well tolerated and significantly inhibits the tumor growth in MV-4-11 subcutaneous xenograft model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ14145845

Cat. No.: HY-132893

AZ14145845 is a highly selective type I1/2 dual **Mer/Axl** kinase inhibitor with in vivo efficacy.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bemcentinib

(R428; BGB324)

Cat. No.: HY-15150

Bemcentinib (R428) is a potent and selective inhibitor of **Axl** with an IC_{50} of 14 nM.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS 777607

(BMS 817378)

Cat. No.: HY-12076

BMS 777607 (BMS 817378) is a **Met-related** inhibitor for **c-Met**, **Axl**, **Ron** and **Tyro3** with IC_{50}s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity...



Purity: 99.04%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cabozantinib

(XL184; BMS-907351)

Cat. No.: HY-13016

Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Cabozantinib-d4

(XL184-d4; BMS-907351-d4)

Cat. No.: HY-13016S1

Cabozantinib-d4 is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cabozantinib-d6

Cat. No.: HY-13016S

Cabozantinib-d6 (XL184-d6) is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CEP-40783

(RXDX-106)

Cat. No.: HY-100946

CEP-40783 is a potent, selective and orally available inhibitor of **AXL** and **c-Met** with IC_{50} values of 7 nM and 12 nM, respectively.



Purity: 99.22%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

DS-1205b free base

Cat. No.: HY-114357A

DS-1205b free base is a potent and selective inhibitor of **AXL kinase**, with an IC_{50} of 1.3 nM. DS-1205b free base also inhibits **MER**, **MET**, and **TRKA**, with IC_{50}s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Dubermatinib

(TP-0903)

Cat. No.: HY-12963

Dubermatinib (TP-0903) is a potent and selective **Axl** receptor tyrosine kinase inhibitor with an IC_{50} value of 27 nM.



Purity: 99.82%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

Gilteritinib

(ASP2215)

Cat. No.: HY-12432

Gilteritinib (ASP2215) is a potent and ATP-competitive **FLT3/AXL** inhibitor with IC_{50}s of 0.29 nM/0.73 nM, respectively.



Purity: 99.55%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Gilteritinib hemifumarate

(ASP2215 hemifumarate)

Cat. No.: HY-12432A

Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive **FLT3/AXL** inhibitor with IC_{50} of 0.29 nM/0.73 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Gilteritinib-d3

(ASP2215-d3)

Cat. No.: HY-12432S

Gilteritinib-d3 (ASP2215-d3) is the deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive **FLT3/AXL** inhibitor with IC_{50}s of 0.29 nM/0.73 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gilteritinib-d8

(ASP2215-d8)

Cat. No.: HY-12432S1

Gilteritinib-d8 is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glesatinib

(MGCD265)

Cat. No.: HY-19642

Glesatinib (MGCD265) is an orally active, potent **MET/SMO** dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glesatinib hydrochloride

(MGCD265 hydrochloride)

Cat. No.: HY-19642A

Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent **MET/SMO** dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).



Purity: 98.25%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LDC1267

Cat. No.: HY-12494

LDC1267 is a highly selective **TAM (Tyro3, Axl and Mer)** kinase inhibitor with IC_{50}s of <5 nM/8 nM/29 nM for Tyro3,Axl and Mer respectively.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Multi-kinase-IN-1

Cat. No.: HY-146014

Multi-kinase-IN-1 (Compound 11k) is a potent **kinase** inhibitor with antitumor activity. Multi-kinase-IN-1 induces cell **apoptosis**, and can be studied for **colorectal cancer**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ningetinib

Cat. No.: HY-107145A

Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with IC_{50}s of 6.7, 1.9 and <1.0 nM for **c-Met**, **VEGFR2** and **Axl**, respectively.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ningetinib Tosylate

Cat. No.: HY-107145

Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with IC_{50}s of 6.7, 1.9 and <1.0 nM for **c-Met**, **VEGFR2** and **Axl**, respectively.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NPS-1034

Cat. No.: HY-100509

NPS-1034 is a dual inhibitor of **AXL** and **MET** with IC_{50}s of 10.3 and 48 nM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ONO-7475

Cat. No.: HY-114358

ONO-7475 is a potent, selective, and orally active **Axl/Mer** inhibitor with IC_{50} values of 0.7 nM and 1.0 nM, respectively. ONO-7475 sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells.



Purity: 99.38%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PROTAC Axl Degrader 1

Cat. No.: HY-144624

PROTAC Axl Degrader 1 is a potent and selective **PROTAC Axl** degrader with an IC_{50} of 0.92 μM. PROTAC Axl Degrader 1 shows anti-proliferation activity, anti-migration activity in vitro. PROTAC Axl Degrader 1 induces **mehuosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Axl Degrader 2

Cat. No.: HY-144627

PROTAC Axl Degrader 2 is a potent and selective **PROTAC Axl** degrader with an IC_{50} of 1.61 μM. PROTAC Axl Degrader 2 shows anti-proliferation activity, anti-migration activity in vitro. PROTAC Axl Degrader 2 induces **mehuosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

R916562

Cat. No.: HY-104075

R916562 is an orally active and selective **Axl/VEGF-R2** inhibitor with IC_{50}s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RU-301

Cat. No.: HY-119039

RU-301 is a pan-**TAM** receptor inhibitor, exerts pan-TAM inhibitory activity by binding at the interface between Gas6 and the Ig1 domain of the respective TAMs with K_d and IC_{50} values of 12 μM and 10 μM, respectively.



Purity: 99.73%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RU-302

Cat. No.: HY-124066

RU-302 is a pan **TAM** inhibitor that blocks the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain. RU-302 effectively blocks Gas6-inducible **Axl** receptor activation with a low micromolar IC_{50} in cell assays, and suppresses lung cancer tumor growth.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SGI-7079

Cat. No.: HY-12964

SGI-7079 is a potent and ATP-competitive **Axl** inhibitor, significantly inhibits the proliferation of SUM149 or KPL-4 cells with an IC_{50} of 0.43 or 0.16 μM, respectively.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TAM-IN-2

Cat. No.: HY-126216

TAM-IN-2 is a TAM inhibitor extracted from patent US 20170275290 A1, pyrrolotriazine compound 0904.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

UNC1062

Cat. No.: HY-117548

UNC1062 is a **MERTK**-selective tyrosine kinase inhibitor, reduces activation of MERTK-mediated downstream signaling, induces **apoptosis** in culture, reduces colony formation in soft agar, and inhibits invasion of melanoma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UNC2250

Cat. No.: HY-15797

UNC2250 is a potent and selective **Mer** inhibitor with an IC_{50} of 1.7 nM, about 160- and 60-fold selectivity over the closely related kinases Axl/Tyro3.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UNC2541

Cat. No.: HY-125510

UNC2541 is a potent and Mer tyrosine kinase (**MerTK**)-specific inhibitor, binds in the MerTK ATP pocket, with an IC_{50} of 4.4 nM, more selective over Axl, Tyro3 and Flt3. UNC2541 inhibits phosphorylated MerTK (pMerTK; EC_{50}, 510 nM).



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

UNC2881

Cat. No.: HY-15798

UNC2881 is a potent and specific Mer kinase inhibitor; inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

UNC4203

Cat. No.: HY-124502

UNC4203 is a potent, orally available and highly selective **MERTK** inhibitor, with IC_{50}s of 1.2 nM, 140 nM, 42 nM and 90 nM for MERTK, AXL, TYRO3 and FLT3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UNC5293

Cat. No.: HY-132200

UNC5293 is a **MERTK**-selective and potent inhibitor (K_i=190 pM). UNC5293 inhibits MERTK (IC_{50}=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UNC569

Cat. No.: HY-117596

UNC569 is a potent, reversible, ATP-competitive and orally active **Mer kinase** inhibitor with an IC_{50} of 2.9 nM and a K_i of 4.3 nM. UNC569 also inhibits **Axl** and **Tyro3** with IC_{50}s of 37 nM and 48 nM, respectively.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

XL092

Cat. No.: HY-138696

XL092 is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including **MET**, **VEGFR2**, **AXL** and **MER**, with IC_{50}s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. XL092 exhibits anti-tumor activity.



Purity: 99.52%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Trk Receptor

Tropomyosin related kinase receptor

Trk receptors are a family of three receptor tyrosine kinases (TrkA, TrkB, and TrkC), each of which can be activated by one or more of four neurotrophins-nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4).

TrkA, TrkB, and TrkC are transmembrane proteins that comprise the TRK receptor family. These receptor tyrosine kinases are expressed in human neuronal tissue, and play an essential role in both the physiology of development and function of the nervous system through activation by neurotrophins (NTs). The latter are specific ligands known as NGF for TrkA, BDGF, and NT-4/5 for TrkB and NT3 for TrkC, respectively.

The binding of the ligand to the receptor triggers the oligomerisation of the receptors and phosphorylation of specific tyrosine residues in the intracytoplasmic kinase domain. This event results into the activation of signal transduction pathways leading to proliferation, differentiation and survival in normal and neoplastic neuronal cells.

(R)-Larotrectinib

((R)-LOXO-101; (R)-ARRY-470) Cat. No.: HY-12866B

(R)-Larotrectinib is a potent **TRK** inhibitor with an IC_{50} value of 28.5 nM for TrkA. (R)-Larotrectinib can be used for researching cancer, inflammatory and certain infectious diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7,8-Dihydroxyflavone

Cat. No.: HY-W013372

7,8-Dihydroxyflavone is a potent and selective **TrkB** agonist that mimics the physiological actions of Brain-derived neurotrophic factor (BDNF). Displays therapeutic efficacy toward various neurological diseases.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Altiratinib

(DCC-2701) Cat. No.: HY-B0791

Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC_{50}s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for **MET**, **TIE2**, **VEGFR2**, **FLT3**, **Trk1**, **Trk2**, and **Trk3** respectively.



Purity: 98.06%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amitriptyline hydrochloride

Cat. No.: HY-B0527A

Amitriptyline hydrochloride is an inhibitor of **serotonin reuptake transporter (SERT)** and **noradrenaline reuptake transporter (NET)**, with K_is of 3.45 nM and 13.3 nM for human SERT and NET, respectively.



Purity: 99.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Amitriptyline-d3 hydrochloride

Cat. No.: HY-135096

Amitriptyline-d3 hydrochloride is the deuterium labeled Amitriptyline (hydrochloride).



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 1 mg, 5 mg, 10 mg

Amitriptyline-d6 hydrochloride

Cat. No.: HY-B0527AS

Amitriptyline-d6 hydrochloride is the deuterium labeled Amitriptyline hydrochloride.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 1 mg, 5 mg, 25 mg

ANA-12

Cat. No.: HY-12497

ANA-12 is a potent and selective **TrkB** antagonist with IC_{50}s of 45.6 nM and 41.1 μM for the high and low affinity sites, respectively.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

AZ-23

(AZ23; AZ 23) Cat. No.: HY-15590

AZ-23 is an ATP-competitive and orally bioavailable **Trk kinase A/B/C** inhibitor with IC_{50}s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively.



Purity: 98.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Belizatinib

(TSR-011) Cat. No.: HY-17603

Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC_{50} of 0.7nM for wild-type recombinant ALK kinase.



Purity: 99.66%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CE-245677

Cat. No.: HY-112423

CE-245677 is a potent reversible inhibitor of **Tie2** and **TrkA/B** kinases with a cellular IC_{50}s of 4.7 and 1 nM.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CH7057288

Cat. No.: HY-107362

CH7057288 is a potent and selective **TRK** inhibitor.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cyclotraxin B

Cat. No.: HY-P1178

Cyclotraxin B, a cyclic peptide, is a highly potent and selective **TrkB** inhibitor without altering the binding of BDNF. Cyclotraxin B non-competitively inhibits BDNF-induced **TrkB** activity with an IC_{50} of 0.30 nM.

Purity: 99.87%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cyclotraxin B TFA

Cat. No.: HY-P1178A

Cyclotraxin B TFA, a cyclic peptide, is a highly potent and selective **TrkB** inhibitor without altering the binding of BDNF. Cyclotraxin B TFA non-competitively inhibits BDNF-induced **TrkB** activity with an IC_{50} of 0.30 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

D5261

Cat. No.: HY-144690

D5261 is a potent, type III allosteric **tropomyosin-related kinase A (TrkA)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DS-1205b free base

Cat. No.: HY-114357A

DS-1205b free base is a potent and selective inhibitor of **AXL kinase**, with an IC_{50} of 1.3 nM. DS-1205b free base also inhibits **MER**, **MET**, and **TRKA**, with IC_{50}s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Entrectinib

(NMS-E628; RXDX-101)

Cat. No.: HY-12678

Entrectinib (NMS-E628) is a potent, orally available, and CNS-active **pan-Trk**, **ROS1**, and **ALK** inhibitor. Entrectinib inhibits TrkA, TrkB, TrkC, ROS1 and ALK with IC_{50} values of 1, 3, 5, 12 and 7 nM, respectively. Antitumor activity.



Purity: 99.32%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FLT3/TrKA-IN-1

Cat. No.: HY-146749

FLT3/TrKA-IN-1 is a potent **FLT3/TrKA** dual kinase inhibitor with the IC_{50}s of 43.8 nM, 97.2 nM, 92.5 nM and 23.6 nM for FLT3, FLT3-ITD, FLT3-TKD and TrKA, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GNF-5837

Cat. No.: HY-13491

GNF-5837 is a potent, selective, and orally bioavailable pan-**tropomyosin receptor kinase (TRK)** inhibitor which display antiproliferative effects in cellular Ba/F3 assays (IC_{50} values of 7 nM, 9 nM and 11 nM for cells containing the fusion proteins **Tel-TrkC**, **Tel-TrkB** and...



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GNF-8625 monopyridin-N-piperazine hydrochloride

Cat. No.: HY-131706A

GNF-8625 monopyridin-N-piperazine hydrochloride (TRKi-2), a TRK inhibitor, which is from the patent WO 2020038415 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GW 441756

Cat. No.: HY-18314

GW 441756 is a potent and specific nerve growth factor (NGF) receptor tyrosine kinases A (**TrkA**) inhibitor (IC_{50}=2 nM), which eliminates the BmK NSPK-induced neurite outgrowth.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

hTrkA-IN-1

Cat. No.: HY-136535

hTrkA-IN-1 is a potent and orally active inhibitor of **TrkA kinase** with an IC_{50} of 1.3 nM, compound 2. extracted from patent WO2015175788. hTrkA-IN-1 can be used for the study of inflammatory disease, such as prostatitis, pelvic, et al.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IHMT-TRK-284

Cat. No.: HY-146697

IHMT-TRK-284 (Compound 34) is a potent, orally active **type II TRK kinase** inhibitor with IC_{50} values of 10.5, 0.7, and 2.6 nM to **TRKA, B**, and **C** respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

K-252a

(SF2370; Antibiotic K 252a; Antibiotic SF 2370)

Cat. No.: HY-N6732

K-252a, a staurosporine analog, inhibits **protein kinase**, with IC_{50} values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca^{2+}/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Larotrectinib

(LOXO-101; ARRY-470)

Cat. No.: HY-12866

Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase **(TRK)** family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Larotrectinib sulfate

(LOXO-101 sulfate; ARRY-470 sulfate)

Cat. No.: HY-12866A

Larotrectinib sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase **(TRK)** family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).



Purity: 99.57%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Larotrectinib-d7

(LOXO-101-d7; ARRY-470-d7)

Cat. No.: HY-12866S

Larotrectinib-d7 (LOXO-101-d7) is the deuterium labeled Larotrectinib.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lestaurtinib

(CEP-701; KT-5555)

Cat. No.: HY-50867

Lestaurtinib (CEP-701;KT-5555) is an ATP-competitive multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases. Lestaurtinib inhibits **JAK2**, **FLT3** and **TrkA** with IC_{50}s of 0.9, 3 and less than 25 nM, respectively.



Purity: 99.92%
Clinical Data: Phase 3
Size: 5 mg

LM22A-4

Cat. No.: HY-100673

LM22A-4 is a specific agonist of **tyrosine kinase receptor B**, used for neurological disease research.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LM22B-10

Cat. No.: HY-104047

LM22B-10 is an activator of **TrkB/TrkC** neurotrophin receptor, and can induce **TrkB**, **TrkC**, **AKT** and **ERK** activation in vitro and in vivo.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

LPM4870108

Cat. No.: HY-132229

LPM4870108 is a potent and orally active **pan-Trk (WT and MT)** inhibitor, with IC_{50}s of 0.2 nM, 2.4 nM, 3.5 nM and 2.3 nM for **TrkC**, **TrkA**, **TrkA^{G595R}** and **TrkA^{G667C}**, respectively. LPM4870108 shows selectivity for Trk over ALK (IC_{50}=182 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Acetyl-5-hydroxytryptamine

(N-Acetylserotonin; Normelatonin; O-Demethylmelatonin) Cat. No.: HY-107854

N-Acetyl-5-hydroxytryptamine is a Melatonin precursor, and that it can potently activate **TrkB** receptor.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

N-Acetyl-5-hydroxytryptamine-d3 (N-Acetylserotonin-d3;

Normelatonin-d3; O-Demethylmelatonin-d3) Cat. No.: HY-107854S

N-Acetyl-5-hydroxytryptamine-d3 (N-Acetylserotonin-d3) is the deuterium labeled N-Acetyl-5-hydroxytryptamine.
N-Acetyl-5-hydroxytryptamine is a Melatonin precursor, and that it can potently activate **TrkB** receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ONO-7475

Cat. No.: HY-114358

ONO-7475 is a potent, selective, and orally active **Axl/Mer** inhibitor with IC_{50} values of 0.7 nM and 1.0 nM, respectively. ONO-7475 sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells.



Purity: 99.38%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Paltimatrectinib

Cat. No.: HY-145587

Paltimatrectinib (compound I-147) is a potent **tyrosine kinase** inhibitor with an IC_{50} of <10 nM for tropomyosin kinases A (TrkA). Paltimatrectinib has the potential for cancer and inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pan-Trk-IN-2

Cat. No.: HY-144028

Compound cpd-1 is a small molecule **Trks** inhibitor with good antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pan-Trk-IN-3

Cat. No.: HY-144069

Pan-Trk-IN-3 (Compound 11g) is a potent inhibitor of pan-**Trk** and their drug-resistant mutants with IC_{50} values of 2, 3, 2, 21, 26, 5, 7 and 6 nM against **TrkA**, **TrkB**, **TrkC**, **TrkA**^{G595R}, **TrkA**^{G667C}, **TrkA**^{G667S}, **TrkA**^{F589L} and **TrkC**^{G623R}, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-06273340

Cat. No.: HY-122616

PF-06273340 is a potent, selective, orally bioavailable and peripherally restricted pan **Trk** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-06733804

Cat. No.: HY-112434

PF-06733804 is a potent **pan-Trk** inhibitor in cell-based assays with IC_{50}s of 8.4 nM, 6.2 nM and 2.2 nM for **TrkA**, **TrkB** and **TrkC**, respectively. Anti-hyperalgesic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-06737007

Cat. No.: HY-112437

PF-06737007 is a potent **pan-Trk** inhibitor in cell-based assays with IC_{50}s of 7.7 nM, 15 nM and 3.9 nM for **TrkA**, **TrkB** and **TrkC**, respectively. Anti-hyperalgesic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-6683324

(Trk-IN-4) Cat. No.: HY-112436

PF-6683324 (Trk-IN-4) is a potent **pan-Trk** inhibitor in cell-based assays with IC_{50}s of 1.9 nM, 2.6 nM and 1.1 nM for **TrkA**, **TrkB** and **TrkC**, respectively. Anti-hyperalgesic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Repotrectinib

(TPX-0005) Cat. No.: HY-103022

Repotrectinib (TPX-0005) is a potent **ROS1** (IC_{50}=0.07 nM) and **TRK** (IC_{50}=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib potently inhibits WT **ALK** (IC_{50}=1.01 nM). Repotrectinib has anti-cancer activity.



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Selitrectinib

(LOXO-195) Cat. No.: HY-101977

Selitrectinib (LOXO-195) is a next-generation **TRK kinase** inhibitor, with IC_{50}s of 0.6 nM and <2.5 nM for **TRKA** and **TRKC**, respectively.



Purity: 99.90%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sitravatinib

(MGCD516; MG-516) Cat. No.: HY-16961

Sitravatinib (MGCD516) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: 99.59%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Sitravatinib malate

(MGCD516 malate; MG-516 malate) Cat. No.: HY-16961A

Sitravatinib malate (MGCD516 malate) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Tavilermide

(MIM-D3) Cat. No.: HY-17622

Tavilermide is a selective, partial agonist of **TrkA**, or a nerve growth factor (NGF) mimetic.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

TIY-7

Cat. No.: HY-146755

TIY-7 is a selective and orally active **tropomyosin receptor kinase (TRK)** inhibitor. TIY-7 shows enzyme inhibitory activity with IC_{50}s of 2.9, 1.1, 0.7, 0.8, 0.8, 0.2 nM for TRKA, $TRKA^{G595R}$, $TRKA^{G667C}$, $TRKA^{F589L}$, $TRKC^{G623R}$, $TRKC^{G696A}$, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trk-IN-1

Cat. No.: HY-12327

Trk-IN-1 (example 9), a potent **tropomyosin-related kinase (Trk)** inhibitor, shows potency against TrkA (3.7 nM) and TrkB (94 nM), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trk-IN-10

Cat. No.: HY-144423

Trk-IN-10 (Compound 14j) is a potent inhibitor of **TRK** (IC_{50} = 0.86, 6.92 nM, against TrkA, $TrkA^{G595R}$, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key drug target in solid tumors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trk-IN-11

Cat. No.: HY-144424

Trk-IN-11 (Compound 14h) is a potent inhibitor of **TRK** (IC_{50} = 1.4, 1.8 nM, against TrkA, $TrkA^{G595R}$, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key drug target in solid tumors. Trk-IN-11 has the potential for the research of cancer disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK-IN-12

Cat. No.: HY-144451

TRK-IN-12 (Compound 9e) is a potent inhibitor of **TRK** (TRK^{G595R} IC_{50} = 13.1 nM). TRK-IN-12 is a macrocyclic derivative compound. TRK-IN-12 shows significant antiproliferative activity in the Ba/F3-LMNA-NTRK1 cell line (IC_{50} = 0.080 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK-IN-13

Cat. No.: HY-146518

TRK-IN-13 is a potent inhibitor of **TRK**. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK-IN-14

Cat. No.: HY-146519

TRK-IN-14 is a potent inhibitor of **TRK**. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK-IN-15

Cat. No.: HY-146521

TRK-IN-15 is a potent inhibitor of **TRK**. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK-IN-16

Cat. No.: HY-146522

TRK-IN-16 is a potent inhibitor of **TRK**. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK-IN-17

Cat. No.: HY-146523

TRK-IN-17 is a potent inhibitor of **TRK**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK-IN-18

Cat. No.: HY-146524

TRK-IN-18 is a potent inhibitor of **TRK**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK-IN-19

Cat. No.: HY-146115

TRK-IN-19 (Compound I-10) is a potent inhibitor of **TRK** (TRKA IC_{50} = 1.1 nM, $TRKA^{G595R}$ IC_{50} = 5.3 nM). TRK-IN-19 has the potential for the research of cancer diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trk-IN-6

Cat. No.: HY-139891

Trk-IN-6 shows excellent in vitro potency on a panel of **TRK** mutants (IC_{50} = 0.2-0.7 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trk-IN-7

Cat. No.: HY-143557

Trk-IN-7 (compound I-6) is a potent **TRK** inhibitor with IC_{50}s of ranging from 0.25-10 nM for TRKA, TRKB and TRKC, respectively. Trk-IN-7 shows inhibition against EML4-ALK (IC_{50}<15 nM) ALK G1202R, ALK C1156Y, ALK R1275Q, ALK F1174L, ALK L1197M, and ALK G1269A (IC_{50}=5-50 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trk-IN-8

Cat. No.: HY-143561

Trk-IN-8 is a potent **TRK** inhibitor with IC_{50}s of 0.42, 0.89 and 1.5 nM for TRKAa, TRKA(G595R) and TRKC(G623R), respectively (WO2021115401A1, compound 3).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trk-IN-9

Cat. No.: HY-144321

Trk-IN-9 (Compound 12) is a potent inhibitor of **TRK**. Trk-IN-9 inhibits the proliferation of Km-12 cell lines. Trk-IN-9 induces the **apoptosis** of Km-12 cells in a concentration-dependent manner. Trk-IN-9 inhibits the phosphorylation of TRK to block downstream pathways.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK/ALK-IN-1

Cat. No.: HY-144732

TRK/ALK-IN-1 (compound 21) is a potent and dual inhibitor of **TRK** and **ALK**. TRK/ALK-IN-1 in the enzymatic assays is in good accordance with anti-proliferative activity with IC_{50} values of 2.2, 9.3 and 38 nM towards TRKA, ALK^{WT} and ALK^{L1196M}, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TrkA-IN-1

Cat. No.: HY-129634

TrkA-IN-1 is a potent and selective **Tropomyosin-related kinase A (TrkA)** inhibitor with an IC_{50} of 99 nM in a cell-based assay. TrkA-IN-1 has analgesic activity.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Tyrphostin AG 879

(AG 879)

Cat. No.: HY-20878

Tyrphostin AG 879 (AG 879) is a tyrosine kinase inhibitor that inhibits **TrkA** phosphorylation (IC_{50} of 10 μM), but not TrkB and TrkC.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

VEGFR

Vascular endothelial growth factor receptor

VEGFRs consist of three subtypes, the fms-like tyrosine kinase Flt-1 (VEGFR1/Flt-1), the kinase domain region, also referred to as fetal liver kinase (VEGFR2/KDR/Flk-1), and Flt-4 (VEGFR3). Each receptor has seven immunoglobulinlike domains in the extracellular domain, a single transmembrane region, and a consensus tyrosine kinase sequence interrupted by a kinase insert domain. VEGFR1 and 2 are expressed on vascular endothelial cells, whereas VEGFR3 is expressed on lymphatic endothelial. The VEGF family members VEGF-A, -B, -C, -D, -E, and PlGF, and the human immunodeficiency (HIV) Tat protein bind in specific patterns to three related receptor protein tyrosine kinases, VEGFR1, 2, and 3, and induce the formation of homo- and heteromeric receptor complexes. Binding of VEGF to VEGFR causes dimerization and autophosphorylation of the receptor. Intracellular proteins such as VEGFR-associated protein (VRAP), PLC, and Sck that associate with specific tyrosine residues of VEGFR are phosphorylated upon receptor activation. Several signal transduction pathways are activated by the binding of VEGF to its receptor, leading to increased proliferation, survival, permeability, and migration of cells.

(Rac)-SAR131675

Cat. No.: HY-123050

(Rac)-SAR131675 is the racemate of SAR131675. SAR131675 is a potent and selective **VEGFR3** inhibitor with an IC_{50} of 23 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Z)-Guggulsterone

Cat. No.: HY-110066

Z-guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing **apoptosis**. Z-guggulsterone inhibits angiogenesis by suppressing the **VEGF–VEGF-R2–Akt** signaling axis.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(Z)-Orantinib

((Z)-SU6668; (Z)-TSU-68)

Cat. No.: HY-10517A

(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of **Flk1/KDR**, **PDGFRβ**, and **FGFR1**, with IC_{50}s of 2.1, 0.008, and 1.2 μM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

10Z-Hymenialdisine

((Z)-Hymenialdisine; Hymenialdisine)

Cat. No.: HY-N6794

10Z-Hymenialdisine ((Z)-Hymenialdisine) is a natural bioactive pyrrole alkaloid.
10Z-Hymenialdisine is a pan kinase inhibitor, and has anticancer activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Methylthienyl-carbonyl-JNJ-7706621

Cat. No.: HY-141685

3-Methylthienyl-carbonyl-JNJ-7706621 is a potent and selective inhibitor of **cyclin-dependent kinase (CDK)**, with IC_{50}s of 6.4 nM and 2 nM for **CDK1/cyclinB** and **CDK2/cyclinA**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4SC-203

Cat. No.: HY-19897

4SC-203 is a potent **multikinase** inhibitor with potential antineoplastic activity. 4SC-203 selectively FLT3/STK1, FLT3 mutated forms, and VEGFRs.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

5Z-7-Oxozeaenol

(FR148083; L783279; LL-Z 1640-2)

Cat. No.: HY-12686

5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of **TAK1** and **VEGF-R2**, with IC_{50}s of 8 nM and 52 nM, respectively.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 1 mg

5α-Hydroxycostic acid

Cat. No.: HY-N2666

5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating **VEGF/VEGFR2** and **Ang2/Tie2** pathways.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

AAL993

Cat. No.: HY-19986

IC_{50}s of 130 nM, 23 nM, and 18 nM for VEGFR1, VEGFR2, and VEGFR3, respectively. AAL993 shows less potently inhibits other tyrosine kinases. AAL993 possesses potent antiangiogenic and antitumor properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acrizanib

(LHA510)

Cat. No.: HY-109020

Acrizanib (LHA510) is a **VEGFR-2** inhibitor, with an IC_{50} of 17.4 nM for BaF3-VEGFR-2.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

AG-13958

(AG-013958) Cat. No.: HY-15492

AG-13958 (AG-013958), a potent **VEGFR tyrosine kinase** inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD).



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AhR modulator-1

Cat. No.: HY-135671

AhR modulator-1 (compound 6-MCDF) is a selective and orally active **aryl hydrocarbon receptor (AhR)** modulator. AhR modulator-1 inhibits metastasis, in part, by inhibiting **prostatic VEGF** production prior to tumor formation. AhR modulator-1 also possess anti-**estrogenic** properties in rat uterus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Altiratinib

(DCC-2701) Cat. No.: HY-B0791

Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC_{50}s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for **MET**, **TIE2**, **VEGFR2**, **FLT3**, **Trk1**, **Trk2**, and **Trk3** respectively.



Purity: 98.06%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AMG-47a

Cat. No.: HY-18303

AMG-47a is a potent and orally active **lymphocyte-specific protein tyrosine kinase (Lck)** inhibitor, with an IC_{50} of 0.2 nM. AMG-47a also inhibits **VEGF2**, **p38α**, **Jak3** and **MLR** and **IL-2** with IC_{50}s of 1 nM, 3 nM, 72 nM, 30 nM and 21 nM, respectively.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AMG-Tie2-1

Cat. No.: HY-13023

AMG-Tie2-1 is an inhibitor of **tunica interna endothelial cell kinase 2 (Tie2)** with an IC_{50} of 1 nM. AMG-Tie2-1 is a VEGFR2 inhibitor with an IC_{50} of 3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AST 487

(NVP-AST 487) Cat. No.: HY-15002

AST 487 is a **RET** kinase inhibitor with IC_{50} of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits **Flt-3** with IC_{50} of 520 nM.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Axitinib

(AG-013736) Cat. No.: HY-10065

Axitinib is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 0.1, 0.2, 0.1-0.3, 1.6 nM for **VEGFR1**, **VEGFR2**, **VEGFR3** and **PDGFRβ**, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Axitinib 13CD3

(AG-013736 13CD3) Cat. No.: HY-10065S

Axitinib 13CD3 (AG-013736 13CD3) is a 13C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 0.1, 0.2, 0.1-0.3, 1.6 nM for **VEGFR1**, **VEGFR2**, **VEGFR3** and **PDGFRβ**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Axitinib-d3

(AG-013736-d3) Cat. No.: HY-10065S1

Axitinib-d3 (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 0.1, 0.2, 0.1-0.3, 1.6 nM for **VEGFR1**, **VEGFR2**, **VEGFR3** and **PDGFRβ**, respectively.



Purity: 97.42%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

AZD2932

Cat. No.: HY-18179

AZD2932 is a potent and multi-targeted kinase inhibitor **VEGFR2**, **PDGFβ**, **Flt-3** and **c-Kit** with IC_{50}s of 8, 4, 7 and 9 nM in cell assay, respectively.



Purity: 96.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bevacizumab

(Anti-Human VEGF, Humanized Antibody) Cat. No.: HY-P9906

Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all **VEGF-A** isoforms with high affinity.

Bevacizumab

Purity: 98.50%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Bevacizumab (PBS)

(Anti-Human VEGF, Humanized Antibody (PBS)) Cat. No.: HY-P9906A

Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all **VEGF-A** isoforms with high affinity.

Bevacizumab (PBS)

Purity: 98.94%
Clinical Data: Launched
Size: 5 mg

BFH772

Cat. No.: HY-100419

BFH772 is a potent oral **VEGFR2** inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC_{50} value of 3 nM.



Purity: 96.38%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BIBF 1202

Cat. No.: HY-15992

BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits **VEGFR2** kinase with an IC_{50} of 62 nM.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BIBF 1202-13C,d3

Cat. No.: HY-15992S

BIBF 1202-13C,d3 is the 13C- and deuterium labeled. BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC50 of 62 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-690514

Cat. No.: HY-10333

BMS-690514 is a potent and orally active inhibitor of **EGFR** and **VEGFR**; has IC_{50}s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

BMS-794833

Cat. No.: HY-10497

BMS-794833 is a **VEGFR2** and **Met** inhibitor extracted from patent WO2009094417, compound example 1; has IC_{50}s of 15 and 1.7 nM, respectively.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Brivanib

(BMS-540215) Cat. No.: HY-10337

Brivanib (BMS-540215) is an ATP-competitive inhibitor against **VEGFR2** with an IC_{50} of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β.



Purity: 99.24%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Brivanib (alaninate)

(BMS-582664) Cat. No.: HY-10336

Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against **VEGFR2** with an IC_{50} of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ.



Purity: 99.45%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

c-Met-IN-11

Cat. No.: HY-147694

c-Met-IN-11 (compound 3) is a potent **c-MET** and **VEGFR-2** inhibitor, with IC_{50} values of 41.4 and 71.1 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cabozantinib

(XL184; BMS-907351) Cat. No.: HY-13016

Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Cabozantinib S-malate

(XL184 S-malate; BMS-907351 S-malate) Cat. No.: HY-12044

Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Cabozantinib-d4

(XL184-d4; BMS-907351-d4) Cat. No.: HY-13016S1

Cabozantinib-d4 is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cabozantinib-d6

Cat. No.: HY-13016S

Cabozantinib-d6 (XL184-d6) is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Cediranib

(AZD2171) Cat. No.: HY-10205

Cediranib (AZD2171) is a highly potent, orally available **VEGFR** tyrosine kinase inhibitor with IC_{50}s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.



Purity: 99.58%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Cediranib maleate

(AZD-2171 maleate) Cat. No.: HY-13049

Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available **VEGFR** inhibitor with IC_{50}s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.



Purity: 99.74%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Chiauranib

(CS2164) Cat. No.: HY-124526

Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Chloropyramine hydrochloride

Cat. No.: HY-B1305

Chloropyramine hydrochloride is a **histamine receptor H1** antagonist which can also inhibit the biochemical function of **VEGFR-3** and **FAK**.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

CP-547632

Cat. No.: HY-13302

CP-547632 is an orally active, ATP-competitive and potent **VEGFR-2** and **FGF** kinases inhibitor with IC_{50}s of 11 nM and 9 nM, respectively. CP-547632 is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 has antitumor efficacy.



Purity: 98.71%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CP-547632 hydrochloride

Cat. No.: HY-13302B

CP-547632 hydrochloride is an orally active, ATP-competitive and potent **VEGFR-2** and **FGF** kinases inhibitor with IC_{50}s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs).



Purity: 98.24%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CP-547632 TFA

Cat. No.: HY-13302C

CP-547632 TFA is an orally active, ATP-competitive and potent **VEGFR-2** and **FGF** kinases inhibitor with IC_{50}s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DMH4

Cat. No.: HY-108443

DMH4 is a potent and selective inhibitor of **VEGFR2** with an IC_{50} of 0.16 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dovitinib

(CHIR-258; TKI258)

Cat. No.: HY-50905

Dovitinib (CHIR-258) is an orally active, potent **multi-targeted tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **CSF-1R**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Dovitinib lactate

(CHIR-258 lactate; TKI-258 lactate)

Cat. No.: HY-10207

Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: 99.62%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dovitinib lactate hydrate

(TKI258 lactate hydrate; CHIR-258 lactate hydrate)

Cat. No.: HY-B0062

Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dovitinib-D8

Cat. No.: HY-50905S

Dovitinib-D8 (CHIR-258-D8) is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-26

Cat. No.: HY-142518

EGFR-IN-26 is a **EGFR** inhibitor extracted from patent WO2019162323A1 compound I-028. EGFR-IN-26 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-57

Cat. No.: HY-146138

EGFR-IN-57 (Compound 25a) is a potent, orally active **EGFR-TK** inhibitor with an IC_{50} of 0.054 μM. EGFR-IN-57 also inhibits **VEGFR-2**, **CK2α**, **topoisomerase IIβ** and **tubulin polymerization** with IC_{50} values of 0.087, 0.171, 0.13 and 3.61 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ENMD-2076

Cat. No.: HY-10987A

ENMD-2076 is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ENMD-2076 Tartrate

Cat. No.: HY-10987

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 98.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

EOC317

(ACTB-1003) Cat. No.: HY-16025

EOC317 (ACTB-1003) is an oral kinase inhibitor with IC_{50}s of 6, 2 and 4 nM for **FGFR1**, **VEGFR2** and **Tie-2**.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Famitinib

(SHR1020) Cat. No.: HY-108713

Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of **c-kit**, **VEGFR-2** and **PDGFRβ** with IC_{50} values of 2.3 nM, 4.7 nM and 6.6 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FGFR3-IN-2

Cat. No.: HY-147714

FGFR3-IN-2 (compound 18b) is a potent and selective **FGFR3** inhibitor, with IC_{50}s of 4.1 nM and 570 nM for **FGFR3** and **VEGFR2**, respectively. FGFR3-IN-2 can be used for the research of bladder cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Foretinib

(XL880; GSK1363089; GSK089; EXEL-2880) Cat. No.: HY-10338

Foretinib is a multi-target tyrosine kinase inhibitor with IC_{50}s of 0.4 nM and 0.9 nM for **Met** and **KDR**.



Purity: 99.77%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fruquintinib

(HMPL-013) Cat. No.: HY-19912

Fruquintinib (HMPL-013) is a highly potent and selective **VEGFR 1/2/3** inhibitor with IC_{50}s of 33, 0.35, and 35 nM, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Gandotinib

(LY2784544) Cat. No.: HY-13034

Gandotinib (LY2784544) is a potent **JAK2** inhibitor with IC_{50} of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC_{50} of 4, 25, 32, 44, and 95 nM.



Purity: 99.82%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Golvatinib

(E-7050) Cat. No.: HY-13068

Golvatinib (E-7050) is a potent dual inhibitor of both **c-Met** and **VEGFR2** kinases with IC_{50}s of 14 and 16 nM, respectively.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK2646264

Cat. No.: HY-112809

GSK2646264 (Compound 44) is a potent and selective **spleen tyrosine kinase (SYK)** inhibitor with a pIC_{50} of 7.1.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GW768505A free base

Cat. No.: HY-125741

GW768505A free base is a potent dual inhibitor of **VEGFR2 (KDR)** and **Tie-2**, with a pIC_{50} of 7.81 for VEGFR2. GW768505A free base has anti-angiogenic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GW806742X

Cat. No.: HY-112292

GW806742X, an ATP mimetic and a potent **MLKL (Mixed Lineage Kinase Domain-Like protein)** inhibitor, binds the MLKL pseudokinase domain with a K_d of 9.3 μM. GW806742X has activity against **VEGFR2** (IC_{50}=2 nM). GW806742X retards MLKL membrane translocation and inhibits necroptosis.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GW806742X hydrochloride

Cat. No.: HY-112292A

GW806742X hydrochloride, an ATP mimetic and a potent **MLKL (Mixed Lineage Kinase Domain-Like protein)** inhibitor, binds the MLKL pseudokinase domain with a K_d of 9.3 μM. GW806742X hydrochloride has activity against **VEGFR2** (IC_{50}=2 nM).



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HDAC-IN-35

Cat. No.: HY-146539

HDAC-IN-35 (Compound 14) is a potent, selective **HDAC** and **VEGFR-2** inhibitor, with IC_{50} values of 0.166 and 13.2 μM for **HDAC6** and **VEGFR-2**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

hVEGF-IN-1

Cat. No.: HY-101931

hVEGF-IN-1, a quinazoline derivative, could specifically bind to the G-rich sequence in the internal ribosome entry site A (IRES-A) and destabilize the G-quadruplex structure. hVEGF-IN-1 binds to the IRES-A (WT) with a K_d of 0.928 μM in SPR experiments.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Hydroxytanshinone IIA

Cat. No.: HY-N7177

Hydroxytanshinone IIA is a hydroxylated metabolite of Tanshinone IIA. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of **VEGF/VEGFR2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hypothemycin

Cat. No.: HY-107417

Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for **VEGFR2/VEGFR1**, **MEK1/MEK2**, **FLT-3**, **PDGFRβ/PDGFRα**, and **ERK1/ERK2**, respectively.



Purity: 96.10%
Clinical Data: No Development Reported
Size: 1 mg

Ilorasertib

(ABT-348)

Cat. No.: HY-16018

Ilorasertib (ABT-348) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits **Aurora C**, **Aurora B**, and **Aurora A** with IC_{50}s of 1 nM, 7 nM, 120 nM, respectively.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 50 mg, 100 mg

Ilorasertib hydrochloride

(ABT-348 hydrochloride)

Cat. No.: HY-16018A

Ilorasertib (ABT-348 hydrochloride) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits **Aurora C**, **Aurora B**, and **Aurora A** with IC_{50}s of 1 nM, 7 nM, 120 nM, respectively.



Purity: 99.67%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Isolinderalactone

Cat. No.: HY-N3001

Isolinderalactone suppresses human glioblastoma growth and angiogenic activity through the inhibition of **VEGFR2** activation in endothelial cells. Isolinderalactone suppresses the expression of **B-cell lymphoma 2 (Bcl-2)**, **survi**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

JI-101

Cat. No.: HY-16265

JI-101 is an orally available multi-kinase inhibitor of **VEGFR2**, **PDGFRβ** and **EphB4** with potent anti-cancer activity.



Purity: 99.43%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

JK-P3

Cat. No.: HY-108933

JK-P3 is a potent and pan **VEGFR2** inhibitor, with IC_{50}s of 7.83 μM, 27 μM and 5.18 μM for VEGFR2, FGFR1 and FGFR3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JNJ-38158471

Cat. No.: HY-18317

JNJ-38158471 is a well tolerated, orally available, highly selective **VEGFR-2** inhibitor, with an IC_{50} of 40 nM. JNJ-38158471 also inhibits **Ret** and **Kit** with IC_{50}s of 180 and 500 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

K00546

Cat. No.: HY-103647

K00546 is a potent **CDK1** and **CDK2** inhibitor with IC_{50}s of 0.6 nM and 0.5 nM for **CDK1/cyclin B** and **CDK2/cyclin A**, respectively. K00546 is also a potent **CDC2-like kinase 1 (CLK1)** and **CLK3** inhibitor with IC_{50}s of 8.9 nM and 29.2 nM, respectively.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ki20227

Cat. No.: HY-10408

Ki20227 is an orally active and highly selective **c-Fms tyrosine kinase (CSF1R)** inhibitor with IC_{50}s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, **VEGFR2** (vascular endothelial growth factor receptor-2), **c-Kit** (stem cell factor receptor) and **PDGFRβ** (platelet-derived growth factor...



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Ki8751

Cat. No.: HY-12038

Ki8751 is a potent **VEGFR2** inhibitor with an IC_{50} of 0.9 nM.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

KRN-633

Cat. No.: HY-12060

KRN-633 is a potent **VEGFR** inhibitor with IC_{50}s of 170, 160 and 125 nM for VEGFR1, VEGFR2 and VEGFR3, respectively.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib

(E7080)

Cat. No.: HY-10981

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib mesylate

(E7080 mesylate)

Cat. No.: HY-10981A

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib-d4

(E7080-d4)

Cat. No.: HY-10981S

Lenvatinib-d4 (E7080-d4) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lenvatinib-d5

(E7080-d5)

Cat. No.: HY-10981S1

Lenvatinib-d5 (E7080-d5) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Linifanib

(ABT-869; AL-39324)

Cat. No.: HY-50751

Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of **VEGFR** and **PDGFR** family with IC_{50}s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity.



Purity: 99.72%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Lucitanib

(E-3810)

Cat. No.: HY-15391



Lucitanib (E-3810) is a novel dual inhibitor of **VEGFR** and **FGFR**, potently and selectively inhibits **VEGFR1**, **VEGFR2**, **VEGFR3**, **FGFR1** and **FGFR2** with IC_{50}s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.

Purity: 98.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MAZ51

Cat. No.: HY-116624



MAZ51 is a selective inhibitor of **VEGFR-3 (Flt-4)** tyrosine kinase. MAZ51 inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. MAZ51 had no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ.

Purity: 98.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

MET kinase-IN-3

Cat. No.: HY-146884



MET kinase-IN-3 (compound 8) is an orally active and potent **MET** inhibitor, with an IC_{50} of 9.8 nM. MET kinase-IN-3 shows good and broad-spectrum antiproliferative activity against cancer cell lines.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MGCD-265 analog

Cat. No.: HY-10991



MGCD-265 analog is a potent and oral active inhibitor of **c-Met** and **VEGFR2** tyrosine kinases, with IC_{50}s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity.

Purity: 98.57%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Midostaurin

(PKC412; CGP 41251)

Cat. No.: HY-10230



Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits **PKCα/β/γ**, **Syk**, **Flk-1**, **Akt**, **PKA**, **c-Kit**, **c-Fgr**, **c-Src**, **FLT3**, **PDFRβ** and **VEGFR1/2** with IC_{50}s ranging from 22-500 nM.

Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

ML786 dihydrochloride

Cat. No.: HY-14979A



ML786 dihydrochloride is a potent and orally bioavailable **Raf** inhibitor, with IC_{50}s of 2.1, 4.2, and 2.5 nM for ^{V600E}**ΔB-Raf**, **wt B-Raf**, and **C-Raf**, respectively. ML786 dihydrochloride also inhibits **Abl-1**, **DDR2**, **EPHA2**, **KDR**, and **RET** (IC_{50}=<0.5, 7.0, 11, 6.2, 0.8 nM).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Motesanib

(AMG 706)

Cat. No.: HY-10228



Motesanib (AMG 706) is a potent ATP-competitive inhibitor of **VEGFR1/2/3** with IC_{50}< **/b>s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret.**.

Purity: 99.99%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Motesanib Diphosphate

(AMG 706 Diphosphate)

Cat. No.: HY-10229



Motesanib Diphosphate (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of **VEGFR1/2/3** with IC_{50}s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret.

Purity: 99.85%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ningetinib

Cat. No.: HY-107145A



Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with IC_{50}s of 6.7, 1.9 and <1.0 nM for **c-Met**, **VEGFR2** and **Axl**, respectively.

Purity: 99.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ningetinib Tosylate

Cat. No.: HY-107145



Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with IC_{50}s of 6.7, 1.9 and <1.0 nM for **c-Met**, **VEGFR2** and **Axl**, respectively.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nintedanib

(BIBF 1120) Cat. No.: HY-50904

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Nintedanib esylate

(BIBF 1120 esylate) Cat. No.: HY-11106

Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Nintedanib-13C,d3

(BIBF 1120-13C,d3) Cat. No.: HY-50904S1

Nintedanib-13C,d3 is the 13C- and deuterium labeled. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nintedanib-d3

(BIBF 1120-d3) Cat. No.: HY-50904S

Nintedanib-d3 (BIBF 1120-d3) is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nintedanib-d8

(BIBF 1120-d8) Cat. No.: HY-50904S2

Nintedanib-d8 is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NVP-ACC789

(ACC-789; ZK202650) Cat. No.: HY-19624

NVP-ACC789 is an inhibitor of human **VEGFR-1**, **VEGFR-2** (mouse **VEGFR-2**), **VEGFR-3** and **PDGFR-β** with IC_{50}s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

NVP-BAW2881

(BAW2881) Cat. No.: HY-100394

NVP-BAW2881 (BAW2881) is a potent and selective **VEGFR2** inhibitor with an IC_{50} of 4 nM.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ODM-203

Cat. No.: HY-119367

ODM-203 is a potent **FGFR** and **VEGFR** families inhibitor with IC_{50}s of 11, 16, 6, 35 nM towards recombinant FGFR1, FGFR2, FGFR3 and FGFR4 as well as 26, 9, 5 nM towards VEGFR1, VEGFR2 and VEGFR3, respectively. ODM-203 exhibits strong anti-tumor activity and induces anti-tumor immunity.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Oglufanide

(H-Glu-Trp-OH; L-Glutamyl-L-tryptophan) Cat. No.: HY-13718

Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits **vascular endothelial growth factor (VEGF)**. Oglufanide can stimulate the immune response to **hepatitic C virus (HCV)** and intracellular bacterial infections.



Purity: 99.49%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Orantinib

(SU6668; TSU-68) Cat. No.: HY-10517

Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with K_is of 2.1 μM, 8 nM and 1.2 μM for **Flt-1**, **PDGFRβ** and **FGFR1**, respectively.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

OSI-930

Cat. No.: HY-10204

OSI-930 is an orally selective inhibitor of **Kit**, **KDR** and **CSF-1R (c-Fms)** with IC_{50}s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits **Flt-1**, **c-Raf**, **Lck** and low activity against **PDGFRα/β**, **Flt-3** and **Abl**. OSI-930 has antitumor activity.



Purity: 98.13%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pamufetinib

(TAS-115)

Cat. No.: HY-12423

Pamufetinib (TAS-115) is a potent **VEGFR** and hepatocyte growth factor receptor (**c-Met/HGFR**)-targeted kinase inhibitor with IC_{50}s of 30 and 32 nM for rVEGFR2 and rMET, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Pamufetinib mesylate

(TAS-115 mesylate)

Cat. No.: HY-12423A

Pamufetinib (TAS-115) mesylate is a potent **VEGFR**and hepatocyte growth factor receptor (**c-Met/HGFR**)-targeted kinase inhibitor, with IC_{50}s of 30 and 32 nM for rVEGFR2 and rMET, respectively.



Purity: 99.19%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pazopanib

(GW786034)

Cat. No.: HY-10208

Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with IC_{50}s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pazopanib Hydrochloride

(GW786034 (Hydrochloride))

Cat. No.: HY-12009

Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with an IC_{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pazopanib-d6

(GW786034-d6)

Cat. No.: HY-10208S

Pazopanib-d6 (GW786034-d6) is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with IC_{50}s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD173074

Cat. No.: HY-10321

PD173074 is a potent **FGFR1** inhibitor with an IC_{50} of 25 nM and also inhibits **VEGFR2** with an IC_{50} of 100-200 nM, showing 1000-fold selectivity for FGFR1 over PDGFR and c-Src.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Pegaptanib sodium

(EYE001; NX1838)

Cat. No.: HY-109561

Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Pentagamavunon-1

(PGV-1)

Cat. No.: HY-136477

Pentagamavunon-1 (PGV-1), a Curcumin analog with oral activity, targets on several molecular mechanisms to induce **apoptosis** including inhibition of angiogenic factors cyclooxygenase-2 (**COX-2**) and vascular endothelial growth factor (**VEGF**). PGV-1 inhibits **NF-κB** activation.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PF 477736

(PF 00477736)

Cat. No.: HY-10032

PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of **Chk1**, with a K_i of 0.49 nM, it is also a **Chk2** inhibitor, with a K_i of 47 nM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PF-03814735

Cat. No.: HY-14574

PF-03814735 is a potent, orally available, ATP-competitive and reversible **aurora A** and **aurora B** inhibitor with IC_{50}s of 0.8 and 0.5 nM, respectively.



Purity: 99.82%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ponatinib

(AP24534)

Cat. No.: HY-12047

Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ponatinib hydrochloride

(AP24534 hydrochloride)

Cat. No.: HY-108766

Ponatinib (AP24534) hydrochloride is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: >98%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg, 100 mg

Ponatinib-d8

(AP24534-d8)

Cat. No.: HY-12047S

Ponatinib D8 (AP24534 D8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 1 mg

PP121

Cat. No.: HY-10372

PP121 is a multi-targeted kinase inhibitor with IC_{50}s of 10, 60, 12, 14, 2 nM for **mTOR**, **DNK-PK**, **VEGFR2**, **Src**, **PDGFR**, respectively.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PTC299

Cat. No.: HY-124593

PTC299 is an orally active inhibitor of **VEGFA mRNA translation** that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of **dihydroorotate dehydrogenase (DHODH)**.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Pz-1

Cat. No.: HY-U00437

Pz-1 is a potent **RET** and **VEGFR2** inhibitor with IC_{50}s of less than 1 nM for both wild type kinases.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

R1530

Cat. No.: HY-13737

R1530 is a highly potent, orally active, dual-acting **mitosis/angiogenesis** inhibitor, with anti-tumor and anti-angiogenic activities. R1530 is a multikinase inhibitor which binds to 31 kinases with K_d values of <500 nM.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

R916562

Cat. No.: HY-104075

R916562 is an orally active and selective **Axl/VEGF-R2** inhibitor with IC_{50}s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RAF265

(CHIR-265)

Cat. No.: HY-10248

RAF265 is a potent **RAF/VEGFR2** inhibitor.



Purity: 99.90%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Ramucirumab

Cat. No.: HY-P9920

Ramucirumab is a human **VEGFR-2** antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D.

Ramucirumab

Purity: 99.40%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Ranibizumab

(RG-6321)

Cat. No.: HY-P9951

Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165). Ranibizumab slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research.

Ranibizumab

Purity: 98.60%
Clinical Data: Launched
Size: 1 mg

Regorafenib

(BAY 73-4506)

Cat. No.: HY-10331

Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with **IC_{50}**s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1**, respectively.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib Hydrochloride

(BAY 73-4506 hydrochloride)

Cat. No.: HY-13308

Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with **IC_{50}**s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib monohydrate

(BAY 73-4506 monohydrate)

Cat. No.: HY-10331A

Regorafenib monohydrate (BAY 73-4506 monohydrate) is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with **IC_{50}**s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib-13C,d3

(BAY 73-4506-13C,d3)

Cat. No.: HY-10331S1

Regorafenib-13C,d3 is the 13C- and deuterium labeled. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Regorafenib-d3

(BAY 73-4506-d3)

Cat. No.: HY-10331S

Regorafenib D3 (BAY 73-4506 D3) is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ripretinib

(DCC-2618)

Cat. No.: HY-112306

Ripretinib (DCC-2618) is an orally bioavailable, selective **KIT** and **PDGFRA** switch-control inhibitor.



Purity: 99.33%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SAR131675

Cat. No.: HY-15458

SAR131675 is a potent and selective **VEGFR3** inhibitor with an **IC_{50}** of 23 nM.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

SCR-1481B1

(c-Met inhibitor 2)

Cat. No.: HY-18711A

SCR-1481B1 (c-Met inhibitor 2) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Semaxinib

(SU5416) Cat. No.: HY-10374

Semaxinib (SU5416) is a potent and selective inhibitor of **VEGFR** (**Flk-1/KDR**) with an IC_{50} of 1.23 μM.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Sitravatinib

(MGCD516; MG-516) Cat. No.: HY-16961

Sitravatinib (MGCD516) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: 99.59%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Sitravatinib malate

(MGCD516 malate; MG-516 malate) Cat. No.: HY-16961A

Sitravatinib malate (MGCD516 malate) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Sorafenib

(Bay 43-9006) Cat. No.: HY-10201

Sorafenib (Bay 43-9006) is a potent and orally active **Raf** inhibitor with IC_{50}s of 6 nM and 20 nM for **Raf-1** and **B-Raf**, respectively. Sorafenib is a multikinase inhibitor with IC_{50}s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for **VEGFR2**, **VEGFR3**, **PDGFRβ**, **FLT3** and **c-Kit**, respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Sorafenib Tosylate

(Bay 43-9006 Tosylate) Cat. No.: HY-10201A

Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active **Raf** inhibitor with IC_{50}s of 6 nM and 20 nM for **Raf-1** and **B-Raf**, respectively.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Sorafenib-13C,d3

Cat. No.: HY-10201S2

Sorafenib-13C,d3 is the 13C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active **Raf** inhibitor with IC_{50}s of 6 nM and 20 nM for **Raf-1** and **B-Raf**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sorafenib-d3

(Bay 43-9006-d3; Donafenib) Cat. No.: HY-10201S

Sorafenib-d3 (Bay 43-9006-d3) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC_{50}s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.



Purity: 99.57%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sorafenib-d4

(Bay 43-9006-d4) Cat. No.: HY-10201S1

Sorafenib-d4 (Bay 43-9006-d4) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC_{50}s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SU 5402

Cat. No.: HY-10407

SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC_{50} of 20 nM, 30 nM, and 510 nM for **VEGFR2**, **FGFR1**, and **PDGFRβ**, respectively.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SU11652

Cat. No.: HY-112452

SU11652 is a potent **receptor tyrosine kinase (RTK)** inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including **VEGFR**, **FGFR**, **PDGFR**, and **Kit**. SU11652 can be uesd for spontaneous cancers expressing Kit mutations research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SU14813

Cat. No.: HY-10501

SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC_{50}s of 50, 2, 4, 15 nM for **VEGFR2**, **VEGFR1**, **PDGFRβ** and **KIT**.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SU14813 maleate

Cat. No.: HY-10501A

SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC_{50}s of 50, 2, 4, 15 nM for **VEGFR2**, **VEGFR1**, **PDGFRβ** and **KIT**.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SU1498

(AG 1498; Tyrphostin SU 1498)

Cat. No.: HY-19326

SU1498 (AG 1498) is a selective inhibitor of the **VEGFR2**; inhibits **Flk-1** with an IC_{50} of value of 700 nM.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

SU4312

Cat. No.: HY-100349

SU4312 is the racemate of (Z)-SU4312 and (E)-SU4312. (Z)-SU4312 inhibits PDGFR and FLK-1 with IC_{50}s of 19.4 and 0.8 μM, respectively. (E)-SU4312 inhibits PDGFR, FLK-1, EGFR, HER-2, and IGF-1R with IC_{50}s of 24.2, 5.2, 18.5, 16.9 and 10.0 μM, respectively.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

SU5204

Cat. No.: HY-126319

SU5204, a tyrosine kinase inhibitor, has IC_{50}s of 4 and 51.5 μM for **FLK-1 (VEGFR-2)** and **HER2**, respectively.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SU5205

Cat. No.: HY-21289

SU5205 is an inhibitor of **VEGFR2 (FLK-1)**, with an IC_{50} of 9.6 μM.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

SU5208

Cat. No.: HY-136209

SU5208 inhibits vascular endothelial growth factor receptor-2 **(VEGFR2)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SU5214

(SU4949)

Cat. No.: HY-21292

SU5214 is a potent **VEGFR2** inhibitor extracted from patent US5834504A, SU5214, has IC_{50}s of 14.8 μM (**FLK-1**) and 36.7 μM (**EGFR**), respectively.



Purity: 98.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SU5408

(VEGFR2 Kinase Inhibitor I)

Cat. No.: HY-103002

SU5408 (VEGFR2 Kinase Inhibitor I) is a potent and cell-permeable inhibitor of **VEGFR2** kinase with an IC_{50} of 70 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Sulfatinib

(HMPL-012)

Cat. No.: HY-12297

Sulfatinib (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against **VEGFR1/2/3**, **FGFR1** and **CSF1R** with IC_{50}s of in a range of 1 to 24 nM.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Sunitinib
(SU 11248) Cat. No.: HY-10255A

Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 80 nM and 2 nM for **VEGFR2** and **PDGFRβ**, respectively.



Purity: 98.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Sunitinib Malate
(SU 11248 Malate) Cat. No.: HY-10255

Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 80 nM and 2 nM for **VEGFR2** and **PDGFRβ**, respectively.



Purity: 99.47%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Sunitinib-d10
(SU 11248-d10) Cat. No.: HY-10255AS

Sunitinib D10 (SU 11248 D10) is a deuterium labeled Sunitinib. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 80 nM and 2 nM for **VEGFR2** and **PDGFRβ**, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sunitinib-d4
Cat. No.: HY-10255AS1

Sunitinib-d4 (SU 11248-d4) is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 80 nM and 2 nM for **VEGFR2** and **PDGFRβ**, respectively.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 1 mg, 25 mg

Surfen dihydrochloride
(Aminoquincarbamide dihydrochloride) Cat. No.: HY-122704A

Surfen dihydrochloride is a potent **HS (heparan sulfate)** antagonist. Surfen binds to glycosaminoglycans. Surfen neutralizes the anticoagulant activity of both unfractionated and low molecular weight heparins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TAK-593
Cat. No.: HY-15506

TAK-593 is a potent **VEGFR** and **PDGFR** family inhibitor with IC_{50}s of 3.2, 0.95, 1.1, 4.3 and 13 nM for VEGFR1, VEGFR2, VEGFR3, PDFGRα and PDFGRβ, respectively.



Purity: 99.62%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tanshinone IIA
(Dan Shen ketone) Cat. No.: HY-N0135

Tanshinone IIA (Tan IIA) is one of the main compositions in the root of red-rooted salvia. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of **VEGF/VEGFR2**.



Purity: 99.74%
Clinical Data: Phase 4
Size: 10 mg, 25 mg, 50 mg

Tanshinone IIA-d6
(Dan Shen ketone-d6) Cat. No.: HY-N0135S

Tanshinone IIA-d6 (Dan Shen ketone-d6) is the deuterium labeled Tanshinone IIA. Tanshinone IIA (Tan IIA) is one of the main compositions in the root of red-rooted salvia. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of **VEGF/VEGFR2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Taurocholic acid sodium
(Sodium taurocholate; N-Cholyltaurine sodium) Cat. No.: HY-N0545

Taurocholic acid sodium (Sodium taurocholate; N-Cholyltaurine sodium) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Immunoregulation effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Taurocholic acid-13C2,15N sodium (Sodium taurocholate-13C2,15N; N-Cholyltaurine-13C2,15N sodium)
Cat. No.: HY-N0545S

Taurocholic acid-13C2,15N sodium (Sodium taurocholate-13C2,15N) is the 13C- and 15N-labeled Taurocholic acid (sodium).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Telatinib

(Bay 57-9352) Cat. No.: HY-10527

Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of **VEGFR2**, **VEGFR3**, **PDGFα**, and **c-Kit** with IC_{50}s of 6, 4, 15 and 1 nM, respectively.



Purity: 98.72%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Telatinib mesylate

(Bay 57-9352 mesylate) Cat. No.: HY-10527C

Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active **VEGFR2**, **VEGFR3**, **PDGFα**, and **c-Kit** inhibitor with IC_{50}s of 6 nM, 4 nM, 15 nM and 1 nM, respectively.



Purity: 99.46%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tesevatinib

(XL-647; EXEL-7647; KD-019) Cat. No.: HY-13314

Tesevatinib (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits **EGFR**, **ErbB2**, **KDR**, **Flt4** and **EphB4** kinase with IC_{50}s of 0.3, 16, 1.5, 8.7, and 1.4 nM.



Purity: 99.21%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg

TG 100572

Cat. No.: HY-10184

TG 100572 is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TG 100572 Hydrochloride

Cat. No.: HY-10185

TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

TG 100801

Cat. No.: HY-10186

TG 100801 is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: 98.60%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg

TG 100801 Hydrochloride

Cat. No.: HY-10187

TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

TIE-2/VEGFR-2 kinase-IN-1

Cat. No.: HY-112294

TIE-2/VEGFR-2 kinase-IN-1 is used for the synthesis of TIE-2 and/or VEGFR-2 inhibitors, extracted from patent WO2003022852, example 14. TIE-2/VEGFR-2 kinase-IN-1 is used for the study of diseases associated with inappropriate angiogenesis.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TIE-2/VEGFR-2 kinase-IN-2

Cat. No.: HY-12572

TIE-2/VEGFR-2 kinase-IN-2 is a potent dual **VEGFR2** and **Tie-2** inhibitor with pIC_{50} values of 8.61 and 8.56, respectively. TIE-2/VEGFR-2 kinase-IN-2 is an anti-angiogenic agent and can be used for cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tinengotinib

Cat. No.: HY-145601

Tinengotinib is the modulator of one or more protein kinases such as **Aurora** kinase and **VEGFR** kinase. Tinengotinib has the potential for the research of these kinase abnormalities diseases mediated, especially cancer-related diseases (extracted from patent WO2018108079A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tivozanib

(AV-951; KRN951) Cat. No.: HY-10977

Tivozanib (AV-951; KRN951) is a highly potent and selective **VEGFR 1/2/3** inhibitor with IC_{50}s of 0.21, 0.16, and 0.24 nM in cell assay, respectively.



Purity: 99.27%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Toceranib

(SU11654; PHA 291639E) Cat. No.: HY-10330

Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



Purity: 96.25%
Clinical Data: Launched
Size: 10 mg, 50 mg

Toceranib phosphate

(SU11654 phosphate; PHA 291639E phosphate) Cat. No.: HY-10330A

Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



Purity: 98.02%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg, 100 mg

Toceranib-d8

Cat. No.: HY-10330S

Toceranib-d8 (SU11654-d8) is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Tyrosine kinase-IN-1

Cat. No.: HY-100315

Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 4, 20, 4, 2 nM for **KDR**, **Flt-1**, **FGFR1** and **PDGFRα**, respectively.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyrphostin A9

(Tyrphostin 9; Malonoben) Cat. No.: HY-15511

Tyrphostin A9, a **PDGFR** inhibitor, is a potent inducer of mitochondrial fission. Tyrphostin A9 emerged as the most potent and selective of 51 tyrosine kinase inhibitors tested against the TNF-induced respiratory burst. Tyrphostin A9 has **anti-influenza virus** activities.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Tyrphostin AG1433

(SU1433; AG1433) Cat. No.: HY-119757

Tyrphostin AG1433 (SU1433) is a **tyrosine kinases** inhibitor. AG1433 is also a selective **PDGFRβ** and **VEGFR-2 (Flk-1/KDR)** inhibitor with IC_{50}s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vandetanib

(ZD6474) Cat. No.: HY-10260

Vandetanib (D6474) is a potent, orally active inhibitor of **VEGFR2/KDR** tyrosine kinase activity (IC_{50}=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of **VEGFR3/FLT4** (IC_{50}=110 nM) and **EGFR/HER1** (IC_{50}=500 nM).



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 500 mg

Vandetanib hydrochloride

(ZD6474 hydrochloride) Cat. No.: HY-10260B

Vandetanib hydrochloride (D6474 hydrochloride) is a potent, orally active inhibitor of **VEGFR2/KDR** tyrosine kinase activity (IC_{50}=40 nM). Vandetanib hydrochloride also has activity versus the tyrosine kinase activity of **VEGFR3/FLT4** (IC_{50}=110 nM) and **EGFR/HER1** (IC_{50}=500 nM).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Vandetanib trifluoroacetate

(ZD6474 trifluoroacetate) Cat. No.: HY-10260A

Vandetanib trifluoroacetate (D6474 trifluoroacetate) is a potent, orally active inhibitor of **VEGFR2/KDR** tyrosine kinase activity (IC_{50}=40 nM).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Vandetanib-d4

Cat. No.: HY-10260S1

Vandetanib-d4 (ZD6474-d4) is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of **VEGFR2/KDR** tyrosine kinase activity (IC_{50}=40 nM).



Purity: >98%
Clinical Data:
Size: 2.5 mg, 1 mg, 5 mg, 10 mg

Vandetanib-d6

(ZD6474-d6)

Cat. No.: HY-10260S

Vandetanib-d6 (ZD6474-d6) is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of **VEGFR2/KDR** tyrosine kinase activity (IC_{50}=40 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vatalanib dihydrochloride (PTK787 dihydrochloride; CGP-797870 dihydrochloride; ZK-222584 dihydrochloride)

Cat. No.: HY-12018

Vatalanib dihydrochloride (PTK787 dihydrochloride) is an inhibitor of **VEGFR2/KDR** with IC_{50} of 37 nM.



Purity: 99.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Vatalanib free base (PTK787 free base; PTK/ZK free base; CGP-79787 free base; ZK-222584 free base)

Cat. No.: HY-10203

Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of **VEGFR2/KDR** with IC_{50} of 37 nM.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Vatalanib-d4 dihydrochloride

Cat. No.: HY-12018S

Vatalanib-d4 (PTK787-d4) dihydrochloride is the deuterium labeled Vatalanib dihydrochloride. Vatalanib (PTK787) dihydrochloride is an inhibitor of **VEGFR2/KDR** with IC_{50} of 37 nM.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

VEGFR-2-IN-10

Cat. No.: HY-139822

VEGFR-2-IN-10 exhibits increased antiangiogenic potency (IC_{50} = 0.7 μM) against VEGF-induced **VEGFR2** phosphorylation without cytotoxic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR-2-IN-11

Cat. No.: HY-145856

VEGFR-2-IN-11 (Compound 8h) is a potent **VEGFR-2** inhibitor with an IC_{50} of 60.27 nM. VEGFR-2-IN-11 shows antitumor activity and induces cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR-2-IN-12

Cat. No.: HY-145864

VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent **VEGFR-2** inhibitor with an IC_{50} of 0.037 μM. VEGFR-2-IN-12 shows high growth inhibition against MCF-7 cells (GI_{50}=1.6 μM). VEGFR-2-IN-12 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR-2-IN-13

Cat. No.: HY-144754

VEGFR-2-IN-13 (Compound 19a) is a potent **VEGFR-2** inhibitor with an IC_{50} of 3.4 nM. VEGFR-2-IN-13 disrupts the HepG2 cell cycle by arresting the G2/M phase and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR-2-IN-14

Cat. No.: HY-144795

VEGFR-2-IN-14 (Compound 5) is a potent **VEGFR-2** inhibitor. VEGFR-2-IN-14 arrests the HepG2 cell growth at the Pre-G1 phase and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR-2-IN-15

Cat. No.: HY-144796

VEGFR-2-IN-15 (Compound 14b) is a potent **VEGFR-2** inhibitor. VEGFR-2-IN-15 arrests the HepG2 cell growth at the Pre-G1 phase and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR-2-IN-16

Cat. No.: HY-144803

VEGFR-2-IN-16 (Compound 15b) is a potent **VEGFR-2** inhibitor with an IC_{50} of 86.36 nM. VEGFR-2-IN-16 shows antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR-2-IN-17

Cat. No.: HY-144804

VEGFR-2-IN-17 (Compound 15a) is a potent **VEGFR-2** inhibitor with an IC_{50} of 67.25 nM. VEGFR-2-IN-17 shows antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR-2-IN-18

Cat. No.: HY-144805

VEGFR-2-IN-18 (Compound 15d) is a potent **VEGFR-2** inhibitor with an IC_{50} of 60 nM. VEGFR-2-IN-18 induces cell **apoptosis**. VEGFR-2-IN-18 shows antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR-2-IN-19

Cat. No.: HY-146367

VEGFR-2-IN-19 (Compound 15b) is a potent **VEGFR2** inhibitor. VEGFR-2-IN-19 induces cell **apoptosis** and increases intracellular **reactive oxygen species** level. VEGFR-2-IN-19 can be used as an anticancer agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR-2-IN-20

Cat. No.: HY-147779

VEGFR-2-IN-20 (Compound 7) is a potent inhibitor of **VEGFR**. VEGFR-2-IN-20 has the potential for the research of cancer diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR-2-IN-5

Cat. No.: HY-18625

VEGFR-2-IN-5 is a **VEGFR2** inhibitor extracted from patent WO2013055780A1, Page 69.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

VEGFR-2-IN-5 hydrochloride

Cat. No.: HY-18625A

VEGFR-2-IN-5 hydrochloride is a **VEGFR2** inhibitor extracted from patent WO2013055780A1, Page 69.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

VEGFR-2-IN-6

Cat. No.: HY-131658

VEGFR-2-IN-6 (example 64) is a **VEGFR2** inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

VEGFR-2-IN-9

(KDR-in-4)

Cat. No.: HY-101628

VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insert domain-containing receptor (**KDR/VEGFR2**) inhibitor with an IC_{50} of 7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR-2/BRAF-IN-1

Cat. No.: HY-146491

VEGFR-2/BRAF-IN-1 (Compound 4b) is a dual **VEGFR-2** and **BRAF** kinases inhibitor with IC_{50} values of 0.049, 0.063 and 0.005 μM against VEGFR-2, $BRAF^{V600E}$ and $BRAF^{WT}$, respectively. VEGFR-2/BRAF-IN-1 induces **apoptosis** and arrests the cell cycle mainly in the G1/S phase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR-2/BRAF-IN-2

Cat. No.: HY-146492

VEGFR-2/BRAF-IN-2 (Compound 4a) is a dual **VEGFR-2** and **BRAF** kinases inhibitor with IC_{50} values of 0.111, 0.089 and 0.071 μM against VEGFR-2, $BRAF^{V600E}$ and $BRAF^{WT}$, respectively. VEGFR-2/BRAF-IN-2 induces **apoptosis** and arrests the cell cycle mainly in the G1 phase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR-3-IN-1

Cat. No.: HY-132305

VEGFR-3-IN-1 is a potent and selective **VEGFR3** inhibitor with an IC_{50} of 110.4 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

VEGFR-IN-1

Cat. No.: HY-101219

VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC_{50}s of 0.02, 0.18, 0.24 7.3, and 7 μM for **KDR**, **Flt-1**, c-Kit, EGF-R, and c-Src, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VEGFR2-IN-1

Cat. No.: HY-145849

VEGFR2-IN-1 is a potent and selective **VEGFR2** inhibitor (IC_{50}=19.8 nM). VEGFR2-IN-1 inhibits cell proliferation and migration through apoptosis activation and **VEGFR2** inhibition.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vorolanib

(CM082; X-82)

Cat. No.: HY-109019

Vorolanib (CM082) is an orally active, potent multikinase **VEGFR/PDGFR** inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895).



Purity: 99.80%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

VS 8

Cat. No.: HY-143491

VS 8 (Compound VS 8) is a potent, orally active **VEGFR-2** inhibitor with significant **anti-angiogenic** effects. VS 8 induces cancer cell **apoptosis** and migration. VS 8 is active against CSCs (Cancer stem cells).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WHI-P180

(Janex 3)

Cat. No.: HY-15769

WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits **RET**, **KDR** and **EGFR** with IC_{50}s of 5 nM, 66 nM and 4 μM, respectively.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

WHI-P180 hydrochloride

(Janex 3 hydrochloride;)

Cat. No.: HY-15769A

WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits **RET**, **KDR** and **EGFR** with IC_{50}s of 5 nM, 66 nM and 4 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Xanthatin

Cat. No.: HY-N3032

Xanthatin is isolated from Xanthium strumarium leaves.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

XL092

Cat. No.: HY-138696

XL092 is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including **MET**, **VEGFR2**, **AXL** and **MER**, with IC_{50}s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. XL092 exhibits anti-tumor activity.



Purity: 99.52%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

YF-452

Cat. No.: HY-120200

YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (**VEGFR2**). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZD-4190

Cat. No.: HY-U00002

ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (**VEGFR2**) and of epidermal growth factor receptor (**EGFR**) signalling, used for the treatment of cancer.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

ZK-261991

Cat. No.: HY-15333

ZK-261991 is an orally active **VEGFR** tyrosine kinase inhibitor with an IC_{50} of 5 nM for VEGFR2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZM 306416

(CB 676475)

Cat. No.: HY-13785

ZM-306416 (CB 676475) is a potent inhibitor of **VEGFR** with IC_{50}s of 0.1 and 2 μM for KDR and Flt, respectively. ZM-306416 is also a **EGFR** inhibitor with an IC_{50} of <10 nM.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

ZM323881

Cat. No.: HY-15467

ZM323881 is a potent and selective **VEGFR2** inhibitor with an IC_{50} of less than 2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZM323881 hydrochloride

Cat. No.: HY-15467A

ZM323881 hydrochloride is a potent and selective **VEGFR2** inhibitor with an IC_{50} of less than 2 nM.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg